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Abstract  
 
Background 
 
People living with HIV (PLWH) are at higher risk of reduced bone mineral 
density (BMD) and fragility fracture compared to the general population. 
Possible causes include: an increased prevalence of general fracture risk 
factors (GFRFs) in PLWH; a direct effect of HIV; and a contributory role of 
antiretroviral therapy.  
 
HIV guidelines recommend FRAX® (www.sheffield.ac.uk/FRAX) for fracture 
risk assessment in PLWH. FRAX®, however, incorporates GFRFs but not HIV 
disease-specific factors. 
 
Hypotheses 
 
1. Both HIV disease-specific factors and GFRFs contribute to reduced BMD 
and fracture risk in PLWH. 
2. FRAX® correlates poorly with BMD in PLWH. 
 
Methods 
 
Phase One: The prevalence of GFRFs and fractures were recorded in PLWH. 
FRAX® 10-year osteoporotic fracture probabilities (FRAX® scores) were 
calculated.  
 
Phase Two: A subset of the Phase One cohort were recruited proportionately 
by race, gender and FRAX® scores (low, intermediate and high) for dual-
energy X-ray absorptiometry BMD measurements, vertebral fracture risk 
assessment and blood and urine sampling for biochemical and immunological 
markers. T-cell and monocyte subsets were assessed using flow cytometry. 
 
Results 
 
Phase One (n = 625): GFRFs were prevalent, but FRAX® scores and fragility 
fracture prevalence were low. 
 
Phase Two (n = 114): FRAX®-incorporated GFRFs and increased cumulative 
 6 
protease inhibitor exposure (but no other HIV disease-specific factor) were 
significant independent determinants of reduced BMD. Non-classical 
monocytes were also associated with reduced BMD. There was a significant 
negative correlation between FRAX® scores and BMD in black patients 
(p=0.003 for lumbar spine and total hip) and between FRAX® hip scores and 
total hip BMD in white patients (p=0.030). Total hip BMD differed significantly 
between patients with low FRAX® hip scores (0.999 ± .113 g cm-2) and high 
FRAX® hip scores (0.882 ± .136g cm-2) (p<0.001).  
 
Conclusions 
 
FRAX®-incorporated GFRFs were the predominant determinants of reduced 
BMD.  FRAX® correlated well with BMD and may be of value for fracture risk 
assessment in specific HIV-positive patient subgroups. 
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year probability of major osteoporotic and hip fracture  
calculated with femoral neck BMD in white British and  
Irish patients within the Phase Two study population  
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List of abbreviations 
 
25-OH-D  25-hydroxyvitamin D 
AIDS   acquired immune deficiency syndrome 
ALP   alkaline phosphatase 
ART   antiretroviral therapy 
ARV   antiretroviral 
AZT   zidovudine 
β-hCG  β-human chorionic gonadotrophin 
BHIVA  British HIV Association 
BMD   bone mineral density 
BMI   body mass index 
BSA   bovine serum albumin 
CD4 cell count CD3+/CD4+ cell count  
CD4 %  CD3+/CD4+ cell percentage of all CD3+ cells  
CD4:CD8  CD3+/CD4+ cell to CD3+/CD8+ cell ratio 
CD8 cell count CD3+/CD8+ cell count 
CD8 %  CD3+/CD8+ cell percentage of all CD3+ cells  
COPD   chronic obstructive pulmonary disease 
CTx   C-terminal telopeptide of collagen type 1 
DF   disoproxil fumarate 
DXA   dual-energy X-ray absorptiometry 
EACS   European AIDS Clinical Society 
eGFR   estimated glomerular filtration rate 
ERK   extracellular signal-regulated kinase 
Gnas   guanine nucleotide-binding protein alpha stimulating 
Got   glutamate oxaloacetate transaminase 
HBV   hepatitis B virus 
HCV   hepatitis C virus 
HIV   human immunodeficiency virus 
hs-CRP  highly sensitive CRP 
IBD   inflammatory bowel disease 
IKK   I kappa B kinase 
IFN-γ   interferon-γ 
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IGF-1   insulin-like growth factor 
IL-4   interleukin-4 
IL-6   interleukin-6 
IL-8   interleukin-8 
INI   integrase inhibitor 
IRIS   immune reconstitution inflammatory syndrome 
JNK-1   c-Jun NH2-terminal kinase-1 
MAPK   mitogen-activated protein kinase 
MCP-1  monocyte chemoattractant protein-1 
M-CSF  macrophage colony stimulating factor 
MIP-1   macrophage inflammation protein-1 
MSM   men who have sex with men 
NICM   non-infectious co-morbidity 
NFATc1  nuclear factor of activated T-cells, cytoplasmic 1 
NF-ĸB   nuclear factor kappa B 
NNRTI  non-nucleoside reverse transcriptase inhibitor 
NOGG  National Orthopaedic Guideline Group 
NRTI   nucleoside/nucleotide reverse transcriptase inhibitor 
OPG   osteoprotegerin 
P1NP   procollagen type 1 N-terminal propeptide 
PBMC   peripheral blood mononuclear cell 
PBS   phosphate buffered saline 
PCP   pneumocystis jiroveci pneumonia 
PCR   polymerase chain reaction 
PI   protease inhibitor   
PI-3K   phosphoinositide-3-kinase 
PLWH   people living with HIV 
PPI   proton pump inhibitor 
PRTD   proximal renal tubular dysfunction 
PTH   parathyroid hormone 
RANK   receptor of activated NF-ĸB 
RANKL  receptor of activated NF-ĸB ligand 
ROS   reactive oxygen species 
RUNX-2  runt-related transcription factor-2 
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s.d.   standard deviation 
Snord 32A  small nucleolar RNA C/D box 32A 
SOD   superoxide dismutase 
SSRI   selective serotonin reuptake inhibitor 
STH   Sheffield Teaching Hospitals NHS Foundation Trust 
TAF   tenofovir alafenamide 
TIMP-3  tissue inhibitor of metalloproteinase-3 
TNF-α   tumour necrosis factor-α  
TRAIL   TNF-related apoptosis-inducing ligand 
TRAF   TNF receptor associated factor 
TRAP   tartrate-resistant acid phosphatase 
TRP   tubular reabsorption of phosphate 
uRBP   urinary retinal binding protein 
VFA   vertebral fracture risk assessment 
VpR   viral protein R 
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1. Introduction 
 
There have been dramatic advances in the management of HIV infection over 
the past few decades, such that the long term outlook for a person diagnosed 
with HIV today differs significantly to that of a person diagnosed with HIV in 
the 1980s or early 1990s. 
 
In the 1980s, in the absence of any effective treatment, a new diagnosis of 
HIV infection was, for the majority of patients, a terminal diagnosis. Patients 
almost inevitably developed severe immunodeficiency – Acquired Immune 
Deficiency Syndrome (AIDS) – and ultimately died from opportunistic 
infections, such as pneumocystic jirvocei pneumonia (PCP), or from AIDS-
associated malignancies, such as Kaposi’s sarcoma.  
 
Over the past few decades, mortality in people living with HIV (PLWH) has, 
however, declined dramatically (UNAIDS/WHO 2017). This was initially as a 
result of improved prophylaxis and treatment of opportunistic infections, but 
was considerably accelerated with the introduction of effective combination 
antiretroviral therapy (ART) in the mid-1990s (Palella et al. 1998).  
 
ART has improved significantly in terms of its efficacy and toxicity since its 
introduction in the mid-1990s. A patient established on ART in the mid-1990s 
could expect to have to take multiple antiretroviral (ARV) tablets multiple times 
a day, with associated significant gastrointestinal and other side effects and a 
high risk of developing longer term ART-related toxicity, including 
lipodystrophy. ART was also then only commenced in patients with a low CD4 
cell count, initially below 200 cells μL-1, leaving patients not on ART with an 
unsuppressed HIV viraemia. On account of ARV-related toxicity and pill-
burden, it was less easy for PLWH to adhere to taking their ART fully and 
missed doses resulted in a higher likelihood of HIV resistance development 
and HIV virological failure. PLWH were commonly switched to alternative ART 
regimens on account of toxicity and/or resistance. In contrast, a person 
diagnosed with HIV in the UK today is established on ART immediately, 
irrespective of CD4 cell count, with a much shorter period of unsuppressed 
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HIV viraemia. Furthermore, ART regimens currently available are more 
efficacious, with a higher barrier to the development of HIV resistance, have 
significantly less day to day side effects and are, more often than not, once 
daily regimens compromising as little as one or two tablets taken once daily, 
significantly improving adherence and the likelihood of achieving good HIV 
control. 
 
In the era of effective and more widely available ART and a markedly reduced 
incidence of opportunistic infections, PLWH now have significantly improved 
life expectancies (Nakagawa et al. 2012). In the UK, PLWH should now 
expect to have a normal life expectancy, similar to HIV-negative people, 
providing that they are diagnosed in good time, established on ART and have 
and undetectable HIV viral load and a good CD4 cell count (May et al. 2014).  
 
It has become evident that a spectrum of non-infectious co-morbidities 
(NICMs) – complications less related to extremes of immunosuppression but 
instead associated with inflammatory changes and accelerated ageing and 
more prevalent in PLWH than in the general population  – can also cause 
significant morbidity and mortality in PLWH (Guaraldi et al. 2011). Reduced 
bone mineral density (BMD) has emerged as one of these NICMs (Amorosa 
and Tebas 2006) and there is concern that, as PLWH age, they will 
experience a higher incidence of fragility fractures and related morbidity and 
mortality. The surveillance and treatment of NICMs, including reduced BMD 
and fragility fractures, will increasingly be a focus of HIV care as the HIV-
positive population ages. 
 
This introduction discusses the evidence linking reduced BMD and fragility 
fractures to HIV infection and ART, with an emphasis on the extent of the 
problem, the risk factors, the pathogenic mechanisms and risk assessment. 
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1.1 The extent of the problem 
 
1.1.1 Prevalence 
 
Cross-sectional studies have consistently demonstrated a significantly higher 
prevalence of reduced BMD in PLWH when compared to age-, race- and sex-
matched HIV-negative controls (Table 1.1) (Tebas et al. 2000; Carr et al. 
2001; Knobel et al. 2001; Moore et al. 2001; Nolan et al. 2001; Loiseau-Peres 
et al. 2002; Bruera et al. 2003; Fernandez-Rivera et al. 2003; Mondy et al. 
2003; Teichmann et al. 2003; Vescini et al. 2003; Amiel et al. 2004; Brown et 
al. 2004; Dolan et al. 2004; Madeddu et al. 2004; Konishi et al. 2005; Yin et al. 
2005; Arnsten et al. 2006; Bolland et al. 2006; Fausto et al. 2006; Garcia 
Aparicio et al. 2006; Arnsten et al. 2007; Cazanave et al. 2008; Jones et al. 
2008; Calmy et al. 2009; Teichman et al. 2009; Libois et al. 2010; Grijsen et 
al. 2013; Negredo et al. 2014). The prevalence of reduced BMD in PLWH – 
defined as a T-score < -1.0 when measured by Dual-Energy X-ray 
Absorptiometry (DXA) measurements at the lumbar spine, total hip or both – 
has varied widely between published cohorts, ranging from 21.2% (Grijsen et 
al. 2013) to 87.5% (Knobel et al. 2001). There is large heterogeneity between 
these cohorts, however, with respect to patient gender, race, age and body 
mass index (BMI), and the nature of the HIV-negative control groups, 
amongst other factors (Goh et al. 2018). 
 
One meta-analysis of pooled prevalence data from eleven cross-sectional 
studies published prior to 2006 demonstrated an overall prevalence of 67% 
reduced BMD and 15% osteoporosis (T-score ≤ -2.5) in 884 HIV-positive 
patients (67% male, predominantly white race, mean age 39.6 years, mean 
BMI 24.1 kg m-2) when compared to 654 HIV-negative age and sex-matched 
controls, with odds ratios of 6.4 (95% CI 3.7, 11.3) and 3.7 (95% CI 2.3, 5.9) 
for reduced BMD and osteoporosis respectively (Brown and Qaqish 2006). A 
more recent meta-analysis of 29 studies (Goh et al. 2018), which included 
four studies that included predominantly black HIV-positive patients (Arnsten 
et al. 2006, Arnsten et al. 2007, Jones et al. 2008, Libois et al. 2010), also 
demonstrated a significantly higher prevalence of reduced BMD in PLWH 
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compared to matched HIV-negative controls, albeit with slightly lower odds 
ratios of 2.4 (95% CI 2.0, 3.8) for lumbar spine BMD and 3.4 (95% CI 2.2, 3.8) 
for total hip BMD.  
 
 
1.1.2 Fracture prevalence and incidence 
 
There is growing evidence in support of a higher incidence of all fractures and 
fragility fractures (defined as a fracture occurring in adult life either 
spontaneously, or arising from trauma which, in a healthy individual, would not 
have resulted in a fracture, i.e. from a fall of standing height or less) in PLWH 
compared with the general population.  Whilst early cross-sectional studies 
reported a very low or even zero incidence of any fracture after HIV diagnosis, 
based on retrospective self-reporting (Carr et al. 2001; Loiseau-Peres et al. 
2002; Teichmann et al. 2003), subsequent larger studies have reported an 
increased fracture rate in PLWH compared to HIV-negative controls (Triant et 
al. 2008, Young et al. 2011 and Hansen et al. 2012). A meta-analysis of 
thirteen studies has reported a modest increase in fracture incidence overall 
in PLWH compared with HIV-negative controls, with pooled incidence rate 
ratios of 1.58 (95% CI 1.25, 2.00) and 1.35 (95% CI 1.10, 1.65) for all 
fractures and for fragility fractures respectively (Shiau et al. 2013). 
 
One population-based study, conducted in a large US-based healthcare 
system, collected data on all vertebral, hip and wrist fractures, identified from 
a patient database using ICM-9-CM codes, occurring in patients attending 
both inpatient and outpatient healthcare settings over 54 months. 8,525 HIV-
positive patients were compared to 2,208,792 HIV-negative individuals in 
groups matched by age (by decade) and ethnicity (Triant et al. 2008). In 
nearly all age and ethnicity groups, there was a significantly greater fracture 
prevalence (approximately 1.5 to 2-fold) in HIV-positive individuals. Of 
interest, the extent of the difference in all fracture prevalence between the 
HIV-positive and -negative groups progressively increased with each 
successive decade of age, in men after the age of 40 years and in women 
between 50 and 70 years, suggesting that fracture susceptibility may increase 
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as the HIV population ages. Similarly, a more recent cohort study, comparing 
HIV-positive male patients to age- and sex-matched HIV-negative controls, 
identified no significant difference in fracture incidence by HIV status between 
men aged 40 to 49 years old, but a significantly higher incidence of all 
fractures and fragility fractures in HIV-positive men aged 50 to 59 years old 
compared to HIV-negative men of the same age – adjusted incidence rate 
ratios of 2.06 (95% CI 1.49, 2.84) and 2.06 (95% CI 1.21, 3.50) for all 
fractures and for fragility fractures respectively (Gonciulea et al. 2017).  
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Study reference 
Location 
HIV-positive patients HIV-negative controls 
First author Year n 
% 
male 
Mean 
age 
years 
% on 
ART 
% 
reduced 
BMD 
% 
osteo-
paenia 
% 
osteo-
porosis 
n 
% 
reduced 
BMD 
% 
osteo-
paenia 
% 
osteo-
porosis 
Tebas et al. 2000 USA 95 100 - - 40.0 - - 17 29.0 - - 
Carr et al.  2001 Australia 222 100 43.0 85.6 51.0 22.0 3.0 n/a - - - 
Knobel et al. 2001 Spain 80 73 41.0 67.5 87.5 67.5 21.2 100 30.0 25.0 5.0 
Moore et al. 2001 UK 105 71 40.0a 86.0 71.0 58.0 13.0 n/a - - - 
Nolan et al.  2001 Australia 183 100 - 84.7 54.1 38.8 15.3 n/a - - - 
Loiseau-Peres et al. 2002 France 47 66 41.5 - 68.1 59.6 8.5 47 34.0 31.9 2.1 
Bruera et al. 2003 Argentina 111 89 34.3 70.2 73.0b 57.7b 15.3b 31 15.4b 15.4b 0.0b 
Fernandez-Rivera et al. 2003 Spain 89 71 37.0a 87.6 43.0 42.0 1.0 n/a - - - 
Mondy et al. 2003 USA 125 86 41.5 - 45.6 - - n/a - - - 
Teichmann et al. 2003 Germany 50 0 37.4 0.0 76.0d 62.0d 14.0d 50 4.0d 4.0d 0.0d 
Vescini et al. 2003 Italy 70 49 41.0 94.3 48.6 40.0 8.6 n/a - - - 
Amiel et al. 2004 France 148 100 41.5 67.6 82.0 66.0 16.0 81 36.0 32.0 4.0 
Brown et al. 2004 USA 51 85 40.1 100.0 62.7 54.9 7.8 22 31.8 31.8 0.0 
Dolan et al. 2004 USA 84 0 41.0 81.0 64.0 54.0 10.0 63 35.0 30.0 5.0 
 
a Median values  b  Femoral neck  c  Total hip       d  Lumbar spine 
 
Table 1.1. Summary of cross-sectional studies reporting prevalence of reduced BMD in HIV-positive patients compared 
with HIV-negative controls (continued on next page)  
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Study reference 
Location 
HIV-positive patients HIV-negative controls 
First author Year n 
% 
male 
Mean 
age 
years 
% on 
ART 
% 
reduced 
BMD 
% 
osteo-
paenia 
% 
osteo-
porosis 
n 
% 
reduced 
BMD 
% 
osteo-
paenia 
% 
osteo-
porosis 
Madeddu et al.  2004 Italy 172 65 38.5 88.4 59.3 44.8 14.5 64 7.8 7.8 0.0 
Konishi et al. 2005 Japan 39 100 41.4 79.5 25.7 23.1 2.6 n/a - - - 
Yin et al. 2005 USA 31 0 56.0 - 77.4 67.4 10.0c 186 56.0 55.0 1.0c 
Arnsten et al. 2006 USA 263 0 44.0 - 27.0 - - 232 19.0 - - 
Bolland et al.  2006 New Zealand 59 100 50.1 - 32.2 28.8 3.4 118 22.0 21.2 0.8 
Fausto et al. 2006 Italy 161 64 38.6 70.2 49.7 - - n/a - - - 
Garcia Aparicio et al. 2006 Spain 30 100 41.0 56.7 57.0 - - n/a - - - 
Arnsten et al.  2007 USA 328 100 54.7 - 55.0 - - 231 51.0 - - 
Cazanave et al. 2008 France 492 73 43.0a 93.1 80.5 53.7 26.8 n/a - - - 
Jones et al. 2008 USA 57 60 61.0 - 67.0d 39.0d 28.0d 47 39.0d 26.0d 13.0d 
Calmy et al. 2009 Australia 153 99 48.0a 100.0 42.0 36.0 4.0 n/a - - - 
Teichmann et al.  2009 Germany 80 100 - - 35.0 35.0 0.0 20 0.0 0.0 0.0 
Grijsen et al.  2013 Netherlands 147 100 - - 21.2 - - 30 13.0 - - 
Negredo et al. 2014 Spain 232 79 28.0a - 67.3 56.5 10.7 75 54.7 50.7 4.0 
 
a Median values  b  Femoral neck  c  Total hip       d  Lumbar spine 
 
Table 1.1. (continued from previous page)
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1.2 Risk factors for reduced BMD in HIV infection 
 
1.2.1 General risk factors 
 
Validated risk factors for reduced BMD and fragility fracture are well 
established for the general population (Kanis et al. 2005). In addition to 
previous fragility fracture and low BMD at the femoral neck, these include: 
increasing age; low BMI; parental history of hip fracture; glucocorticoid 
exposure; rheumatoid arthritis; current smoking; alcohol consumption ≥ 3 
units per day; hypogonadism, including post-menopausal status in women; 
prolonged immobility; malabsorption and liver cirrhosis (Kanis et al. 2005). In 
addition, other well reported associations exist, including vitamin D deficiency, 
opiate (Pedrazzoni et al. 1993) and other substance dependence (Whyte et 
al. 2009) and the use of selective serotonin uptake inhibitor (SSRI) 
antidepressants (Haney et al. 2010).  Multiple studies show that many of 
these risk factors are increased in HIV-positive populations, such as rates of 
smoking (Fuster et al. 2009; Levine et al. 2010), opiate use (Cooper et al. 
2003) and depression requiring SSRI treatment (Pence et al. 2006). Alcohol 
and other substance misuse are associated with high-risk sexual intercourse 
and consequently increased HIV incidence, particularly amongst men who 
have sex with men (MSM) (Mimiaga et al. 2008; Shuper et al. 2010). Patients 
presenting late in their illness with AIDS usually have a low BMI (Maas et al. 
1998). Immune reconstitution inflammatory syndrome (IRIS) may require 
prolonged courses of glucocorticoid therapy (Meintjes et al. 2008), as may 
treatment of HIV-associated malignancies (Weiss et al. 2006). Chronic 
diarrhoea resulting in malabsorption and nutritional deficiency can occur 
secondary to opportunistic infections or HIV directly. Androgen deficiency was 
common in the pre-ART era in men presenting with AIDS-associated wasting 
(Dobs et al. 1996) and is still seen in HIV-infected men on ART presenting 
with weight loss (Rietschel et al. 2000).  
 
Vitamin D deficiency (25-hydroxyvitamin D (25-OH-D) <50 nmol l-1) is highly 
prevalent in PLWH, with reported prevalence ranging from 38% (Manion et al. 
2017) to 89% (Cervero et al. 2018). There are conflicting reports as to 
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whether vitamin D deficiency is more prevalent in PLWH than in the general 
population, however (Sherwood et al. 2012, Hidron et al. 2015). Whilst the key 
determinants of vitamin D deficiency in PLWH are the same as for the general 
population, including black race (Welz et al. 2010, Sherwood et al. 2012) and 
reduced sunlight exposure (Paul et al. 2010, Welz et al. 2010), HIV disease-
specific determinants of vitamin D have also been identified: these include 
nadir CD4 cell count less than 200 cells μl-1 and cumulative exposure to the 
non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (Welz et al. 
2010, Wohl et al. 2014). Whether or not vitamin D deficiency contributes to 
the increased prevalence of reduced BMD in PLWH remains unclear: one 
South African study has reported a significant correlation between lower 25-
OH-D levels and total hip BMD (Dave et al. 2015), whereas other studies have 
not observed any significant association (Sherwood et al. 2012, Cotter et al. 
2014).  
 
Considering the high prevalence of the above general risk factors in PLWH, it 
could be argued that the increased prevalence of reduced BMD in PLWH is 
unsurprising. Certainly low BMI (Nolan et al. 2001; Mondy et al. 2003; Dolan 
et al. 2004; Fausto et al. 2006; Cazanave et al. 2008; Brown et al. 2009; Yin 
et al. 2012) and low weight before starting ART (Carr et al. 2001), increasing 
age (Fausto et al. 2006; Cazanave et al. 2008), non-black race ( Brown et al. 
2009), steroid use (Mondy et al. 2003), smoking (Mondy et al. 2003; Dolan et 
al. 2006), low testosterone in men (Calmy et al. 2009), post-menopausal state 
(Yin et al. 2012), hepatitis B or C co-infection (Lo Re et al. 2009; Sharma et al. 
2010), heroin (Sharma et al. 2010) and methadone use (Sharma et al. 2011) 
have all been reported, using multivariate logistic regression models, to be 
independent risk factors for decreased BMD or increased fragility fractures in 
PLWH. 
 
The majority of comparative cross-sectional studies, however, have compared 
HIV-positive individuals to age-, sex-, ethnicity-, BMI- and, for females, 
menopausal state-matched HIV-negative controls and have still identified a 
significant decrease in BMD in PLWH, suggesting the existence of 
independent HIV disease-specific and potentially also ART-associated factors 
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in the pathogenesis of decreased BMD in PLWH. It is very challenging, 
however, to separate HIV disease-specific factors from the confounding effect 
of general risk factors, which are over-represented in the HIV-positive 
population.  
 
 
1.2.2 HIV disease-specific risk factors 
 
1.2.2.1 Evidence supporting an independent role of HIV infection 
 
As well as establishing the contribution of general osteoporosis risk factors 
within the HIV-positive population, cross-sectional and longitudinal studies 
have also related changes in BMD to HIV disease-specific factors, for 
example duration of HIV infection, HIV viral load and CD4 cell count, to 
determine whether these represent independent risk factors for reduced BMD 
in PLWH and consequently whether HIV infection is a risk factor for reduced 
BMD in its own right. 
 
The extent of the rise in CD4 cell count was directly proportional to the BMD 
increase at the lumbar spine in one longitudinal study of patients on ART, with 
no significant relationship between BMD and weight or fat change, suggesting 
a negative effect of HIV on BMD and a potentially beneficial role for ART 
(Dolan et al. 2006). The BMD increase in this study was also independently 
associated with having an undetectable HIV viral load. In support of this 
finding, a high HIV viral load at the time of DXA correlated positively with 
reduced BMD in one cross-sectional study (Fausto et al. 2006), although 
neither high HIV viral load nor low CD4 cell count were associated with 
reduced BMD in other studies (Knobel et al. 2001; Moore et al. 2001; 
Teichmann et al. 2003; Yin et al. 2010). The relationship with ART is complex, 
however, with a low or undetectable HIV viral load – perhaps a surrogate 
marker for patients taking ART – being identified as an independent risk factor 
for reduced BMD in two other studies (Mondy et al. 2003; Cazanave et al. 
2008).  
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A low nadir CD4 cell count has been shown to be an independent risk factor 
for both reduced BMD and increased fracture incidence after adjustment for 
BMI (Moore et al. 2001; Cazanave et al. 2008; Brown et al. 2009; Dao et al. 
2010; Young et al. 2011). Nadir CD4 cell count could act as a surrogate 
marker for the duration of HIV infection, which is usually difficult to accurately 
determine as it often has little relationship with the date of HIV diagnosis. 
Despite this, time from date of HIV diagnosis and, by implication, prolonged 
exposure to unsuppressed HIV was also found to be an independent risk 
factor for loss of BMD in three studies (Bruera et al. 2003; Mondy et al. 2003; 
Dolan et al. 2006). Nevertheless, duration from diagnosis could also act as a 
surrogate for the length of ART exposure. It could equally be argued that low 
nadir CD4 count acts merely as a marker for other established risk factors for 
decreased BMD, such as low BMI, immobility or chronic diarrhoea. 
 
 
1.2.2.2 How HIV-1 infection might directly influence bone turnover 
 
Osteoblast and osteoclast function is influenced by a number of factors 
modulated during HIV-1 infection, including pro-inflammatory cytokines such 
as tumour necrosis factor-α (TNF-α), expression of RANKL (receptor of 
activated NF-κB ligand) and osteoprotegerin (OPG), vitamin D and calcium 
metabolism and hormone levels (Amorosa and Tebas 2006; Pan et al. 
2006a). Although there is not convincing evidence that osteoblasts or 
osteoclasts are directly infected, their function may be modulated by a variety 
of HIV proteins (see below). The HIV envelope glycoprotein, gp 120, can 
induce TNF-α dependent apoptosis of osteoblast cell lines or primary cells 
(Gibellini et al. 2008). Conversely, a different in vitro study showed no 
evidence that gp120 induced osteoblast apoptosis, but instead increased 
osteoblast proliferation, which was inhibited by inhibition of the gp120 
receptor, CXCR4 (Cummins et al. 2011). The difference in the findings of 
these two studies may be explained by relative differences in osteoblast cell 
surface expression of CXCR4 – relatively low surface expression in the study 
by Gibellini et al. (2008) and relatively high in the study by Cummins et al. 
(2011). gp120 may also increase osteoblast alkaline phosphatase (ALP) 
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activity and cell proliferation and decrease cellular apoptosis via Wnt/β-
catenin signalling (Butler et al. 2013).   
 
Inflammatory conditions modify bone metabolism, including a variety of 
factors released by T cells and macrophages such as TNF-α, interferon-γ 
(IFN-γ), interleukin-4 (IL-4), macrophage inflammation protein-1 (MIP-1) and 
RANKL (Pan et al. 2006b). Markers of bone resorption in advanced HIV 
infection correlate with TNF-α levels (Aukrust et al. 1999). During HIV 
infection, the cytokine profile favours TNF-α expression and increased viral 
replication, whilst there is a shift towards a TH2 cytokine balance, with 
decreased production of IFN-γ (Clerici and Shearer 1993). This leads to less 
IFN-γ-induced downregulation of RANKL (Takayanagi et al. 2000) and, in 
turn, increased binding of RANKL to RANK, which is expressed on the 
surface of preosteoclasts; increased RANKL-RANK binding subsequently 
results in increased osteoclast activity and bone resorption (Wei et al. 2005).  
 
OPG acts as decoy receptor, binding to RANKL and preventing RANKL-
RANK binding and osteoclast activation (Theoleyre et al. 2004). A number of 
studies suggest HIV proteins can shift the OPG/RANKL ratio in favour of 
RANKL-mediated osteoclastic activation (Gibellini et al. 2007). HIV Vpr (viral 
protein R), a factor needed for viral replication, being required for the nuclear 
import of the HIV-1 pre-integration complex, upregulates RANKL, potentiating 
glucocorticoid-induced stimulation of RANKL (Fakruddin and Laurence 2005). 
gp120 also stimulates RANKL (Fakruddin and Laurence 2003). ARV-naïve 
HIV-positive patients have increased serum RANKL levels and reduced 
OPG/RANKL ratios, which correlate with the HIV viral load and the Z-score 
obtained by densitometry (Gibellini et al. 2007). RANKL is not only produced 
by osteoblasts but also activated T cells, which represent a likely source of 
enhanced RANKL expression in light of their increased numbers during HIV 
infection (Kong et al. 2000).  
 
Although the natural inhibitor of RANKL, OPG, is also enhanced in the serum 
of ART-naïve patients (Gibellini et al. 2007), increased binding of OPG to 
another factor upregulated by HIV, TNF-related apoptosis-inducing ligand 
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(TRAIL), in preference to RANKL, limits its availability to inhibit osteoclast 
activation by RANKL (Yang et al. 2003; Herbeuval et al. 2005). RANK 
(receptor of activated NF-ĸB) signalling via tumour necrosis factor receptor-
associated factor 6 (TRAF-6) facilitates nuclear factor kappa B (NF-ĸB) 
activation and phosphorylates (activates) c-Jun NH2-terminal kinase (JNK) 1 
and Akt facilitating osteoclastogenesis (Wong et al. 1999; Srivastava et al. 
2001). gp120 may also stimulate RANKL via activation of extracellular signal-
regulated kinase (ERK) signalling (Fakruddin and Laurence 2003). The HIV-1 
Tat protein has also been shown to enhance RANKL/macrophage colony 
stimulating factor (M-CSF)-induced osteoclast differentiation by increasing 
mRNA expression of specific osteoclast differentiation markers (Gibellini et al. 
2010). Nevertheless, the specific RANK signalling events activated by HIV-1 
are still being delineated.  
 
RANKL appears to limit the susceptibility of mitochondria to oxidative stress 
induced dysfunction in response to nucleos(t)ide reverse transcriptase 
inhibitors (NRTIs) by mechanisms that do not involve alterations in levels of 
mitochondrial superoxide dismutase (SOD) (Pan et al. 2006). Whilst these 
observations have been made in macrophage cell lines, if replicated in 
osteoclasts, they suggest that a potential mechanism of enhanced 
osteoclastogenesis in response to RANKL could therefore be maintenance of 
mitochondrial metabolism, despite increasing cell stress, and therefore 
maintenance of osteoclast viability and prevention of apoptotic death, in 
contrast to the TNF-α dependent apoptosis triggered by HIV in osteoblasts 
(Gibellini et al. 2008). HIV proteins gp120 and the gag structural protein p55 
suppress osteoblast activity in cell lines with upregulation of runt-related 
transcription factor-2 (RUNX-2) and decreased release of RANKL (Cotter et 
al. 2007). p55 also suppresses osteoblast differentiation from mesenchymal 
stem cells (Cotter et al. 2007). The mechanisms by which HIV-1 infection 
might directly or indirectly influence bone turnover are summarised in Figures 
1.1a and 1.1b. 
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Figures 1.1a and 1.1b. Mechanisms by which HIV-1 infection might directly or 
indirectly influence bone turnover. (1) HIV protein p55 suppresses osteoblast 
differentiation; (2) HIV envelope protein gp120 induces TNF-α dependent 
osteoblast apoptosis; (3) TNF-α upregulates RANKL; (4) decreased production of 
IFN-γ and decreased IFN-γ-mediated downregulation of RANKL; (5) HIV proteins 
gp120 and VpR upregulate RANKL; (6) increased numbers of activated T-cells in 
HIV infection;(7) pro-inflammatory cytokines upregulate osteoblast OPG 
secretion;(8) upregulation of TRAIL with increased OPG-TRAIL binding limiting 
RANKL-OPG binding; (9) decreased IFN-γ-mediated proteosomal degradation of 
TRAF-6; (10) TNF-α activates NF-κB signalling; and (11)  gp120 activates ERK 
signalling downstream of RANK-RANKL binding, enhancing osteoclast survival and 
differentiation. 
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1.2.3 Role of antiretroviral therapy 
 
It would seem logical that ART should stabilise BMD loss through suppression 
of HIV viraemia, immune recovery and a reduction in the immune activation 
and inflammation associated with increased bone turnover and BMD loss in 
PLWH (described in Section 1.2.2.2). Mixed conclusions from cross-sectional 
and longitudinal studies, however, suggest that the relationship between ART 
and BMD in PLWH is more complex. 
 
 
1.2.3.1 Cross-sectional data for and against a role for antiretroviral therapy 
 
An early meta-analysis of pooled data from ten cross-sectional studies 
conducted between 2000 and 2005 (Table 1.2), compared 824 ART-treated 
(experienced) patients with 202 ART-naїve patients and found a significant 
reduction in BMD in the ART-treated patients, odds ratio 2.5 (95% CI 1.8, 3,7) 
(Brown and Qaqish 2006). BMI was similar between ART-experienced and 
ART-naїve groups, with the exception of one study (Garcia Aparicio et al. 
2006), although there was no adjustment for other potentially important 
confounding factors such as patient age or duration of HIV infection.  
 
Further analyses have examined individual classes of ARVs (individual ARVs 
are listed by drug class in Table 1.3). Pooled meta-analysis of 14 studies 
demonstrated significantly lower BMD in protease inhibitor (PI)-treated 
patients (n = 791), odds ratio 1.5 (95% CI 1.1, 2.0), compared with non-PI-
treated patients (n = 410) (Brown and Qaqish 2006). An Australian cross-
sectional study of 153 predominantly male HIV-positive patients also identified 
boosted PI use (median duration 51 months) as an independent risk factor for 
reduced BMD (Calmy et al. 2009). The same study observed an association 
between the use of tenofovir disoproxil fumarate (DF) and increased bone 
turnover, but with no significant association between tenofovir DF use 
(median duration 28 months) and BMD. A more recent, albeit smaller, 
Spanish cross-sectional study identified the combined use of a boosted PI 
with tenofovir DF as an independent risk factor for reduced BMD in HIV-
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positive patients (Cervero et al. 2018); the same study also identified a history 
of tenofovir DF use, but not PI use, as a separate risk factor.  
 
PI-naїve patients on NNRTI-containing ART did not have an increased risk of 
reduced BMD when compared to ART-naïve patients (Bongiovanni et al. 
2006).  
 
Three large retrospective analyses have explored the relationship between 
ART exposure and fracture risk. Only one identified an increased risk of 
fragility fracture with cumulative exposure to ARVs on multivariate analysis 
and specifically only with cumulative exposure to tenofovir DF or to the 
ritonavir-boosted PI lopinavir (Bedimo et al. 2012); another, however, found 
no association between tenofovir DF exposure and fracture incidence, 
(Gedmintas et al. 2017). Furthermore, one study actually identified a reduced 
fracture risk in ART-treated HIV-positive patients compared to those not on 
treatment (Mundy et al. 2012). 
 
 
 
 
 
Table 1.3. Antiretroviral drugs listed by drug class (NRTIs = 
nucleos(t)ide reverse transcriptase inhibitors; NNRTIs = non-nucleoside 
reverse transcriptase inhibitors; PIs = protease inhibitors) 
NRTIs NNRTIs PIs Newer drug classes 
Abacavir 
Didanosine 
Emtricitabine 
Lamivudine 
Stavudine 
Tenofovir disoproxil 
fumarate (TDF) 
Tenofovir 
alafenamide (TAF) 
Zidovudine 
Efavirenz 
Etravirine 
Nevirapine 
Rilpivirine 
Amprenavir 
Atazanavir 
Darunavir 
Fosamprenavir 
Indinavir 
Lopinavir/ritonavir 
Nelfinavir 
Ritonavir 
Saquinavir 
Tipranavir 
Chemokine receptor 
antagonists 
Maraviroc 
Entry inhibitors 
Enfuvirtide (T20) 
Integrase inhibitors 
Dolutegravir 
Elvitegravir/cobicistat 
Raltegravir 
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Study reference 
Location 
ART-experienced ART-naïve Comparative analysis 
First author Year n 
% reduced 
BMD 
n 
% reduced 
BMD 
Odds ratio 
(95% CI) 
p-value 
Carr et al. 2001 Australia 189 25 32 6 - NS 
Knobel et al. 2001 Spain 54 98 26 69 - NS 
Bruera et al. 2003 Argentina 78 69 33 55 - NS 
Fernandez-Rivera et al. 2003 Spain 78 44 11 27 - NS 
Vescini et al. 2003 Italy 66 74 4 50 - - 
Amiel et al. 2004 France 100 77 48 50 - NS 
Madeddu et al. 2004 Italy 152 63 20 35 - NS 
Fausto et al. 2006 Italy 113 51 48 46 
2.61 
(0.66,10.27) 
0.17 
Garcia Aparicio et al. 2006 Spain 17 53 13 62 - NS 
Cazanave et al. 2008 France 458 - 34 - 
0.28 
(0.06, 1.31) 
0.11 
Zuccotti et al. 2010 Italy 71 - 15 - - NS 
 
NS = not significant   
 
 
Table 1.2. Summary of cross-sectional studies comparing prevalence of reduced BMD in ART-naїve and in ART-treated 
HIV-positive patients (NS = not significant)
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1.2.3.2 Longitudinal data for and against a role for antiretroviral therapy 
 
Longitudinal studies examining the changes in BMD over time have been 
conducted in both HIV-positive patients well established on ART (ART-stable) 
and in patients who are ART-naїve.  
 
Studies conducted in ART-stable patients have confirmed lower baseline 
BMD in PLWH when compared to HIV-negative controls (Dolan et al. 2006; 
Yin et al. 2010). Over 2 to 2.5 years follow up, however, neither of these 
studies identified any significant difference in BMD decline between ART-
stable HIV-positive patients and HIV-negative controls. Moreover, a recent 
meta-analysis, pooling the results of six longitudinal studies, concluded that 
BMD was, in general, stable in ART-stable patients, when followed up for a 
minimum of 48 weeks (Bolland et al. 2011). 
 
Longitudinal studies in ART-naїve HIV-positive patients have shown a 
different picture, however. The Gilead 903 Study compared tenofovir DF with 
stavudine in combination with lamivudine and efavirenz in ART-naïve 
individuals (Gallant et al. 2004). This study identified an initial significant loss 
in BMD at 24 weeks at the lumbar spine and at 48 weeks at the total hip in 
both the tenofovir DF and the stavudine-treated groups, with significantly 
greater reduction at the lumbar spine in the tenofovir DF-treated group. 
Subsequently stabilisation of bone loss was observed in both groups, followed 
by partial recovery of BMD at the lumbar spine in both treatment groups, 
although BMD did not return to baseline over the 144 weeks of follow up. In 
the same study, BMD at the total hip remained static over time. The more 
recent ASSERT and ACTG A5224s studies also identified a similar pattern of 
BMD loss with subsequent stabilisation at both the total hip and lumbar spine 
in ART-naїve patients randomised to either tenofovir DF/emtricitabine-based 
ART or abacavir/lamivudine-based ART, with again greater initial BMD loss at 
both the total hip and lumbar spine in the tenofovir DF-treated group 
(Stellbrink et al. 2010; McComsey et al. 2011).  
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Greater initial BMD decline has also been observed following initiation of 
boosted PI-containing ART regimens when compared with PI-sparing NNRTI-
containing ART regimens (Duvivier et al. 2009, McComsey et al. 2011).  
 
A meta-analysis of longitudinal BMD measurements pooled from 37 studies of 
treatment-naїve patients starting ART has demonstrated this initial 
accelerated but short-term loss of BMD in the first one to two years following 
ART initiation as a generalised pattern (Bolland et al. 2011). Moreover, two 
studies comparing ART-naïve HIV-positive patients who immediately start 
ART with those who defer starting ART – the large multinational START trial 
(Hoy et al. 2017) and a smaller study in patients with primary HIV infection 
(Vlot et al. 2018) – both identified a significantly steeper decline in BMD loss 
in the immediate treatment groups compared to the deferred treatment 
groups.   
 
The same pattern of BMD loss seen in treatment-naїve patients initiating ART 
has also been observed in switch studies, in which patients already 
established on ART undergo an ART regimen change, again with more 
profound effects seen with tenofovir DF. One Australian study randomised 
357 HIV-positive individuals already on ART to change to either tenofovir 
DF/emtricitabine-based ART or abacavir/lamivudine-based ART (Martin et al. 
2009). At 96 weeks, there was a significant difference between the two 
treatment arms, with a significant net reduction in BMD at the total hip with 
tenofovir DF-emtricitabine at 48 and 96 weeks compared to a non-significant 
net increase in the abacavir-lamivudine group. These results were not 
adjusted for change in BMI, however, and a modest reduction in weight and 
lean mass was observed in the tenofovir DF-emtricitabine group.  
 
 
1.2.3.3 Trends in bone turnover markers before and after initiation of 
antiretroviral therapy 
 
The levels of bone turnover markers, including osteocalcin and procollagen 
type 1 N-terminal propeptide (P1NP) – both markers of bone formation – and 
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C-terminal telopeptide of collagen type 1 (CTx) – a sensitive marker of bone 
resorption – have also been measured in PLWH both before and after 
initiation of ART. 
 
In one US study of 52 white male patients, in whom HIV acquisition and 
seroconversion occurred under observation, ostoecalcin levels measured both 
before and after the time of HIV seroconversion were found to be significantly 
lower after seroconversion compared to before seroconversion, with no 
observed significant change in P1NP or CTx, suggesting an overall reduction 
in bone formation following HIV seroconversion (Slama et al .2017). This was 
consistent with another study that demonstrated that ART-naïve PLWH have 
lower level bone turnover markers, including P1NP and CTx, compared to 
HIV-negative age-, gender- and BMI-matched healthy controls (Zhang et al. 
2013). Furthermore, a Norwegian study of 73 ART-naïve HIV-positive patients 
observed markedly low osteocalcin levels, as well as increased CTx levels, in 
patients with more advanced HIV infection with high unsuppressed plasma 
HIV RNA and low CD4+ T cell counts (Aukrust et al.), supporting the notion 
that bone formation is reduced relative to bone resorption in the context of 
unsuppressed HIV infection. 
 
Following initiation of ART, however, the levels of bone turnover markers –
including both markers of bone formation and bone resorption – appear to 
increase. Increases in osteocalcin, P1NP, CTx and bone-specific ALP were 
observed in 26 male patients initiating ART during primary HIV infection, with 
significantly higher levels of bone turnover markers observed 24 weeks after 
ART initiation compared with 9 patients in whom ART was not initiated (Vlot et 
al. 2018). A similar trend of significant increases in osteocalcin, P1NP, CTx 
and bone-specific ALP after initiation of ART was observed in a large study of 
833 HIV-positive patients followed up for 144 weeks, with bone turnover 
marker levels peaking at 48 or 96 weeks following ART initiation and then 
stabilising (Tebas et al. 2015). Furthermore, the magnitude of bone turnover 
marker increase was greater in patients commencing tenofovir DF-containing 
ART than abacavir containing ART. Bone turnover markers have also been 
observed to be higher in patients established on PI-containing ART compared 
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with non-PI containing ART (Kinai et al. 2017). Switching patients from 
tenofovir DF-containing ART to non-tenofovir DF-containing ART has resulted 
in a reduction in levels of bone turnover markers in several large studies, with 
associated improvements in BMD measuerments (Bloch et al. 2014, Negredo 
et al. 2015, McComsey et al. 2018). 
 
 
1.2.3.4 How antiretroviral therapy might influence bone turnover 
 
The mechanisms by which ART might influence bone turnover remain 
unclear. Proposed mechanisms are summarised in Figures 1.2a, 1.2b and 
1.2c. 
 
Most information exists for the use of PIs, but results have been conflicting 
and the relevance of culture models incubated with PIs in vitro debated. The 
PIs nelfinavir and indinavir have been shown to decrease osteoblast activity in 
vitro (Malizia et al. 2007). Gene array experiments of primary osteoblasts 
suggest tissue inhibitor of metalloproteinase-3 (TIMP-3) is upregulated whilst 
siRNA inhibition of TIMP-3 reverses these effects, enhancing calcium 
deposition and production of ALP (Malizia et al. 2007).  A further study from 
the same group implicated upregulation of the pro-inflammatory cytokine 
genes monocyte chemoattractant protein (MCP)-1 and interleukin-8 (IL-8) in 
osteoblasts as a contributory factor (Malizia et al. 2007).  
 
Results with PIs are clouded by differences in responses to different agents; 
in one study nelfinavir and lopinavir reduced osteoblast activity and OPG 
secretion, whilst ritonavir, indinavir, saquinavir and nelfinavir, but not lopinavir 
or amprenavir induced osteoclast activity (Jain and Lenhard 2002). Despite 
these observations there is not clear cut evidence from clinical trials that PIs 
trigger bone demineralization (Amorosa and Tebas 2006). One potential 
explanation may be that ritonavir also appears to block RANK signalling, 
blocking recruitment of TRAF-6 recruitment to RANK-containing lipid rafts and 
inhibiting Akt signalling pathways that lead to NF-ĸB activation and 
oseoclastogenesis (Wang et al. 2004). Interestingly, ritonavir did not alter 
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signalling via other pathways downstream of RANK such as JNK-1 or ERK in 
this study and indinavir had no effect on osteoclastogenesis. The exact effects 
of PIs on RANK signalling is, however, complex since, at a lower dose than 
used in the prior study, ritonavir and, in addition, saquinavir reversed the 
physiological inhibition to RANK signalling provided by IFN-γ mediated 
proteasomal degradation of TRAF-6 and restored JNK1 activation (Fakruddin 
and Laurence 2003). Potentiation of signalling at these doses of PI might be 
relevant in the context of relatively preserved IFN-γ levels, as might appear 
early in disease or after some reversal of HIV-induced perturbation of cytokine 
bias by ART has reduced the HIV viral load. 
 
Microarray analysis suggested inhibition of osteoblast and enhancement of 
osteoclast function could involve changes in canononical Wnt signalling, with 
inhibition of β-catenin nuclear translocation, a proposed mechanism by which 
Wnt suppresses osteoclastic differentiation, contributing to the increased 
osteoclast activity (Modarresi et al. 2009) (Figures 1.2b and 1.2c). These 
array studies suggested ritonavir upregulates non-canonical Wnt proteins 5B 
and 7B, which antagonise canonical Wnt signalling and enhance 
ubiquitination (and hence degradation) of β-catenin with the overall effect of 
preventing the inhibitory effect of β-catenin on osteoclast differentiation. 
Ritonavir-mediated upregulation of Wnt proteins 5A and 5B in human and 
murine osteoclast precursors has since been demonstrated elsewhere 
(Santiago et al. 2012). Since canonical Wnt also facilitates osteoblast release 
of the soluble RANKL decoy OPG, the authors speculated that alterations in 
Wnt signalling could also effect osteoclast development by indirect effects on 
osteoblasts, but this remains to be tested directly. Ritonavir also upregulated 
the inhibitor of apoptosis Bcl-XL in this study. 
 
Although PIs may affect molecular pathways involved in homeostasis in vitro, 
the physiological consequences are not yet clear. One group in whom these 
changes may translate into alterations of measured BMD, however, may be 
children. HIV-positive children or adolescents receiving PI-containing ART 
had decreased OPG/RANKL ratios, as compared to HIV-negative controls, 
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which normalised after PI-therapy was switched to the NNRTI efavirenz (Mora 
et al. 2007). 
 
Zidovudine enhances RANKL-dependent osteoclastogenesis in cell lines and 
primary cells, as evidenced by increased expression of the tartrate-resistant 
acid phosphatase (TRAP) promoter and also osteoclastic activity and loss of 
BMD (Pan et al. 2004; Pan et al. 2006). As discussed above, RANKL could 
prevent reactive oxygen species (ROS) induced mitochondrial damage in the 
presence of NRTIs such as zidovudine, thus preventing osteoclast apoptosis 
(Pan et al. 2006). Some, but not other studies, have identified a link between 
nucleoside-induced impairment of osteoblast function and mitochondrial 
toxicity (Carr et al. 2001; Cossarizza and Moyle 2004). RANKL may prevent 
nucleoside analogue induced mitochondrial toxicity, explaining the lack of 
mitochondrial toxicity observed (Pan et al. 2006).  
 
There is currently relatively less information on the molecular mechanisms of 
tenofovir’s potential effects on bone homeostasis. Tenofovir alters the 
transcriptional profile of osteoblasts, altering genes involved in cell signalling, 
cell cycle and amino acid metabolism (Grigsby et al. 2010a). A recent gene 
array analysis of primary osteoclasts identified genes downregulated by 
tenofovir, including guanine nucleotide-binding protein alpha stimulating 
(Gnas), a G-protein receptor involved in mitogen-activated protein kinase 
(MAPK)/ERK signalling, whose loss of function has been associated with 
impaired osteoblast activity, and glutamate oxaloacetate transaminase (Got) 
2, a mitochondrial enzyme whose loss of function has also been linked to 
impaired bone homeostasis (Grigsby et al. 2010b). Although not further 
verified, a further gene downregulated in this study was small nucleolar RNA 
C/D box 32A (Snord 32A), a transcript implicated in gene expression, RNA 
processing and protein trafficking.  
 
The ability of tenofovir to induce either isolated renal phosphate wasting or a 
Fanconi-like syndrome with proximal renal tubular dysfunction (PRTD) has 
been reported in case reports in association with osteomalacia or reduced 
BMD (summarised by Fux et al. (Fux 2007)) and has led to speculation that 
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the BMD loss seen in association with tenofovir DF might be caused by renal 
phosphate wasting. The prevalence of PRTD in HIV-positive patients on 
tenofovir DF is reportedly rare, however (Woodward et al. 2009). Furthermore, 
bone abnormalities were reported in only 0.1% of 10,343 HIV-positive patients 
taking tenofovir DF in a four-year prospective study (Nelson et al. 2007), 
although subclinical bone abnormalities were not reported.  
There is little information on the mechanism by which other factors may 
influence bone turnover. Both PI- and non-PI -containing ART have been 
associated with impairment of vitamin D metabolism (Cozzolino et al. 2003; 
Gyllensten et al. 2006; Conesa-Botella et al. 2010). PIs may reduce 25α-
hydroxylase activity in hepatocyte and 1α-hydroxylase in monocyte cell lines 
(Cozzolino et al. 2003). Efavirenz may accelerate catabolism of 1,25-
hydroxyvitamin D3 through the upregulation of 25-hydroxyvitamin D3-24-
hydroxylase (CYP24) (Barrett et al. 2002; Gyllensten et al. 2006).  
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Figures 1.2a and 1.2b (above) and 1.2c (next page). Mechanisms by which 
antiretrovirals might influence bone turnover. (1) Nelfinavir and indinavir 
decrease osteoblast activity in vitro; (2) nelfinavir and lopinavir downregulate 
OPG secretion; (3) ritonavir, indinavir, saquinavir and nelfinavir induce 
osteoclast activity; (4) ritonavir prevents downstream RANK intracellular 
signalling by blocking TRAF-6 recruitment to RANK lipid rafts; (5) low dose 
ritonavir and saquinavir inhibit IFN-γ-mediated proteasomal degradation of 
TRAF-6 and (6) restore JNK-1 activation; (7) ritonavir inhibits Akt signalling; (8) 
ritonavir upregulates non-canonical Wnt proteins 5B and 7B, antagonising 
canonical Wnt signalling and inhibition of β-catenin ubiquitination and 
degradation, with decreased β-catenin-mediated OPG release in osteoblasts 
and (9) increased osteoclast differentiation; (10) tenofovir downregulates Gnas 
which alters MAPK/ERK signalling, impairing osteoblast activity. 
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1.2.3.4 Newer antiretrovirals and bone mineral density  
 
Patients on ART have historically received two NRTI drugs in combination 
with either a boosted PI or an NNRTI. In recent years, however, integrase 
inhibitors (INIs) – a newer class of ARVs – are being increasingly used 
alongside NRTIs in place of PIs or NNRTIs in patients newly starting or 
switching ART. Furthermore, the use of dual therapy and NRTI-sparing ART 
regimens is also increasing, as evidence in support of their efficacy and more 
favourable safety profile is emerging.  
 
Cobicistat-boosted elvitegravir – an INI – co-formulated with tenofovir 
DF/emtricitabine resulted in significantly less BMD loss at both 48 and 96 
weeks following ART initiation in ART-naïve patients compared with tenofovir 
DF/emtricitabine co-administered with ritonavir-boosted atazanavir (Rockstroh 
et al. 2013). Furthermore, raltegravir – another INI – resulted in significantly 
less BMD loss at 48 weeks following ART initiation in ART-naïve patients 
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compared with tenofovir DF/emtricitabine when each were combined with 
ritonavir-boosted darunavir (Bernadino et al. 2015).  
 
Even more recently, tenofovir alafenamide (TAF) – a new tenofovir pro-drug 
and alternative NRTI to tenofovir DF – has become available for clinical use. 
Phase 3 studies demonstrated significantly less BMD loss at 48 weeks and 96 
weeks following initiation of TAF-containing ART in ART-naïve HIV-positive 
patients compared with tenofovir DF-containing ART (Sax et al. 2015, Wohl et 
al. 2016). Whether or not use of TAF in place of tenofovir DF will result in 
reduced fragility fracture incidence over time, however, remains to be seen. 
 
 
1.3 Fracture risk assessment in PLWH 
 
PLWH have a higher prevalence of reduced BMD and a higher incidence of 
fragility fractures than the general population.  To date, however, there have 
been very few published studies on the use of osteoporosis risk or fracture 
risk assessment tools in this population. 
 
The WHO Collaborating Centre for Metabolic Bone Diseases in Sheffield has 
undertaken a comprehensive review and a number of meta-analyses of 
published risk factors within the general population.  The outcome of this 
work, the FRAX® tool (www.shef.ac.uk/FRAX) has been validated as an 
effective tool for predicting a patient’s fracture risk based upon their age, 
gender, BMI, menopausal status and other validated general osteoporosis risk 
factors, with or without BMD results at the femoral neck if available (Kanis et 
al. 2008a; Johansson et al. 2009; Kanis et al. 2009). The tool is valid for men 
and women aged 40 to 90 years and provides an estimate of an individual’s 
ten-year probability of major osteoporotic fracture (hip, clinical vertebral, wrist 
or proximal humerus) or hip fracture alone. The output of the tool has been 
coupled to a guideline from the National Osteoporosis Guideline Group in the 
UK (NOGG) to determine who should be considered for BMD assessment 
and/or therapy to reduce fracture risk (Kanis et al. 2008b; Compston et al. 
2009). Of note, the FRAX® tool is one of several well validated fracture risk 
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assessment calculators that are available, which also include the Garvan 
Institute Fracture Risk Calculator (Nguyen et al. 1993) and, for UK use only, 
the QFracture®-2016 risk calculator (Hippisley-Cox and Coupland 2012). 
 
British HIV Association (BHIVA) Guidelines recommend the use of FRAX® for 
fracture risk assessment in PLWH (BHIVA 2016). Guidelines published by the 
European AIDS Clinical Society (EACS) in 2017 also recommend FRAX® 
score calculation in HIV-positive patients aged 40 years or more, with the 
added recommendation that HIV infection is incorporated into FRAX® as a 
“secondary osteoporosis” risk factor (EACS 2017). As FRAX® does not 
incorporate HIV-disease specific risk factors, however, the appropriateness of 
its use in PLWH remains a subject of research.  
 
Only two studies have compared FRAX®-calculated 10-year probabilities of 
fragility fracture (estimated incidence) to observed 10-year fragility fracture 
incidence in PLWH (Yin et al. 2016, Yang et al. 2018). Each of these two US 
studies – one exclusively in older male patients and the other in female 
patients – concluded that FRAX® was less accurate at predicting observed 
10-year fragility fracture incidence in PLWH than in HIV-negative controls, 
particularly in older and higher risk patients. Furthermore, each study also 
observed that the sensitivity of FRAX® to predict observed fragility fracture 
incidence was improved in PLWH by incorporating HIV infection into FRAX® 
as a “secondary osteoporosis” risk factor. Of note, one of these was a 
retrospective study in which data on parental hip fracture and the presence of 
other “secondary osteoporosis” risk factors was not available and therefore 
not included in FRAX® calculations (Yin et al. 2016). In addition, there was a 
significantly higher prevalence of HCV co-infection – an additional fracture risk 
factor (Lo Re et al. 2012) also not incorporated into FRAX® – in the HIV-
positive men. Moreover, observed fragility fracture incidence was actually 
quite low. 
 
Where FRAX® is not used, screening with DXA is currently recommended for 
the following HIV-positive patient groups: post-menopausal women; men 
more than or equal to 50 years of age; individuals with a history of fragility 
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fracture; individuals with a high risk for falls; individuals with clinical 
hypogonadism; and those who have been on oral glucocorticoid treatment (at 
least 5 mg prednisolone or equivalent) for more than three months (EACS 
2017). DXA screening could also be considered in younger men with other 
risk factors, namely low BMI and/or nadir CD4 count <200 cells µL-1 (Mary-
Krause et al. 2012).  
 
 
1.4 Summary of current evidence 
 
The prevalence of reduced BMD and incidence of fragility fractures are 
increased in PLWH compared with HIV-negative controls. There are many 
potential explanations for this (Figure 1.3) – an increased prevalence of 
general osteoporosis risk factors in the HIV-positive population, a likely direct 
effect of HIV infection itself and, in addition, a possible contributory role of 
ART – with accelerated bone loss within the first one to two years following 
ART initiation or switch – with potential mechanisms identified for both HIV 
infection and ART. The interplay between these multiple factors and their 
relative contribution to reduced BMD and increased fracture risk in PLWH, 
however, remains unclear.  
 
At present there is no adequate risk assessment tool validated in the HIV-
positive population to help predict who is at risk of reduced BMD or fragility 
fracture and who may benefit from BMD assessment and preventative 
treatments.  
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Figure 1.3. Factors contributing to reduced BMD in people living with 
HIV over time compared with HIV-negative individuals (adapted from 
Mallon et al. 2010). (HAART = highly-active antiretroviral therapy)  
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1.5 Study hypotheses and aims  
 
Primary hypotheses: 
 
1. BMD in PLWH is determined by HIV disease-related risk factors – 
related to HIV infection or its treatment – as well as established general 
risk factors.  
 
2. 10-year probability of major osteoporotic fractures calculated using 
FRAX® (derived from general fracture risk factors alone) correlates 
poorly with BMD in PLWH. 
 
Secondary hypotheses: 
 
1. The prevalence or distribution of both general risk factors and HIV-
disease specific risk factors are similar in both black and white, black 
male and white male and black female and white female PLWH. 
 
 
2. The effects of both general risk factors and HIV-disease specific risk 
factors on BMD and on fracture prevalence are similar in both black and 
white, black male and white male and black female and white female 
PLWH. 
 
3. The correlation between 10-year probability of major osteoporotic 
fractures calculated using FRAX® with BMD is similar in both black and 
white PLWH. 
 
Aims 
 
1. To determine the prevalence of both general risk factors, HIV disease-
specific factors and fractures in PLWH in the Sheffield HIV Cohort 
(Chapter 3). 
 
2. To assess the relationship between BMD and both general and HIV-
disease specific clinical risk factors in order to establish the key clinical 
determinants of BMD in PLWH in the Sheffield HIV Cohort (Chapter 4). 
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3. To assess the relationship between BMD and both general and HIV-
disease specific biochemical markers, including 25-OH-D, in order to 
establish the key biochemical determinants of BMD in PLWH in the 
Sheffield HIV Cohort (Chapter 5). 
 
4. To assess the relationship between BMD and markers of inflammation 
and immune activation in order to establish the key inflammatory or 
immunological determinants of BMD in PLWH in the Sheffield HIV 
Cohort (Chapter 6). 
 
5. To asses the correlation between 10-year probability of major 
osteoporotic and hip fractures calculated using FRAX® with and without 
BMD in PLWH in the Sheffield HIV Cohort (Chapter 7). 
 
More specific aims are detailed within the introductions to results chapters 3, 
4, 5, 6 and 7 respectively. 
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2. Materials and Methods 
 
2.1 Scientific Peer Review, Ethics and Research and Development approvals 
 
The protocol for this study underwent successful local scientific peer review 
and was approved by the regional Research Ethics Committee (reference 
12/YH/0131) and the Sheffield Teaching Hospitals NHS Foundation Trust 
(STH) Research Department. 
 
 
2.2 Phase One: Assessment of patient demographics, fracture prevalence 
and prevalence of risk factors for reduced BMD  
 
HIV-positive patients within the Sheffield HIV Cohort, attending STH 
outpatient clinics in the Department of Infection and Tropical Medicine and the 
Department of Genitourinary Medicine, were recruited prospectively over a 
period of twelve months, from 1 October 2009 to 30 September 2010. Clinical 
data was collected by patient interview within routine clinic appointments and 
by subsequent medical record review. Data was collected and recorded on a 
pre-designed questionnaire. 
 
Baseline patient demographics were recorded, including gender, age, race 
and country of origin. Patients’ height and weight were measured and their 
BMI calculated.  
HIV-specific data were recorded, including the date of HIV diagnosis, the 
likely route of HIV transmission, the current HIV viral load, the current CD4 
cell count, the nadir CD4 cell count, the presence of hepatitis B or C co-
infection, any history of lipodystrophy and a full ART history. Current CD4 cell 
count was analysed by the STH Cell Markers Laboratory; the most recent 
CD4 cell count within six months before or after the clinic appointment was 
recorded. HIV viral load (plasma HIV RNA) was quantified using polymerase 
chain reaction (PCR) by the STH Virology Laboratory using the COBAS® 
AmpliPrep/COBAS® TaqMan® HIV-1 Test, version 2.0 (TaqMan 96) (Roche 
Molecular Systems, Inc.) with a lower limit of detection of 20 copies of HIV 
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RNA ml-1; the most recent plasma HIV RNA within six months before or after 
the clinic appointment was recorded.  
The presence of general osteoporotic risk factors (Table 2.1) was established, 
including the history and nature of any previous fractures and specifically any 
fragility fractures (defined in Chapter 1, Section 1.1.2) sustained in adulthood. 
The number of falls within the preceding 12 months was also recorded.  
 
 Prior fragility fracture 
 Parental history of hip fracture 
 Rheumatoid arthritis 
 Current tobacco smoking 
 Alcohol consumption ≥3 units 
per day 
 Significant ever use of 
glucocorticoids (>3 months at 
a dose equivalent to 
prednisolone 5mg daily or 
more) 
 One or more other disorder 
strongly associated with 
osteoporosis (grouped in 
FRAX® under “secondary 
osteoporosis” risk factors): 
- hypogonadism 
- chronic diarrhoea (≥ 1 
month) 
- malabsorption 
- inflammatory bowel disease 
- organ transplant recipient 
- untreated longstanding 
hyperthyroidism 
- type 1 diabetes mellitus 
- chronic obstructive 
pulmonary disease (COPD) 
- prolonged immobility (≥ 1 
month) 
- liver cirrhosis 
 
Table 2.1. General risk factors for fragility fracture, as incorporated into 
FRAX® 
 
 
Venous blood was obtained and tested for total 25-OH D (25-OH-D2 and 25-
OH-D3). Testosterone was tested in male patients (to assess for 
hypogonadism – see below). Blood samples were analysed by the STH 
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Clinical Chemistry Laboratory. 25-OH D was analysed using the COBAS® 
Elecsys Vitamin D Total Assay, an electrochemiluminescence binding assay, 
with a lower limit of quantification of 7.5 nmol l-1 and an upper limit of 
quantification of 175.0 nmol l-1. Patients with a history of current or previous 
vitamin D and/or calcium replacement or supplementation were excluded from 
subsequent 25-OH D and related biochemical data analyses. 
 
The 10-year probabilities of major osteoporotic fractures and hip fractures 
were calculated (without femoral neck BMD and without including HIV as a 
“secondary osteoporosis” risk factor) using FRAX® 
(www.sheffield.ac.uk/FRAX), by inputting demographic and clinical data 
(Figure 2.1). Country specific FRAX® calculators were used, where available, 
according to a patient country of origin. The US Black FRAX® calculator was 
used for all patients of black race, in the absence of any other country-specific 
calculator specific to patients of black race.  
 
Definite male hypogonadism was defined as a patient with a previous 
confirmed diagnosis of male hypogonadism, or with morning (pre-10am) 
testosterone of <12nmol l-1 in combination with hypogonadal symptoms, i.e. 
erectile dysfunction, loss of morning erections or loss of sexual libido. 
Possible male hypogonadism was defined as a patient with a random (later 
than 10am) testosterone of <12nmol l-1 but without subsequent confirmatory 
pre-10am testosterone, in combination with hypogonadal symptoms. Female 
hypogonadism was defined as premature menopause, i.e. onset < 45 years of 
age.  
 
The presence of other general risk factors for reduced BMD not incorporated 
into FRAX® was also recorded, including current or previous: Depo-Provera® 
use (female patients only); anticonvulsant therapy; hyperparathyroidism; 
growth hormone deficiency; rosiglitazone or pioglitazone use; SSRI 
antidepressant use; use of a proton pump inhibitor (PPI) for more than five 
years; anastrozole, letrozole or exemestane use; opiate dependence; 
cannabis use or other recreational drug use. 
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Figure 2.1. Example of data entry into the FRAX® calculator, without 
femoral neck BMD, to generate 10-year probability of major osteoporotic 
fracture and hip fracture (www.sheffield.ac.uk/FRAX)  
 
 
 
 
2.3 Selection of patients for further analysis within study Phase Two 
 
2.3.1 Phase Two patient sample size calculation and selection strategy  
 
Patient selection for the Phase Two study was informed by a sample size 
calculation, to ensure that analysis would be possible to assess the difference 
in BMD between three equal groups of patients (tertiles) with either low, 
intermediate or high FRAX®-calculated 10-year probability of major 
osteoporotic fracture. 
 
The expected difference in BMD between the lowest and highest FRAX® 
probability tertiles is at least one population standard deviation (s.d.) 
(approximately 0.1g cm-2) which approximates to a doubling of fracture risk, 
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but even smaller differences are of clinical relevance.  A total of 39 patients 
per tertile would allow detection of a 0.65 s.d. difference with 80% power at a 
significance of p < 0.05.  The sample size was therefore set at 40 patients per 
tertile. 
 
Patients were recruited for Phase Two study analysis from the Phase One 
study cohort based upon Phase One FRAX®-calculated 10-year probabilities 
of major osteoporotic fracture (without femoral neck BMD data), with the aim 
of recruiting patients equally (1:1:1) from low, intermediate and high fracture 
risk groups, to create equal-sized low, intermediate and high fracture risk 
tertiles of 40 patients each (120 patients in total) for Phase Two study 
analysis.  
 
In order to be able to compare patients of black race versus white race, 
patient recruitment from the Phase One study population for Phase Two study 
analysis was also stratified simultaneously to recruit equal numbers of black 
and white patients, i.e. 60 within each racial subgroup. 
 
 
2.3.2 Phase Two inclusion criteria 
 
All HIV-1 seropositive patients aged 18 or above, receiving their HIV care 
within the Sheffield HIV Cohort, were potentially eligible for recruitment into 
Phase Two of the study. 
 
 
2.3.3 Phase Two exclusion criteria 
 
The following patients were excluded from the Phase Two study: 
 
 HIV-2 seropositive individuals; 
 
 patients of non-black non-white race; 
 
 patients currently or previously on bone replacement therapy (e.g. a 
bisphosphonate); 
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 patients currently or previously on hormone replacement therapy 
(including testosterone replacement therapy in men); 
 
 patients for whom clinical data was incomplete, e.g. an incomplete ART 
history; 
 
 patients with concurrent illness or recent vaccination within the preceding 
14 days of their study visit; 
 
 patients on current oral or inhaled glucocorticoid therapy; 
 
 pregnant females; 
 
 patients with a history of any known condition that would interfere with the 
acquisition and/or assessment of DXA scans at either the hip, spine or 
whole body site, including more than one prosthesis (a single prosthesis 
being acceptable); 
 
 bilateral fractures or replacement at the hip. 
 
Patients with a history of current or previous vitamin D and/or calcium 
replacement or supplementation were not excluded from the Phase Two 
study, but were excluded from 25-OH D and related biochemical data 
analyses. 
 
 
2.4 Methods for Phase Two  
 
2.4.1 Phase Two recruitment, patient information and informed consent 
 
Phase Two study patients were recruited over a 25-month period, from 30 
April 2013 to 31 May 2015. Patients were approached during their routine HIV 
outpatient clinic attendances. Patient study eligibility was assessed by 
questionnaire. Eligible patients were provided with a Patient Information 
Sheet. Interested and eligible patients were offered a separate study visit 
appointment. Patients were instructed to attend between 8am and 10am, 
following an overnight fast. At the study visit, patient eligibility was re-
confirmed. Pregnancy was excluded in pre-menopausal female patients by 
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same day urine β-human chorionic gonadotrophin (β-hCG) testing. Patient 
informed consent was obtained from all study participants before proceeding 
with further study assessments.  
 
 
2.4.2 Re-assessment of patient demographics, fracture prevalence and 
prevalence of risk factors for reduced BMD 
 
The same clinical data, as collected for Phase One of the study (Section 2.2), 
was re-collected for all Phase Two patients by patient interview and by 
medical record review. Data was collected and recorded using the same pre-
designed questionnaire. 
 
 
2.4.3 Venous blood and urine sampling 
 
Venous blood and midstream urine was collected from fasted study 
participants between 8am and 10am.  
 
Venous blood samples were tested for: CD4 cell count and percentage, CD8 
cell count and percentage and CD4:CD8 ratio (performed by STH Cell 
Markers Laboratory); HIV viral load (performed by STH Virology Laboratory – 
see Section 2.2 for details); total 25-OH-D (see Section 2.2 for details), PTH, 
ALP, corrected calcium, phosphate, liver function, renal function (including 
creatinine), glucose, bicarbonate, insulin-like growth factor-1 (IGF-1), 
testosterone (in male volunteers only), sex hormone binding globulin, 
luteinising hormone, follicule stimulating hormone and oestradiol (performed 
by STH Biochemistry Laboratory); highly sensitive CRP (hs-CRP) (performed 
by STH Immunology Laboratory) and D-dimer (performed by STH 
Coagulation Laboratory). An additional 40ml of blood was collected in a pre-
heparinised Falcon tube for further analysis (see Section 2.4.4). 
 
In addition to dipstick testing for the presence of β-hCG in premenopausal 
women, to exclude pregnancy prior to undergoing imaging studies, urine was 
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also tested by dipstick for the presence of glucose and protein. Urine was 
subsequently analysed (in parallel with serum creatinine and phosphate) for 
protein, albumin, microalbumin, phosphate and creatinine, to enable 
calculations of protein and albumin creatinine ratios and tubular resoprtion of 
phosphate (analysis and calculations performed by STH Clinical Chemistry 
Laboratory). Urine was also analysed for retinal binding protein (performed by 
STH Immunology Laboratory). 
 
 
2.4.4 Peripheral blood mononuclear cell isolation 
 
Whole blood (obtained as described in Section 2.4.3) was subjected to 
density centrifugation (RAD 500 at 4°C for 23 minutes) using Ficoll-Paque to 
separate plasma and peripheral blood mononuclear cells (PBMCs). Plasma 
was separated and transferred to cryovials as 1ml aliquots and stored at         
-80°C, for subsequent interleukin-6 (IL-6) measurement (see Section 2.4.6). 
Freshly isolated PBMCs were washed twice in phosphate buffered saline 
(PBS) and resuspended in PBS + 0.1% bovine serum albumin (BSA) (FACS 
buffer) at a concentration of 1x106 cells ml-1. 
 
 
2.4.5 Flow cytometry 
 
The percentage of activated CD3+/CD4+ and CD3+/CD8+ T cells was 
assessed by expression of CD25 and HLA-DR – an MHC class II cell surface 
receptor (the gating strategy for CD3+/CD4+ and CD3+/CD8+ T cell analysis is 
displayed in Figure 2.2). The percentage of monocytes within classical, non-
classical and intermediate populations was determined using relative CD14 
and CD16 expression (the monocyte gating strategy is displayed in Figure 
2.3). 
 
PBMCs resuspended in FACS buffer at a concentration of 1x106 cells ml-1  
(obtained in Section 2.4.3) underwent further centrifugation (RAD 500 at 4°C 
for 10 minutes). Cell pellets were resuspended in 100μl FACS buffer and 
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incubated for 45 minutes with 2 μl of mouse anti-human antibodies (1μg ml-1) 
against cell surface markers, summarised in Table 2.2, and with 1 μl 
UV/DMSO (LIVE/DEAD Fixable Blue Cell Stain Kit, UV excitable, Life 
technologies). Unstained cells, single antibody stained cells and “fluorescence 
minus one” stained cells were processed simultaneously as controls. 2 μl of 
mouse anti-human antibodies (1μg ml-1) was added to compensation beads 
(ArC Amine Reactive and AbC anti-mouse compensation beads, Life 
Technologies) in 100μl FACS buffer and incubated simultaneously. Following 
incubation, cells and beads were washed twice in FACS buffer and fixed in 
1% paraformaldehyde. 
 
Flow cytometric measurements were performed using a four-colour LSRII flow 
cytometer (BD Biosciences). Forward and side scatter light was used to 
identify cell populations by size and granularity. Flow cytometric 
measurements were used to determine the percentage of CD25 and HLA-DR 
expression in both CD3+/CD4+ and CD3+/CD8+ viable lymphocytes, and to 
determine the relative percentages of classical, intermediate and non-
classical viable monocytes using their relative CD14 and CD16 expression. In 
all flow cytometry experiments, 50,000 events were captured and analysed 
with FlowJo™ software version 10.0.6 (Tree Star, Inc.).  
 
 
 
Human cell marker Fluorochrome Laser/voltage Manufacturer 
CD3 fluorescin isothiocyanate (FITC) Blue 530 eBioscience 
CD4 
peridinin chlorophyll protein (PerCP)- 
eFluor® 710 
Blue 695 eBioscience 
CD8 Brilliant Violet 421 Violet 450 BioLegend 
CD14 allophycocyanin (APC)-eFluor® 780 Red 780 eBioscience 
CD16 PE (phycoerythrin)-Cy7 Blue 780 eBioscience 
CD25 PE Blue 575 eBioscience 
HLA-DR Alexa Fluor®780 Red 730 eBioscience 
 
Table 2.2. Mouse anti-human antibodies used to determine cell surface 
marker expression 
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Figure 2.2. Flow cytometry gating strategy for CD3+/CD4+ and CD3+/CD8+ 
T cell analysis of CD25 and HLA-DR expression 
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Figure 2.3. Flow cytometry gating strategy for analysis of monocyte 
subpopulations 
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2.4.6 Measurement of interleukin-6 
 
IL-6 was quantified on plasma samples (obtained as described in Section 
2.4.4) from a subset of Phase Two study patients using the Quantiglow® IL-6 
specific enzyme-linked immunosorbant assay (QS6000B, R&D Systems). 
Methods were carried out in accordance with the standard protocol provided 
by the manufacturer. 
 
Standards were generated by serial dilution of a reconstituted IL-6 top 
standard (30,000 pg ml-1). The standard curve produced included values of 
1500, 300, 60, 12, 2.4 and 0.48 pg ml-1. 
 
100 μl of assay diluent was added to each well of the 96-well IL-6 microplate.  
100 μl of either thawed Phase Two study patient plasma or a standard 
solution was then added to each well. Wells were then sealed and incubated 
at room temperature on a horizontal orbital plate shaker (Helidorph Rotamax, 
150 rpm) for 2 hours. Following incubation, the microplate was washed four 
times with wash buffer. 200 μl of IL-6 conjugate was then added to each well. 
Wells were re-sealed and incubated at room temperature on the plate shaker 
for a further 3 hours. Following the second incubation, the washing step was 
repeated. 100 μl of working glow reagent (4 ml glow reagent A and 8ml glow 
reagent B) was then added to each well. The wells were then re-sealed and 
the microplate immediately wrapped in foil and incubated at room temperature 
for a further 15 minutes. 
 
Following incubation, the microplate was transferred to the Varioskan® Flash 
(Thermoskan Scientific) plate reader.  Relative light units were measured 
using the following settings: 1 minute lag time; 0.5 second per well read time; 
summation mode; auto gain. Results were collected using Scan it RE for 
Varioskan® version 2.4.3 software. Data was analysed using Graph Pad Prism 
version 6.0, within which a standard curve was generated and Phase Two 
study patient plasma IL-6 concentration was extrapolated. 
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2.4.7 Imaging 
 
DXA was used to assess BMD at the lumbar spine, total hip, femoral neck 
and total body and to assess body composition. The prevalence of sub-clinical 
vertebral fractures was investigated by vertebral fracture assessment (VFA).  
All examinations were performed using a Discovery A bone densitometer 
(Hologic Inc., Bedford, MA, USA). 
 
 
2.4.8 Calculation of 10-year probabilities of major osteoporotic fractures and 
hip fractures using FRAX® 
 
10-year probabilities of major osteoporotic fractures and hip fractures were re-
calculated using FRAX® (as described for Phase One study patients in 
Section 2.2), initially without femoral neck BMD and without including HIV as a 
“secondary osteoporosis” risk factor. FRAX® probabilities were then 
recalculated with incorporation of HIV as a “secondary osteoporosis” risk 
factor (Figure 2.4) (for patients with one or other significant disorder 
significantly associated with reduced BMD (not including HIV), “secondary 
osteoporosis” was already included within the original FRAX® calculation and 
therefore FRAX® probabilities were not altered by inclusion of HIV). Finally, 
FRAX® probabilities were recalculated with inclusion of femoral neck BMD 
data, but without including HIV as a “secondary osteoporosis” risk factor 
(Figure 2.5). 
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Figure 2.4. Example of data entry into the FRAX® calculator, without 
femoral neck BMD, but with inclusion of HIV as a “secondary 
osteoporosis” risk factor, to generate 10-year probability of major 
osteoporotic fracture and hip fracture (www.sheffield.ac.uk/FRAX)  
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Figure 2.5. Example of data entry into the FRAX® calculator, with femoral 
neck BMD, to generate 10-year probability of major osteoporotic fracture 
and hip fracture (www.sheffield.ac.uk/FRAX)  
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2.5 Statistical Methods 
 
Statistical analyses were performed using IBM® SPSS® Statistics software 
(version 25). Statistical significance was defined as a two-tailed p-value < 
0.05. 
 
Continuous variables were assessed for normality using histograms and 
normality plots. Pearson correlation was used to assess the relationship 
between two parametric continuous variables; Spearman correlation was 
used to assess the relationship between two continuous variables including at 
least one non-parametric variable. The difference in the distribution of a 
parametric continuous variable between two populations was analysed using 
the independent sample (unpaired) T Test. The difference in the distribution of 
a non-parametric continuous variable between two populations was analysed 
using the Mann-Whitney U Test. 
 
Respective analyses were performed for all patients within each of the Phase 
One and Phase Two study populations, as well as within black and white 
racial subgroups and within black male, black female, white male and white 
female race / gender subgroups. 
 
The primary outcome measure within the Phase Two study was BMD, 
measured at the lumbar spine, hip and femoral neck and for total body. 
Independent predictors of BMD were assessed using a generalised linear 
regression model (further details provided in Chapter 4, Section 4.9). 
Generalised linear regression models were also used to determine 
independent predictors of 25-OH-D (using Phase One data) and serum 
phosphate and tubular resoprtion of phosphate (using Phase Two data) 
(further details provided in Chapter 5).  
 
The correlations between FRAX® probabilities (with and without inclusion of 
HIV as a “secondary osteoporosis” risk factor) and BMD were calculated in all 
Phase Two patients and within black and white patient subgroups. Differences 
in BMD between Phase Two patients within either low, intermediate or high 
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FRAX® probability tertiles were also analysed. The percentage change in 
FRAX® probabilities calculated with femoral neck BMD compared to without 
femoral neck BMD was described within black and white patient subgroups. 
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3. Prevalence of general and HIV disease-specific fracture risk factors 
and fractures in people living with HIV in Sheffield 
 
3.1 Introduction 
 
In the era of widely available and effective combination ART, the incidence of 
opportunistic infections in PLWH has significantly decreased (Palella et al. 
1998) and, with access to ART, life expectancy for PLWH is now expected to 
be similar to people who are HIV-negative (Nakagawa et al. 2012). Over the 
past two decades, however, it has become evident that a spectrum of NICMs, 
including reduced BMD and increased fragility fractures, can also cause 
significant morbidity and mortality in PLWH and that these NICMs are more 
prevalent in PLWH than in age-, gender- and ethnicity-matched controls 
(Guaraldi et al. 2011).  
 
On account of a higher prevalence of reduced BMD (Brown and Qaqish 2006) 
there is concern that, as PLWH age, they will experience a higher incidence of 
fragility fracture and increased associated morbidity and mortality compared 
to the general population. Several large retrospective population studies have 
documented an increased incidence of all fractures and specifically fragility 
fractures (defined by site of fracture) in PLWH vs. age- and sex-matched HIV-
negative controls (Triant et al. 2008, Young et al. 2011, Hansen et al. 2012) 
and, in addition, have observed an increase in fracture incidence with 
increased age in PLWH (Triant et al. 2008).  
 
Reduced BMD and increased fracture incidence in PLWH are most likely 
attributable to a combination of factors, including an over-representation of 
general fracture risk factors – both those incorporated into the FRAX® 
assessment tool (Table 2.1) and those not incorporated into FRAX® – as well 
as HIV disease-specific fracture risk factors, including ART-related risk factors 
and non-ART-related risk factors (Goh et al. 2016, Hoy and Young 2016).  
 
With respect to general fracture risk factors, multiple studies have shown that 
many of these are more prevalent in PLWH such as rates of smoking (Fuster 
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et al. 2009; Levine et al. 2010), alcohol and other substance misuse, 
particularly amongst MSMs (Mimiaga et al. 2008; Baliunas et al. 2009; 
Browne and Wechsberg 2010; Reisner et al. 2010; Shuper et al. 2010).  
 
The relative contribution of these general risk factors to reduced BMD and 
increased fracture risk in PLWH relative to the contribution of HIV disease-
specific risk factors – including nadir CD4 count and past history of AIDS-
defining illness (Cazanave et al. 2008, Gedmintas et al. 2017), HCV co-
infection (Lo Re V et al. 2009, Gedmintas et al. 2017) and exposure to 
specific ARVs, including PIs (Brown and Qaqish 2006, McComsey et al. 2011, 
Bedimo et al. 2012) and tenofovir DF (Gallant et al. 2004, McComsey et al. 
2011, Cervero et al. 2018) – is, however, not known. It is therefore not yet 
established whether the use of FRAX® as a tool for assessment of fragility 
fracture risk – incorporating general fracture risk factors only – is appropriate 
in PLWH, in spite of FRAX® being recommended for use in PLWH in both 
national and international HIV guidelines (BHIVA 2016, EACS 2017). 
 
The Sheffield HIV Cohort is more than 50% Black and more than 40% female, 
in contrast to the predominantly white male HIV cohorts in which reduced 
BMD and/or increased fracture risk have mostly been reported. BMD, fracture 
risk and fracture incidence may therefore differ significantly within the 
Sheffield HIV Cohort compared to other published HIV cohorts, particularly if 
fracture risk factor prevalence differs significantly between patients of different 
race and gender.  
 
This chapter aims to answer the following questions: 
 
1. How prevalent are fracture risk factors and fractures in PLWH within the 
Sheffield HIV Cohort? 
 
2. Is there a difference in the prevalence of different fracture risk factors in 
PLWH according to race and gender? 
 
3. Can an overexpression of general fracture risk factors account for fragility 
fracture incidence alone, and therefore could FRAX® be a valid tool for the 
assessment of fragility fracture risk in PLWH, or do additional non- FRAX® 
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incorporated general risk factors and/or HIV disease-specific risk factors 
contribute also? 
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3.2 Phase One study population demographics: race, ethnicity, gender, age, 
height, weight and BMI 
 
625 patients were recruited to Phase One of the study from the Sheffield HIV 
Cohort. 53.0% were of black race (n = 331: Black African = 323; Black British 
= 6; Black Caribbean = 2), 43.8% of white race (n = 274: White British or 
White Irish = 248; White European = 21; White Other = 5) and 3.2% of non-
black non-white race (n = 20: mixed ethnicity = 9; South East Asian = 6; 
Afghan = 2; Arabic = 1; Indian = 1; Sri Lankan = 1). Patients originated from 
48 different countries: 51.8% of patients originated from African countries (n = 
324); 41.8% from the UK or Republic of Ireland (n = 261); and 6.4% from 
other countries (n = 40) (as listed in Table 3.1).  
 
Black patients were predominantly female (65.0%), compared with white and 
non-black non-white patients who were predominantly male (82.5% and 
65.0% respectively).  
 
Patient age, height, weight and BMI are summarised by patient race and 
gender in Table 3.2. The distribution of patient age, height, weight and BMI in 
black male, black female, white male and white female patient subgroups are 
compared in Figures 3.1 to 3.4. On account of the relatively small number of 
patients of non-black non-white race recruited, statistical analyses were not 
performed within this racial subgroup. 
 
The mean patient age was 40.7 ± 9.6 years. White patients were significantly 
older than black patients overall (p = 0.002), although there was no significant 
difference in patient age between black male and black female (p = 0.076), 
white male and white female (p = 0.185), black male and white male (p = 
0.109) and black female and white female (p = 0.642) patient subgroups. 
 
 
 
  
 95 
Continent / country n Continent / country n Continent / country n 
Africa 324 Europe 281 Central America 2 
Zimbabwe 188 United Kingdom 259 Jamaica 2 
Zambia 25 Portugal 9   
Eritrea 14 Italy 2 South America 4 
Ethiopia 11 Poland 2 Argentina 1 
Somalia 11 Republic of Ireland 2 Brazil 1 
South Africa 9 Slovakia 2 Chile 1 
Cameroon 8 Spain 2 Guyana 1 
Congo 8 Denmark 1   
Nigeria 8 Germany 1   
Kenya 6 Greece 1   
Malawi 6     
Uganda 5 Asia & Middle East 11   
Burundi 4 Thailand 3   
Ivory Coast 4 Afghanistan 2   
Liberia 4 Malaysia 2   
Tanzania 3 Burma 1   
Angola 2 India 1   
Sierra Leone 2 Iraq 1   
Botswana 1 South Korea 1   
D.R.C. 1     
The Gambia 1 Australasia 1   
Ghana 1 Australia 1   
Mauritius 1     
Mozambique 1     
Senegal 1     
 
Table 3.1. Country of birth of patients within the Phase One study 
population (D.R.C. = Democratic Republic of Congo) 
 
 
 
The mean patient BMI was 26.6 ± 5.1 kg m-2. Black patients had a 
significantly higher BMI than white patients (p < 0.001), with black females 
having a significantly higher BMI than both black males and white females (p 
< 0.001 and p = 0.025 respectively), although black male BMI was not 
significantly higher than white male BMI (p = 0.185), nor was white female 
BMI significantly higher than white male BMI (p = 0.068).
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All 
(n = 625) 
 
Black  
(n = 331) 
 
White  
(n = 274) 
Non-Black Non-White  
(n =20) 
 
Male  
(n = 116) 
 
Female         
(n = 215) 
Male 
(n = 226) 
Female  
(n = 48) 
Male  
(n = 13) 
Female  
(n = 7) 
Mean age ± s.d. years 40.7 ± 9.6 40.7 ± 9.0 38.9 ± 7.9 42.8 ± 10.5 40.5 ± 12.4 37.3 ± 9.5 35.1 ± 9.3 
Mean height ± s.d. m 171 ± 9.8a 1.76 ± 0.07b 1.63 ± 0.06c 1.78 ± 0.07d 1.63 ± 0.08 1.76 ± 0.05 1.63 ± 0.11 
Mean weight ± s.d. kg 78.0 ± 15.6e 80.0 ± 15.7f 76.7 ±15.4g 80.03 ± 14.8 71.4 ± 18.0h 75.1 ± 7.9 66.4 ± 23.3 
Mean BMI ± s.d. kg m-2 26.6 ± 5.1i 25.7 ± 4.7j 28.7 ± 5.5k 25.3 ± 4.4l 26.6 ± 5.4m 24.3 ± 2.3 24.7 ± 6.9 
                                       
           a5 missing values          b1 missing value         c3 missing values       d1 missing value         
                                     e3 missing values           f1 missing value         g1 missing value           h1 missing value 
            i6 missing values           j1 missing value         k3 missing values       l1 missing value          m1 missing value 
 
 
Table 3.2. Age, height, weight and BMI for all (n=625), black (n=331), white (n=274) and non-black non-white (n=20) patient 
subgroups within the Phase One study population 
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Figure 3.1. Distribution of age in black male (n = 116), black female (n = 
215), white male (n = 226) and white female (n = 48) patients within the 
Phase One study population 
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Figure 3.2. Distribution of height in black male (n = 115), black female (n 
= 212), white male (n = 225) and white female (n = 48) patients within the 
Phase One study population 
 
 
 
 
 
 
 
Figure 3.3. Distribution of weight in black male (n = 115), black female (n 
= 214), white male (n = 226) and white female (n = 47) patients within the 
Phase One study population 
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Figure 3.4. Distribution of BMI in black male (n = 115), black female (n = 
214), white male (n = 226) and white female (n = 47) patients within the 
Phase One study population 
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3.3 Prevalence of HIV disease-specific risk factors  
 
HIV disease-specific risk factors for reduced BMD and/or fragility fracture for 
the Phase One study population are summarised by race and gender in Table 
3.3. The distributions of nadir CD4 cell count and current CD4 cell count in 
black male, black female, white male and white female patient subgroups are 
compared in in Figure 3.5 and Figure 3.6 respectively. 
 
The median nadir CD4 cell count for all recruited patients was 217 cells μL-1 
(range 1 to 1050). The nadir CD4 cell count was significantly lower in black 
patients than in white patients (p < 0.001) and in black males than in white 
males (p < 0.001), but was not significantly lower in black females compared 
with white females (p = 0.098), black males compared with black females (p = 
0.095) or white males compared with white females (p = 0.538). 
 
The median current cell CD4 count for all recruited patients was 457 cells μL-1 
(range 2 to 1842). Whilst there was no significant difference in current CD4 
count between black and white patients overall (p = 0.054), current CD4 cell 
count was significantly lower in black males compared with both white males 
(p = 0.002) and black females (p = 0.001) respectively, with no significant 
difference between white and black females (p = 0.154) or between white 
males and white females (p = 0.199). 
 
78.2% of recruited patients had a history of having ever been on ART, 73.8% 
were currently taking ART and 63% of patients had a suppressed HIV viral 
load, i.e. plasma HIV RNA < 40 copies ml-1 on their most recent sample. A 
slightly greater proportion of black patients had a history of prior ART, were on 
current ART and had a suppressed HIV viral load compared with white 
patients, both overall and when comparing black males with white males and 
black females with white females. The proportions of patients with a history of 
prior ART, on current ART and with a suppressed HIV viral load were slightly 
higher in both black males and white males compared with black females and 
white females respectively. 
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All 
(n = 625) 
 
Black  
(n = 331) 
 
White  
(n = 274) 
Non-Black Non-White  
(n = 20) 
 
Male  
(n = 116) 
 
Female          
(n = 215) 
Male 
(n = 226) 
Female  
(n = 48) 
Male  
(n = 13) 
Female  
(n = 7) 
Median nadir CD4 cell count  
 
(range) cells μL-1   
217a                                    
(1 – 1050) 
187b 
(2 – 578) 
198c 
(2 294) 
248d 
(1 – 1050) 
265e 
(1 – 1020) 
304 
(8 – 856) 
144 
(33 – 423) 
Median current CD4 cell count  
 
(range) cells μL-1   
457f                          
(2 – 1842) 
405 
(2 – 1019) 
488g 
(16 – 1189) 
468 
(13 – 1842) 
550 
(4 – 1144) 
382 
(91 – 921) 
344 
(106 – 632) 
Ever ART n (%) 489 (78.2) 98 (84.5) 178 (82.8) 169 (74.8) 34 (70.8) 7 (53.8) 4 (57.1) 
Current ART n (%) 461 (73.8) 96 (82.8) 160 (74.4) 164 (72.6) 29 (60.4) 7 (53.8) 4 (57.1) 
Plasma HIV RNA copies ml-1 393 (63.0)h 78 (67.2) 149 (69.6)i 133 (58.8) 24 (50.0) 5 (38.5) 4 (57.1) 
                                 
 
                                       a19 missing values            b2 missing values       c9 missing values           d6 missing values            e2 missing values  
                                 f1 missing value                                        g1 missing value    
                      h1 missing value                                        i1 missing value         
                                     
 
 
Table 3.3. Nadir and current CD4 cell count, ART exposure and current plasma HIV RNA for all (n = 625), black (n = 331), 
white (n = 274) and non-black non-white (n = 20) patients within the Phase One study population 
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Figure 3.5. Distribution of nadir CD4 cell count in black male (n = 114), 
black female (n = 206), white male (n = 220) and white female (n = 44) 
patients within the Phase One study population 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Distribution of current CD4 cell count in black male (n = 116), 
black female (n= 214), white male (n = 226) and white female (n = 48) 
patients within the Phase One study population 
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Current and ever ARV exposure is summarised for all patients by ARV drug 
class in Table 3.4 and by main NRTI in Table 3.5.  
 
Approximately twice as many patients were either currently on or had ever 
taken the NRTI tenofovir DF compared with the NRTI abacavir. Approximately 
twice as many patients were either currently on or had ever taken an NNRTI 
compared with a PI. Very small proportions of patients had a history of 
exposure, either currently or previously, to ARVs from the INI, CCR5 receptor 
antagonist or fusion inhibitor drug classes. 
 
 
3.4 Falls prevalence 
 
The number of self-reported falls, classified into no falls, one single fall or 
multiple falls, within the preceding 12 months is detailed in Table 3.6 for all 
patients and by patient race and gender subgroups. Overall, 541 patients 
(86.7%) reported no falls, 47 (7.5%) one single fall and 36 (5.8%) multiple falls 
(median 5, range 2 to 365). There was no difference in the relative proportions 
of patients reporting no falls vs. one single fall vs. multiple falls when 
comparing black male, black female, white male and white female patient 
subgroups (Figure 3.7). 
 
In general, neither age nor BMI had a significant bearing as to whether 
patients self-reported no falls, one single fall or multiple falls in the preceding 
12 months, neither in all Phase One patients, nor within black male, black 
female, white male and white female subgroups overall, except within black 
female patients in whom patients reporting multiple falls were significantly 
older than patients reporting one single fall (p = 0.037) and within white 
female patients in whom patients reporting multiple falls had a significantly 
higher BMI than patients reporting either no falls (p = 0.014) or one single fall 
(p = 0.033) (Figures 3.8 and 3.9).
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ARV class Exposure 
All 
(n = 625) 
 
Black 
(n = 331) 
 
White 
(n = 274) 
Non-Black Non-White 
(n = 20) 
 
Male 
(n = 116) 
 
Female 
(n = 215) 
Male 
(n = 226) 
Female 
(n = 48) 
 
Male 
(n = 13) 
 
Female 
(n = 7) 
NRTI 
Current n (%) 455 (72.8) 95 (81.9) 161 (74.9) 161 (71.2) 28 (58.3) 7 (53.8) 4 (57.1) 
Ever n (%) 488 (78.1) 98 (84.5) 178 (82.8) 167 (73.9) 34 (70.8) 7 (53.8) 4 (57.1) 
NNRTI 
Current n (%) 302 (48.3) 75 (64.7) 101 (47.0) 102 (45.1) 15 (31.3) 6 (46.2) 3 (42.9) 
Ever n (%) 394 (63.0) 91 (78.4) 137 (63.7) 134 (59.3) 22 (45.8) 7 (53.8) 3 (42.9) 
PI 
Current n (%) 168 (26.9) 24 (20.7) 61 (28.3) 66 (29.2) 16 (33.3) 0 (0.0) 1 (14.3) 
Ever n (%) 240 (38.4) 31 (26.7) 95 (44.2) 91 (40.3) 21 (43.8) 1 (7.7) 1 (14.3) 
INI 
Current n (%) 11 (1.8) 0 (0.0) 0 (0.0) 10 (4.4) 1 (2.1) 0 (0.0) 0 (0.0) 
Ever n (%) 13 (2.1) 1 (0.9) 0 (0.0) 11 (4.9) 1 (2.1) 0 (0.0) 0 (0.0) 
CCR5 receptor 
antagonist 
Current n (%) 3 (0.5) 0 (0.0) 2 (0.9) 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 
Ever n (%) 4 (0.6) 0 (0.0) 3 (1.4) 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 
Fusion inhibitor 
Current n (%) 1 (0.2) 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 
Ever n (%) 7 (1.1) 0 (0.0) 0 (0.0) 5 (2.2) 2 (4.2) 0 (0.0) 0 (0.0) 
 
Table 3.4. Antiretroviral class for all, black, white and non-black non-white patients within the Phase One study population 
(NRTI = nucleos(t)ide reverse transcriptase inhibitor, NNRTI = non-nucleoside reverse transcriptase inhibitor, PI = 
protease inhibitor, INI = integrase inhibitor) 
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NRTI Exposure 
All 
(n = 625) 
 
Black  
(n = 331) 
 
White  
(n = 274) 
Non-Black Non-White  
(n = 20) 
 
Male  
(n = 116) 
 
Female  
(n = 215) 
Male 
(n = 226) 
Female  
(n = 48) 
 
Male  
(n = 13) 
 
Female  
(n = 7) 
Tenofovir DF 
Current n (%) 294 (47.0) 58 (50.0) 88 (40.9) 119 (52.7) 21 (43.8) 4 (30.8) 4 (57.1) 
Ever n (%) 319 (51.0) 62 (53.4) 97 (45.1) 126 (55.8) 26 (54.2) 4 (30.8) 4 (57.1) 
Abacavir 
Current n (%) 142 (22.7) 35 (30.2) 58 (27.0) 38 (16.8) 7 (14.5) 3 (23.1) 0 (0.0) 
Ever n (%) 219 (35.0) 48 (41.3) 85 (39.5) 70 (31.0) 12 (25.0) 3 (23.1) 1 (14.3) 
Zidovudine 
Current n (%) 33 (5.3) 10 (8.6) 23 (10.7) 15 (6.7) 4 (8.3) 1 (7.7) 1 (14.3) 
Ever n (%) 142 (22.7) 35 (30.2) 107 (49.8) 74 (32.7) 20 (41.7) 3 (23.1) 1 (14.3) 
 
Table 3.5. Nucleos(t)ide reverse transcriptase inhibitor (NRTI) exposure for all, black, white and non-black non-white 
patients within the Phase One study population (tenofovoir DF = tenofovir disoproxil fumarate) 
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All 
(n = 624)a 
 
Black  
(n = 330)a 
 
White  
(n = 274) 
Non-Black Non-White  
(n = 20) 
 
Male  
(n = 116) 
 
Female  
(n = 214)a 
Male 
(n = 226) 
Female  
(n = 48) 
Male  
(n = 13) 
Female  
(n = 7) 
No falls n (%) 541 (86.7) 105 (90.5) 187 (87.4) 192 (84.9) 38 (79.2) 12 (92.3) 7 (100.0) 
Single fall n (%) 47 (7.5) 8 (6.9) 15 (7.0) 16 (7.1) 7 (14.6) 1 (7.7) 0 (0.0) 
Multiple falls n (%) 36 (5.8) 3 (2.6) 12 (5.6) 18 (8.0) 3 (6.2) 0 (0.0) 0 (0.0) 
                                           
              a 1 missing value                                      a 1 missing value               
 
Table 3.6. Number of self-reported falls within the preceding 12 months by patient race and gender within the Phase One 
study population
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Figure 3.7. Percentage of black male (n = 116), black female (n = 214), 
white male (n = 226) and white female (n = 48) patients within the Phase 
One study population reporting no falls, one single fall or multiple falls 
within the preceding 12 months 
 
 
3.5 Fracture prevalence  
 
The median number of self-reported fractures in adulthood was 0 (range 0 – 
6) in 566 patients for whom fracture history was provided. The number and 
proportion of patients having sustained either no, one or multiple fractures are 
detailed by patient race and gender subgroups in Table 3.7 and Figure 3.10. 
A higher proportion of white patients had sustained a single fracture in 
adulthood than either black or non-black non-white patients and within each 
racial subgroup a higher proportion of male patients had sustained a single 
fracture in adulthood than female patients. Only a small proportion of patients 
reported multiple fractures in adulthood overall, with a higher proportion of 
multiple fractures reported in white patients compared with black patients 
(there were no cases of multiple fractures reported in non-black non-white 
patients).
No falls Single fall Multiple falls
0
20
40
60
80
100
Number of falls within preceding 12 months
%
 p
a
ti
e
n
ts
Black male
Black female
White male
White female
 108 
 
 
 
 
Figure 3.8. Age distribution of patients reporting no falls, one single fall 
or multiple falls within the preceding 12 months in black male (n = 116), 
black female (n = 214), white male (n = 226) and white female (n = 48) 
patients within the Phase One study population 
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Figure 3.9. BMI distribution of patients reporting no falls, one single fall 
or multiple falls within the preceding 12 months in black male (n = 115), 
black female (n = 211), white male (n = 225) and white female (n = 47) 
patients within the Phase One study population  
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All 
(n = 566) 
 
Black  
(n = 292) 
 
White  
(n = 254) 
Non-Black Non-White  
(n = 20) 
 
Male  
(n = 101) 
 
Female  
(n = 191) 
Male 
(n = 209) 
Female  
(n = 45) 
Male  
(n = 13) 
Female  
(n = 7) 
No fracture n (%) 456 (80.6) 90 (89.1) 180 (94.2) 132 (63.2) 35 (77.8) 12 (92.3) 7 (100.0) 
Single fracture n (%) 83 (14.7) 10 (9.9) 6 (3.1) 59 (28.2) 7 (15.5) 1 (7.7) 0 (0.0) 
Multiple fractures n (%) 27 (4.8) 1 (1.0) 5 (2.6) 18 (8.6) 3 (6.7) 0 (0.0) 0 (0.0) 
                                 
 
                               
 
Table 3.7. Number of self-reported fractures in adulthood by patient race and gender within the Phase One study 
population
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Figure 3.10. Percentage of black male (n = 101), black female (n = 191), 
white male (n = 209) and white female (n = 45) patients within the Phase 
One study population reporting no fractures, one single fracture or 
multiple fractures in adulthood 
 
 
 
151 fractures were reported in 110 (19.4%) of patients. The median age of 
first fracture and most recent fracture was 28 years (range 18 to 56) and 32 
years (range 18 to 58) respectively. Patients reporting one single fracture in 
adulthood (n = 83) and patients reporting multiple fractures in adulthood (n = 
27) were significantly older than patients reporting no fractures in adulthood (n 
= 456) (p = 0.040 and p = 0.001 for single fracture and multiple fractures 
respectively). Patients reporting multiple fractures in adulthood were 
significantly older than those reporting no fractures in adulthood in both black 
female and white male patient subgroups (p = 0.036 and p = 0.046 
respectively), but with no other significant association of patient age and 
number of fractures within subgroups otherwise (Figure 3.11).   
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Figure 3.11. Age distribution of patients reporting no fractures, one 
single fracture or multiple fractures in adulthood in black male (n = 101), 
black female (n = 191), white male (n = 209) and white female (n = 45) 
patients within the Phase One study population (NS = not significant) 
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Whilst there was a trend to white female patients reporting multiple fractures 
to be older also, this was not statistically significant. 
 
BMI was significantly higher in patients reporting multiple fractures in 
adulthood compared to those reporting one single fracture in adulthood only 
(p = 0.014), but with no significant difference in BMI between patients 
reporting no fractures versus one single fracture (p = 0.079), or between 
patients reporting no fractures versus multiple fractures (p = 0.114). 
Furthermore, BMI was not significantly different in patients reporting no 
fractures vs. patients reporting one single fracture within any patient race-
gender subgroup either, although BMI was significantly higher in black female 
patients reporting multiple fractures versus those reporting no fractures (p = 
0.009, Figure 3.12). 
 
The body region and specific site of each reported fracture is detailed in 
Figure 3.13 and Table 3.8 respectively. The vast majority of fractures were 
traumatic in nature. Only five patients (0.8 %) reported fragility fractures in 
adulthood, two black patients (both female) and three white patients (two 
female and one male), median age 50 years (range 41 to 57). Further details 
regarding these five individuals, the site of their fragility fractures, their 
associated risk factors and FRAX®-derived fracture risk are summarised in 
Table 3.9.  
 
Four of the patients with past fragility fracture had at least one FRAX®-
incorporated general fracture risk factor; the fifth (black female) patient had 
two non-FRAX®-incorporated general fracture risk factors – SSRI and Depo-
Provera® use – as well as three HIV disease-specific risk factors, namely low 
current and nadir CD4 cell count and an unsuppressed HIV viral load. FRAX®-
calculated probabilities of both major osteoporotic and hip fractures were high 
in the three white patients and relatively high (compared with other black 
patients in the Phase One study population) in the two black patients. 
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Figure 3.12. BMI distribution of patients reporting no fractures, one 
single fracture or multiple fractures in adulthood in black male (n = 100), 
black female (n = 188), white male (n = 208) and white female (n = 44) 
patients within the Phase One study population (NS = not significant) 
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Figure 3.13. Body region sites of self-reported fractures in adulthood in 
patients within the Phase One study population (151 fractures self-
reported in 110 of 566 patients) 
 
 
 
 
Body region / site n Body region / site n Body region / site n 
Pelvis and lower limb 68 Shoulder and upper limb 50 Skull / facial 12 
Tibia and/or fibula / ankle 27 Wrist / scaphoid 19 Jaw 5 
Foot / toe(s) 25 Hand / finger(s) / thumb 19 Nose 3 
Femur 6 Shoulder / scapula 3 Maxilla 2 
Not specified lower limb 5 Humerus 3 Skull 1 
Patella 2 Forearm 3 Eye socket 1 
Hip 1 Not specified upper limb 3   
Pelvis 1     
      
Thorax 8 Vertebral 2 Site not specified 9 
Rib(s) 5     
Clavicle 2 Multiple simultaneous 
sites 
2   
Sternum 1   
 
 
Table 3.8. Specific sites of self-reported fractures in adulthood in 
patients within the Phase One study population (151 fractures self-
reported in 110 of 566 patients) 
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 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Number of fragility 
fractures 
1 1 1 1 2 
Site of fracture(s) Femur Hip Vertebral Arm 
Humerus; 
vertebral 
Age at time of 
fracture(s) years 
49 32 56 28 40 
Current age years 50 57 58 41 42 
Gender Female Female Male Female Female 
Ethnicity White British White British White British Black African Black British 
Country of origin UK UK UK Zimbabwe UK 
BMI kg m-2 19.1 26.3 33.2 41.0 32.1 
FRAX® 10-year 
probability of major 
osteoporotic fracture 
(not including BMD) 
13.0 18.0 13.0 1.0 1.5 
FRAX® 10-year 
probability of hip 
fracture (not including 
BMD) 
4.4 4.8 2.6 0.2 0.2 
FRAX® incorporated 
risk factor(s) 
Low BMI; 
current smoker; 
chronic 
diarrhoea; 
malabsorption 
Prednisolone 
use; current 
smoker 
Prednisolone 
use; IBD 
Type 1 DM - 
Other (non-FRAX® 
incorporated) risk 
factors 
SSRI use - ITU stay - 
SSRI use; 
depo-provera 
use (12 years) 
+ secondary 
amenorrhoea 
Current CD4 cells μL-1 896 569 851 552 182 
Nadir CD4 cells μL-1 257 569 105 441 138 
Ever ART Yes No Yes Yes No 
Current ART Yes No Yes Yes No 
Months of ART 53 0 31 3 0 
HIV RNA <40 copies 
ml-1 
Yes No Yes No No 
 
Table 3.9. Characteristics of the five individuals with a history of fragility 
fracture within the Phase One study population 
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3.6 Prevalence of general fracture risk factors 
 
The percentage prevalence of FRAX®-incorporated validated general (i.e. not 
HIV disease-specific) fracture risk factors (excluding age, BMI, race and 
gender), as listed in Table 2.1, is shown for Phase One patients by patient 
race and gender in Figure 3.14. Further detail as to the percentage 
prevalence of individual “other risk factors”, i.e. other disorders strongly 
associated with osteoporosis (included in FRAX® under the label of 
“Secondary Osteoporosis”) is shown by patient race and gender in Figure 
3.15.  
 
 
 
Figure 3.14. Percentage prevalence of FRAX®-incorporated HIV-
independent validated osteoporotic risk factors for black male (n = 116), 
black female (n = 215), white male (n = 226) and white female (n = 48) 
patients within the Phase One study population. “Tobacco” = current 
tobacco smoking; “Alcohol” = alcohol consumption ≥3 units per day; 
“Steroids” = significant oral glucocorticoid steroid use; “Rheumatoid” = 
rheumatoid disease; “Parental Hip” = parental family history of hip 
fracture; “Other risk factor” = at least one of: hypogonadism, chronic 
diarrhoea, prolonged immobility, malabsorption, inflammatory bowel 
disease, chronic obstructive pulmonary disease, cirrhosis, type 1 
diabetes mellitus, untreated hyperthyroidism, organ transplant recipient 
or osteogenesis imperfecta. 
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The percentage prevalence of definite and possible male hypogonadism 
(defined in Section 2.2) is shown by patient race in Figure 3.16. The 
percentage prevalence of female hypogonadism (premature menopause 
onset at age less than 45 years), as well of menopause (any age of onset) 
and other non-FRAX® incorporated female-specific risk factors for reduced 
BMD, is shown by patient race in Figure 3.17. 
 
 
 
 
 
 
 
 
Figure 3.15. Percentage prevalence of FRAX®-incorporated “other” HIV-
independent validated osteoporotic risk factors for black male (n = 116), 
black female (n = 215), white male (n = 226) and white female (n = 48) 
patients within the Phase One study population. IBD = inflammatory 
bowel disease; COPD = chronic obstructive pulmonary disease; T1DM = 
type 1 diabetes mellitus; HyperT4 = untreated hyperthyroidism; Organ 
Tx = organ transplant recipient; OI = osteogenesis imperfecta in 
adulthood. 
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Figure 3.16. Percentage prevalence of definite and possible male 
hypogonadism in black (n = 109) and white (n = 214) male patients within 
the Phase One study population 
 
 
 
 
Figure 3.17. Percentage prevalence of female hypogonadism 
(menopause onset <45 years of age) and of other female-specific non-
FRAX® incorporated fracture risk factors in black (n=215) and white 
(n=48) female patients within the Phase One study population. “Depo 
use” = ever use of Depo-Provera®. 
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Current tobacco smoking, “other risk factors” (as one grouping) and alcohol 
consumption more than or equal to three units per day were the most 
prevalent general fracture risk factors within Phase One patients (excluding 
age, BMI and ethnicity) – 24.2%, 13.0% and 11.7% prevalence respectively – 
although tobacco smoking and alcohol consumption were much more 
prevalent in white patients (43.8% and 23.0% prevalence respectively) than in 
black patients (8.8% and 2.7% prevalence respectively) and in male patients 
(34.7% and 18.6% prevalence respectively) than in female patients (10.4% 
and 2.6% prevalence respectively). Significant glucocorticoid use was more 
prevalent in female patients (10.4%) than in male patients (3.4%). 
 
Amongst the “other risk factors”, current or previous hypogonadism was the 
most prevalent risk factor for patients of both black and white race. Male 
hypogonadism was confirmed in 8.6% of male patients, with a possible but 
unconfirmed diagnosis in a further 7.4%, with little difference in prevalence 
observed between black and white male patients. Premature menopause was 
reported in 3.0% of female patients overall, with a slightly higher prevalence in 
white female patients (4.3%) versus black female patients (2.8%). 12.4% of all 
female patients were post-menopausal, again with a higher prevalence in 
white females (21.3%) versus black females patients (10.7%). History of 
primary amenorrhoea, secondary amenorrhoea and Depo-Provera® use were 
all more common in black female patients (7.5%, 20.8% and 14.9% 
respectively) than in white female patients, however (4.3%, 13.3% and 4.2% 
respectively). 
 
Of other recorded general fracture risk factors not incorporated into FRAX®, 
current or previous SSRI antidepressant use, cannabis use, “other” (non-
cannabis non-opiate) recreational drug use and opiate dependence were the 
most frequently reported overall (Figure 3.18), although more so in male 
patients compared with female patients and in patients of white race 
compared to patients of black race with respect to SSRI and cannabis use, 
with little or no self-reported “other” recreational drug or opiate use reported in 
black patients. 
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Figure 3.18. Percentage prevalence of non-FRAX®-incorporated general 
fracture risk factors for black male (n = 116), black female (n = 215), 
white male (n = 226) and white female (n = 48) patients within the Phase 
One study population. “SSRI” = ever use of a selective serotonin 
reuptake inhibitor; “cannabis” = ever use of cannabis; “other drug” = 
ever use of non-cannabis non-opiate recreational drug; “opiate” = 
history of opiate dependency; “PPI>5yrs” = use of proton pump inhibitor 
continuously for >5 years; “anticonvulsant” = ever use of anticonvulsant 
drug; “ICU” = past intensive care unit inpatient admission; “glitazone” = 
ever use of a glitazone drug; “GH deficiency” = history of confirmed 
growth hormone deficiency diagnosis; “anastrazole’ = ever use of 
anastrazole, letrozole or exemestane. 
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3.7 FRAX®-calculated probability of major osteoporotic fractures and hip 
fracture 
 
The distribution of FRAX®-calculated 10-year probabilities (not incorporating 
BMD measurement) of major osteoporotic fracture and of hip fracture are 
shown for the Phase One study population in Figures 3.19 and 3.20 
respectively, grouped by patient race and gender. (Further detail with respect 
to which FRAX® calculator was used for each patient, dependent on patient 
race and country of origin, is included in Section 2.2.) 
 
The median FRAX® -calculated 10-year risk of major osteoporotic fracture was 
1.6% (range 0.2 – 19.0) for all patients (n = 619), 0.6% (range 0.2 – 7.0) for 
black patients (n = 327), 2.6% (range 0.6 – 19.0) for white patients (n = 272) 
and 2.2% (range 0.3 – 3.7) for non-black non-white patients (n = 20). Black 
patients had significantly lower 10-year risk of major osteoporotic fracture 
compared to white patients (p < 0.001). There was no significant difference in 
FRAX® -calculated 10-year risk of major osteoporotic fracture by gender 
between black male and black female patients or between white male and 
white female patients, however (Figure 3.19). 
 
The median FRAX® -calculated 10-year risk of hip fracture was 0.1% (range 
0.0 – 8.4) for all patients, 0.0% (range 0.0 – 1.5) for black patients, 0.3% 
(range 0.0 – 8.4) for white patients and 0.2% (range 0.0 – 0.3) for non-black 
non-white patients. Black patients had significantly lower risk of hip fracture 
compared with white patients (p < 0.000), but there was no significant 
difference in risk of hip fracture between black male and black female patients 
or between white male and white female patients (Figure 3.20). 
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Figure 3.19. Distribution of FRAX® calculated 10-year probabilities of 
major osteoporotic fracture (not incorporating BMD) in black male (n = 
115), black female (n = 212), white male (n = 225) and black female (n = 
47) patients within the Phase One study population 
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Figure 3.20. Distribution of FRAX® calculated 10-year probabilities of hip 
fracture (not incorporating BMD) in black male (n = 115), black female (n 
= 212), white male (n = 225) and black female (n = 47) patients within the 
Phase One study population 
Black male Black female White male White female
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3.8 Discussion 
 
The population recruited to Phase One of this study (n = 625), representing 
approximately 80% of PLWH within the Sheffield HIV Cohort (n = circa 800 at 
time of Phase One study recruitment), was heterogenous with respect to race, 
country of origin, gender and age, with a reasonably balanced representation  
of both black and white patients (53.0% and 43.8% respectively) and male 
and female patients (56.8% male). Black patients were predominantly female 
and generally younger than white patients, who were predominantly male and 
generally older. The majority of patients were overweight, i.e. BMI >25 kg m-2, 
with BMI significantly higher in black female patients compared with both 
black male and white female patients. 
 
In terms of potential HIV disease-specific fracture risk factors, black patients, 
and specifically black male patients, had significantly lower nadir CD4 cell 
count compared with white patients, perhaps on account of increased time 
from HIV acquisition to diagnosis and initiation of ART in immigrant black 
African patients (Page et al. 2009), in addition to CD3+/CD4+ and CD3+/CD8+ 
T cell counts in general being lower in patients of black race compared to 
patients of white race and in males compared with females (Bosire et al. 
2013). Overall, the proportions of patients on current ART (73.8%) and with a 
suppressed HIV viral load (63.0%) within the study population were lower than 
expected. In light of changes to national ARV prescribing policy since 2017, 
with all patients now qualifying for ART initiation at the time of HIV diagnosis, 
the proportion of patients taking ART and with a suppressed HIV viral load 
would now be expected to be much higher. 
 
Regarding specific ARV use, approximately twice as many patients had been 
exposed to an NNRTI compared to a PI and to the NRTI tenofovir DF 
compared to the NRTI abacavir, with very low numbers of patients having 
been exposed to other newer ARV drug classes, including to INIs. Again, 
more recent changes to ARV availability, ARV drug cost and national ARV 
prescribing policy would most likely now result in far greater INI use with less 
NNRTI use. With some ARVs now available in generic form and with 
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pressures to save costs within UK healthcare systems, the use of abacavir – 
available as a generic drug ahead of tenofovir DF – is also likely to have now 
increased within this cohort relative to tenofovir DF use. Of further note, this 
study was conducted before the availability of the new tenofovir pro-drug TAF, 
the availability of which would also be expected to result in reduced tenofovir 
DF use. 
 
1 in 6 patients reported having fallen in the preceding 12 months and the 
majority of these patients reported falling only once in the past year, with very 
few patients recording more frequent falls. In contrast to other published data 
(Sharma et al. 2018), older age did not result in significantly increased fall 
frequency in the Phase One study population overall, although older age was 
significantly associated with increased fall frequency in black females. As the 
Phase One cohort was relatively young (mean age 40.7 ± 9.6 years), 
however, the effects of age on falls frequency may not have been as 
apparent, on account of the relatively low proportion of older patients included 
in the Phase One analysis in comparison with the study by Sharma et al. 
(2018) (median age 49 years). More specific assessments of frailty were not 
assessed within the Phase One population and therefore no comparison of 
frailty with falls frequency was possible. 
 
There was a relatively high proportion of patients with FRAX®-incorporated 
general fracture risk factors in the Phase One study population, most notably 
current tobacco smoking, significant alcohol consumption and hypogonadism. 
Current tobacco smoking and significant alcohol consumption were more 
prevalent in white patients compared with black patients, tobacco smoking 
was more prevalent in black males than in black females and significant 
alcohol consumption was more prevalent in both black males and white males 
than in black females and white females respectively. Hypogonadism was 
more prevalent in males than females, although in males this also included 
“possible” as well as “definite” hypogonadism (defined in Chapter 2, Section 
2.2). History of parental hip fracture was uncommon overall, perhaps 
reflecting the young age of patients within the cohort and therefore also the 
relatively young age of their parents who would not yet have reached an age 
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to be significantly more likely to sustain a hip fracture. Furthermore, the 
parents of black African patients may have died prematurely before reaching 
old age and being at risk of hip fracture. Black African patients may also have 
lost contact with their parents following migration to the UK and therefore 
parental fracture history might be less accurate for these patients. 
 
There was also a high prevalence of non-FRAX®-incorporated general 
osteoporotic risk factors in this study population, including SSRI use, cannabis 
use, opiate dependence and non-cannabis non-opiate recreational drug use, 
again more so in male and white patients than in female and black patients, 
as well as secondary amenorrhoea and Depo-Provera® use in predominantly 
black female patients.  
 
In spite of a high prevalence of FRAX®-incorporated general osteoporotic risk 
factors, FRAX®-derived 10-year probabilities of both major osteoporotic 
fracture and hip fracture (FRAX® scores) were low overall, although with some 
higher risk outlier patients, in this relatively young population in whom the 
majority were overweight. Black patients had significantly lower FRAX® scores 
than white patients, in part reflecting younger age, higher BMI and a lower 
prevalence of FRAX®-incorporated general osteoporotic risk factors than 
white patients, but also due to the use of a black-race specific FRAX®-
calculator (US Black) in black patients, assuming higher BMD and therefore 
lower fragility fracture risk in black populations versus non-black populations. 
Whether or not it is appropriate to use the US Black FRAX®-calculator in black 
patients who have immigrated to the UK from sub-Saharan Africa is unknown. 
One study compared lumbar spine and hip BMD in healthy black females 
living in Zimbabwe to black females living in the US and found BMD to be 
lower in black females living in Zimbabwe, although the black females living in 
Zimbabwe also had significantly lower BMI (Mukwasi et al. 2015). One would 
expect weight and BMI to increase in black Africans following migration to the 
US or to other developed countries such as the UK; the findings of this study 
are therefore not necessarily applicable to black African immigrants to the UK 
from Zimbabwe or other sub-Saharan African countries, for whom use of the 
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US Black FRAX®-calculator following immigration and weight gain may well 
be appropriate. 
 
Almost 1 in 5 patients reported a history of fracture in adulthood, with fracture 
frequency significantly greater with older age; the vast majority of these were 
traumatic non-fragility fractures, however, with only a very small proportion of 
patients (0.8%, n = 5) with a history of fragility fracture. Fragility fractures 
occurred in young as well as in older patients (median age of occurrence 40 
years old, range 28 to 56 years). Of note, all fiver patients with a history of 
fragility fracture had at least one general fracture risk factor, although HIV 
disease-specific fracture risk factors were also present in these patients.  
 
The generally low FRAX® scores observed within the Phase One study 
population and the low prevalence of fragility fractures, as well as the 
observation that all five patients with a history of fragility fracture had at least 
one general fracture risk factor and three had high FRAX® scores, could 
support the hypothesis that general fracture risk factors play a more 
significant role in reduced BMD and fragility fracture risk than HIV disease-
specific risk factors in PLWH. This could suggest that the widely reported 
increased prevalence of reduced BMD and increased fracture incidence in 
HIV-positive patient cohorts may be more due to an over representation of 
general fracture risk factors within HIV-positive populations than HIV disease-
specific risk factors. FRAX® could, therefore, be a valid tool for the 
assessment of fragility fracture risk in PLWH. 
 
Drawing these conclusions from the Phase One study population data is 
limited, however, by the generally low prevalence of fragility fractures, the 
absence of an HIV-negative control group to compare the prevalence of 
general fracture risk factors, the lack of BMD data and the lack of longitudinal 
data, with FRAX® predicting future fragility fracture risk and not historic fragility 
fracture prevalence. It remains also possible, therefore, that although FRAX® 
scores were low, the high prevalence of general risk factors, when combined 
with superimposed HIV disease-specific risk factors, could put many more 
 129 
patients at risk of sustaining a fragility fracture in the future as this cohort 
ages. 
 
 
3.9 Conclusions 
 
1. General fracture risk factors were highly prevalent within the Sheffield HIV 
Cohort, although FRAX® scores and fragility fracture prevalence was very 
low (0.8%), reflecting the young age of the study population; it is likely, 
however, that fracture risk and incidence will increase as the Sheffield HIV 
Cohort ages. 
 
2. There is a difference in the prevalence of specific fracture risk factors 
between patients of different race and gender, e.g. higher BMI in black 
females (protective) and increased smoking and alcohol consumption in 
white and male patients, therefore specific sub-populations of PLWH are 
likely to be at higher risk of fragility fracture than PLWH in general. 
 
3. Whilst general fracture risk factors could account for fragility fracture 
incidence alone and FRAX® could potentially be a valid tool for the 
assessment of fragility fracture risk in this population, general fracture risk 
factors would need to be over represented in PLWH in general to explain 
the increased prevalence of fragility fractures observed compared to the 
general population. Without an HIV-negative control group to compare 
general fracture risk factor prevalence, however, this cannot be 
demonstrated. 
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4. Clinical determinants of bone mineral density in people living with HIV 
in Sheffield  
 
4.1 Introduction 
 
BMD is consistently lower in PLWH than in age- and sex-matched HIV-
negative controls (Brown and Qaqish 2006, Goh et al. 2018). The extent of 
reduced BMD in PLWH varies widely between published cohorts, however, 
with reduced BMD prevalence (T-score < -1.0) ranging from 21.2% (Grijsen et 
al. 2013) up to 87.5% (Knobel et al. 2001). There is large heterogeneity 
between different HIV cohorts from which BMD data have been reported with 
respect to patient gender, race, age and BMI, amongst other factors, however 
(Goh et al. 2018). The prevalence of osteopaenia (T-score < -1.0 and > -2.5) 
and osteoporosis (T-score ≤ -2.5) in PLWH was 52% and 15% respectively 
(67% reduced BMD overall) in one meta-analysis of pooled data from eleven 
cross-sectional studies published prior to 2006 (pooled cohort: n = 884, 67% 
male, mean age 39.6 years, mean BMI 24.1 kg m-2) (Brown and Qaqish 
2006), but with only one of the eleven studies including a significant number 
of black patients (Dolan et al. 2004). In four more recently published studies 
that included a majority of black patients (range 54% to 75%) (Arnsten et al. 
2006, Arnsten et al. 2007, Jones et al. 2008, Libois et al. 2010), prevalence of 
reduced BMD ranged from 27% in one study (n = 263, 100% female, mean 
age 44 ± 5 years) (Arnsten et al. 2006) to 67% in another (n = 57, 60% male, 
mean age 61 ± 5 years) (Jones et al. 2008).  
 
FRAX®-incorporated general fracture risk factors – well established predictors 
of BMD and fracture risk in the general population (Kanis et al. 2005) – have 
also been shown to be significantly associated with reduced BMD and/or 
increased fracture risk in PLWH, including older age, non-Black race, female 
gender, low BMI, smoking, steroid exposure and hypogonadism (Arnsten et 
al. 2007; Calmy et al. 2009, Carr et al. 2015, Cazanave et al. 2008, Dolan et 
al. 2006, Mondy et al. 2003). It is postulated that an overexpression of these 
general risk factors in PLWH may contribute to the increased prevalence of 
reduced BMD in PLWH compared to the general population (Mallon et al. 
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2010). Other factors that have been associated with reduced BMD and/or 
increased fracture risk in the general population, for example SSRI use 
(Haney et al. 2010), opiate use (Pedrazzoni et al. 1993) and other non-opiate 
recreational drug use (Reece et al. 2009), may also be over-represented in 
PLWH (Cooper et al. 2003, Pence et al. 2006) and therefore also contribute. 
In addition, HBV and HCV co-infection (Lo Re et al. 2009; Sharma et al. 2010) 
and sexual activity between men (Grijsen et al. 2013), each over-represented 
in PLWH overall, have all been reported to be independent risk factors for 
decreased BMD or increased fractures in PLWH. 
 
HIV disease-specific risk factors are also likely to contribute to the increased 
prevalence of reduced BMD in PLWH, however. Low nadir CD4 cell count 
(Cazanave et al. 2008), an unsuppressed HIV viral load (Fausto et al. 2006) 
increased time since HIV diagnosis (Mondy et al. 2003, Dolan et al. 2006) and 
the presence of lipodystrophy (Huang et al. 2001) have each been 
significantly associated with reduced BMD in PLWH. Whilst ART can reverse 
or stabilise bone mineral loss by suppression of HIV viraemia and reduction of 
HIV-associated inflammation and bone resorption (Gibellini et al. 2007, 
Gibellini et al. 2008), the relationship between ART and BMD is more 
complex.  
 
There is now consensus of opinion that, irrespective of the combination of 
ARVs used to treat HIV, BMD declines during the first one to two years 
following ART initiation or switch, before subsequent stabilisation (Bolland et 
al. 2011). The rate of initial BMD decline, however, is greater with certain 
ARVs compared to others, e.g. with tenofovir DF compared to other NRTIs 
(Gallant et al. 2004, McComsey et al. 2011, Stellbrink et al. 2010) or with PIs 
compared to NNRTIs (Duvivier et al. 2009, McComsey et al. 2011). 
Furthermore, the effects of PIs on reduced BMD appear to be independent of 
the co-administered booster (ritonavir or cobicistat) effect of increasing 
tenofovir plasma levels when tenofovir DF and boosted PIs are co-
administered (Rockstroh et al. 2013). 
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The prevalence of reduced BMD has never previously been assessed in the 
Sheffield HIV Cohort. It is therefore not known how the burden of reduced 
BMD in this heterogenous population (54% black, 55% male) of relatively 
young age (mean 40.7 years old) and high BMI (mean 26.6 kg m-2) compares 
to other published HIV cohorts. Furthermore, the relative contribution of 
general versus HIV disease-specific risk factors to reduced BMD has not been 
determined in this cohort and the best approach to identify PLWH within 
Sheffield at highest risk of reduced BMD and future fragility fractures is yet to 
be established. 
 
This chapter aims to answer the following questions: 
 
1. How representative is the Phase Two study population of the larger 
Phase One study population, i.e. can Phase Two study conclusions be 
extrapolated to the wider Sheffield HIV Cohort? 
 
2. What is the distribution of BMD in the Phase Two study population, 
including the prevalence of osteopaenia and osteoporosis, are there 
differences between race / gender subgroups and how do BMD 
measurements compare to other published HIV cohorts and to the 
general population? 
 
3. What is the effect of general fracture risk factors – both those 
incorporated into FRAX® and those not incorporated into FRAX® – and 
HIV disease-specific factors, including ARV exposure, on BMD in the 
Phase Two study population and are there differences between race / 
gender subgroups? 
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4.2 Phase Two study population demographics and comparison to Phase One 
study population 
 
114 patients were recruited to Phase Two of the study, 52 (45.6%) of black 
race and 62 (54.4%) of white race.  Black patients were 92.3% black African 
and 7.7% black British (97.6% and 1.8% respectively in Phase One study 
population), with 50% from Zimbabwe (58% in Phase One). White patients 
were 91.9% white British or white Irish (92.7% in Phase One), 5.7% white 
European (7.7% in Phase One), with one patient from each of Malta, Portugal 
and Slovakia, and 3.2% white other (1.8% in Phase One) with one patient 
from Australia and one from Chile. 
 
The distribution of patient age, height, weight and BMI is detailed within black 
male, black female, white male and white female patient subgroups and 
compared with the larger Phase One study population in Table 4.1. The 
proportions of black male, black female, white male and white female patients 
recruited to Phase Two of the study were representative of the proportions 
within the larger Phase One study population. Both overall and between each 
race / gender-matched subgroup, Phase Two patients were, on average, 
older than Phase One patients (mean age 47.9 ± 10.8 years versus 40.7 ± 9.6 
years for all patients) and black female patients in the Phase Two population 
were overall heavier and had a higher BMI than black female patients in the 
Phase One population. 
 
Within the Phase Two study population, there was no significant difference in 
age between each of the four race / gender subgroups (Table 4.2). Black 
males and white males were significantly taller than black females and white 
females respectively (p < 0.001 for both); black males and white females 
were, on average, shorter than white males and black females respectively, 
although not significantly (p = 0.061 and p = 0.273 respectively). Black 
females were, on average, heavier compared to both black males and white 
females, but this difference was only significant between black females and 
white females (p = 0.017). Black females also had a higher BMI than white 
females, although not significantly (p = 0.052). Black female BMI was 
 134 
 
 
Phase One study population1 (n=605) 
 
 
Phase Two study population (n=114) 
 
 
Black (n=331) 
 
White (n=274) 
 
Black (n=52) 
 
White (n=62) 
 
Male  
(n=116) 
 
Female 
(n=215) 
Male 
(n=226) 
Female  
(n=48) 
Male 
(n=15) 
Female  
(n=37) 
 
Male  
(n=52) 
 
Female 
(n=10) 
Race/gender subgroup  
% of study population  
19.2 35.5 37.4 7.9 13.2 32.5 45.6 8.8 
Mean age ± sd  
(range) years 
40.7 ± 9.0 
(21 – 71) 
38.9 ± 7.9  
(19 – 63) 
42.8 ± 10.5 
(20 – 75) 
40.5 ± 12.4 
(18 – 76) 
49.3 ± 9.9 
(31 – 72) 
44.8 ± 8.5 
(32 – 63) 
49.9 ± 12.1 
(32 – 76) 
46.6 ± 11.6 
(22 – 62) 
Mean height ± sd  
(range) m 
1.76 ± 0.07 
(161 – 192) 
1.63 ± 0.06 
(147 – 181) 
1.78 ± 0.07 
(160 – 203) 
1.63 ± 0.08 
(140 – 179) 
1.74 ± 0.06 
(1.63 – 1.82) 
1.62 ± 0.04 
(1.49 – 1.70) 
1.77 ± 0.06 
(1.61 – 1.90) 
1.60 ± 0.06 
(1.50 – 1.71) 
Mean weight ± sd  
(range) kg 
80.0 ± 15.7 
(46.6 – 145.0) 
76.7 ±15.4 
(44.4 – 135.1) 
80.03 ± 14.8 
(50.0 – 135.8) 
71.4 ± 18.0 
(37.5 – 112.3) 
79.7 ± 15.4 
(56.8 – 117.6) 
83.5 ± 16.3 
(48.3 – 115.1) 
78.9 ± 12.0 
(51.1 – 110.0) 
69.6 ± 13.3 
(46.7 – 86.7) 
Mean BMI ± sd  
(range) kg m-2 
25.7 ± 4.7 
(15.0 – 43.8) 
28.7 ± 5.5 
(15.5 – 50.9) 
25.3 ± 4.4 
(16.0 – 44.6) 
26.6 ± 5.4 
(15.5 – 37.2) 
26.3 ± 4.53 
(20.6 – 37.1) 
31.7 ± 5.65 
(20.4 – 42.7) 
25.1 ± 3.3 
(16.9 – 34.0) 
27.3 ± 6.2 
(18.5 – 38.5) 
 
1. Excluding 20 non-black non-white patients 
 
Table 4.1. Distributions of race, gender, age, height, weight and BMI within the Phase One population versus the Phase 
Two study population 
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Patient race / gender 
subgroup 
n 
Age  
years 
Height  
m 
Weight 
kg 
BMI 
kg m-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
All patients 114 47.9 ± 10.8 - 1.70 ± 0.09 - 79.7 ± 14.3 - 27.6 ± 5.42 - 
Black male 15 49.3 ± 9.9 
.148 
1.74 ± 0.06 
<.001 
79.7 ± 15.4 
.419 
26.3 ± 4.53 
.002 
Black female 37 44.8 ± 8.5 1.62 ± 0.04 83.5 ± 16.3 31.7 ± 5.65 
Black male 15 49.3 ± 9.9 
.994 
1.74 ± 0.06 
.061 
79.7 ± 15.4 
.872 
26.3 ± 4.53 
.489 
White male 52 49.9 ± 12.1 1.77 ± 0.06 78.9 ± 12.0 25.1 ± 3.3 
Black female 37 44.8 ± 8.5 
.404 
1.62 ± 0.04 
.273 
83.5 ± 16.3 
.017 
31.7 ± 5.65 
.052 
White female 10 46.6 ± 11.6 1.60 ± 0.06 69.6 ± 13.3 27.3 ± 6.2 
White male 52 49.9 ± 12.1 
.688 
1.77 ± 0.06 
<.001 
78.9 ± 12.0 
.028 
25.1 ± 3.3 
.358 
White female 10 46.6 ± 11.6 1.60 ± 0.06 69.6 ± 13.3 27.3 ± 6.2 
 
Table 4.2. Differences in distribution of age, height, weight and BMI between black male, black female, white male and 
white female patients within the Phase Two study population
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significantly higher than black males, however (p = 0.002). White males were 
significantly heavier than white females (p = 0.028), but with no significant 
difference in BMI between the two subgroups. 
 
BMI increased with age in all patients, although not significantly (r = 0.144, p = 
0.128); this was also observed in all patient race / gender subgroups and was 
significant in black female patients (p = 0.041); the rate of BMI increase with 
age was steeper in female patients (r = 0.337 and r = 0.333 in black and white 
females respectively) than in male patients (r = 0.166 and r = 0.257 in black 
and white males respectively) (Figure 4.1). 
 
 
4.3 BMD measurements, T-scores and Z-scores by race and gender 
 
 
The distributions of lumbar spine, total hip, femoral neck and total body BMD 
measurements in the four race / gender patient subgroups are shown in Table 
4.3 and Figure 4.2.  
 
Whilst mean total body BMD was lower in female patients compared with 
male patients of the same race and in white patients compared with black 
patients of the same gender, there were no statistically significant differences 
between any patient subgroup. There were no significant differences in 
lumbar spine, total hip or femoral neck BMD between patients of the same 
race but different gender, or of the same gender but different race. 
 
The percentage prevalence of normal BMD (T-score ≥ -1.0), osteopaenia (T-
score < -1.0 and > -2.5) and osteoporosis (T-score ≤ -2.5) for lumbar spine 
and total hip are shown for each patient subgroup in Figure 4.3. Reference 
range data used to calculate black male and black female T-scores were 
sourced from Kelly et al. (1990) and Looker et al. (1998) for lumbar spine and 
total hip respectively. The percentage prevalence of Z-score ≥ -1.0, Z-score < 
-1.0 and > -2.5 and Z-score ≤ -2.5 for each BMD site are shown for each 
patient subgroup in Figure 4.4. The differences in distribution of T- and Z-
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scores between patient subgroups are shown in Tables 4.4 and 4.5 
respectively and in Figure 4.5. 
 
 
 
 
 
 
Figure 4.1. Relationship between age and BMI in all patients (n = 114), 
black males (n = 15), black females (n = 37), white males (n = 52) and 
white females (n = 10) within the Phase Two study population  
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Patient race / gender 
subgroup 
n 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
All patients 114 1.004 ± .130 - 0.959 ± .133 - 0.813 ± .135 - 1.102 ± .102 - 
Black male 15 0.970 ± .142 
.123 
0.991 ± .152 
.926 
0.835 ± .169 
.579 
1.123 ± .087 
.548 
Black female 37 1.035 ± .131 0.987 ± .115 0.860 ± .136 1.106 ± .981 
Black male 15 0.970 ± .142 
.515 
0.991 ± .152 
.180 
0.835 ± .169 
.109 
1.123 ± .087 
.461 
White male 52 0.994 ± .120 0.937 ± .131 0.777 ± .106 1.102 ± .100 
Black female 37 1.035 ± .131 
.919 
0.987 ± .115 
.840 
0.860 ± .136 
.785 
1.106 ± .981 
.214 
White female 10 0.990 ± .159 0.927 ± .162 0.788 ± .166 1.055 ± .143 
White male 52 0.994 ± .120 
.362 
0.937 ± .131 
.190 
0.777 ± .106 
.163 
1.102 ± .100 
.197 
White female 10 0.990 ± .159 0.927 ± .162 0.788 ± .166 1.055 ± .143 
 
Table 4.3. Differences in distribution of lumbar spine, total hip, femoral neck and total body BMD measurements between 
black male, black female, white male and white female patients within the Phase Two study population 
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Figure 4.2. Difference in distribution of lumbar (L-) spine, total hip, 
femoral neck and total body BMD in black male (n=15), black female 
(n=37), white male (n=52) and white female (n=10) patients within the 
Phase Two study population 
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Figure 4.3. Percentage prevalence of normal BMD (T-score ≥ -1.0), 
osteopaenia (T-score < -1.0 and > -2.5) and osteoporosis (T-score ≤ -2.5) 
for lumbar (L-) spine and total hip in black male (n=15), black female 
(n=37), white male (n=52) and white female (n=10) patients within the 
Phase Two study population
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Figure 4.4. Percentage prevalence of Z-scores ≥ -1.0, between < -1.0 and 
> -2.5 and ≤ -2.5 for lumbar (L-) spine and total hip in black male (n=15), 
black female (n=37), white male (n=52) and white female (n=10) patients 
within the Phase Two study population
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Patient race / gender 
subgroup 
n 
Lumbar spine T-score Total hip T-score 
Mean ± s.d. p-value Mean ± s.d. p-value 
All patients 114 -0.627 ± 1.225 - -0.344 ± 1.143 - 
Black male 15 -1.107 ± 1.305 
.010 
-0.380 ± 1.111 
.069 
Black female 37 -0.111 ± 1.187 0.249 ± 1.104 
Black male 15 -1.107 ± 1.305 
.473 
-0.380 ± 1.111 
.162 
White male 52 -0.867 ± 1.079 -0.788 ± 0.948 
Black female 37 -0.111 ± .1.187 
.307 
0.249 ± .1.104 
.318 
White female 10 -0.570 ± 1.460 -0.170 ± 1.378 
White male 52 -0.867 ± 1.079 
.455 
-0.788 ± 0.948 
.085 
White female 10 -0.570 ± 1.460 -0.170 ± 1.378 
 
 
Table 4.4. Differences in distribution of lumbar spine and total hip T-scores between black male, black female, white male 
and white female patients within the Phase Two study population 
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Patient race / gender 
subgroup 
n 
Lumbar spine Z-score Total hip Z-score 
Mean ± s.d. p-value Mean ± s.d. p-value 
All patients 114 -0.557 ± 1.299 - -0.096 ± 0.973 - 
Black male 15 -1.680 ± 1.201 
.002 
-0.313 ± 0.971 
.205 
Black female 37 -0.386 ± 1.307 0.049 ± 0.901 
Black male 15 -1.680 ± 1.201 
.001 
-0.313 ± 0.971 
.818 
White male 52 -0.488 ± 1.115 -0.250 ± 0.927 
Black female 37 -0.386 ± 1.307 
.280 
0.049 ± 0.901 
.216 
White female 10 0.140 ± 1.512 0.490 ± 1.273 
White male 52 -0.488 ± 1.115 
.129 
-0.250 ± 0.927 
.034 
White female 10 0.140 ± 1.512 0.490 ± 1.273 
 
 
 
Table 4.5. Differences in distribution of lumbar spine, total hip and total body Z-scores between black male, black female, 
white male and white female patients within the Phase Two study population 
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Figure 4.5. Difference in distribution of lumbar (L-) spine and total hip T- 
and Z-scores in black male (n=15), black female (n=37), white male 
(n=52) and white female (n=10) patients within the Phase Two study 
population 
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In the Phase Two study population overall, the prevalence of osteopaenia (T-
score <-1 and >-2.5) and osteoporosis (T-score ≤-2.5) respectively were 
33.3% and 9.6% for lumbar spine and 23.7% and 2.7% for total hip. 
 
Eight (53.3%) black male patients had osteoporosis at the lumbar spine and a 
further four (26.7%) had lumbar spine osteopaenia, leaving only three (20.0%) 
patients with normal lumbar spine BMD as defined by T-score.  Lumbar spine 
T-scores were lower in black males than in white males and significantly lower 
than in black females (p = 0.010), with contrastingly low proportions of 
patients with lumbar spine osteoporosis in black females, white males and 
white females (2.7%, 3.8% and 0.0% respectively). A greater proportion of 
black female patients had normal lumbar spine BMD than white female 
patients (81.1% versus 60.0%). Lumbar spine Z-scores were also significantly 
lower in black males compared with both black females (p = 0.002) and white 
males (p = 0.001).  
 
In contrast, the distribution of hip T- and Z-scores were more similar between 
the four patient subgroups, with very few patients with hip osteoporosis across 
all subgroups; the proportion of patients with normal total hip BMD was higher 
in both black male and female patients compared with white male and female 
patients (80.0% and 83.8% versus 65.4% and 70.0% respectively).  
 
 
4.4 Age, height, weight and BMI as determinants of BMD in PLWH 
 
Correlations between age, height, weight and BMI and lumbar spine, total hip, 
femoral neck and total body BMD are shown in Table 4.6 for all Phase Two 
patients and for each patient race / gender subgroup in Appendix 1, Tables 
A1.1 to A1.4.  
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All patients (n = 114) 
Lumbar spine BMD  
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
r p-value r p-value r p-value r p-value 
Age -0.158 .094 -0.107 .258 -0.187 .046 -0.149 .115 
Height 0.039 .684 0.045 .638 -0.060 .524 0.174 .064 
Weight 0.472 <.001 0.523 <.001 0.453 <.001 0.312 .001 
BMI 0.391 <.001 0.469 <.001 0.471 <.001 0.212 .023 
 
Table 4.6. Relationship between age, height, weight and BMI and lumbar spine, total hip, femoral neck and total 
body BMD in all Phase Two patients (n=114)  
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Figure 4.6. Relationship between age and lumbar spine, total hip, 
femoral neck and total body BMD in all Phase Two patients (n=114)  
 
 
 
Whilst BMD decreased at each site with increasing patient age, this was only 
significant in all patients at the femoral neck (p = 0.046) (Figure 4.6), with a 
steeper decline in BMD with increasing age seen in black male patients 
(comparative lumbar spine BMD subgroup data shown in Figure 4.7) but with 
no significant correlation between age and BMD within any race / gender 
subgroup (Appendix 1, Tables A1.1 to A1.4). 
 
Whereas BMD did not change significantly with height, neither in all patient 
analysis nor within race / gender subgroup analyses, BMD significantly 
increased with both increases in weight and BMI at each site in all patients (p 
< 0.001, p < 0.001, p < 0.001 and p = 0.001 for weight and lumbar spine, total 
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hip, femoral neck and total body BMD respectively; p < 0.001, p < 0.001, p < 
0.001 and p = 0.023 for BMI and lumbar spine, total hip, femoral neck and 
total body BMD respectively), with a similar relationship between BMD and 
weight and BMD and BMI (relationship between BMD and BMI shown for all 
patients in Figure 4.8). A similar relationship was observed between weight 
and BMD and BMI and BMD within each race / gender subgroup, although 
weight and BMI correlations with BMD were not statistically significant at 
every BMD site within every subgroup (Appendix 1, Tables A1.1 to A1.4). 
 
 
 
 
 
 
Figure 4.7. Relationship between age and lumbar (L-) spine BMD in black 
male (n = 15), black female (n = 37), white male (n = 52) and white female 
(n = 10) patients within the Phase Two study population 
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Figure 4.8. Relationship between BMI and lumbar spine, total hip, 
femoral neck and total body BMD in all Phase Two patients (n=114)  
 
 
 
 
4.5 FRAX®-incorporated general fracture risk factors as determinants of BMD 
in PLWH 
 
The differences in lumbar spine, total hip, femoral neck and total body BMD 
according to either the presence or absence of FRAX®-incorporated general 
fracture risk factors are shown for all Phase Two recruited patients in Tables 
4.7 and 4.8. (The effects of race, gender, age and BMI on BMD – also 
FRAX®-incorporated general fracture risk factors – have already been 
described in Sections 4.3 and 4.4.) Differences in BMD by risk factor 
presence or absence within each of the four race / gender patient subgroups 
are detailed in Appendix 1, Tables A1.5 to A1.12. 
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Whilst there was a trend to lower BMD at the lumbar spine, total hip and 
femoral neck in current smokers compared with non-smokers (Figure 4.9), the 
differences in BMD were not significant at any site (p = 0.249, p = 0.139 and p 
= 0.091 for lumbar spine, total hip and femoral neck respectively), nor were 
these differences significant within any patient subgroup. Average current 
alcohol consumption ≥3 units per day was associated with lower BMD at all 
sites in all patients, however, and significantly so for total hip and femoral 
neck BMD in all patients (p = 0.017 and p = 0.002 respectively) (Figure 4.10); 
reduced BMD with increased alcohol consumption was more marked in black 
male patients (p = 0.010, p = 0.004 and p = 0.005 for lumbar spine, total hip 
and femoral neck respectively), although with no significant difference 
observed at any site in white male patients (p = 0.884, p = 0.449 and p = 
0.248 for lumbar spine, total hip and femoral neck respectively) (Figure 4.11). 
(No black female patients and only one white female patient reported 
consumption of ≥3 units per day.) 
 
Significant steroid exposure (defined in Table 2.1), contrary to expectation, 
was associated with higher BMD at all sites in all patients and this was 
statistically significant for total body BMD (p = 0.045) (Figure 4.12). Six of the 
seven patients with significant steroid exposure were white males, in whom 
the increase in BMD compared with the 46 white males without significant 
steroid exposure was significant for total body (p = 0.007).  The six white male 
patients with significant steroid exposure were, on average, younger (mean 
age 46.2 ± 10.0 years) compared with the 46 male patients without significant 
steroid exposure (mean age 50.4 ± 12.4 years) and with a higher BMI (mean 
26.9 ± 4.4 kg m-2 vs. 24.9 ± 3.6 kg m-2), although not significantly. Of the six 
patients with significant steroid exposure, none had a diagnosis of rheumatoid 
arthritis, one had a diagnosis of inflammatory bowel disease (IBD) and one 
had COPD respectively, compared with one patient with rheumatoid arthritis, 
no patients with IBD and one patient with COPD in those without significant 
steroid exposure. 
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Fracture risk factor 
Risk 
factor 
present 
n (%) 
Lumbar spine BMD       
g cm-2 
Total hip BMD               
g cm-2 
Femoral neck BMD     
g cm-2 
Total body BMD          
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Current smoking 
No 92 (80.7) 1.010 ± .127 
.249 
0.968 ± .129 
.139 
0.823 ± .134 
.091 
1.100 ± .101 
.704 
Yes 22 (19.3) 0.975 ± .143 0.922 ± .144 0.768 ± .135 1.109 ± .109 
Current alcohol 
≥3 units d-1 
No 95 (83.3) 1.013 ± .129 
.105 
0.973 ± .132 
.017 
0.830 ± .135 
.002 
1.108 ± .106 
.146 
Yes 19 (16.7) 0.959 ± .133 0.893 ± .117 0.727 ± .103 1.071 ± .078 
Fragility fracture 
history 
No 104 (91.2) 1.102 ± .122 
.029 
0.966 ± .125 
.081 
0.817 ± .131 
.250 
1.107 ± .102 
.061 
Yes 10 (8.8) 0.918 ± .185 0.889 ± .190 0.765 ± .168 1.044 ± 0.90 
Significant steroid 
exposure 
No 107 (93.9) 0.999 ± .130 
.179 
0.957 ± .130 
.407 
0.811 ± .136 
.595 
1.097 ± .100 
.045 
Yes 7 (6.1) 1.068 ± .127 0.999 ± .172 0.839 ± .134 1.177 ± .124 
Parental hip fracture 
No 111 (97.4) 1.003 ± .131 
.745 
0.959 ± .130 
.666 
0.813 ± .134 
.661 
1.101 ± .103 
.558 
Yes 3 (2.6) 1.028 ± .140 0.992 ± .240 0.779 ± .191 1.136 ± .105 
Rheumatoid arthritis 
No 113 (97.4) 1.005 ± .130 
.235 
0.962 ± .130 
.024 
0.815 ± .133 
.067 
1.103 ± .102 
.245 
Yes 1 (2.6) 0.849 .662 0.567 0.983 
Other disorders* 
No 75 (65.8) 1.016 ± .133 
.150 
0.981 ± .134 
.016 
0.836 ± .142 
.010 
1.119 ± .102 
.012 
Yes 39 (34.2) 0.979 ± .123 0.918 ± .122 0.768 ± .108 1.069 ± .096 
 
*other disorders strongly associated with osteoporosis, including: chronic diarrhoea, prolonged immobility, hyopgonadism, chronic obstructive pulmonary 
disease, malabsorption, inflammatory bowel disease, untreated hyperthyroidism, type 1 diabetes mellitus, liver cirrhosis, organ transplant receipt and 
osteogenesis imperfecta (no patients recruited to Phase Two study with any of the latter four disorders) 
 
Table 4.7. Differences in lumbar spine, total hip, femoral neck and total body BMD in all Phase Two patients (n=114) 
according to presence or absence of FRAX®-incorporated general fracture risk factors 
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Fracture risk factor* 
Risk 
factor 
present 
n (%) 
Lumbar spine BMD       
g cm-2 
Total hip BMD               
g cm-2 
Femoral neck BMD     
g cm-2 
Total body BMD          
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Chronic diarrhoea 
No 99 (86.8) 1.003 ± .135 
.909 
0.967 ± .134 
.110 
0.820 ± .137 
.144 
1.107 ± .104 
.219 
Yes 15 (13.2) 1.007 ± .098 0.908 ± .114 0.765 ± .112 1.072 ± .091 
Prolonged immobility 
No 101 (88.6) 1.009 ± .125 
.169 
0.967 ± .013 
.072 
0.820 ± .133 
.111 
1.103 ± .101 
.727 
Yes 13 (11.4) 0.957 ± .046 0.897 ± .151 0.756 ± .142 1.093 ± .115 
Hypogonadism 
No 103 (90.4) 1.008 ± .133 
.272 
0.962 ± .134 
.503 
0.817 ± .138 
.304 
1.108 ± .103 
.051 
Yes 11 (9.6) 0.962 ± .093 0.933 ± .126 0.773 ± .094 1.044 ± .743 
Male hypogonadism 
(n=67) 
No 60 (89.6) 0.991 ± .130 
.687 
0.951 ± .137 
.664 
0.794 ± .126 
.438 
1.114 ± .099 
.095 
Yes 7 (10.4) 0.971 ± .058 0.927 ± .139 0.755 ± .114 1.048 ± .055 
Female 
hypogonadism (n=47) 
No 43 (91.5) 1.032 ± .136 
.246 
0.977 ± .129 
.632 
0.849 ± .150 
.553 
1.100 ± .109 
.286 
Yes 4 (8.5) 0.948 ± .148 0.945 ± .117 0.803 ± .038 1.039 ± .111 
Chronic obstructive 
pulmonary disease 
No 112 (98.3) 1.004 ± .132 
.814 
0.960 ± .133 
.544 
0.814 ± .135 
.376 
1.102 ± .103 
.566 
Yes 2 (1.7) 0.982 ± .034 0.903 ± .131 0.728 ± .087 1.061 ± .026 
Malabsorption 
No 113 (99.1) 1.004 ± .131 
.626 
0.960 ± .133 
.796 
0.814 ± .135 
.225 
1.102 ± .103 
.793 
Yes 1 (0.9) 0.940 0.925 0.649 1.075 
Inflammatory bowel 
disease 
No 113 (99.1) 1.001 ± .128 
.032 
0.958 ± .133 
.391 
0.812 ± .135 
.515 
1.102 ± .103 
.969 
Yes 1 (0.9) 1.1281 1.073 0.901 1.106 
Untreated 
hyperthyroidism 
No 113 (99.1) 1.005 ± .131 
.445 
0.960 ± .133 
.511 
0.813 ± .135 
.601 
1.103 
.237 
Yes 1 (0.9) 0.904 0.872 0.742 .981 
 
 
Table 4.8. Differences in lumbar spine, total hip, femoral neck and total body BMD in all Phase Two patients (n=114) 
according to presence or absence of FRAX®-incorporated “other disorders strongly associated with osteoporosis” 
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Figure 4.9. Differences in lumbar (L-) spine, total hip, femoral neck and 
total body BMD in non-smokers (n=92) compared to current smokers 
(n=22) within the Phase Two study population 
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Figure 4.10. Differences in lumbar (L-) spine, total hip, femoral neck and 
total body BMD in Phase Two patients consuming on average <3 units 
alcohol per day (n=95) compared to patients consuming on average ≥3 
units alcohol per day (n=19)  
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Figure 4.11. Differences in lumbar (L-) spine and total hip BMD in black 
males consuming on average <3 units alcohol per day (n=11) compared 
to black males consuming on average ≥3 units alcohol per day (n=4) and 
in white males consuming on average <3 units alcohol per day (n=38) 
compared to white males consuming on average ≥3 units alcohol per 
day (n=14) within the Phase Two study population 
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Figure 4.12. Differences in lumbar (L-) spine, total hip, femoral neck and 
total body BMD in Phase Two patients without significant steroid 
exposure (n=107) compared to patients with significant steroid exposure 
(n=7) 
 
 
 
 
 
Rheumatoid arthritis was associated with reduced BMD at all sites and with 
significantly reduced BMD at both the total hip and femoral neck (p = 0.024 
and p = 0.067 respectively), although in one patient only compared with 113 
without rheumatoid arthritis. Of note, the 35-year old white male patient with 
rheumatoid arthritis had never been treated with steroids (treated with the 
anti-TNF-α monoclonal antibody infliximab), but had a very low BMI (16.9 kg 
m-2).  
 
No sig. steroids Sig. steroids
0.0
0.5
1.0
1.5
L-spine
L
-s
p
in
e
 B
M
D
 (
g
 c
m
-2
)
p = 0.179
No sig. steroids Sig. steroids
0.0
0.5
1.0
1.5
Femoral neck
F
e
m
o
ra
l 
n
e
c
k
 B
M
D
 (
g
 c
m
-2
)
p = 0.595
No sig. steroids Sig. steroids
0.0
0.5
1.0
1.5
Total hip
T
o
ta
l 
h
ip
 B
M
D
 (
g
 c
m
-2
)
p = 0.407
No sig. steroids Sig. steroids
0.8
1.0
1.2
1.4
1.6
Total body
T
o
ta
l 
b
o
d
y
 B
M
D
 (
g
 c
m
-2
) p = 0.045*
 157 
The prevalence of Phase Two recruited patients reporting a history of parental 
hip fracture was only 2.6% (n = 3) – one black female and two white male 
patients – and there was no significant difference in BMD at any site 
comparing these three patients with the 111 patients without parental hip 
fracture history (Table 4.7). 
 
39 patients with a history of current or past “other disorders strongly 
associated with osteoporosis” (as defined by and incorporated into FRAX®) 
had lower lumbar spine BMD (p = 0.150) and significantly lower total hip, 
femoral neck and total body BMD (p = 0.016, p = 0.010 and p = 0.012 
respectively) compared with 75 patients without a history of “other disorder” 
(Figure 4.13). Within patient race / gender subgroups, however, a significant 
reduction in BMD in patients with a history of “other disorder” was only 
observed in black female patients (eight patients (21.6%) with a history of 
“other disorder”) and only for total body BMD (p = 0.007).   
 
With respect to each specific “other disorder”, when analysing all Phase Two 
patients collectively (Table 4.8), the only significant difference identified was 
increased BMD at the lumbar spine in the one white male patient with a 
diagnosis of IBD (p = 0.032) when compared to the 113 patients without IBD 
(the patient with IBD also had a history of significant steroid exposure). 
Although not significant, there was also a trend to reduced lumbar spine, total 
hip and femoral neck BMD in patients with a history of prolonged immobility 
compared to those without (p = 0.169, p = 0.072 and p = 0.111 respectively) 
(Figure 4.14) and reduced total body BMD in all patients with hypogonadism 
(p = 0.051) compared to patients without hypogonadism. 
 
Within patient race / gender subgroups, prolonged immobility was only 
significantly associated with reduced BMD in black male patients (p = 0.035, p 
= 0.009 and p = 0.160 for lumbar spine, total hip and femoral neck BMD 
respectively), although with only one black male with a history of prolonged 
immobility (patient 54 years old, with below average BMI 20.6 kg m-2 and a 
current smoker) compared with 14 black males without. 
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Figure 4.13. Differences in lumbar (L-) spine, total hip, femoral neck and 
total body BMD in Phase Two patients without (n=75) compared to 
patients with (n=39) a significant history of FRAX®-defined “other 
disorders strongly associated with osteoporosis”, including: chronic 
diarrhoea, prolonged immobility, hyopgonadism, chronic obstructive 
pulmonary disease, malabsorption, inflammatory bowel disease, 
untreated hyperthyroidism, type 1 diabetes mellitus, liver cirrhosis, 
organ transplant receipt and osteogenesis imperfecta (no patients 
recruited to Phase Two study with any of latter four disorders) 
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Figure 4.14. Differences in lumbar (L-) spine, total hip, femoral neck and 
total body BMD in Phase Two patients without (n=101) compared to 
those with (n=13) a history of prolonged immobility 
 
 
Female hypogonadism (premature menopause, onset before 45 years of 
age), reported in three (8.1%) of black female patients, was associated with 
significantly reduced total body BMD (p = 0.037), compared with black 
females without hypogonadism. No such difference was seen in white female 
patients (p = 0.418), albeit with only one white female patient reporting 
premature menopause, nor when analysing black and white female patients 
together (p = 0.286).  
 
Current or past male hypogonadism was not associated with any significant 
difference in BMD at any site in black male patients, white male patients or in 
male patients analysed together. 
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Ten (8.8%) patients had sustained at least one fragility fracture in the Phase 
Two study population overall: two (13.3%), two (5.4%), four (7.7%) and two 
(20.0%) patients within black male, black female, white male and white female 
subgroups respectively. Three old fragility fractures were diagnosed on 
vertebral fracture assessment only without patient self-reported history; one, 
four and five fragility fractures were reported at the hip, wrist and lower 
thoracic or lumbar spine respectively. Patients with fragility fracture history 
had, overall, lower BMD at each site compared with patients without a fragility 
fracture history (Figure 4.15), although this was only significant at the lumbar 
spine (p = 0.029). Within each patient race / gender subgroup, BMD was also 
lower at each BMD site in patients with a history of fragility fracture, but only 
significantly lower in black female patients for lumbar spine BMD only (p = 
0.033). 
 
 
Figure 4.15. Differences in lumbar (L-) spine, total hip, femoral neck and 
total body BMD in Phase Two patients without a history of fragility 
fracture (n=104) compared to those with a history of fragility fracture 
(n=10) (FF = fragility fracture) 
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4.6 Non-FRAX®-incorporated general fracture risk factors as determinants of 
BMD in PLWH 
 
The effects of ever use of SSRIs, use of a PPI for five years or longer, ever 
use of cannabis, ever significant use of opiates, ever “other” recreational drug 
use (excluding cannabis and opiates) and (for female patients) a history of 
primary or secondary amenorrhoea or of Depo-Provera® use  – other general 
fracture risk factors not incorporated into FRAX®  – on BMD are detailed for all 
patients in Table 4.9 and for each patient race gender subgroup in Appendix 
1, Tables A1.13 to A1.16. 
 
In all Phase Two patients, neither SSRI exposure, PPI exposure for five years 
or more, ever use of cannabis, nor significant opiate use had any observable 
effect on BMD at any site. In black male patients, ever cannabis use (n = 2) 
was associated with a significantly greater total body BMD in black male 
patients (p = 0.040) and PPI exposure for five years or more (n = 1) was 
associated with a significantly lower femoral neck BMD (p = 0.039); 
conversely in black female patients, PPI exposure for five years or more (n = 
2) was associated with significantly greater femoral neck BMD (p = 0.013). 
Ever use of other (non-cannabis, non-opiate) recreational drugs, almost 
exclusively reported in white male patients only (n = 13, 25.0%) excepting one 
white female patient, was associated with lower BMD at all sites, but not 
significantly. 
 
In female patients, neither a history of primary amenorrhoea, secondary 
amenorrhoea, nor self-reported ever use of Depo-Provera® had any 
significant effect on BMD at any site or within either racial subgroup. 
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Fracture risk factor 
Risk 
factor 
present 
n (%) 
Lumbar spine BMD       
g cm-2 
Total hip BMD               
g cm-2 
Femoral neck BMD     
g cm-2 
Total body BMD          
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
SSRI exposure 
No 79 (69.3) 1.005 ± .116 
.914 
0.961 ± .115 
.815 
0.814 ± .118 
.824 
1.103 ± .090 
.879 
Yes 35 (30.7) 1.002 ± .160 0.955 ± .168 0.808 ± .169 1.100 ± .127 
PPI exposure more 
than 5 years 
No 106 (93.0) 1.004 ± .126 
.923 
0.965 ± .129 
.546 
0.813 ± .128 
.867 
1.103 ± .102 
.772 
Yes 8 (7.0) 0.999 ± .188 0.932 ± .183 0.805 ± .220 1.092 ± .112 
Cannabis use 
No 92 (80.7) 1.005 ± .123 
.842 
0.964 ± .132 
.433 
0.816 ± .137 
.570 
1.096 ± .095 
.183 
Yes 22 (19.3) 0.999 ± .162 0.939 ± .135 0.798 ± .130 1.128 ± .130 
Other recreational 
drug use 
No 100 (87.7) 1.011 ± .130 
.094 
0.967 ± .134 
.084 
0.820 ± .139 
.139 
1.107 ± .106 
.153 
Yes 14 (12.3) 0.949 ± .127 0.902 ± .110 0.763 ± .091 1.065 ± .063 
Significant opiate use 
No 112 (98.2) 1.004 ± .130 
.735 
0.959 ± .131 
.713 
0.813 ± .135 
.953 
1.102 ± .102 
.846 
Yes 2 (1.8) 0.973 ± .243 0.994 ± .278 0.807 ± .194 1.116 ± .201 
Primary amenorrhoea 
(n=47) 
No 40 (85.1) 1.019 ± .140 
.482 
0.968 ± .126 
.433 
0.836 ± .139 
.339 
1.090 ± .110 
.502 
Yes 7 (14.9) 1.059 ± .126 1.010 ± .149 0.893 ± .175 1.121 ± .111 
Secondary 
amenorrhoea (n=47) 
No 26 (55.3) 1.024 ± .157 
.971 
0.976 ± .139 
.907 
0.845 ± .157 
.991 
1.089 ±.128 
.683 
Yes 21 (44.7) 1.026 ± .112 0.972 ± .114 0.854 ± .131 1.102 ± .083 
Depo-provera® use 
(n=47) 
No 31 (66.0) 1.018 ± .136 
.627 
0.972 ± .131 
.841 
0.849 ± .150 
.795 
1.091 ± .110 
.717 
Yes 16 (34.0) 1.039 ± .142 0.980 ± .122  0.837 ± .138 1.103 ± .028 
 
Table 4.9. Differences in lumbar spine, total hip, femoral neck and total body BMD in all Phase Two patients (n=114) 
according to presence or absence of non-FRAX®-incorporated other general fracture risk factors
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4.7 HIV disease-specific factors unrelated to antiretroviral therapy as 
determinants of BMD in PLWH 
 
The relationship between time since HIV diagnosis and nadir CD4 cell count 
with lumbar spine, total hip, femoral neck and total body BMD in all Phase 
Two patients is shown in Table 4.10 (race / gender subgroup analyses are 
included in Appendix 1, Tables A1.17, A1.19, A1.21 and A1.23). The 
differences in lumbar spine, total hip, femoral neck and total body BMD in all 
Phase Two patients according to the presence or absence of other HIV 
disease-specific factors unrelated to ART are detailed in Table 4.11 (subgroup 
analyses are included in Appendix 1, Tables A1.18, A1.20, A1.22 and A1.24). 
 
Whilst BMD at each site decreased with increased time since HIV diagnosis, 
this relationship was not significant in all Phase Two patients; within subgroup 
analyses, the rate of BMD decline with increasing time since HIV diagnosis 
was steeper in black male patients, with a significant correlation for lumbar 
spine (p = 0.027), than in the other three subgroups within which there was no 
significant correlation. This mirrored the relationship seen between BMD and 
age (correlation of lumbar spine BMD with age and time since HIV diagnosis 
respectively compared in black males and black females in Figure 4.16). 
There was a significant correlation between time since HIV diagnosis and age 
in all patients (r = 0.331, p < 0.001) (Figure 4.17). 
 
There was no observed significant relationship between nadir CD4 cell count 
and BMD at any site in all patients, and this was also observed in all 
subgroups, with the exception of black males in whom, contrary to 
expectation, a significant decline in BMD at both the total hip and femoral 
neck (p = 0.029 and  = 0.004 respectively) was seen with an increase in nadir 
CD4 cell count. The relationship between nadir CD4 cell count and femoral 
neck BMD is demonstrated within each patient subgroup in Figure 4.18. 
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HIV disease-specific fracture risk factor 
Lumbar spine BMD       
g cm-2 
Total hip BMD               
g cm-2 
Femoral neck BMD     
g cm-2 
Total body BMD          
g cm-2 
r p-value r p-value r p-value r p-value 
Time since HIV diagnosis years -0.133 .158 -0.061 .520 -0.079 .406 -0.077 .413 
Nadir CD4 cell counta cells μL-1 -0.094 .323 -0.023 .811 -0.120 .206 -0.032 .742 
 
a 2 missing values (n=112) 
 
Table 4.10. Relationship between time since HIV diagnosis and nadir CD4 cell count and lumbar spine, hip, femoral neck 
and total body BMD in all Phase Two patients (n = 114) 
 
 
HIV disease-specific 
fracture risk factor 
Risk 
factor 
present 
n (%) 
Lumbar spine BMD       
g cm-2 
Total hip BMD               
g cm-2 
Femoral neck BMD     
g cm-2 
Total body BMD          
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Mode of HIV 
acquisition 
Hetero 74 (64.9) 1.021 ± .139 
.087 
0.973 ± .129 
.208 
0.835 ± .143 
.030 
1.105 ± .105 
.019 
MSM 38 (33.3) 0.977 ± .107 0.939 ± .139 0.777 ± .108 1.099 ± .099 
Serious illness at time 
of HIV diagnosis 
No 82 (71.9) 0.999 ± .133 
.507 
0.958 ± .124 
.880 
0.807 ± .121 
.490 
1.098 ± .106 
.538 
Yes 32 (28.1) 1.017 ± .125 0.962 ± .155 0.827 ± .167 1.111 ± .094 
Previous intensive 
care admission 
No 106 (93.0) 1.000 ± .129 
.360 
0.958 ± .134 
.649 
0.813 ± .136 
.843 
1.101 ± .106 
.643 
Yes 8 (7.0) 1.045 ± .147 0.980 ± .124 0.803 ± .131 1.118 ± .045 
Chronic HBV infection 
No 110 (96.5) 1.005 ± .127 
.662 
0.961 ± .131 
.441 
0.814 ± .135 
.520 
1.102 ± .104 
.930 
Yes 4 (3.5) 0.976 ± .224 0.909 ± .187 0.770 ± .159 1.098 ± .075 
Current or past 
chronic HCV infection 
No 112 (98.2) 1.006 ± .130 
.179 
0.961 ± .133 
.455 
0.814 ± .136 
.478 
1.101 ± .101 
.653 
Yes 2 (1.8) 0.881 ± .112 0.889 ± .131 0.745 ± .107 1.135 ± .227 
Lipodystrophy 
No 102 (89.5) 1.002 ± .128 
.728 
0.961 ± .133 
.772 
0.813 ± .139 
.943 
1.102 ± .105 
.992 
Yes 12 (10.5) 1.016 ± .154 0.949 ± .135 0.810 ± .094 1.102 ± .082 
 
Table 4.11. Differences in lumbar spine, total hip, femoral neck and total body BMD in all Phase Two patients (n = 114) 
according to presence or absence of HIV disease-specific fracture risk factors (“Hetero” = HIV acquisition through sexual 
intercourse between a man and woman, “MSM” = HIV acquisition through sexual intercourse between men)
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Figure 4.16. Correlation of lumbar (L-) spine BMD with age and time 
since HIV diagnosis respectively in black males (n = 15) and black 
females (n = 37) within the Phase Two study population 
 
 
 
 
 
 
 
Figure 4.17. Relationship between age and time since HIV diagnosis in 
all patients (n = 114) within the Phase Two study population 
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Figure 4.18. Relationship between nadir CD4 cell count and femoral neck 
BMD in black male (n = 14), black female (n = 36), white male (n = 52) and 
white female patients (n = 10) within the Phase Two study population 
 
 
 
 
Of other HIV disease-specific factors, only mode of HIV acquisition had a 
significant effect on BMD (Table 4.11), with significantly lower femoral neck 
and total body BMD in patients who acquired HIV infection via sexual 
intercourse between men versus patients who acquired HIV infection via 
sexual intercourse between a man and a woman (p = 0.030 and p = 0.019 for 
femoral neck and total body respectively). 38 patients who acquired HIV 
infection via sexual intercourse between men where almost universally white 
male (97.4%), however, with the exception of one black male, in contrast to 
the 74 patients who acquired HIV infection via sexual intercourse between a 
man and a woman who were predominantly black and female. Within the 
white male subgroup there was no significant difference in BMD at any site 
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between 37 white male patients who acquired HIV infection via sexual 
intercourse between men and 14 white male patients who acquired HIV 
infection via sexual intercourse between a man and a woman. (Only one 
Phase Two recruited patient acquired HIV infection via injecting drug use and 
one via an unknown route, with no other modes of transmission reported.) 
 
Neither serious illness at time of HIV diagnosis, previous intensive care 
admission, chronic HBV infection, current or past chronic HCV infection or 
lipodystrophy (lipoatrophy and/or lipohypertrophy) had any significant 
relationship with BMD at any site in all patients. Of note, the prevalence of 
some risk factors, notably chronic HBV infection (3.5%, n = 4) and current or 
past chronic HCV infection (1.8%, n = 2), were low in Phase Two recruited 
patients. Whilst chronic HBV infection was associated with significantly lower 
BMD at the lumbar spine and total hip in black male patients, only one patient 
with chronic HBV infection was included within this subgroup; this 54-year old 
patient had other risk factors, including low BMI (20.6kg m-2), being a current 
smoker and with an average alcohol consumption ≥3 units per day. 
 
 
4.8 Antiretroviral therapy and related HIV disease-specific factors as 
determinants of BMD in PLWH 
 
The effects of ART on BMD are summarised for all Phase Two patients in 
Tables 4.12 to 4.19. Further race / gender subgroup analyses are detailed in 
Appendix 1, Tables A1.25 to A1.56. 
 
There was no significant difference between BMD at any site in Phase Two 
patients currently on or ever exposed to ART versus those not currently on or 
never exposed to ART respectively, nor was there a significant difference in 
BMD at any site between patients with suppressed plasma HIV RNA versus 
patients with unsuppressed HIV RNA (Table 4.12). Of note, numbers of 
patients not currently on ART, never exposed to ART or with detectable 
plasma HIV RNA either above 40 copies ml-1 or above 200 copies ml-1 were 
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relatively small within the Phase Two study population (n = 4, n = 3, n = 12 
and n = 8 respectively). 
 
Overall, there was no significant change in BMD at each site with either 
increased continuous time on ART or increased cumulative time ever on ART 
at the time of BMD measurement (Table 4.13), with a similar relationship 
observed within each race / gender subgroup except for black males, in whom 
BMD decreased at each site with increased ART exposure (significant 
between total body BMD and cumulative ART exposure, p = 0.046) (Tables 
A1.26, A1.42, A1.33 and A1.50). The relationship between quantitative ART 
exposure and BMD in all patients and within each race / gender subgroup 
(Figure 4.19) was similar to that of age and BMD described in Section 4.4 
(Figure 4.6 and 4.7). 
 
All but one of the 110 Phase Two patients currently on ART were also on at 
least one NRTI and all of the 111 patients ever on ART had been on at least 
one NRTI at one point. There were no significant differences in BMD between 
patients currently on or ever exposed to an NRTI compared with those not 
currently on or never exposed to an NRTI, with only very few patients not 
currently on or never exposed an NRTI for comparison (Table 4.14). The 
relationship between BMD at each site with both continuous and cumulative 
NRTI exposure was also similar to that seen with any ART (Table 4.15). No 
significant variation was observed within any of the four race / gender 
subgroups (Tables A1.27, A1.28, A1.35, A1.36, A1.43, A1.44, A1.51 and 
A1.52). 
 
With respect to specific NRTI exposure, there was no significant difference in 
BMD observed between patients either currently on or ever exposed to either 
tenofovir DF, abacavir or zidovudine (AZT) compared to patients either not 
currently on or never exposed to tenofovir DF, abacavir or AZT, except for 
current AZT and femoral neck BMD, with the four patients currently on AZT 
(all male, one black and three white) having significantly lower femoral neck 
BMD than the 110 patients not on AZT (p = 0.043) (Table 4.14, Figure 4.20). 
This difference was attributed to the one black male currently on AZT, who 
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had lower BMD at all sites compared with the 14 black males not on AZT 
(lumbar spine and hip BMD significantly lower, p = 0.035 and p = 0.009 
respectively, Table A1.27). No difference in BMD was observed within the 
white male patient subgroup between patients currently on or not currently on 
AZT (Table A1.43). The black male patient currently on AZT was the same 
54-year old current smoker with significant average alcohol consumption, 
current HBV infection and low BMI, described in Section 4.7. 
 
There was no significant difference observed in the relationship between 
either the duration of continuous or cumulative tenofovir DF, abacavir or AZT 
exposure and BMD at any site (Table 4.15) (comparative relationships with 
cumulative tenofovir DF, abacavir and AZT duration and lumbar spine BMD 
are illustrated in Figure 4.21). 
 
51.8% Phase Two patients (n = 59) were currently on an NNRTI and 78.1% (n 
= 89) had ever been exposed to an NNRTI.  The mean BMD in patients 
currently on or ever exposed to an NNRTI, currently on efavirenz or currently 
on or ever exposed to nevirapine was higher for each BMD site than in 
patients not currently on or never exposed to NNRTIs, efavirenz and 
nevirapine respectively (Table 4.16). Although differences in BMD were not 
significant between respective groups, the differences in BMD between 
patients currently on an NNRTI versus not currently on an NNRTI approached 
significance at the lumbar spine, total hip and femoral neck (p = 0.095, p = 
0.061, p = 0.083) (Figure 4.22). Total hip, femoral neck and total body BMD 
were significantly higher in black male patients currently on an NNRTI (n = 8) 
than in black male patients not currently on an NNRTI (n = 7) (p = 0.032, p = 
0.031, p = 0.035 for total hip, femoral neck and total body respectively) (Table 
A1.29) and lumbar spine BMD was significantly higher in black female 
patients currently on nevirapine (n = 3) than black females not currently on 
nevirapine (n = 34) (p = 0.044) (Table A1.37). 
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HIV antiretroviral 
therapy-related 
factor 
Exposure 
or 
presence 
n (%) 
Lumbar spine BMD       
g cm-2 
Total hip BMD               
g cm-2 
Femoral neck BMD     
g cm-2 
Total body BMD          
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Current ART 
No 4 (3.5) 1.028 ± .089 
.704 
1.003 ± .072 
.508 
0.802 ± .124 
.873 
1.139 ± .044 
.461 
Yes 110 (96.5) 1.003 ± .132 0.958 ± .134 0.813 ± .136 1.100 ± .104 
Ever ART 
No 3 (2.6) 1.056 ± .084 
.481 
0.980 ± .069 
.782 
0.809 ± .151 
.959 
1.150 ± .047 
.413 
Yes 111 (97.4) 1.003 ± .131 0.959 ± .134 0.813 ± .135 1.100 ± .103 
Plasma HIV RNA    
<40 copies ml-1 
No 12 (10.5) 0.998 ± .122 
.872 
0.998 ± .157 
.294 
0.828 ± .193 
.683 
1.131 ± .081 
.296 
Yes 102 (89.5) 1.004 ± .132 0.955 ± .130 0.811 ± .128 1.099 ± .105 
Plasma HIV RNA    
<200 copies ml-1 
No 8 (7.0) 1.105 ± .149 
.803 
1.006 ± .160 
.308 
0.824 ± .225 
.800 
1.127 ± .090 
.487 
Yes 106 (93.0) 1.003 ± .130 0.956 ± .131 0.812 ± .127 1.100 ± .103 
 
Table 4.12. Differences in lumbar spine, total hip, femoral neck and total body BMD in all Phase Two patients (n = 114) 
according to exposure to or presence of general HIV antiretroviral therapy (ART)-related factors 
 
 
 
HIV antiretroviral therapy-related factor 
Lumbar spine BMD       
g cm-2 
Total hip BMD               
g cm-2 
Femoral neck BMD     
g cm-2 
Total body BMD          
g cm-2 
r p-value r p-value r p-value r p-value 
Continuous number of months on ARTa  -0.091 .339 -0.115 .229 -0.077 .421 -0.116 .224 
Cumulative number of months ever on ARTa -0.061 .524 -0.035 .713 -0.029 .765 -0.063 .507 
 
a 2 missing values (n=112) 
 
Table 4.13. Relationship between continuous number of months on antiretroviral therapy (ART) at time of BMD 
measurement or cumulative number of months ever on ART with lumbar spine, total hip, femoral neck and total body BMD 
in all Phase Two patients (n = 114)
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Figure 4.19. Relationship between cumulative antiretroviral therapy (ART) exposure 
and lumbar (L-) spine BMD in all (n = 112), black male (n = 15), black female (n = 35), 
white male (n = 52) and white female (n = 10) patients within the Phase Two study 
population
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HIV antiretroviral 
therapy-related 
factor 
Exposure  n (%) 
Lumbar spine BMD       
g cm-2 
Total hip BMD               
g cm-2 
Femoral neck BMD     
g cm-2 
Total body BMD          
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Current NRTI 
No 5 (4.4) 1.043 ± .075 
.498 
0.962 ± .117 
.963 
0.835 ± .163 
.712 
1.150 ± .040 
.284 
Yes 109 (95.6) 1.001 ± .132 0.959 ± .134 0.812 ± .134 1.100 ± .104 
Ever NRTI 
No 3 (2.6) 1.056 ± .084 
.481 
0.980 ± .069 
.782 
0.809 ± .151 
.959 
1.150 ± .047 
.967 
Yes 111 (97.4) 1.003 ± .131 0.959 ± .134 0.813 ± .135 1.100 ± .103 
Current TDF 
No 35 (30.7) 1.006 ± .141 
.915 
0.963 ± .125 
.864 
0.818 ± .131 
.787 
1.107 ± .090 
.750 
Yes 79 (69.3) 1.003 ± .126 0.958 ± .137 0.810 ± .138 1.100 ± .108 
Ever TDF 
No 28 (24.6) 1.031 ± .133 
.210 
0.987 ± .113 
.212 
0.841 ± .127 
.200 
1.122 ± .089 
.243 
Yes 86 (75.4) 0.995 ± .129 0.951 ± .138 0.803 ± .136 1.096 ± .106 
Current ABC 
No 82 (71.9) 1.006 ± .125 
.769 
0.962 ± .134 
.746 
0.815 ± .138 
.761 
1.105 ± .106 
.663 
Yes 32 (28.1) 0.998 ± .146 0.953 ± .131 0.806 ± .128 1.095 ± .094 
Ever ABC 
No 62 (54.4) 1.010 ± .128 
.571 
0.969 ± .134 
.384 
0.820 ± .146 
.530 
1.103 ± .105 
.928 
Yes 52 (45.6) 0.996 ± .134 0.948 ± .132 0.804 ± .121 1.101 ± .100 
Current AZT 
No 110 (96.5) 1.008 ± .128 
.043 
0.961 ± .130 
.392 
0.815 ± .134 
.352 
1.101 ± .103 
.793 
Yes 4 (3.5) 0.875 ± .143 0.903 ± .221 0.751 ± .159 1.115 ± .108 
Ever AZT 
No 72 (63.2) 1.009 ± .123 
.553 
0.958 ± .129 
.905 
0.814 ± .139 
.869 
1.097 ± .096 
.511 
Yes 42 (36.8) 0.994 ± .143 0.961 ± .141 0.810 ± .129 1.110 ± .114 
 
Table 4.14. Differences in lumbar spine, total hip, femoral neck and total body BMD in all Phase Two patients (n = 114) 
according to current or ever exposure to at least one nucleos(t)ide reverse transcriptase inhibitor (NRTI), tenofovir DF 
(TDF), abacavir (ABC) and zidovudine (AZT) 
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HIV antiretroviral therapy-related factor 
Lumbar spine BMD       
g cm-2 
Total hip BMD               
g cm-2 
Femoral neck BMD     
g cm-2 
Total body BMD          
g cm-2 
r p-value r p-value r p-value r p-value 
Continuous number of months on NRTIa  -0.065 .497 -0.084 .376 -0.052 .588 -0.113 .237 
Cumulative number of months ever on NRTIa -0.076 .427 -0.054 .569 -0.028 .772 -0.101 .289 
Continuous number of months on TDF -0.067 .480 -0.135 .154 -0.101 .284 -0.160 .089 
Cumulative number of months ever on TDF -0.094 .317 -0.136 .151 -0.107 .257 -0.155 .100 
Continuous number of months on ABCb 0.007 .945 -0.013 .893 -0.025 .795 -0.010 .918 
Cumulative number of months ever on ABCb -0.030 .750 -0.048 .613 -0.054 .569 -0.013 .888 
Continuous number of months on AZT -0.163 .083 -0.069 .464 -0.071 .453 0.012 .900 
Cumulative number of months ever on AZTa -0.051 .595 0.028 .771 0.025 .790 0.039 .685 
 
a 2 missing values (n=112) 
b 1 missing value (n=113) 
 
Table 4.15. Relationship between continuous number of months on or cumulative number of months ever on either at 
least one NRTI (nucleos(t)ide reverse transcriptase inhibitors), tenofovir DF (TDF), abacavir (ABC) or zidovudine (AZT) 
with lumbar spine, total hip, femoral neck and total body BMD in all Phase Two patients (n = 114) 
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Figure 4.20. Differences in lumbar (L-) spine BMD in all Phase Two 
patients (n = 114) either not currently on or currently on tenofovir DF 
(TDF) (no current TDF: n = 28; current TDF: n = 86), abacavir (ABC) (no 
current ABC: n = 82; current ABC: n = 32) or zidovudine (AZT) (no 
current AZT: n = 110; current AZT: n = 4) 
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Figure 4.21. Relationship between lumbar (L-) spine BMD and 
cumulative exposure to tenofovir DF (TDF) (n = 114), abacavir (ABC)     
(n = 113) and zidovudine (AZT) (n = 112) within the Phase Two study 
population
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HIV antiretroviral 
therapy-related 
factor 
Exposure  n (%) 
Lumbar spine BMD       
g cm-2 
Total hip BMD               
g cm-2 
Femoral neck BMD     
g cm-2 
Total body BMD          
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Current NNRTI 
No 55 (48.2) 0.983 ± .118 
.095 
0.935 ± .132 
.061 
0.790 ± .132 
.083 
1.099 ± .089 
.790 
Yes 59 (51.8) 1.023 ± .139 0.982 ± .131 0.834 ± .135 1.104 ± .115 
Ever NNRTI 
No 25 (21.9) 0.970 ± .125 
.148 
0.929 ± .146 
.190 
0.789 ± .151 
.319 
1.098 ± .084 
.816 
Yes 89 (78.1) 1.013 ± .131 0.968 ± .128 0.819 ± .130 1.103 ± .107 
Current EFV 
No 76 (66.7) 0.996 ± .129 
.403 
0.952 ± .137 
.406 
0.807 ± .140 
.557 
1.105 ± .098 
.638 
Yes 38 (33.3) 1.018 ± .134 0.974 ± .125 0.823 ± .125 1.096 ± .112 
Ever EFV 
No 43 (37.7) 1.006 ± .144 
.886 
0.946 ± .144 
.394 
0.804 ± .156 
.591 
1.115 ± .101 
.289 
Yes 71 (62.3) 1.002 ± .122 0.968 ± .126 0.818 ± .122 1.094 ± .103 
Current NVP 
No 105 (92.1) 1.001 ± .127 
.378 
0.958 ± .130 
.663 
0.809 ± .132 
.733 
1.100 ± .102 
.493 
Yes 9 (7.9) 1.041 ± .175 0.978 ± .168 0.850 ± .175 1.125 ± .117 
Ever NVP 
No 92 (80.7) 0.998 ± .125 
.341 
0.958 ± .130 
.783 
0.807 ± .130 
.354 
1.093 ± .095 
.068 
Yes 22 (19.3) 1.028 ± .154 0.966 ± .149 0.837 ± .155 1.138 ± .124 
 
Table 4.16. Differences in lumbar spine, total hip, femoral neck and total body BMD in all Phase Two patients (n = 114) 
according to current or ever exposure to at least one non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz 
(EFV) and nevirapine (NVP) 
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HIV antiretroviral therapy-related factor 
Lumbar spine BMD       
g cm-2 
Total hip BMD               
g cm-2 
Femoral neck BMD     
g cm-2 
Total body BMD          
g cm-2 
r p-value r p-value r p-value r p-value 
Continuous number of months on NNRTIa  0.161 .089 0.147 .120 0.133 .159 -0.014 .883 
Cumulative number of months ever on NNRTIb 0.174 .066 0.178 .061 0.168 .076 -0.011 .911 
Continuous number of months on EFV 0.098 .300 0.075 .430 0.048 .611 -0.070 .462 
Cumulative number of months ever on EFVa 0.088 .351 0.128 .177 0.120 .205 -0.090 .343 
Continuous number of months on NVPa 0.041 .667 -0.023 .808 0.012 .902 -0.052 .583 
Cumulative number of months ever on NVPa 0.065 .491 0.006 .949 0.050 .600 0.134 .158 
 
a1 missing value (n=113) 
b2 missing values (n=112) 
 
Table 4.17. Relationship between continuous number of months on or cumulative number of months ever on, at time of 
BMD measurement, at least one non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz (EFV) or nevirapine 
(NVP) with lumbar spine, total hip, femoral neck and total body BMD in all Phase Two patients (n = 114) 
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Figure 4.22. Differences in lumbar (L-) spine, total hip, femoral neck and 
total body BMD between Phase Two patients currently on a nucleoside 
reverse transcriptase inhibitor (NNRTI) (n = 59) versus those not 
currently on an NNRTI (n = 55) 
 
 
 
The relationship between continuous or cumulative NNRTI exposure and BMD 
was more complex and differed for different BMD sites and within different 
patient subgroups. In all Phase Two patients, neither the duration of  
continuous or cumulative NNRTI, nevirapine or efavirenz exposure had any 
significant relationship with BMD at any site, although with a general trend of 
slight increase in lumbar spine, total hip and femoral neck BMD (but no 
change in total body BMD) with increased duration of exposure to an NNRTI, 
nevirapine or efavirenz (Table 4.17). In black male patients, increased 
continuous number of months on an NNRTI was associated with a significant 
increase in total hip, femoral neck and total body BMD (r = 0.575 p = 0.025, r 
= 0.590 p = 0.021 and r = 0.570 p = 0.027 respectively) (Table A1.30). In black 
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female patients, increased continuous or cumulative exposure to efavirenz 
was associated with a decrease in BMD at all sites, which was significant for 
total body BMD (r = -0.344 p = 0.037 and r = -0.458 p = 0.005 for continuous 
and cumulative efavirenz exposure respectively) (Table A1.30). 
 
In contrast to NNRTI exposure, the mean BMD in patients with current 
exposure to a PI (n = 49) or who had ever been exposed to a PI  (n = 67) was, 
overall, less than in patients without current PI exposure (n = 65) or ever PI 
exposure (n = 47), although differences in BMD were not significant at any site 
(Table 4.18). Increased continuous exposure to a PI was associated with a 
significant reduction in lumbar spine and total hip BMD (r = -0.240 p = 0.011 
and r = -0.220 p = 0.019 respectively), however, and increased cumulative 
exposure to a PI was associated with a significant reduction in lumbar spine, 
total hip and femoral neck BMD (r = -0.247 p = 0.009, r = -0.271 p = 0.004 and 
r = -0.229 p = 0.015 respectively) (Table 4.19, Figure 4.23). Of note, 23 Phase 
Two patients currently on a PI were not concurrently on an NNRTI and 32 
patients currently on an NNRTI were not concurrently on a PI (27 patients 
were on both concurrently and 32 patients were on neither). 
 
Only a small proportion of Phase Two patients were either currently on or had 
ever taken an INI (8.8% (n = 10) and 13.2% (n = 15) respectively). Current INI 
use was associated with lower BMD overall and significantly lower femoral 
neck BMD (p = 0.022) (Table 4.19, Figure 4.24). Furthermore, the duration of 
continuous exposure to an INI was associated with reduced BMD overall and 
this relationship was significant for femoral neck BMD (r = -0.210, p = 0.025). 
Patients had only been on an INI for a relatively short duration (median 13 
months, interquartile range 4 to 54 months). Nine patients were currently on 
raltegravir and only one patient currently on elvitegavir/cobicistat (the latter co-
formulated and therefore by default co-administered with tenofovir DF and 
emtricitabine). Three patients were concurrently on an INI and a PI (no 
patients were concurrently on an INI and an NNRTI). 
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HIV antiretroviral 
therapy-related 
factor 
Exposure  n (%) 
Lumbar spine BMD       
g cm-2 
Total hip BMD               
g cm-2 
Femoral neck BMD     
g cm-2 
Total body BMD          
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Current PI 
No 65 (57.0) 1.018 ± .129 
.163 
0.977 ± .127 
.114 
0.821 ± .136 
.439 
1.100 ± .103 
.836 
Yes 49 (43.0) 0.984 ± .131 0.937 ± .138 0.801 ± .134 1.104 ± .103 
Ever PI 
No 47 (41.2) 1.022 ± .126 
.209 
0.986 ± .120 
.069 
0.830 ± .127 
.263 
1.108 ± .099 
.622 
Yes 67 (58.8) 0.991 ± .133 0.940 ± .139 0.801 ± .140 1.098 ± .106 
Current INI 
No 104 (91.2) 1.007 ± .133 
.435 
0.966 ± .133 
.074 
0.821 ± .134 
.022 
1.104 ± .106 
.526 
Yes 10 (8.8) 0.973 ± .101 0.888 ± .118 0.720 ± .108 1.082 ± .049 
Ever INI 
No 99 (86.8) 1.004 ± .133 
.979 
0.961 ± .130 
.784 
0.814 ± .127 
.832 
1.100 ± .104 
.645 
Yes 15 (13.2) 1.003 ± .113 0.951 ± .156 0.806 ± .186 1.113 ± .094 
 
Table 4.18. Differences in lumbar spine, total hip, femoral neck and total body BMD in all Phase Two patients (n = 114) 
according to current or ever exposure to at least one protease inhibitor (PI) or integrase inhibitor (INI) 
 
 
HIV antiretroviral therapy-related factor 
Lumbar spine BMD       
g cm-2 
Total hip BMD               
g cm-2 
Femoral neck BMD     
g cm-2 
Total body BMD          
g cm-2 
r p-value r p-value r p-value r p-value 
Continuous number of months on PIa -0.240 .011 -0.220 .019 -0.164 .083 -0.052 .588 
Cumulative number of months ever on PIb -0.247 .009 -0.271 .004 -0.229 .015 -0.111 .245 
Continuous number of months on INI -0.096 .308 -0.154 .101 -0.210 .025 -0.048 .614 
Cumulative number of months ever on INI -0.016 .864 -0.036 .704 -0.055 .559 0.048 .612 
 
a1 missing value (n=113)  
b2 missing values (n=112) 
 
Table 4.19. Relationship between continuous number of months on or cumulative number of months ever on, at time of 
BMD measurement, at least one protease inhibitor (PI) or integrase inhibitor (INI) with lumbar spine, total hip, femoral 
neck and total body BMD in all Phase Two patients (n = 114)
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Figure 4.23. Relationship between lumbar (L-) spine, total hip, femoral 
neck and total body BMD and cumulative exposure to a protease 
inhibitor (PI) in Phase Two patients (n = 112) 
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Figure 4.24. Differences in lumbar (L-) spine, total hip, femoral neck and 
total body BMD between Phase Two patients currently on an integrase 
inhibitor (INI) (n = 10) versus those not currently on an INI (n = 104) 
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4.9 Summary of clinical determinants of BMD by multivariate analysis 
 
General and HIV disease-specific clinical factors found to have either 
significant (p < 0.05) or borderline significant (p ≥ 0.05 and < 0.10) association 
with BMD at one or more site the Phase Two study population are listed in 
Table 4.20.  
 
 
Risk factor 
BMD site 
Lumbar spine Total hip Femoral neck Total body 
Age .094 .258 .046 .115 
Height .684 .638 .524 .064 
Weight <.001 <.001 <.001 .001 
Body mass index <.001 <.001 <.001 .023 
Alcohol ≥ 3 units d-1 .105 .017 .002 .146 
Prior fragility fracture .029 .081 .250 .061 
Steroid exposure .179 .407 .595 .045 
Rheumatoid arthritis .235 .024 .067 .245 
“Other disorders” .150 .016 .010 .012 
MSM HIV acquisition .087 .208 .030 .019 
Current AZT .043 .392 .352 .793 
Cumulative AZT .595 .028 .025 .685 
Continuous PI .011 .019 .083 .588 
Cumulative PI .009 .004 .015 .245 
Current INI .435 .074 .022 .526 
Continuous INI .308 .101 .025 .614 
Current smoking .249 .139 .091 .704 
Other drug use .094 .084 .139 .153 
Continuous TDF .480 .154 .284 .089 
Continuous AZT .083 .464 .453 .900 
Current NNRTI .095 .061 .083 .790 
Continuous NNRTI .089 .120 .159 .883 
Cumulative NNRTI .066 .061 .076 .911 
Ever PI .209 .069 .263 .622 
 
Table 4.20. General and HIV disease-specific factors with significant (p < 
0.05) or borderline significant (p ≥ 0.05 and < 0.10) associations with 
BMD at one or more site from univariate analysis 
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Risk factors with significant or borderline associations with BMD at each site 
were taken forward for multivariate analysis within separate generalised linear 
models for each of lumbar spine, total hip, femoral neck and total body BMD. 
BMI was put forward for multivariate analysis, a product of both height and 
weight, which were not put forward separately. For other risk factors that were 
not independent, e.g. continuous, cumulative and ever PI exposure, only the 
risk factor with the most significant association on univariate analysis was 
taken forward for multivariate analysis.  
 
Although not significantly associated with BMD at every site in univariate 
analysis, age was included in multivariate analysis models for BMD at each 
site, as a potential confounder for time-dependent risk factors, e.g. continuous 
or cumulative ARV exposures.  
 
Backward elimination was used to determine risk factors with significant 
association with BMD within multivariate analysis models (detailed in 
Appendix A1.2), with stepwise elimination continuing until all residual risk 
factors achieved significance of p < 0.10. Age was maintained in each model, 
irrespective of significance, for reasons explained above. Risk factors with 
significant (p < 0.05) or borderline significant (p ≥ 0.05 and < 0.10) association 
with BMD following multivariate analysis are shown for lumbar spine, total hip, 
femoral neck and total body in Tables 4.21, 4.22, 4.23 and 4.24 respectively. 
 
For both lumbar spine and total body BMD, the only significant covariates or 
factors associated with BMD following multivariate analysis were general 
fracture risk factors (i.e. not HIV disease-specific) and, furthermore, these 
were all FRAX®-incorporated general fracture risk factors. Both reduced BMI 
and a history of fragility fracture were both significantly associated with 
reduced BMD for both lumbar spine (p < 0.001 for BMI and p = 0.005 for 
fragility fracture history) and total body (p = 0.030 for BMI and p = 0.018 for 
fragility fracture history); in addition, history of one or more other disorder 
associated with osteoporosis was significantly associated with reduced total 
body BMD (p = 0.012) and significant steroid exposure was significantly 
associated with increased total body BMD (p = 0.002).  
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Covariate / factor Factor present 
Estimated 
marginal mean 
g/cm2 
Standard Error Wald Chi-Square p-value 
BMI - - - 26.347 <.001 
Fragility fracture history 
No 1.007 0.011 
9.317 .005 
Yes 0.896 0.035 
 
Table 4.21. Covariates and factors with significant (p < 0.05) or borderline significant (p ≥ 0.05 and < 0.10) association with 
lumbar spine BMD following multivariate analysis  
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Covariate / factor Factor present 
Estimated 
marginal mean 
g/cm2 
Standard Error Wald Chi-Square p-value 
BMI - - - 26.669 <.001 
Fragility fracture history 
No 0.843 0.055 
4.286 .038 
Yes 0.766 0.063 
Rheumatoid arthritis 
No 0.921 0.018 
4.687 .030 
Yes 0.688 0.108 
Other disorder 
No 0.832 0.056 
6.086 .014 
Yes 0.777 0.058 
Cumulative no. of months ever on AZT - - - 3.404 .065 
Cumulative no. of months ever on PI - - - 8.484 .004 
 
Table 4.22. Covariates and factors with significant (p < 0.05) or borderline significant (p ≥ 0.05 and < 0.10) association with 
total hip BMD following multivariate analysis (AZT = zidovudine; PI = boosted protease inhibitor) 
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Covariate / factor Factor present 
Estimated 
marginal mean 
g/cm2 
Standard Error Wald Chi-Square p-value 
BMI - - - 24.874 <.001 
Age - - - 3.026 .082 
Rheumatoid arthritis 
No 0.805 0.011 
2.991 .084 
Yes 0.614 0.113 
Other disorder 
No 0.738 0.057 
5.994 .014 
Yes 0.681 0.059 
Cumulative no. of months ever on AZT - - - 3.154 .076 
Cumulative no. of months ever on PI - - - 7.728 .007 
 
Table 4.23. Covariates and factors with significant (p < 0.05) or borderline significant (p ≥ 0.05 and < 0.10) association with 
femoral neck BMD following multivariate analysis (AZT = zidovudine; PI = boosted protease inhibitor) 
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Covariate / factor Factor present 
Estimated 
marginal mean 
g/cm2 
Standard Error Wald Chi-Square p-value 
BMI - - - 4.727 .030 
Fragility fracture history 
Yes 1.149 0.019 
5.549 .018 
No 1.074 0.032 
Significant steroid exposure 
Yes 1.054 0.016 
9.277 .002 
No 1.168 0.036 
Other disorders 
Yes 1.136 0.023 
6.242 .012 
No 1.087 0.023 
 
Table 4.24. Covariates and factors with significant (p < 0.05) or borderline significant (p ≥ 0.05 and < 0.10) association with 
total BMD following multivariate analysis 
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Covariates and factors with significant or borderline significant association 
with either total hip or femoral neck BMD were similar for each and 
overlapped with covariates and factors significantly associated with lumbar 
spine and total body BMD. As for lumbar spine and total body, reduced BMI 
was significantly associated with reduced BMD at both total hip (p < 0.001) 
and femoral neck (p < 0.001). History of one or more other disorders 
associated with osteoporosis was also significantly associated with reduced 
BMD for both total hip (p = 0.014) and femoral neck (p = 0.014). Fragility 
fracture history was also significantly associated with reduced total hip BMD 
(p = 0.038) but not femoral neck BMD. Rheumatoid arthritis was significantly 
associated with reduced BMD, independent of BMI, for total hip (p = 0.030), 
with borderline significant association for femoral neck (p = 0.084). Age, whilst 
included in multivariate analysis models for each BMD site, was not 
significantly associated with reduced BMD for any site, although borderline 
significant association between increased age and reduced BMD was 
observed for femoral neck (p = 0.082).  
 
In addition to FRAX®-incorporated general fracture risk factors, greater 
cumulative duration of months ever on a PI was also significantly associated 
with reduced BMD for both total hip (p = 0.004) and femoral neck (p = 0.007). 
Borderline significant association between greater cumulative duration of 
months ever on AZT and reduced BMD was also observed for both total hip (p 
= 0.065) and femoral neck (p = 0.076). No other HIV disease-specific 
covariate or factor was significantly associated with BMD at any site following 
multivariate analysis. 
 
Phase Two patient subgroups were too small to allow race / gender-specific 
multivariate analysis. 
 
 
4.10 Discussion 
 
The Phase Two study population was representative of the wider Phase One 
study population and therefore also of the Sheffield HIV Cohort with respect to 
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relative proportions of patients by race and gender (excluding the small 
numbers of non-black non-white patients in the Phase One cohort who were 
excluded from Phase Two analysis). The Phase Two study population was, 
however, on average older and, with respect to black female patients, heavier 
and with a higher BMI than the Phase One study population.  
 
The older age of the Phase Two study population relative to Phase One in 
part reflects targeted recruitment into Phase Two of the study, which aimed to 
ensure equal proportions of high, intermediate and low fracture risk patients 
respectively. This recruitment strategy therefore resulted in an over-
representation of higher fracture risk patients – and therefore also older 
patients – in Phase Two relative to Phase One. It was also more challenging 
to recruit younger patients to attend for additional study visits for BMD 
measurement outside routine clinic visits. Furthermore, Phase Two study 
visits were conducted between three to six years after demographic data was 
collected within the preceding Phase One study.  
 
As weight and BMI increase with age, it follows that the older Phase Two 
population would also be heavier and have a higher BMI than the Phase One 
population, especially with respect to female patients. Phase Two data could 
therefore exaggerate the current burden of reduced BMD in the wider (and on 
average younger) Sheffield HIV Cohort. Higher BMI, however, specifically in 
black female patients, may offset the effects of older age on BMD in the 
Phase Two study population.   
 
Fragility fracture prevalence was much higher in the Phase Two study 
population than the Phase One study population (8.8%, n = 10 vs. 0.8%, n = 
5). The time lag (plus three to six years) between Phase One and Phase Two, 
the older mean age of the Phase Two cohort, the proportionally higher 
number of patients with either high or intermediate fracture risk recruited to 
Phase Two versus Phase One, as well as the inclusion of sub-clinical 
vertebral fractures detected only by vertebral fracture risk assessment in 
Phase Two (three of the ten fragility fractures reported in Phase Two), could 
all account for this difference. 
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The prevalence of reduced BMD within the Phase Two study population was 
42.6% for lumbar spine (33.3% osteopaenia, 9.6% osteoporosis) and 26.4% 
for hip (23.7% osteopaenia, 2.7% osteoporosis). This places the Phase Two 
cohort in the lower half of the range of reduced BMD prevalence reported 
across other HIV cohorts (Goh et al. 2018) and less than the 67% prevalence 
reported from another meta-analysis of pooled data from predominantly 
Caucasian HIV patients (Brown and Qaqish 2006). When compared to other 
HIV cohorts with a higher proportion of black patients, the Phase Two 
observed reduced BMD prevalence was also lower, however, although one of 
these studies with reduced BMD prevalence of 67% had a comparatively 
much older HIV cohort (mean age 61.5 ± 5 years) (Jones et al. 2008).  
 
Whilst there was a trend to lower BMD in white patients compared with black 
patients and white female patients compared with white male patients within 
the Phase Two study population, there was no significant difference in BMD at 
any site between any race / gender subgroup, perhaps due to relatively small 
patient numbers within comparative subgroups.  
 
The prevalence of reduced BMD as determined by T-score did vary between 
race / gender subgroups at the lumbar spine – 80% in black males, 50% in 
white males, 40% in white females and 19% in black females – and at the hip 
– 35% in white males, 30% in white females, 20% in black males and 16% in 
black females. The higher prevalence of reduced lumbar spine BMD in black 
male Phase Two patients compared to other race / gender subgroups is likely 
to be exaggerated by the recruitment of proportionally more high or 
intermediate fracture risk (older) black males into the Phase Two study than 
low risk (younger) black males and therefore may not be reflective of the 
prevalence of reduced BMD in black males within the wider Sheffield HIV 
Cohort. 
 
No comparative HIV-negative control group was included in this study, limiting 
comparisons of BMD to the general population. Meta-analyses of BMD in 
PLWH have consistently demonstrated a higher prevalence of and greater 
odds ratios for reduced BMD in PLWH when compared to age- and sex-
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matched HIV-negative controls (Brown and Qaqish 2006, Goh et al. 2018). 
The mean lumbar spine and total hip Z-scores for Phase Two patients (Table 
4.5) suggest BMD measurements below age-, sex- and ethnicity-matched 
population means for all patient race / gender subgroups at each BMD site 
(except for the mean total hip Z-score in black female patients which was 
normal). The range of Z-scores for each BMD site in Phase Two was wide, 
however, and the number of patients within each subgroup relatively small, 
especially with respect to black males and white females. Furthermore, using 
UK black population data as a comparator for black patients of African origin 
may be suboptimal: BMD measurements in healthy Zimbabwean females 
were lower than in US black female patients in another study, although BMI 
was also lower in Zimbabwean black females than in US black females 
(Mukwasi et al. 2015). 
 
There was some commonality in significant determinants of BMD at each site 
within the Phase Two study population. Following multivariate analysis, BMI 
was a significant predictor of BMD at every site and the strongest predictor of 
BMD for lumbar spine, total hip and femoral neck BMD (p < 0.001 for each); 
fragility fracture history was also a significant predictor of BMD at the lumbar 
spine, total hip and for total body (although not femoral neck). The presence 
of one or more other disorders associated with osteoporosis (collectively, but 
not individually) was also a significant predictor of BMD for total hip, femoral 
neck and total body (although not lumbar spine). Rheumatoid arthritis was a 
significant independent predictor of total hip BMD (borderline significance for 
femoral neck). Significant steroid exposure, however, was only a significant 
predictor of total body BMD only (p = 0.002) and was, unusually, associated 
with significantly higher BMD than in patients without significant steroid 
exposure. The association of age with BMD was only borderline significant for 
femoral neck BMD only (p = 0.082). In terms of other general fracture risk 
factors, whilst alcohol consumption ≥ 3 units d-1 was significantly associated 
with reduced BMD at the hip and femoral neck on univariate analysis, this was 
not significant on multivariate analysis. Non-FRAX® general fracture risk 
factors, such as SSRI use, Depo-Provera® use in female patients and 
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recreational drug use, were not significantly associated with BMD in this 
cohort.  
 
In addition to FRAX®-incorporated general fracture risk factors, the only other 
factor – and the only HIV disease-specific factor – significantly associated with 
reduced BMD was increased cumulative PI exposure (independent of age) 
with respect to total hip (p = 0.004) and femoral neck (p = 0.007) (not lumbar 
spine or total body). Increased cumulative AZT exposure was associated with 
reduced BMD at the total hip and femoral neck with borderline significance. 
Whilst increased continuous tenofovir DF exposure was significantly 
associated with reduced total body BMD in univariate analysis, this was seen 
on multivariate analysis.  
 
These results again support the notion that general risk factors contribute 
more to BMD (and therefore also to fracture risk) than HIV disease-specific 
factors in PLWH. With all significant predictors of both lumbar spine and total 
body BMD included in FRAX®, “unmodified” FRAX®  – i.e. without the addition 
of HIV as a “secondary osteoporosis” risk factor – could therefore be a valid 
tool to predict non-hip fragility fractures in this population. FRAX® could be a 
reasonable tool to predict hip and femoral neck fractures also – with the 
majority of significant determinants of total hip and femoral neck BMD also 
included in FRAX® – although perhaps with the need for some modification of  
FRAX® to incorporate cumulative PI exposure in order to improve hip fracture 
prediction accuracy. The relatively small size of the Phase Two study 
population, the relatively low prevalence of patients with some risk factors 
within this population (e.g. injecting drug use (0.9%); HCV coinfection (1.8%)) 
and the lack of equal and sufficiently sized groups of patients either with and 
without individual fracture risk factors for comparative analysis limit the 
robustness of these findings, however, and therefore the ability to apply these 
conclusions to the wider Sheffield HIV Cohort and to PLWH in general. 
 
Individual race / gender subgroups were too small to adequately assess 
whether or not individual covariates or factors had a greater or lesser impact 
on BMD in any one race / gender subgroup compared to another. 
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4.11 Conclusions 
 
1. The Phase Two study population was older than the Phase One study 
population and therefore Phase Two BMD measurements may be lower 
overall than they would be on average for the wider Sheffield HIV Cohort, 
although higher BMI in Phase Two patients versus Phase One patients 
may offset this.  
 
2. The prevalence of reduced BMD in the Phase Two study population was 
lower than average when compared with data reported from other HIV 
cohorts, but, based on Z-scores, BMD was still lower than in the general 
population; there were no significant differences in BMD at any site 
between patients of different race and gender. 
 
3. FRAX®-incorporated general fracture risk factors were more significant 
than both non-FRAX®-incorporated general fracture risk factors and HIV 
disease-specific factors in determining BMD (and therefore also fracture 
risk) in PLWH, although cumulative PI exposure was also a significant 
predictor of total hip and femoral neck BMD; FRAX® might therefore be a 
valid tool for predicting fragility fracture risk in PLWH, with or without 
modification for cumulative PI exposure to improve accuracy of hip 
fracture probability prediction.  
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5. Distribution, determinants and effects of 25-hydroxyvitamin D and 
other biochemical factors, including their effect on bone mineral 
density, in people living with HIV in Sheffield 
 
5.1 Introduction 
 
Vitamin D deficiency – defined as 25-OH-D <50 nmol l-1 – is highly prevalent 
within PLWH, with reported prevalence within HIV cohorts ranging from 38% 
(Manion et al. 2017) to 89% (Cervero et al. 2018). Whether or not vitamin D 
deficiency is more prevalent in PLWH than in the general population remains 
equivocal, with conflicting data reported (Sherwood et al. 2012, Hidron et al. 
2015,). Indeed, many of the significant determinants of vitamin D deficiency in 
PLWH are not HIV disease-specific, including black race (Welz et al. 2010, 
Sherwood et al. 2012), reduced sunlight exposure (Paul et al. 2010, Welz et 
al. 2010), increased BMI (Dao et al. 2011) and renal insufficiency (Dao et al. 
2011).  
 
Emerging data, however, suggests that HIV disease-specific factors do 
contribute to 25-OH-D levels. 25-OH-D has been shown to be lower in HIV-
positive patients on ART compared with age- and sex-matched ART-naïve 
HIV-infected patients (Garcia et al. 2006, Paul et al. 2010), implicating ART as 
a potential 25-OH-D determinant. NNRTI use (Mueller et al. 2010) and, 
moreover, exposure to efavirenz (but not nevirapine, nor the newer NNRTI 
rilpivirne) has been specifically implicated (Welz et al. 2010, Wohl et al. 2014), 
with potent induction of 25-hydroxylase (CYP3A4) and 24-hydroxylase 
(CYP24) enzymes by efavirenz causing accelerated catabolism of vitamin D 
metabolites (Gyllensten et al. 2006). Low nadir CD4 cell count is another HIV 
disease-specific factor found to be significantly associated with lower 25-OH-
D levels (Welz et al. 2010). (The relationship between 25-OH-D and chronic 
inflammation and immune activation in HIV will be examined in Chapter 6.) 
 
Data linking reduced levels of 25 OH-D to reduced BMD in PLWH remains 
less clear. A recent South African study demonstrated lower total hip (but not 
lumbar spine) BMD in patients with lower 25-OH-D (Dave et al. 2015), which 
 196 
was in contrast to the findings of other studies in which no significant 
association was identified between BMD and 25-OH-D, after adjusting for 
general fracture risk factors (Sherwood et al. 2012, Cotter et al. 2014). A 
Southern Indian study linked 25-OH-D to hyperparathyroidism and 
hyperparathyroidism to reduced BMD in PLWH, although 25-OH-D was not 
associated with BMD directly (Paul et al. 2010). There is a paucity of 
published data regarding the effect of vitamin D deficiency on falls frequency 
and fracture prevalence in PLWH. 
 
In addition to hyperparathyroidism in the context of vitamin D deficiency (Paul 
et al. 2010), hyperparathyroidism in PLWH has also been independently 
associated with the NRTI tenofovir DF, with higher PTH levels observed within 
the first 48 weeks following initiation of tenofovir DF/emtricitabine than 
following initiation of abacavir/lamivudine, but without any effect noted on 
serum and urine phosphate and calcium (Masia et al. 2012); this association 
may not necessarily persist in patients well established on tenofovir DF-based 
ART, however (Samarawickrama et al. 2018). Moreover, tenofovir DF has 
been associated with renal phosphate wasting (Fux et al. 2007), accelerated 
renal function decline (Calza et al. 2009) and, less commonly, PRTD (Fux et 
al. 2007, Calza et al. 2009) in PLWH and it has been postulated that renal 
phosphate wasting could be one mechanism by which tenofovir DF may 
cause greater bone loss than non-tenofovir DF containing ART in PLWH. The 
renal and bone effects of tenofovir DF are likely to be potentiated by co-
administration with a boosted PI (Calmy et al. 2009, Calza et al. 2011, 
Mizushima et al. 2018). In one cross-sectional study, both lumbar spine and 
hip BMD were lower in patients with PRTD than in those without, but the 
differences in BMD were not significant (Calmy et al. 2009). 
 
This chapter aims to answer the following questions: 
 
1. What is the distribution of 25-OH-D within the Sheffield HIV Cohort and 
how does this compare to other HIV cohorts? 
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2. What are the general and HIV disease-specific determinants of 25-OH-D 
within the Sheffield HIV Cohort and do these differ to those identified in 
other HIV cohorts? 
 
3. Are there significant associations between 25-OH-D and BMD, falls 
frequency and fracture prevalence within the Sheffield HIV Cohort? 
 
4. What is the distribution of serum phosphate within the Sheffield HIV 
Cohort, what are its general and HIV disease-specific determinants – 
including assessment of association with tenofovir DF exposure – and 
what are its effects on BMD, falls frequency and fracture prevalence? 
 
5. What is the distribution or prevalence of other “biochemical” factors – 
namely serum PTH, serum corrected calcium, renal phosphate wasting 
(measured as percentage of tubular reabsorption of phosphate (TRP)), 
PRTD and renal insufficiency (measured as race-adjusted estimated 
glomerular filtration rate (eGFR)) – within the Phase Two study 
population, what are their general and HIV disease-specific determinants 
and what are their effects on BMD? 
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5.2 Distribution, determinants and effects of 25-hydroxyvitamin D in PLWH 
 
5.2.1 Distribution and determinants of 25-hydroxyvitamin D in PLWH 
 
The distribution of 25-OH-D in the Phase One study cohort is shown in Table 
5.1 (n = 575, excluding 33 patients for whom no 25-OH-D result was available 
and a further 17 patients either currently taking vitamin D supplementation or 
having taken vitamin D supplementation in the past). Table 5.1 and Figure 5.1 
also detail the distribution of 25-OH-D by patient race / gender subgroups. 
The percentage prevalence of Phase One patients with 25-OH-D <25 nmol l-1 
(severe deficiency), 25 – 49.9 nmol l-1 (non-severe deficiency), 50 – 74.9 nmol 
l-1 (insufficiency) and ≥75 nmol l-1 (normal) was 35.5%, 46.7%, 9.9% and 7.9% 
respectively. Greater proportions of black patients had 25-OH-D <25 nmol l-1 
or <50 nmol l-1 compared to white patients (Figure 5.1), with 25-OH-D 
significantly lower in black males compared to white males (p < 0.001), in 
black females compared to white females (p = 0.001) and in black patients 
compared to white patients (p < 0.001). 25-OH-D was also significantly lower 
in female patients (of whom 78.2% were of black race) compared with male 
patients (of whom 64.3% were of white race) (p < 0.001), although with 25-
OH-D also significantly lower in white females compared with white males (p = 
0.017) (no significant difference observed in 25-OH-D between black males 
and black females). 
 
There was a significant difference in 25-OH-D according to season of 
sampling (winter  = December to February, spring = March to May, summer = 
June to August and autumn = September to November) with 25-OH-D 
significantly higher if sampled in summer as opposed to non-summer months 
(p = 0.004) (Table 5.2 and Figure 5.2). Atypically, some very high 25-OH-D 
values (greater than 150 nmol l-1) were observed in patients sampled in 
autumn (in two patients) and in winter (one patient), with none in patients 
sampled in spring or summer. Whilst patients reporting current or previous 
vitamin D and/or calcium supplementation were excluded from analysis, no 
data was collected or available with respect to recent sunbed use or overseas 
travel.
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All 
(n = 575) 
 
Black  
(n = 294) 
 
White  
(n = 261) 
Non-Black Non-White  
(n = 20) 
 
Male  
(n = 107) 
 
Female         
(n = 187) 
Male 
(n = 216) 
Female  
(n = 45) 
Male  
(n = 13) 
Female  
(n = 7) 
Median 25-OH-D nmol l-1 29.6  24.1 25.9 38.7 30.6 25.2 37.2  
IQR 20.8 – 42.8 18.5 – 30.0 17.8 – 35.6 28.7 – 62.4 25.2 – 47.6 18.0 – 27.4 23.7 – 46.6 
Range  9.9 – 191.1 9.9 – 75.6 9.9 – 85.3 11.5 – 191.1 13.1 – 116.7 9.9 – 41.5 19.4 – 104.3 
                              
Table 5.1. 25-hydroxyvitamin D (25-OH-D) for all (n = 575), black (n = 331), white (n = 274) and non-black non-white (n = 20) 
patient subgroups within the Phase One study population (25-OH-D values <10.0 nmol l-1 (lowest limit of quantification) 
recorded as 9.9 nmol l-1)
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Figure 5.1. Distribution of and differences between 25-hydroxyvitamin D 
(25-OH-D) in black male (n = 107), black female (n=187), white male (n = 
216) and white female (n= 45) patient subgroups within the Phase One 
study population (25-OH-D values <10.0 nmol l-1 (lowest limit of 
quantification) recorded as 9.9 nmol l-1) 
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Winter 
(n = 216) 
Spring                            
(n = 139) 
Summer 
(n = 56) 
Autumn 
(n = 164) 
Median 25-OH-D nmol l-1 29.0 28.7 33.8 30.2 
IQR 20.0 – 41.8 20.7 – 39.6 27.0 – 57.9 20.1 – 41.5 
Range  9.9 – 191.1 9.9 – 131.4 9.9 – 112.9 9.9 – 176.2 
                              
Table 5.2. Distribution of 25-hydroxyvitamin D (25-OH-D) within the Phase One study according to season of sampling    
(25-OH-D values <10.0 nmol l-1 (lowest limit of quantification) recorded as 9.9 nmol l-1) (winter  = December to February, 
spring = March to May, summer = June to August and autumn = September to November)
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Figure 5.2. Distribution of 25-hydroxyvitamin D (25-OH-D) within the 
Phase One study population according to season of sampling (25-OH-D 
values <10.0 nmol l-1 (lowest limit of quantification) recorded as 9.9 nmol 
l-1) (winter  = December to February (n = 216), spring = March to May (n = 
139), summer = June to August (n = 56) and autumn = September to 
November (n = 164)) 
 
 
 
 
 
 
Figure 5.3. Relationship between 25-hydroxyvitamin D (25-OH-D) and 
patient age within the Phase One study population (n = 575) (25-OH-D 
values <10.0 nmol l-1 (lowest limit of quantification) recorded as 9.9 nmol 
l-1) 
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Figure 5.4. Relationship between 25-hydroxyvitamin D (25-OH-D) and 
patient body mass index (BMI) within the Phase One study population (n 
= 570) (25-OH-D values <10.0 nmol l-1 (lowest limit of quantification) 
recorded as 9.9 nmol l-1)  
 
 
 
 
There was a significant association between 25-OH-D and age, with an 
increase-in 25-OH-D with older age (r = 0.096, p = 0.021) (Figure 5.3), but 
there was no significant association between 25-OH-D and either patient 
weight (r = 0.057, p = 0.169) or BMI (r = -0.060, p = 0.153) (Figure 5.4). 
 
With respect to HIV disease-specific factors, there was a significant positive 
correlation between 25-OH-D and nadir CD4 cell count (r = 0.097, p = 0.022) 
(Figure 5.5), but no significant association between 25-OH-D and current CD4 
cell count (r = 0.069, p = 0.100), nor any significant difference in 25-OH-D 
between patients with or without HIV viral load <40 copies ml-1 (p = 0.228) or 
<200 copies ml-1 (p = 0.257), although median 25-OH-D and interquartile 
range of 25-OH-D were lower in patients with suppressed HIV viral load at 
either cut-off value than in patients with unsuppressed HIV viral load (Table 
5.3). 
0 20 40 60
0
50
100
150
200
BMI (kg m-2)
2
5
-h
y
d
ro
x
y
v
it
a
m
in
 D
 (
n
m
o
l 
l-
1
)
r = -0.060
p = 0.153
 204 
 
 
Figure 5.5. Relationship between 25-hydroxyvitamin D (25-OH-D) and 
patient nadir CD4 cell count (cells μL-1) within the Phase One study 
population (n = 558) (25-OH-D values <10.0 nmol l-1 (lowest limit of 
quantification) recorded as 9.9 nmol l-1)  
 
 
 
 
 
25-OH-D was not significantly different in Phase One patients with either 
current or ever exposure to any ART or to any NRTI compared with Phase 
One patients without respective exposures (p = 0.067, p = 0.170, p = 0.088 
and p = 0.0164 for current ART exposure, ever ART exposure, current NRTI 
exposure and ever NRTI exposures respectively), however median 25-OH-D 
and interquartile range of 25-OH-D were lower in patients with ART or NRTI 
exposures compared with patients without (Table 5.3). Neither the duration of 
continuous or cumulative ART had any significant association with 25-OH-D   
(r = -0.018, p = 0.672 and r = 1.000, p = 0.710 for continuous and cumulative 
ART exposure respectively) (continuous and cumulative duration of NRTI data 
not collected within the Phase One study population). 
0 500 1000 1500
0
50
100
150
200
Nadir CD4 cell count (cells µL-1)
2
5
-h
y
d
ro
x
y
v
it
a
m
in
 D
 (
n
m
o
l 
l-
1
)
r = 0.097
p = 0.022*
 205 
HIV disease-specific factor  n 
25-hydroxyvitamin D nmol l-1 
p-value 
Median IQR Range 
Plasma HIV RNA <40 copies ml-1 
No 218 31.3 21.4 – 31.3 9.9 – 176.2 
.228 
Yes 357 29.1 20.7 – 40.8 9.9 – 191.1 
Plasma HIV RNA <200 copies ml-1 
No 176 30.3 22.3 – 46.9 9.9 – 117.8 
.257 
Yes 399 29.3 20.5 – 41.1 9.9 – 191.1 
Current ART 
No 152 32.0 22.8 – 47.2 9.9 – 176.2 
.067 
Yes 423 29.1 20.4 – 40.9 9.9 – 191.1 
Ever ART 
No 129 30.0 22.7 – 47.1 9.9 – 117.8 
.170 
Yes 446 29.4 20.6 – 41.2 9.9 – 191.1 
Current NRTI 
No 158 31.4 22.5 – 47.1 9.9 – 176.2 
.088 
Yes 417 29.1 20.5 – 41.0 9.9 – 191.1 
Ever NRTI 
No 130 30.3 22.9 – 47.1 9.9 – 117.8 
.164 
Yes 445 29.4 20.6 – 41.2 9.9 – 191.1 
Current NNRTI 
No 297 31.9 23.4 – 46.4 9.9 – 176.2 
<.001 
Yes 278 27.3 19.2 – 39.5 9.9 – 191.1 
  
Table 5.3 (continued overleaf) Differences in 25-hydroxyvitamin D in patients with or without exposure to HIV disease-
specific antiretroviral treatment (ART)-related factors within the Phase One study population (n = 575) (NRTI = 
nucleos(t)ide reverse transcriptase inhibitors; NNRTI =  non-nucleoside reverse transcriptase inhibitor; PI = protease 
inhibitor; EFV = efavirenz; NVP = nevirapine; 25-hydroxyvitamin D values <10.0 nmol l-1 (lowest limit of quantification) 
recorded as 9.9 nmol l-1) 
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HIV disease-specific factor  n 
25-hydroxyvitamin D nmol l-1 
p-value 
Median IQR Range 
Ever NNRTI 
No 216 30.9 23.1 – 45.3 9.9 – 174.8 
.051 
Yes 359 28.8 19.9 – 39.5 9.9 – 191.1 
Current EFV 
No 376 31.3 23.1 – 46.2 9.9 – 191.1 
<.001 
Yes 199 26.7 18.5 – 37.4 9.9 – 121.6 
Ever EFV 
No 314 31.6 23.4 – 45.9 9.9 – 191.1 
<.001 
Yes 261 27.4 19.2 – 39.7 9.9 – 131.4 
Current NVP 
No 507 29.8 21.0 – 43.3 9.9 – 176.2 
.488 
Yes 68 28.3 20.2 – 40.7 10.7 – 191.1 
Ever NVP 
No 454 28.8 20.4 – 41.3 9.9 – 174.8 
.034 
Yes 121 31.9 23.6 – 48.7 10.7 – 191.1 
Current PI 
No 420 28.6 19.8 – 43.3 9.9 – 191.1 
.017 
Yes 155 31.9 24.5 – 41.9 9.9 – 174.8 
Ever PI 
No 357 28.6 20.1 – 42.2 9.9 – 191.1 
.098 
Yes 218 31.4 22.5 – 43.3 9.9 – 176.2 
  
Table 5.3 (continued from overleaf) Differences in 25-hydroxyvitamin D3 in patients with or without exposure to HIV 
disease-specific antiretroviral treatment (ART)-related factors within the Phase One study population (n = 575) (NRTI = 
nucleos(t)ide reverse transcriptase inhibitors; NNRTI =  non-nucleoside reverse transcriptase inhibitor; PI = protease 
inhibitor; EFV = efavirenz; NVP = nevirapine; 25-hydroxyvitamin D values <10.0 nmol l-1 (lowest limit of quantification) 
recorded as 9.9 nmol l-1)
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Figure 5.6. Distribution of 25-hydroxyvitamin D (25-OH-D) in Phase One 
patients not currently on versus currently on and never exposed to 
versus ever exposed to any non-nucleoside reverse transcriptase 
inhibitor (NNRTI), efavirenz (EFV) or nevirapine (NVP) (25-OH-D values 
<10.0 nmol l-1 (lowest limit of quantification) recorded as 9.9 nmol l-1)  
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Figure 5.7. Relationship between 25-hydroxyvitamin D (25-OH-D) and 
both continuous and cumulative duration (months) of efavirenz (EFV) 
and nevirapine (NVP) in Phase One patients (25-OH-D values <10.0 nmol 
l-1 (lowest limit of quantification) recorded as 9.9 nmol l-1)  
 
 
 
25-OH-D was significantly lower in patients with current exposure to NNRTIs 
(p < 0.001), with current or ever efavirenz exposure (p < 0.001 and p = 0.001 
respectively) and with ever nevirapine exposure (p = 0.032) compared with  
Phase One patients without respective exposures, but with no significant 
difference in 25-OH-D in patients with ever versus never NNRTI exposure (p = 
0.051) or with current versus not current nevirapine exposure (p = 0.488) 
(Table 5.3 and Figure 5.6). Both longer continuous duration of efavirenz and 
longer cumulative duration of efavirenz exposures were associated with 
significantly lower 25-OH-D values (r = -0.174, p < 0.001 and r = -0.156, p 
<0.001 respectively); the duration of continuous exposure to nevirapine had 
no significant relationship with 25-OH-D, however (r = -0.022, p = 0.599) and 
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longer cumulative duration of nevirapine exposure was associated with 
significantly higher 25-OH-D values (r = 0.038, p = 0.034) (Figure 5.7). 
 
Phase One patients with current, but not ever, PI exposure had a significantly 
higher 25-OH-D than Phase One patients not currently on a PI (p = 0.017, 
Table 5.3 and Figure 5.8) (continuous and cumulative PI exposure not 
collected within the Phase One study population). 
 
 
 
 
 
Figure 5.8. Distribution of 25-hydroxyvitamin D (25-OH-D) in Phase One 
patients not currently on versus currently on and never exposed to 
versus ever exposed to any protease inhibitor (PI) (25-OH-D values <10.0 
nmol l-1 (lowest limit of quantification) recorded as 9.9 nmol l-1)  
 
 
 
 
The prevalence of patients with a history of either chronic diarrhoea, 
malabsorption or liver cirrhosis were low within the Phase One study 
population for whom 25-OH-D data was available for analysis: 2.6% (n = 15), 
0.7% (n = 4) and 0.7% (n = 4) respectively. There was no significant 
difference in 25-OH-D between patients with or without a history of chronic 
diarrhoea, malabsorption or liver cirrhosis (p = 0.708, p = 0.257 and p = 0.065 
respectively, Table 5.4). 
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Factor Factor present n 
25-hydroxyvitamin D nmol l-1 
p-value 
Median IQR Range 
Chronic diarrhoea 
No 560 29.5 20.7 – 42.8 9.9 – 191.1 
.708 
Yes 15 29.8 22.5 – 29.8 14.8 – 99.5 
Malabsorption 
No 571 29.4 20.7 – 42.8 9.9 – 191.1 
.257 
Yes 4 35.5 32.8 – 46.6  32.4 – 49.9 
Liver cirrhosis 
No 571 29.4 20.7 – 42.6 20.7 – 42.6 
.065 
Yes 4 43.4 39.0 – 56.2 38.6 – 59.3 
  
Table 5.4. Differences in 25-hydroxyvitamin D in patients with or without a history of chronic diarrhoea, malabsorption or 
liver cirrhosis within the Phase One study population (n = 575) (25-hydroxyvitamin D values <10.0 nmol l-1 (lowest limit of 
quantification) recorded as 9.9 nmol l-1) 
 
Factor Factor present n 
25-hydroxyvitamin D nmol l-1 
p-value 
Median IQR Range 
Race-adjusted eGFR <90 ml min-1 
No 54 31.8 18.8 – 54.7 12.4 – 176.0 
<.001 
Yes 27 46.6 35.8 – 83.5 14.8 – 151.3 
Race-adjusted eGFR <60 ml min-1 
No 78 36.8 25.1 – 69.9 12.4 – 176.0 
.560 
Yes 3 35.6 - 35.1 – 82.6 
  
Table 5.5. Differences in 25-hydroxyvitamin D in patients with or without race-adjusted eGFR <90 ml min-1 or <60 ml min-1 
within the Phase Two study population (n = 81) (25-hydroxyvitamin D values <10.0 nmol l-1 (lowest limit of quantification) 
recorded as 9.9 nmol l-1)
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eGFR adjusted for race (x1.159 in patients of black race) was available for 
Phase Two study patients only (n = 114), of whom 81 patients had never 
received vitamin D supplementation and for whom analysis of 25-OH-D 
determinants was possible. Patients with race-adjusted eGFR <90 ml min-1 
had significantly higher 25-OH-D than patients with race-adjusted eGFR ≥90 
ml min-1 (p < 0.001) (Table 5.5). There was no significant difference in 25-OH-
D between patients with race-adjusted eGFR <60 ml min-1 versus those with 
race-adjusted eGFR ≥60 ml min-1 (p = 0.560), although only three patients 
had race-adjusted eGFR <60 ml min-1 (Table 5.5). 
 
Factors and co-variates found to have either significant (p < 0.05) or 
borderline significant (p ≥ 0.05 and < 0.10) with 25-OH-D within the Phase 
One study population are summarised in Table 5.6.  
 
Factor / covariate p-value Factor / co-variate p-value 
Black race <.001 Current ART .067 
Female gender <.001 Current NRTI .088 
Age .021 Ever NNRTI .051 
Summer sampling .004 Ever PI .098 
Nadir CD4 cell count .022 Liver cirrhosis .065 
Current NNRTI <.001  
Current EFV <.001 
Ever EFV .001 
No. mths continuous EFV <.001 
No. mths cumulative EFV <.001 
Ever NVP .032 
No. mths cumulative NVP .034 
Current PI .017 
 
Table 5.6. Factors and co-variates with significant (p < 0.05) or 
borderline significant (p ≥ 0.05 and < 0.10) associations with 25-
hydroxyvitamin D from univariate analysis within the Phase One study 
population  
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Factors and covariates with significant (p < 0.05) association with 25-OH-D 
were taken forward for multivariate analysis using a generalised linear model. 
Current NNRTI class exposure – non-independent of individual efavirenz and 
nevirapine exposure-related factors and covariates – was not taken forward 
for multivariate analysis. Furthermore, as no patients were on both efavirenz 
and nevirapine, nor on efavirenz and a PI or nevirapine and a PI 
simultaneously, efavirenz, nevirapine and PI exposure-related factors were 
also likely to be co-dependent; therefore, as efavirenz exposure had the 
strongest association with 25-OH-D on univariate analysis, only efavirenz 
exposure-related factors and not nevirapine or PI-exposure related factors 
were taken forward for multivariate analysis. Current efavirenz exposure was 
included over ever, continuous or cumulative efavirenz exposure. 20 non-
black non-white patients were excluded from the multivariate analysis, which 
included only patients of black or white race. 
 
Backward elimination was used to determine factors and covariates with 
significant association with 25-OH-D within the multivariate analysis model 
(detailed in Appendix A2.1), with stepwise elimination continuing until all 
residual risk factors achieved significance of p < 0.05. Factors and covariates 
with significant association with 25-OH-D following multivariate analysis are 
shown in Table 5.7. Only race (black versus white race), season of sampling 
(summer versus non-summer) and current efavirenz exposure were 
significantly associated with 25-OH-D on multivariate analysis, with summer 
sampling being associated with significantly higher 25-OH-D measurements 
and black race and current efavirenz exposure being associated with 
significantly lower 25-OH-D measurements.  
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Covariate / factor Factor present 
Estimated 
marginal mean 
nmol l-1 
Standard Error Wald Chi-Square p-value 
 White race 
No 30.900 1.837 
98.189 <.001 
Yes 49.964 2.001 
Summer season of sampling 
No 35.847 1.0472 
8.011 .005 
Yes 45.017 3.111 
Current efavirenz 
No 43.247 1.741 
7.825 .005 
Yes 37.617 2.126 
 
Table 5.7. Covariates and factors with significant (p < 0.05) association with 25-hydroxyvitamin D in the Phase One study 
population (n = 538) following multivariate analysis  
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5.2.2 Effects of 25-hydroxyvitamin D in PLWH 
 
The relationships between 25-OH-D and lumbar spine, total hip, femoral neck 
and total body BMD within the Phase Two study population, excluding Phase 
Two patients ever treated with vitamin D supplementation, are shown in 
Figure 5.9. Whilst there was a negative correlation between 25-OH-D and 
BMD, this was not significant at any BMD site (Figure 5.9). 
 
Furthermore, there was no significant correlation between 25-OH-D and BMD 
at any site in either black patients (r = 0.048, p = 0.798 for lumbar spine; r = -
0.149, p = 0.425 for total hip; r = -0.066, p = 0.724 for femoral neck and r = 
0.007, p = 0.968 for total body) or white patients (r = -0.230, p = 0.109 for 
lumbar spine; r = -0.162, p = 0.261 for total hip; r = -0.135, p = 0.349 for 
femoral neck and r = -0.086, p = 0.553 for total body) when analysed 
separately. 
 
There was no significant difference in 25-OH-D in all, black and white Phase 
One patients self-reporting no falls, one single fall or multiple falls within the 
previous twelve months (Table 5.8). 
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Figure 5.9. Relationship between 25-hydroxyvitamin D and lumbar (L-) 
spine, total hip, femoral neck and total body BMD in the Phase Two 
study population (n = 81) 
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Phase One patient group 
Number of falls                
in last 12 months 
n 
25-hydroxyvitamin D nmol l-1 
p-value 
Median IQR Range 
All patients 
None 500 29.7 20.7 – 42.4 9.9 – 191.1 
.199 Single 41 26.8 20.8 – 39.7 11.8 – 91.4 
Multiple 33 32.3 22.5 – 54.3 12.1 – 121.6 
Black patients 
None 261 25.6 18.1 – 34.8 9.9 – 85.3 
.492 Single 20 24.2 16.7 – 27.4 14.6 – 50.3 
Multiple 12 22.4 19.4 – 34.5 16.4 – 56.7 
White patients 
None 220 37.4 27.6 – 57.7 11.5 – 191.1 
.635 Single 20 36.0 24.6 – 50.3 11.8 – 91.4 
Multiple 21 38.1 28.7 – 85.6 12.1 – 121.6 
  
Table 5.8 Differences in 25-hydroxyvitamin D between all (n = 574), black (n = 293) and white (n = 261) Phase One patients 
self-reporting no falls, one single fall or multiple falls in last 12 months (25-hydroxyvitamin D values <10.0 nmol l-1 (lowest 
limit of quantification) recorded as 9.9 nmol l-1) 
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Phase One patient group 
Number of fractures        
in adulthood 
n 
25-hydroxyvitamin D nmol l-1 
p-value 
Median IQR Range 
All patients 
None 419 28.7 19.8 – 39.9 9.9 – 191.1 
<.001 Single 81 33.9 24.5 – 52.7 12.5 – 131.4 
Multiple 25 40.5 25.9 – 60.4 17.1 – 99.1 
Black patients 
None 241 24.5 17.8 – 32.1 9.9 – 81.0 
.069 Single 16 29.1 25.7 – 43.7 16.4 – 61.4 
Multiple 4 23.0 18.1 – 48.8 17.1 – 56.7 
White patients 
None 159 37.3 28.7 – 56.0 11.5 – 191.1 
.409 Single 64 35.9 24.4 – 62.5 12.5 – 131.4 
Multiple 21 46.4 31.2 – 68.2 22.6 – 99.1 
 
Table 5.9 Differences in 25-hydroxyvitamin D between all (n = 525), black (n = 261) and white (n = 244) Phase One patients 
self-reporting no fractures, one single fracture or multiple fractures in adulthood (25-hydroxyvitamin D values <10.0 nmol 
l-1 (lowest limit of quantification) recorded as 9.9 nmol l-1) 
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Figure 5.10. Distribution of 25-hydroxyvitamin D (25-OH-D) in black (n = 
261) and white (n = 244) Phase One patients reporting no fractures, one 
single fracture or multiple fractures in adulthood (25-OH-D values <10.0 
nmol l-1 (lowest limit of quantification) recorded as 9.9 nmol l-1)  
 
 
Whilst there was a significant difference in 25-OH-D in all Phase One patients 
reporting either no fractures, one single fracture or multiple fractures in 
adulthood overall (p < 0.001) (Table 5.9), within black and white patient 
subgroups, this difference was only significant between black patients 
reporting no fractures (n = 241) and black patients reporting one single 
fracture (n = 16) (p = 0.021), with 25-OH-D higher in patients reporting one 
single fracture (Figure 5.10).  
 
In terms of fragility fractures specifically, analysis of Phase Two patients (in 
whom vertebral fracture assessment was performed) revealed no significant 
difference in 25-OH-D between white patients without prior fragility fracture (n 
= 47, median 25-OH-D 45.4 nmol l-1, IQR 32.9 – 79.5) and those with prior 
fragility fracture (n = 3, median 25-OH-D 61.6 nmol l-1, range 35.1 – 82.6) (p = 
0.728). (The other seven Phase Two patients with prior fragility fracture, 
including all four black patients with prior fragility fracture, were either 
previously on or currently on vitamin D supplementation and therefore 
excluded from analysis.) 
 
0 1 ≥2
0
20
40
60
80
100
Number of fractures in adulthood
2
5
-h
y
d
ro
x
y
v
it
a
m
in
 D
 (
n
m
o
l 
l-
1
)
Black
p = 0.021*
p = 0.385
p = 0.898
0 1 ≥2
0
50
100
150
200
250
Number of fractures in adulthood
2
5
-h
y
d
ro
x
y
v
it
a
m
in
 D
 (
n
m
o
l 
l-
1
)
White
p = 0.602
p = 0.252
p = 0.201
 219 
 
Figure 5.11. Relationship between 25-hydroxyvitamin D and serum 
correct calcium (corr. calcium), serum phosphate, serum parathyroid 
hormone and tubular reabsorption of phosphate (TRP) in the Phase Two 
study population (n = 81) 
 
 
 
The relationships between 25-OH-D and serum corrected calcium, serum 
phosphate, TRP and serum PTH measurements are shown in Figure 5.11 for 
Phase Two patients (n = 81). Whilst there was no significant correlation 
between 25-OH-D and serum phosphate (r = -0.039, p = 0.733), there was a 
significant positive correlation between serum corrected calcium and 25-OH-D 
(r = 0.292, p = 0.008) and a significant negative correlation between serum 
PTH and 25-OH-D (r = -0.427, p < 0.001) and, unexpectedly, TRP and 25-
OH-D (r = -0.360, p = 0.001). A significant negative correlation between TRP 
and 25-OH-D was also observed in white patients on subgroup analysis (r =  -
0.282, p = 0.047), but not in black patients (r = -0.051, p = 0.788).  
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5.3 Distribution, determinants and effects of serum phosphate in PLWH 
 
5.3.1 Distribution and determinants of serum phosphate in PLWH 
 
The distribution of fasted serum phosphate within the Phase Two study 
population (n = 81) is shown in Figure 5.12 (mean 0.97 ± 0.16 mmol l-1, 
normal range 0.80 – 1.50 mmol l-1). 12 (14.8%) Phase Two patients had mild 
hypophosphataemia (serum phosphate 0.60 to 0.79 mmol l-1); no patients had 
serum phosphate measurements less than 0.60 mmol l-1. 
 
 
Figure 5.12. Distribution of serum phosphate in the Phase Two study 
population (n =81) 
 
 
 
There was no significant association between serum phosphate and patient 
age (r = -0.154, p = 0.169), weight (r = -0.413, p = 0.202) or BMI (r = 0.090, p 
= 0.425). Serum phosphate was significantly higher in black patients (mean 
1.02 ± 0.15 nmol l-1, n = 31) than in white patients (mean 0.94 ± 0.17 nmol l-1, 
n = 50) (p = 0.049) and in female patients (mean 1.05 ± 0.14 nmol l-1, n = 31) 
than in male patients (mean 0.92 ± 0.16 nmol l-1, n = 50) (p = 0.001). Serum 
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phosphate was not significantly different between black male (n = 10) and 
black female (n = 21), white male (n = 41) and white female (n = 9), black 
male and white male or black female and white female patients, however, 
although there was a trend to lower serum phosphate in white males (mean 
0.92 ± 0.16 nmol l-1) compared to white females (mean 1.07 ± 0.14 nmol l-1) 
(Figure 5.13). 
 
 
 
 
 
Figure 5.13. Distribution of serum phosphate in black male (n = 10), 
black female (n = 21), white male (n = 41) and white female (n = 9) Phase 
Two patients 
 
 
 
Patients with race-adjusted eGFR <90 ml min-1 (n = 27) also had significantly 
lower serum phosphate (mean 0.90 ± 0.15 mmol l-1) than patients with race-
adjusted eGFR ≥90 ml min-1 (mean 1.01 ± 0.16 mmol l-1, n = 54) (p = 0.006). 
Similarly, in patients with race-adjusted eGFR <60 ml min-1 (n = 3) serum 
phosphate was also lower (mean 0.83 ± 0.20 mmol l-1) than in patients with 
race-adjusted eGFR ≥60 ml min-1 (mean 0.98 ± 0.16 mmol l-1, n = 78), but not 
significantly (p = 0.123).   
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With respect to HIV disease-specific factors, nadir CD4 cell count had no 
significant effect on serum phosphate (r = 0.165, p = 0.147), although serum 
phosphate was significantly higher with higher current CD4 cell count (r = 
0.355, p = 0.001), which was also observed in black and white patient 
subgroups separately (r = 0.409, p = 0.022 and r = 0.378, p = 0.007 
respectively).  
 
There was no significant difference in serum phosphate between patients with 
or without HIV viral load suppression with plasma HIV RNA <40 copies ml-1 (p 
= 0.707) or <200 copies ml-1 (p = 0.737). Furthermore, there was no identified 
significant difference in serum phosphate in patients with or without either 
current or ever ART, NRTI, tenofovir DF, abacavir, NNRTI, efavirenz, 
nevirapine or PI exposure, although serum phosphate ranges were lower in 
patients currently on or ever exposed to ART or an NRTI (only very few 
patients not on or never exposed to either) or to tenofovir DF, but not to 
abacavir (Table 5.10). There was also a trend to reduced serum phosphate 
with longer continuous or cumulative exposure to ART (r = -0.200, p = 0.077 
and r = -0.216 and p = 0.056 respectively), NRTIs (r = -0.175, p = 0.123 and r 
= -0.213 and p = 0.060 respectively) and tenofovir DF (r = -0.213, p = 0.060 
and r = -0.213 and p = 0.174 respectively), but not abacavir (r = 0.020, p = 
0.857 and r = -0.031, p = 0.981 respectively) (Table 5.11 and Figure 5.14). 
Serum phosphate was also significantly lower with longer cumulative duration 
of NNRTI exposure (r = -0.233, p = 0.038). 
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HIV antiretroviral therapy-related 
factor 
Exposure n 
Mean serum PO4 
± s.d. mmol l-1 
p-value 
Current ART 
No 2 1.105 ± .106 
.242 
Yes 79 0.967 ± .164 
Ever ART 
No 2 1.105 ± .106 
.242 
Yes 79 0.967 ± .164 
Current NRTI 
No 4 1.045 ± .116 
.354 
Yes 77 0.966 ± .166 
Ever NRTI 
No 2 1.105 ± .106 
.242 
Yes 79 0.967 ± .164 
Current TDF 
No 26 0.988 ± .181 
.498 
Yes 55 0.962 ± .156 
Ever TDF 
No 23 0.998 ± .185 
.346 
Yes 58 0.959 ± .155 
Current ABC 
No 56 0.968 ± .153 
.838 
Yes 25 0.976 ± .184 
Ever ABC 
No 43 0.978 ± .145 
.643 
Yes 38 0.961 ± .185 
Current NNRTI 
No 35 0.970 ± .148 
.975 
Yes 46 0.971 ± .177 
Ever NNRTI 
No 14 1.034 ± .108 
.109 
Yes 67 0.957 ± .171 
Current EFV 
No 54 0.966 ± .171 
.711 
Yes 27 0.980 ± .152 
Ever EFV 
No 31 0.987 ± .143 
.473 
Yes 50 0.960 ± .176 
Current NVP 
No 72 0.974 ± .155 
.545 
Yes 9 0.939 ± .232 
Ever NVP 
No 62 0.976 ± .152 
.593 
Yes 19 0.953 ± .203 
Current PI 
No 45 0.969 ± .161 
.928 
Yes 36 0.972 ± .169 
Ever PI 
No 34 0.967 ± .173 
.878 
Yes 47 0.973 ± .159 
 
Table 5.10. Differences in serum phosphate in Phase Two patients (n = 
81) according to current or ever exposure to antiretroviral therapy (ART), 
individual ART classes and specific NRTIs and NNRTIs 
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HIV antiretroviral therapy-related factor r p-value 
Continuous number of months on ART -0.200 .077 
Cumulative number of months ever on ART -0.216 .056 
Continuous number of months on NRTI -0.175 .123 
Cumulative number of months ever on NRTI -0.213 .060 
Continuous number of months on TDF -0.212 .174 
Cumulative number of months ever on TDF -0.180 .109 
Continuous number of months on ABC 0.020 .857 
Cumulative number of months ever on ABC -0.003 .981 
Continuous number of months on NNRTI -0.111 .329 
Cumulative number of months ever on NNRTI -0.233 .038 
Continuous number of months on EFV -0.013 .909 
Cumulative number of months ever on EFV -0.089 .430 
Continuous number of months on NVP -0.129 .254 
Cumulative number of months ever on NVP -0.079 .484 
Continuous number of months on PI -0.006 .955 
Cumulative number of months ever on PI -0.005 .967 
 
Table 5.11. Relationship between continuous number of months on or 
cumulative number of months ever on antiretroviral therapy (ART), 
individual ART classes and specific nucleos(t)ide reverse transcriptase 
inhibitors (NRTIs), namely tenofovir disoproxil fumarate (TDF) and 
abacavir (ABC), and non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), namely efavirenz (EFV) and nevirapine (NVP) with serum 
phosphate in Phase Two patients (n = 81) 
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Figure 5.14. Relationship between serum phosphate and duration of 
continuous or cumulative exposure to tenofovir disoproxil fumarate 
(TDF) and abacavir (ABC) in the Phase Two study population (n = 81) 
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Factors and co-variates found to have either significant (p < 0.05) or 
borderline significant (p ≥ 0.05 and < 0.10) association with serum phosphate 
within the Phase Two study population are summarised in Table 5.12. These 
factors and covariates were taken forward for multivariate analysis, as 
described for 25-OH-D in Section 5.2.1. ART exposure-related covariates 
were deselected in favour of more specific NRTI and NNRTI class exposure-
related covariates. (Further detail is included in Appendix 2.2.) 
 
Factors and covariates with significant association (p < 0.05) with serum 
phosphate following multivariate analysis were: female gender (associated 
with higher serum phosphate, p = 0.020), race-adjusted eGFR <90 ml min-1 
(associated with lower serum phosphate, p = 0.023) and current CD4 cell 
count (increased CD4 cell count associated with higher serum phosphate, p = 
0.026) (Table 5.13). 
 
 
 
 
Factor / covariate p-value Factor / co-variate p-value 
White race .049 No. of continuous mths on ART .077 
Female gender .001 No. of cumulative mths on ART .056 
Race-adjusted eGFR <90 ml min-1 .006 No. of cumulative mths on NRTI .060 
Current CD4 cell count .001  
No. of cumulative mths on NNRTI .038 
 
Table 5.12. Factors and co-variates with significant (p < 0.05) or 
borderline significant (p ≥ 0.05 and < 0.10) associations with serum 
phosphate from univariate analysis within the Phase Two study 
population
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Covariate / factor Factor present 
Estimated 
marginal mean 
mmol l-1 
Standard Error Wald Chi-Square p-value 
 Female gender 
No 0.926 0.029 
5.436 .020 
Yes 1.010 0.030 
Race-adjusted eGFR <90 ml min-1 
No 1.009 0.020 
5.201 .023 
Yes 0.928 0.304 
Current CD4 cell count - - - 4.928 .026 
 
Table 5.13. Covariates and factors with significant (p < 0.05) association with serum phosphate in the Phase Two study 
population (n = 81) following multivariate analysis  
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5.3.2 Effects of serum phosphate in PLWH 
 
There was no significant relationship between serum phosphate and BMD at 
any site in the Phase Two study population (Figure 5.15). Furthermore, no 
relationship between serum phosphate and BMD at any site was observed 
within each of the four patient race / gender subgroups (data not shown).  
 
 
 
Figure 5.15. Relationship between serum phosphate and lumbar (L-) 
spine, hip, femoral neck and total BMD in the Phase Two study 
population (n = 81) 
 
 
The relationships between serum phosphate and serum corrected calcium, 
PTH and TRP respectively are shown in Figure 5.16. There was no observed 
relationship between serum phosphate and serum corrected calcium. Serum 
parathyroid hormone levels decreased with increased serum phosphate, but 
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not significantly. There was a significant positive correlation between TRP and 
serum phosphate, however (r = 0.333, p = 0.003). 
 
There was no significant difference in serum phosphate in Phase Two 
patients self-reporting no falls, one single fall or multiple falls within the 
previous 12 months (Table 5.14) or no fractures, one fracture or multiple 
fractures in adulthood (Table 5.15). The few included patients with a history of 
fragility fracture (n = 3) had lower mean serum phosphate (0.93 ± 0.23 mmol  
l-1) compared to patients without (0.97 ± 0.16 mmol l-1, n = 78) but this 
difference was not significant (p = 0.667). 
 
 
 
Figure 5.16. Relationship between serum phosphate and serum correct 
calcium (corr. calcium), serum parathyroid hormone and tubular 
reabsorption of phosphate (TRP) in the Phase Two study population (n = 
81)  
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Phase Two patient group 
Number of falls in last 12 
months 
n 
Serum phosphate mmol l-1 
p-value 
Mean s.d. 
All patients 
None 68 0.974 .163 
.878 Single 5 0.944 .157 
Multiple 8 .0953 .198 
  
Table 5.14. Differences in serum phosphate between all (n = 81) Phase Two patients self-reporting no falls, 
one single fall or multiple falls in last 12 months  
 
 
 
 
Phase Two patient group 
Number of fractures in 
adulthood 
n 
Serum phosphate mmol l-1 
p-value 
Mean s.d. 
All patients 
None 56 0.978 .155 
.836 Single 18 0.956 .197 
Multiple 7 0.950 .165 
  
Table 5.15. Differences in serum phosphate between all (n = 81) Phase Two patients self-reporting no falls, 
one single fall or multiple fractures in adulthood  
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5.4 Distribution, determinants and effects of other biochemical markers in 
PLWH 
 
5.4.1 Parathyroid hormone 
 
Median PTH in all, black and white Phase Two patients was 57 ng l-1 (IQR 
44.0 – 72.5), 73 ng l-1 (IQR 37.0 – 167.0) and 48.5 ng l-1 (IQR 38.8 – 61.3) 
respectively (normal range 15.0 – 65.0 ng l-1), with PTH significantly higher in 
black patients than in white patients (p < 0.001). PTH was also significantly 
higher in black males (median 80.0 ng l-1, IQR 60.0 – 98.0) than in white 
males (median 47.0 ng l-1 IQR 37.5 – 61.5) (p = 0.001), but with no significant 
difference between black females (median 71.0 ng l-1, IQR 52.5 – 88.5) and 
white females (median 59.0 ng l-1, IQR 49.0 – 65.5) (p = 0.114), between 
black males and black females (p = 0.348) or between white males and white 
females (p = 0.113). 
 
The relationships between PTH and 25-OH-D and serum phosphate have 
been described in Sections 5.2.2 and 5.3.2 respectively. Predictably, there 
was a negative correlation between serum corrected calcium and PTH           
(r = -0.190, p = 0.090) and TRP increased significantly with increased PTH    
(r = 0.273, p = 0.014) (Figure 5.17).  
 
There was no significant relationship identified between current or ever 
tenofovir DF exposure and serum PTH levels (p = 0.567 and p = 0.297 
respectively). Whilst there was a negative correlation between both duration 
of continuous tenofovir DF exposure and duration of cumulative tenofovir DF 
exposure and serum PTH (r = -0.108 and r = -0.214 for continuous and 
cumulative tenofovir DF exposure respectively), which was in contrast to the 
positive correlation seen between both duration of continuous abacavir 
exposure and duration of cumulative abacavir exposure and PTH (r = 0.183 
and r = 0.184 respectively), these correlations were not significant (p = 0.336 
and p = 0.055 for continuous and cumulative tenofovir DF exposure 
respectively). Furthermore, after adjusting for 25-OH-D, the relationship  
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Figure 5.17. Relationship between serum parathyroid hormone and 
serum correct calcium (corr. calcium) and tubular reabsorption of 
phosphate (TRP) in the Phase Two study population (n = 81) 
 
 
between the duration of cumulative tenofovir DF exposure and PTH became 
even less significant (p = 0.500). 
 
There was no significant relationship observed between PTH and BMD at any 
site (r = 0.006, p = 0.956 for lumbar spine, r = 0.110, p = 0.330 for hip, r = 
0.095, p = 0.400 for femoral neck and r = -0.068, p = 0.547 for total body). 
 
 
5.4.2 Serum corrected calcium 
 
Mean serum corrected calcium in Phase Two patients was 2.25 ± 0.10 mmol  
l-1 (normal range 2.20 – 2.60), with no significant difference observed between 
patient race / gender subgroups. The relationships between serum corrected 
calcium and 25-OH-D, serum phosphate and PTH have been described in 
Sections 5.2.2, 5.3.2 and 5.4.1 respectively. TRP increased with increased 
serum corrected calcium (r = 0.106), but not significantly (p = 0.348).  
 
There was no significant relationship observed between serum corrected 
calcium and BMD at any site (r = 0.044, p = 0.699 for lumbar spine, r = 0.048, 
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p = 0.673 for total hip, r = -0.003, p = 0.979 for femoral neck and r = 0.080, p 
= 0.479 for total body). 
 
 
5.4.3 Tubular reabsorption of phosphate 
 
Median TRP in Phase Two patients was 87.0% (IQR 83 – 90, range 54 – 97) 
(normal range 82– 95). 21.3% patients (n = 17) had TRP <82%. TRP was 
significantly higher in black patients compared to white patients (p < 0.001), 
black females compared to white females (p = 0.004) and in black females 
compared to black males (p = 0.028) (Figure 5.18). TRP decreased 
significantly with age (r = -0.346, p = 0.002) and increased significantly with 
BMI (r = 0.247, p = 0.027) (Figure 5.19). TRP was significantly lower in 
patients with race-adjusted eGFR <90 ml min-1 compared to those with eGFR 
≥ 90 ml min-1 (median 88.0%, IQR 76.0 – 97.0) (p < 0.001, Figure 5.20).  
 
 
 
 
 
 
Figure 5.18. Distribution of tubular reabsorption of phosphate (TRP) in 
black males (n= 9), black females (n = 21), white males (n = 41) and white 
females (n = 9) within the Phase Two study population (n = 81) 
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Figure 5.19. Relationship between tubular reabsorption of phosphate 
(TRP) with age and body mass index (BMI) in the Phase Two study 
population (n = 81) 
 
 
 
 
 
 
 
 
 
 
Figure 5.20. Distribution of tubular reabsorption of phosphate (TRP) in 
patients with race-adjusted eGFR ≥90 ml min-1 (n = 53) and <90 ml min-1 
(n = 27) within the Phase Two study population (n = 81) 
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There was no difference in TRP between Phase Two patients currently on 
tenofovir DF compared to those not currently on tenofovir DF (p = 0.799), with 
a similar range of TRP observed in patients currently on abacavir to those 
currently on tenofovir DF (Table 5.16). Furthermore, there was no significant 
relationship between TRP and duration of continuous exposure to tenofovir 
DF (r = -0.024, p = 0.832) (Table 5.17).  
 
Patients currently on efavirenz had a signifcantly higher percentage of TRP 
than those not currently on efavirenz (p = 0.040), but no significant difference 
was seen between patients currently on or not currently on nevirapine (p = 
0.532) (Table 5.16). Furthermore, there was a trend to a lower percentage of 
TRP with longer continuous duration of efavirenz exposure (r = -0.219, p = 
0.051), but again no relationship seen with nevirapine (Table 5.17).  
 
In terms of ARV drug class exposure, whilst there was no significant 
relationship between duration of continuous exposure to NNRTIs combined 
and tubular phosphate resorption, a longer duration of continuous PI exposure 
was associated with a significantly higher percentage of tubular phosphate 
resorption (r = 0.254, p = 0.023) (Table 5.17). 
 
The relationships between TRP and 25-OH-D, serum phosphate, PTH and 
corrected calcium have been described in Sections 5.2.2, 5.3.2, 5.4.1 and 
5.4.2 respectively. 
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HIV antiretroviral 
therapy-related 
factor 
Exposure n 
Tubular reabsorption of 
phosphate % 
p-value 
Median IQR 
Current TDF 
No 25 87.0 82.5 – 88.0 
.799 
Yes 55 87.0 82.0 – 90.0 
Current ABC 
No 56 87.0 82.0 – 90.0 
.584 
Yes 24 87.0 83.3 – 88.0 
Current NNRTI 
No 34 86.0 77.5 – 89.3 
.190 
Yes 46 87.5 82.8 – 90.0 
Current PI 
No 44 86.0 79.0 – 88.0 
.063 
Yes 36 88.0 83.3 – 90.8 
Current EFV 
No 53 86.0 79.0 – 89.5 
.040 
Yes 27 88.0 85.0 – 90.0 
Current NVP 
No 71 87.0 83.0 – 90.0 
.532 
Yes 9 83.0 80.5 – 89.0 
 
Table 5.16. Differences in tubular reabsorption of phosphate in Phase 
Two patients (n = 81) according to current exposure to tenofovir 
disoproxil fumarate (TDF), abacavir (ABC), non-nucleoside reverse 
transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), efavirenz 
(EFV) and nevirapine (NVP) 
 
 
 
 
 
HIV antiretroviral therapy-related factor r p-value 
Continuous number of months on TDF -0.024 .832 
Continuous number of months on ABC -0.050 .660 
Continuous number of months on NNRTI 0.079 .487 
Continuous number of months on PI 0.254 .023 
Continuous number of months on EFV -0.219 .051 
Continuous number of months on NVP -0.097 .397 
 
Table 5.17. Relationship between continuous number of months on 
tenofovir disoproxil fumarate (TDF), abacavir (ABC), non-nucleoside 
reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), 
efavirenz (EFV) and nevirapine (NVP) with tubular reabsorption of 
phosphate in Phase Two patients (n = 81) 
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Factors and co-variates found to have either significant (p < 0.05) or 
borderline significant (p ≥ 0.05 and < 0.10) association with TRP within the 
Phase Two study population are summarised in Table 5.18 (serum phosphate 
(p = 0.003) excluded as a likely effect of TRP). These factors and covariates 
were taken forward for multivariate analysis, as described for 25-OH-D3 in 
Section 5.2.1. (Further detail is included in Appendix 2.3.) 
 
Factors and covariates with significant association (p < 0.05) with TRP 
following multivariate analysis were: female gender (associated with higher 
TRP, p = 0.013), race-adjusted eGFR <90 ml min-1 (associated with lower 
tubular resorption of phosphate, p <0.001) and current efavirenz (associated 
with higher TRP, p = 0.031) (Table 5.19). 
 
 
 
 
Factor / covariate 
p-
value 
Factor / co-variate 
p-
value 
White race <.001 Parathyroid hormone .090 
Female gender <.001 No. of continuous months on EFV .077 
Age .002 Current PI .056 
BMI .027  
Race-adjusted eGFR <90 ml min-1 <.001 
25-hydroxyvitamin D .001 
Current EFV .040 
No. of continuous months on PI .023 
 
Table 5.18. Factors and co-variates with significant (p < 0.05) or 
borderline significant (p ≥ 0.05 and < 0.10) associations with tubular 
reabsorption of phosphate from univariate analysis within the Phase 
Two study population 
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Covariate / factor Factor present 
Estimated 
marginal mean % 
Standard Error Wald Chi-Square p-value 
 Female gender 
No 82.5 0.90 
6.218 .013 
Yes 86.2 1.28 
Race-adjusted eGFR <90 ml min-1 
No 88.4 0.85 
28.504 <.001 
Yes 80.2 1.35 
Current efavirenz 
No 82.8 0.89 
4.649 .031 
Yes 85.9 1.28 
 
Table 5.19. Covariates and factors with significant (p < 0.05) association with tubular reabsorption of phosphate in the 
Phase Two study population (n = 81) following multivariate analysis  
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There was no significant relationship observed between TRP and BMD at any 
site (r = 0.093, p = 0.411 for lumbar spine, r = 0.039, p = 0.731 for hip, r = 
0.109, p = 0.338 for femoral neck and r = 0.013, p = 0.907 for total body). 
 
 
5.4.4 Proximal renal tubular dysfunction 
 
81 patients within the Phase Two study population without previous or current 
vitamin D supplementation were assessed for PRTD. Four biochemical 
markers were used to establish the presence or absence of PRTD, namely: 
isolated glycosuria in absence of plasma hyperglycaemia; serum bicarbonate 
<22 mmol l-1; urinary retinal binding protein (uRBP) >15 mg l-1; and TRP 
<82% in the absence of 25-OH-D < 50nmol l-1. “Absence of PRTD” was 
defined as the absence of all four markers, “possible PRTD” was defined as 
the presence of one of the four markers and “probable PRTD” was defined as 
the presence of two or more of the four markers. 
 
One patient was diagnosed with probable PRTD (isolated glycosuria, uRBP 
65 mg l-1 and TRP 59% (25-OH D3 82.6 nmol l-1), 16 patients had possible 
PRTD (eight had low TRP with normal 25-OH-D, seven had serum 
bicarbonate <22 mmol l-1 and one had isolated glycosuria) and 56 patients did 
not have PRTD. A further eight patients had insufficient evidence to make a 
diagnosis of either absent or possible PRTD (no markers present, but one or 
more marker not tested). The one patient with probable PRTD was a 60-year 
old white male patient, BMI 25.4 kg m-2, with current CD4 cell count 593 cells 
μl-1 and undetected plasma HIV RNA on ART (212 months continuous 
duration) comprising tenofovir DF (124 months continuous duration), 
etravirine (44 months continuous duration) and a boosted PI (16 months 
continuous duration). His fasting serum phosphate was also low (0.67 mmol   
l-1). His eGFR was low (48 ml min-1). He had sustained one fragility fracture 
(distal radius) aged 59 years old. He had no other FRAX®-incorporated 
general fracture risk factors, but had relatively elevated FRAX®-calculated 10-
year probabilities of major osteoporotic fracture (7.7%) and hip fracture 
(1.2%), with BMD assessment advised. 
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BMD was significantly reduced at the lumbar spine in the one patient with 
probable PRTD compared with patients with absent or only possible PRTD (p 
= 0.046), but with no significant difference observed for total hip, femoral neck 
or total BMD (p = 0.086, p = 0.247 and p = 0.141 respectively) (Table 5.20). 
There was no significant difference in BMD between patients with absent 
PRTD compared with patients with possible PRTD at any site (p = 0.933, p = 
0.220, p = 0.210 and p = 0.634 for lumbar spine, total hip, femoral neck and 
total body respectively). 
 
 
5.4.5 Race-adjusted estimated glomerular filtration rate 
 
 
The relationships between race-adjusted eGFR and different ARV exposures 
are summarised in Table 5.20. Phase Two patients with race-adjusted eGFR 
< 90 ml min-1 (n = 27) had longer median duration of both continuous and 
cumulative tenofovir DF exposure (43 months (IQR 0 – 59) and 48 months 
(IQR 0 – 67) respectively) than those with race-adjusted eGFR ≥ 90 ml min-1 
(n = 54) (16 months (IQR 0 – 43) and 23 months (IQR 0 – 45) respectively), 
but this did not meet statistical significance (p = 0.068 and p = 0.069 for 
continuous and cumulative tenofovir DF exposure respectively). There was no 
noticeable difference in duration of continuous or cumulative exposure to 
abacavir, NNRTIs or PIs between patients with race-adjusted eGFR either < 
90 ml min-1 or ≥ 90 ml min-1, however.  
 
There was no difference in BMD at any site between patients with race-
adjusted eGFR < 90 ml min-1 or ≥ 90 ml min-1, nor in patients with race-
adjusted eGFR either < 60 ml min-1 or ≥ 60 ml min-1 (Tables 5.21 and 5.22).  
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Patient race / gender 
subgroup 
n 
Lumbar spine BMD      
g cm-2 
Total hip BMD                      
g cm-2 
Femoral neck BMD      
g cm-2 
Total body BMD           
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Absent PRTD 56 1.011 ± .135 
.933 
0.981 ± .126 
.220 
0.825 ± .132 
.210 
1.107 ± .133 
.634 
Possible PRTD 16 1.014 ± .100 0.936 ± .125 0.780 ± .103 1.092 ± .084 
Absent PRTD 56 1.011 ± .135 
.062 
0.981 ± .126 
.075 
0.825 ± .132 
.239 
1.107 ± .133 
.157 
Probable PRTD 1 0.751 0.749 0.666 0.943 
Possible PRTD 16 1.014 ± .100 
.022 
0.936 ± .125 
.166 
0.780 ± .103 
.297 
1.092 ± .084 
.106 
Probable PRTD 1 0.751 0.749 0.666 0.943 
Absent or possible PRTD 72 1.011 ± .128 
.046 
0.971 ± .126 
.086 
0.815 ± .127 
.247 
1.103 ± .107 
.141 
Probable PRTD 1 0.751 0.749 0.666 0.943 
 
Table 5.20. Distribution of lumbar spine, total hip, femoral neck and total body BMD measurements between patients 
without proximal renal tubular disorder (PRTD) (n = 56), patients with possible PRTD (n = 16) and patients with probable 
PRTD (n = 1) within the Phase Two study population 
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Race-adjusted 
eGFR                  
≥90 ml min-1          
n = 54 
Race-adjusted 
eGFR                  
<90 ml min-1         
n = 27 
p-value 
Median (IQR) duration of continuous 
TDF exposure months 
16 (0 – 43) 43 (0 – 59) .068 
Median (IQR) duration of cumulative 
TDF exposure months 
23 (0 – 45) 48 (0 – 67) .069 
Median (IQR) duration of continuous 
ABC exposure months 
0 (0 – 45) 0 (0 – 65) .816 
Median (IQR) duration of cumulative 
ABC exposure months 
0 (0 -52) 0 (0 – 65) .952 
Median (IQR) duration of continuous 
NNRTI exposure months 
18 (0 – 53) 40 (0 – 97) .156 
Median (IQR) duration of cumulative 
NNRTI exposure months 
38 (4 – 8) 47 (19 – 97) .308 
Median (IQR) duration of continuous 
PI exposure months 
1 (0 – 39) 0 (0 – 25) .560 
Median (IQR) duration of cumulative 
PI exposure months 
13 (0 – 48) 0 (0 – 33) .107 
 
Table 5.21. Differences in median duration of continuous or cumulative 
exposure to tenofovir disoproxil fumarate (TDF), abacavir (ABC), non-
nucleoside reverse transcriptase inhibitors (NNRTIs) and protease 
inhibitors (PIs) between Phase Two patients with either race-adjusted 
estimated glomerular filtration rate (eGFR) ≥90 ml min-1 (n = 54) or race-
adjusted eGFR <90 ml min-1 (n = 27) 
 
 
 Race-adjusted eGFR                  
≥90 ml min-1                    
n = 54 
Race-adjusted eGFR                  
<90 ml min-1                    
n = 27 
p-value 
Mean lumbar spine BMD 
± s.d. g cm-2 
1.020 ± .127 1.000 ± .136 .656 
Mean total hip BMD          
± s.d. g cm-2 
0.975 ± .119 0.957 ± .137 .542 
Mean femoral neck BMD 
± s.d. g cm-2 
0.828 ± .125 0.784 ± .114 .126 
Mean total body BMD      
± s.d. g cm-2 
1.117 ± .097 1.081 ± .118 .146 
 
Table 5.22. Differences in lumbar spine, total hip, femoral neck and total 
body BMD between Phase Two patients with either race-adjusted 
estimated glomerular filtration rate (eGFR) ≥90 ml min-1 (n = 54) or race-
adjusted eGFR <90 ml min-1 (n = 27) 
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 Race-adjusted eGFR                  
≥60 ml min-1                    
n = 78 
Race-adjusted eGFR                  
<60 ml min-1                    
n = 3 
p-value 
Mean lumbar spine BMD 
± s.d. g cm-2 
1.017 ± .125 0.991 ± .269 .736 
Mean total hip BMD          
± s.d. g cm-2 
0.971 ± .124 0.916 ± .162 .459 
Mean femoral neck BMD 
± s.d. g cm-2 
0.816 ± .122 0.738 ± .141 .284 
Mean total body BMD      
± s.d. g cm-2 
1.107 ± .105 1.041 ± .087 .288 
 
Table 5.23. Differences in lumbar spine, total hip, femoral neck and total 
body BMD between Phase Two patients with either race-adjusted 
estimated glomerular filtration rate (eGFR) ≥60 ml min-1 (n = 78) or race-
adjusted eGFR <60 ml min-1 (n = 3) 
 
 
 
 
5.5 Summary of biochemical determinants of BMD  
 
Of the various biochemical parameters analysed, only the presence of 
probable PTRD was associated with a significant reduction in BMD and only 
at the lumbar spine. There was no significant reduction in BMD with reduced 
25-OH-D, nor was there any significant relationship observed between BMD 
and serum phosphate, serum PTH, serum corrected calcium, TRP or race-
adjusted eGFR. 
 
 
5.6 Discussion 
 
The prevalence of severe vitamin D deficiency, non-severe vitamin D 
deficiency and vitamin D insufficiency within the Phase One study population 
(35.5%, 46.7% and 9.9% respectively) was similar to the prevalence reported 
from another UK HIV cohort with a similar (albeit slightly higher) proportion of 
black versus white patients (reporting prevalence of 34.8%, 38.7% and 17.7% 
respectively) (Welz et al. 2010). In keeping with the findings of this and one 
other study (Welz et al. 2010, Sherwood et al. 2012), there were significantly 
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higher proportions of vitamin D deficiency and severe vitamin D deficiency in 
black patients (92.1% and 48.6% respectively) compared to white patients 
(69.7% and 19.9% respectively) within the Phase One study population. Other 
significant determinants of reduced 25-OH-D in the Phase One study 
population, namely non-summer sampling, efavirenz (but not nevirapine) 
exposure, were also consistent with published data from other HIV cohorts 
(Welz et al. 2010, Dao et al. 2011, Wohl et al. 2014);  
 
As expected, there was a significant negative correlation between 25-OH-D 
and serum corrected calcium and a significant positive correlation with serum 
PTH. Unusually, however, there was also a significant negative correlation 
between 25-OH-D and TRP and not the expected positive correlation. The 
heterogeneity of the patient cohort with respect to its race and gender mix 
may have complicated the analysis of some of the biochemical data, masking 
or altering relationships between respective variables. Whilst race / gender 
subgroup analyses are possible, the smaller numbers within each subgroup 
increases the risk of analyses being skewed by outlier values, for example 
patients with very high 25-OH-D secondary to recent sunbed use or overseas 
travel, or from undisclosed supplement use. 
 
In keeping with the majority of other published reports (Sherwood et al. 2012, 
Cotter, et al. 2014), there was also no identified significant association 
between 25-OH-D and BMD at any site. In addition, there was no significant 
association between 25-OH-D and falls frequency, although the numbers of 
patients reporting falls was low in this young cohort. Unexpectedly, 25-OH-D 
measurements were significantly higher in patients with increased fracture 
frequency overall, however fracture frequency was higher in white patients 
than in black patients in the Phase One study population (Section 3.5) and 
therefore differences in 25-OH-D most likely reflect differences in patient race 
between the no, single and multiple fracture patient groups. Whilst 25-OH-D 
was significantly lower in black patients reporting one single fracture in 
adulthood compared with no fractures, there was no significant difference 
between black patients reporting multiple fractures and no fractures. The very 
small numbers of black patients reporting single or multiple fractures in 
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adulthood increases the risk of results being skewed by outlier patients within 
the single or multiple fracture groups. Notably there was no significant 
difference in 25-OH-D measurements between patients with or without a prior 
fragility fracture, although the numbers of patients with prior fragility fracture 
included in the analysis were very low.  
 
The majority of the Phase Two study population had normal serum 
phosphate, with only twelve patients (14.8%) having mild hypophosphataemia 
and no patients having moderate or severe hypophosphataemia. Whilst there 
was a trend to lower serum phosphate with increased tenofovir DF exposure, 
this was not significant. There was also a trend to lower serum phosphate with 
both increased NRTI exposure and ART exposure overall, reflecting the 
predominance of tenofovir DF use in Phase Two patient ART regimens over 
the main alternative NRTI abacavir, with which there was no observed 
relationship with serum phosphate. As hypophosphataemia is usually only 
transient, it is perhaps not surprising that no significant relationships were 
identified between serum phosphate and any ARV in otherwise stable and 
asymptomatic patients. Low race-adjusted eGFR was significantly associated 
with reduced serum phosphate, however, as was reduced tubular resorption 
of phosphate. As with 25-OH-D, serum phosphate had no significant effect on 
BMD or on falls frequency or fracture prevalence. 
 
Current efavirenz use was significantly associated with increased TRP on 
multivariate analysis, although this is most likely to be an effect of increased 
TRP in the context of efavirenz-related lower 25-OH-D levels and secondary 
hyperparathyroidism. As with serum phosphate, TRP was also significantly 
lower in patients with race-adjusted eGFR <90ml min-1. There was no 
significant effect of increased tenofovir DF exposure on TRP, however. It 
seems likely, therefore, that renal phosphate wasting reported in PLWH on 
tenofovir DF (Fux et al. 2007) could be idiosyncratic and not a general or 
dose-dependent effect of tenofovir DF. Of note, there was no observed effect 
of TRP on BMD.  
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A probable diagnosis of PRTD was made in only one patient out of 78 
assessed within the Phase Two study population, in spite of two thirds of 
Phase Two patients being on tenofovir DF with or without a boosted PI. This 
is in accordance with other reports, which noted that PRTD in PLWH on 
tenofovir DF occurred very rarely (Nelson et al. 2007, Woodward et al. 2009). 
The absence of a universally accepted clinical definition of PRTD limits the 
ability to make too many comparisons with other studies, however. Whilst it is 
not possible to comment on significant associations of PRTD in PLWH from 
our own study, the one patient with probable PRTD did have several risk 
factors typically associated with PRTD in PLWH. These included increased 
age, prolonged exposure to tenofovir DF in combination with a PI and reduced 
eGFR (Calza et al. 2011), although reduced eGFR could have been an effect 
of PRTD and/or tenofovir DF also. A probable diagnosis of PRTD was the 
only “biochemical” factor significantly associated with reduced BMD in this 
cohort, although at the lumbar spine only. The one patient with probable 
PRTD had also sustained a recent fragility fracture, suggesting PRTD as both 
a risk factor for reduced BMD and fragility fractures in PLWH.  
 
 
5.7 Conclusions 
 
1. The prevalence of vitamin D deficiency within the Sheffield HIV cohort 
was high and akin to other HIV cohorts with similar patient demographics. 
 
2. In concordance with other published data, black race, non-summer 
sampling and exposure to efavirenz were each significant independent 
predictors of reduced 25-OH-D; no novel determinants of reduced 25-OH-
D in PLWH were identified within the Sheffield HIV Cohort, however. 
 
3. 25-OH-D was not a significant determinant of BMD at any site; in addition, 
25-OH-D was not significantly associated with falls frequency or fragility 
fracture prevalence. 
 
4. Few patients had hypophosphataemia, with no moderate or severe 
hypophosphataemia identified. 
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5. Race-adjusted eGFR <90 ml min-1, male gender and low current CD4 cell 
count were each significant independent predictors of serum phosphate; 
whilst there was a trend to lower serum phosphate in patients with 
increased tenofovir DF exposure, this was not significant. 
 
6. Serum phosphate was not a significant determinant of BMD at any site, 
nor was serum phosphate significantly associated with falls frequency or 
fracture prevalence. 
 
7. Increased exposure to tenofovir DF was associated with reduced race-
adjusted eGFR (borderline significance only), but not reduced TRP. 
 
8. Of other biochemical factors examined, including serum PTH, serum 
corrected calcium, TRP, PRTD and race-adjusted-eGFR, only probable 
PRTD, identified in one patient only, was significantly associated with 
BMD, with BMD significantly reduced at the lumbar spine, but at no other 
site. PRTD may also be a risk factor for fragility fracture. 
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6. Inflammatory and immunological determinants of bone mineral 
density and 25-hydroxyvitamin D3 in people living with HIV in Sheffield 
 
 
The IL-6 analysis work included in this chapter was performed by Dr Rebecca 
Marlor, with the assistance of Katie Cooke. Dr Marlor has kindly agreed for 
me to include her IL-6 results within my wider analysis. 
 
 
6.1 Introduction 
 
Immunological markers typically associated with either late HIV presentation 
or poor HIV disease control – namely low current CD4 cell count <200 cells  
μl-1, low nadir CD4 cell count and low baseline CD4 cell count prior to initiation 
of ART – have been independently associated with either reduced BMD or 
higher fragility fracture incidence in PLWH (Cazanave et al. 2008, Yong et al. 
2011, Grant et al. 2013, Borges et al. 2017, Gedmentas et al. 2017). This 
suggests that HIV infection, independent of any effect of ART, contributes to 
the higher prevalence of reduced BMD and fragility fracture incidence seen in 
PLWH compared with the general population, either directly or through HIV-
mediated immune dysregulation and associated inflammation. Indeed, 
mechanisms have been identified detailing how HIV proteins, activated 
immune cells and pro-inflammatory cytokines can alter the balance between 
osteoclast and osteoblast activity, mediated through RANK, RANKL, OPG 
and TRAIL, increasing bone turnover and bone loss, summarised by Stone et 
al. (2010) and detailed in Chapter 1, Section 1.2.2.2. 
 
In longitudinal studies of previously ART-naïve HIV-positive patients, higher 
baseline levels of the pro-inflammatory cytokine IL-6 and of hs-CRP, a marker 
of inflammation, at ART initiation have each been associated with increased 
bone loss after one and two years of ART treatment (Hileman et al. 2014, 
Brown et al. 2015). Whilst there is growing evidence to support persisting 
immune activation and a chronic pro-inflammatory state in HIV-positive 
patients well established on ART with immune recovery (Brenchley et al. 
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2006), evidence in support of an ongoing association between pro-
inflammatory markers and reduced BMD in patients stable on ART is lacking. 
In contrast to IL-6, which decreases with increasing time on ART in PLWH, 
hs-CRP levels remain stable (Hattab et al. 2014) and therefore could, 
arguably, indicate ongoing inflammation that could contribute to longer-term 
bone loss beyond ART initiation. In one cross-sectional study of 142 HIV-
positive patients stable on ART with a median ART duration of 56 months and 
with mean CD4 cell count 604 cells μl-1, there was, however, no significant 
correlation between BMD and hs-CRP, nor IL-6, nor other pro-inflammatory 
markers, including D-dimer and TNF-α (Erlandson et al. 2014). Of note, whilst 
there is no existing evidence supporting an association between D-dimer and 
BMD in PLWH, D-dimer has been implicated in the pathogenesis of other 
NICMs in PLWH, notably cardiovascular disease (Ford et al. 2010). 
 
A low CD3+/CD4+ cell to CD3+/CD8+ cell ratio (CD4:CD8) has also been 
independently associated with a higher risk of NICMs in PLWH established on 
ART, including cardiovascular disease, renal disease and non-AIDS-
malignancies, (Serrano-Villar et al. 2014a, Serrano-Villar et al. 2014b, 
Castilho et al. 2016), but with no data published to date describing the 
relationship between CD4:CD8 and either BMD or fracture incidence in 
PLWH. 
 
As already observed with IL-6 and hs-CRP, higher baseline expression of 
some T cell activation markers – specifically CD38 and HLA-DR in 
CD3+/CD4+ T-cell – also resulted in greater BMD loss at 96 weeks following 
ART initiation in previously ART-naïve HIV-positive patients, although at the 
lumbar spine only (Brown et al. 2015). There is conflicting data regarding the 
association of T cell activation and BMD in PLWH stable on ART. One cross-
sectional study observed no association between BMD and the percentage 
expression of CD38 and HLA-DR in CD3+/CD4+ and CD3+/CD8+ T cells 
(Erlandson et al. 2014), whereas another identified a significant and 
independent negative correlation between BMD and each of CD3+/CD4+ T cell 
expression of CD28, CD3+/CD4+ T cell expression of HLA-DR and CD3+/CD8+ 
T cell expression of HLA-DR (Gazzola et al. 2013). 
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As with D-dimer and CD4:CD8, a higher peripheral blood percentage of non-
classical monocytes (CD14dim CD16++) relative to other monocyte population 
subsets has been associated with an increased risk of cardiovascular disease 
in PLWH stable on ART (Chow et al. 2016, Zungsontiporn et al. 2016). There 
is a paucity of published data describing the association between monocyte 
population subsets and BMD in PLWH, however, with just one cross-sectional 
study of HIV-positive patients stable on ART observing no significant 
relationship between monocyte population subsets and BMD (Erlandson et al. 
2014). 
 
The relationship between vitamin D, immune activation and inflammation in 
PLWH is complex, with reduced vitamin D levels likely to contribute to 
increased immunological hyperactivity and, in turn, chronic immune activation 
and inflammation likely to contribute to reduced vitamin D, a result of reduced 
synthesis and plasma concentrations of vitamin D binding protein – a negative 
acute phase protein – in response to inflammation (Hang et al. 1998). 
Elevated levels of proinflammatory cytokines and other markers of 
inflammation, including IL-6, TNF-α, hs-CRP and D-dimer, have been 
associated with severe vitamin D deficiency in PLWH, including in patients 
stable on ART (Ansemant et al. 2013, Manion et al. 2017). Furthermore, 
increased percentages of non-classical monocytes have also been associated 
with reduced 25-OH-D levels in PLWH (Manion et al. 2017).  
 
This chapter aims to answer the following questions: 
 
1. What are the distributions and general and HIV-disease specific 
associations of inflammatory markers, T cell CD4 and CD8 subsets, T cell 
activation markers and peripheral blood monocyte population subsets in 
PLWH within the Sheffield HIV Cohort? 
 
2.  What is the relationship between inflammatory markers, T cell CD4 and 
CD8 subsets, T cell activation markers and monocyte subsets with BMD 
and 25-OH-D in PLWH within the Sheffield HIV Cohort? 
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6.2 Distribution and associations of inflammatory markers and their 
relationships with BMD and 25-hydroxyvitamin D in PLWH 
 
6.2.1 Distribution and general, immunological and HIV disease-specific 
associations of inflammatory markers in PLWH 
 
The distributions of D-dimer (normal range: 0 – 500 μg l-1), hs-CRP (normal 
range: 0 – 3 mg l-1) and IL-6, measured within the Phase Two study 
population, are summarised in all patients and within each patient race / 
gender subgroups in Table 6.1. Differences in the distributions of D-dimer, hs-
CRP and IL-6 between patient race / gender subgroups are highlighted in 
Figures 6.1 to 6.3. 
 
D-dimer was significantly higher in females than in males overall (p = 0.006), 
but this difference was only significant between black males and black 
females on patient race / gender subgroup analysis (p = 0.018) and not 
significant between white males and white females (p = 0.117) (Figure 6.2). 
Hs-CRP was also significantly higher in females than in males (p < 0.001) and 
in black patients than in white patients (p < 0.001), with hs-CRP also 
significantly higher in black males compared to white males (p = 0.044) and in 
black females compared to white females (p = 0.008), but with no statistically 
significant difference between black males and black females or between 
white males and white females (Figure 6.3). IL-6 was also higher in females 
compared to males and in black patients compared to white patients, but 
these differences were not of statistical significance (Figure 6.4). 
 
D-dimer, hs-CRP and IL-6 each had a significant positive correlation with 
each other (r = 0.231 p = 0.032 for D-dimer and hs-CRP, r = 0.412 p = 0.010 
for D-dimer and IL-6 and r = 0.649, p < 0.001 for hs-CRP and IL-6). 
 
The relationships between D-dimer, hs-CRP and IL-6 with general factors, 
immunological markers and HIV disease-specific factors are summarised in 
Tables 6.2 to 6.5.  
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  All Black male Black female White male White female 
D-dimer μg l-1 
n 88 13 32 35 9 
Median 250 208 295 222 327 
IQR 78 – 8772  140 – 258 196 – 595  158 – 311  197 – 1433  
hs-CRP mg l-1 
n 89 12 32 36 9 
Median 1.98 1.98 4.72 1.18 1.42 
IQR 0.98 – 4.69 1.09 – 7.81 2.54 – 8.22 0.82 – 2.32 0.51 – 3.36 
IL-6 pg ml-1 
n 41 4 11 23 3 
Median 0.716 0.610 0.911 0.596 3.051 
IQR 0.506 – 1.503 0.288 – 0.880 0.667 – 1.473 0.452 – 1.522 - 
 
Table 6.1. Distribution of D-dimer, highly sensitive CRP (hs-CRP) and interleukin-6 (IL-6) in all patients, black male, black 
female, white male and white female patients within the Phase Two study population
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Figure 6.1. Distribution of D-dimer in black males (n = 13), black females 
(n = 32), white males (n = 35) and white females (n = 9) within the Phase 
Two study population  
 
 
 
  
 
 
Figure 6.2. Distribution of highly sensitive CRP (hs-CRP) in black males 
(n = 12), black females (n = 32), white males (n = 56) and white females 
(n = 9) within the Phase Two study population  
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Figure 6.3. Distribution of interleukin-6 (IL-6) in black males (n = 4), black 
females (n = 11), white males (n = 23) and white females (n = 3) within 
the Phase Two study population 
 
 
 
There was a significant positive correlation between both D-dimer and hs-
CRP with both BMI and percentage subtotal body fat (p = 0.002 and p = 0.018 
for D-dimer with BMI and percentage subtotal body fat respectively; p <0.001 
for hs-CRP with BMI and percentage subtotal body fat respectively) (Figure 
6.4).  
 
Of note, the differences observed in D-dimer between black males and black 
females and in hs-CRP between black and white females were no longer 
significant after adjusting for BMI (p = 0.201 and p = 0.135 respectively); the 
difference in hs-CRP between black and white males, however, remained 
significant after adjusting for BMI (p = 0.007). 
 
 
Neither D-dimer, hs-CRP nor IL-6 had any significant relationship with current 
CD3+/CD4+ cell count (CD4 cell count), current CD3+/CD4+ cell percentage of 
all CD3+ cells (CD4 %), current CD3+/CD8+ cell count (CD8 cell count), 
current CD3+/CD8+ cell percentage of all CD3+ cells (CD8 %), nor current 
CD4:CD8 (Table 6.2). There was, however, a significant negative correlation 
between hs-CRP and nadir CD4 cell count (r = -0.234, p = 0.027) (Figure 6.5). 
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D-dimer (n = 88) hs-CRP (n = 89) IL-6 (n = 41) 
r p-value r p-value r p-value 
Age years 0.185 .084 0.120 .262 0.279 .077 
Weight kg 0.193 .071 0.205 .054 0.106 .508 
Body mass index kg m-2 0.324 .002 0.446 <.001 0.257 .105 
Sub-total body fat % 0.252 .018 0.541 <.001 0.307 .051 
Nadir CD4 cell count cells μl-1 0.010 .929 -0.234 .027 0.075 .639 
Current CD3+/CD4+ cell count cells μl-1 -0.054 .620 -0.083 .441 -0.100 .533 
Current CD3+/CD4+ cell %  -0.041 .707 -0.108 .312 -0.109 .497 
Current CD3+/CD8+ cell count cells μl-1 -0.002 .983 0.131 .222 0.152 .344 
Current CD3+/CD8+ cell %  0.041 .708 0.162 .129 0.175 .274 
Current CD4:CD8 ratio -0.071 .511 -0.143 .180 -0.142 .376 
Number of years since HIV diagnosis 0.028 .795 0.106 .323 0.201 .207 
Number of months continuous ART exposure -0.040 .711 0.151 .160 0.118 .462 
Number of months continuous TDF exposure -0.128 .236 0.109 .308 0.116 .472 
Number of months continuous ABC exposure 0.083 .444 -0.033 .757 0.014 .930 
Number of months continuous NNRTI exposure -0.092 .397 0.105 .328 0.157 .328 
Number of months continuous PI exposure 0.113 .299 0.144 .181 0.134 .404 
 
Table 6.2. Relationships between general, immunological and HIV disease-specific factors and D-dimer, highly sensitive 
CRP (hs-CRP) and interleukin-6 (IL-6) in the Phase Two study population (ART = antiretroviral therapy; TDF = tenofovir 
disoproxil fumarate; ABC = abacavir, NNRTI = non-nucleoside reverse transcriptase inhibitor, PI = protease inhibitor) 
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Factor  n 
D-dimer μg l-1 
p-value 
Median IQR 
Plasma HIV RNA  
<40 copies ml-1 
No 8 349 180 – 1024  
.289 
Yes 80 248 180 – 387  
Plasma HIV RNA  
<200 copies ml-1 
No 6 405 184 – 405  
.197 
Yes 82 248 179 – 370  
Current ART 
No 2 310 153 – 310  
1.000 
Yes 86 250 180 – 398  
Current TDF 
No 24 268 181 – 655  
.440 
Yes 64 250 177 – 352  
Current ABC 
No 65 250 176 – 349  
.260 
Yes 23 317 184 – 674  
Current NNRTI 
No 40 258 177 – 459  
.666 
Yes 48 243 180 – 338  
Current PI 
No 39 222 169 – 327  
.191 
Yes 49 263 189 – 404  
 
Table 6.3. Differences in D-dimer according to the presence or absence 
of HIV disease-specific factors in the Phase Two study population (ART 
= antiretroviral therapy; TDF = tenofovir disoproxil fumarate; ABC = 
abacavir, NNRTI = non-nucleoside reverse transcriptase inhibitor, PI = 
protease inhibitor) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 257 
 
Factor  n 
hs-CRP mg l-1 
p-value 
Median IQR 
Plasma HIV RNA  
<40 copies ml-1 
No 9 5.48 1.34 – 9.86 
.079 
Yes 80 1.83 0.97 – 4.28 
Plasma HIV RNA  
<200 copies ml-1 
No 7 5.48 1.33 – 9.80 
.256 
Yes 82 1.92 0.97 – 4.35 
Current ART 
No 3 1.33 - 
.219 
Yes 86 2.51 0.99 – 4.71 
Current TDF 
No 25 1.35 0.87 – 5.82 
.616 
Yes 64 2.55 1.04 – 4.65 
Current ABC 
No 66 0.99 2.53 – 4.67 
.623 
Yes 23 1.41 0.86 – 5.81 
Current NNRTI 
No 40 1.57 0.89 – 4.60 
.473 
Yes 49 2.53 1.00 – 4.71 
Current PI 
No 40 1.49 0.99 – 4.58 
.465 
Yes 49 2.57 0.93 – 4.75 
 
Table 6.4. Differences in highly sensitive CRP (hs-CRP) according to the 
presence or absence of HIV disease-specific factors in the Phase Two 
study population (ART = antiretroviral therapy; TDF = tenofovir 
disoproxil fumarate; ABC = abacavir, NNRTI = non-nucleoside reverse 
transcriptase inhibitor, PI = protease inhibitor) 
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Factor  n 
IL-6 pg ml-1 
p-value 
Median IQR 
Plasma HIV RNA  
<40 copies ml-1 
No 6 0.938 0.688 – 2.687 
.284 
Yes 35 0.701 0.493 – 1.484 
Plasma HIV RNA  
<200 copies ml-1 
No 5 0.936 0.556 – 3.043 
.360 
Yes 36 0.707 0.500 – 1.481 
Current ART 
No 2 0.614 - 
.549 
Yes 39 0.716 0.519 – 1.522 
Current TDF 
No 27 0.614 0.493 – 1.522 
.602 
Yes 14 0.716 0.510 – 1.420 
Current ABC 
No 8 0.716 0.493 – 1.522 
.924 
Yes 23 0.766 0.510 – 1.420 
Current NNRTI 
No 27 0.707 0.458 – 1.230 
.318 
Yes 14 0.717 0.559 – 2.330 
Current PI 
No 18 0.701 0.460 – 1.473 
.478 
Yes 23 0.751 0.577 – 2.004 
 
Table 6.5. Differences in interleukin-6 (IL-6) according to the presence or 
absence of HIV disease-specific factors in the Phase Two study 
population (ART = antiretroviral therapy; TDF = tenofovir disoproxil 
fumarate; ABC = abacavir, NNRTI = non-nucleoside reverse 
transcriptase inhibitor, PI = protease inhibitor) 
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Figure 6.4. Relationships between D-dimer, highly sensitive CRP (hs-
CRP) and interleukin-6 (IL-6) and body mass index (BMI) and percentage 
subtotal fat measurements in the Phase Two study population 
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Figure 6.5. Relationship between nadir CD4 cell count and highly 
sensitive CRP (hs-CRP) within the Phase Two study population (n = 87) 
 
 
Median D-dimer, hs-CRP and IL-6 were all higher in Phase Two patients with 
plasma HIV RNA greater than 40 copies ml-1 and 200 copies ml-1 compared 
with patients with plasma HIV RNA les than 40 copies ml-1 and 200 copies  
ml-1 respectively, but with only few patients with unsuppressed plasma HIV 
RNA within the Phase Two study population, these differences were not 
significant (Tables 6.3 to 6.5). The vast majority of Phase Two patients were 
currently on ART, including most of the patients with detectable plasma HIV 
RNA, with no significant difference in D-dimer, hs-CRP or IL-6 observed in 
patients either currently on or not currently on ART. Furthermore, there was 
no significant association with any inflammatory marker and the duration of 
continuous or cumulative ART exposure, nor were there any ARV class or 
drug-specific associations observed (Tables 6.2 to 6.5). 
 
 
6.2.2 Relationships between inflammatory markers and BMD and 25-
hydroxyvitamin D in PLWH 
 
No significant association was observed between D-dimer, hs-CRP or IL-6 
with BMD at any site or with 25-OH-D (Table 6.6) (the relationships between 
hs-CRP and lumbar, total hip, femoral neck and total body BMD are shown in 
Figure 6.6). 
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D-dimer (n = 88) hs-CRP (n = 89) IL-6 (n = 41) 
r p-value r p-value r p-value 
Lumbar spine BMD g cm-2  0.125 .246 0.015 .888 -0.167 .298 
Total hip BMD g cm-2 0.041 .702 0.076 .478 0.011 .947 
Femoral neck BMD g cm-2 0.139 .197 0.046 .666 -0.121 .451 
Total body BMD g cm-2 1.196 .067 0.002 .982 -0.134 .403 
25-hydroxyvitamin D nmol l-1 0.137a .297 0.003b .980 0.080c .653 
 
            a 28 missing values              b 27 missing values       c 7 missing values  
 
Table 6.6. Relationships between lumbar spine, total hip, femoral neck and total body bone mineral density (BMD) and 25-
hydroxyvitamin D and D-dimer, highly sensitive CRP (hs-CRP) and interleukin-6 (IL-6) in the Phase Two study population 
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Figure 6.6. Relationship between highly sensitive CRP (hs-CRP) and 
lumbar (L-) spine, total hip, femoral neck and total body BMD within the 
Phase Two study population (n = 89) 
 
 
 
6.3 Distribution and associations of T cell CD4 and CD8 subsets and their 
relationships with BMD and 25-hydroxyvitamin D in PLWH 
 
6.3.1 Distribution and general and HIV disease-specific associations of T cell 
CD4 and CD8 subsets in PLWH 
 
The distributions of current CD4 cell count, current CD4 %, current CD8 cell 
count, current CD8 % and CD4:CD8 for all patients, black males, black 
females, white males and white females within the Phase Two study 
population are shown in Table 6.7. There was no significant difference in the 
distribution of current CD4 cell count, CD4 %, CD8 cell count, CD8% or 
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CD4:CD8 between black and white patients (p = 0.760, p = 0.574, p = 0.488, 
p = 0.716 and p = 0.607 respectively). Within patient race / gender subgroups, 
the only significant differences identified were between black females and 
white females, with significantly higher CD8 % (p = 0.023) and lower 
CD4:CD8 (p = 0.033) in black females compared with white females, and 
between white males and white females, with significantly lower CD4 cell 
count (p = 0.021), higher CD8 % (p = 0.017) and lower CD4:CD8 (p = 0.012) 
in white males compared with white females. (The distribution of nadir CD4 
cell count has already been described within the Phase One and Phase Two 
study populations, including within patient race / gender subgroups, in 
Chapters 3 and 4 respectively.) 
 
Other general and HIV disease-specific associations of current CD4 cell 
count, CD4 %, CD8 cell count, CD8% and CD4:CD8 within the Phase Two 
study population are summarised in Tables 6.8 to 6.13. CD4 cell count, CD4 
% and CD4:CD8 each had a significant positive correlation with nadir CD4 cell 
count. In addition, CD4 cell count, CD4 % and CD4:CD8 all increased with 
longer duration of continuous or cumulative ART and were higher in patients 
with suppressed plasma HIV RNA and in patients with either current or ever 
ART exposure than in patients with unsuppressed plasma HIV RNA or without 
ART exposure (significant correlations detailed in Tables 6.8 to 6.13). In 
contrast, CD8 % decreased with longer duration of ART and was lower in 
patients with suppressed plasma HIV RNA or with ART exposure than in 
patients with unsuppressed plasma HIV RNA or without ART exposure 
(significant correlations detailed in Tables 6.8 to 6.13). CD4 cell count, CD4 % 
and CD4:CD8 all decreased with age, but not significantly (Table 6.8). There 
was no significant association between BMI and T cell CD4 and CD8 subsets 
(Table 6.8).
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All                           
(n = 114) 
Black males  
(n = 15) 
Black females 
(n = 37) 
White males  
(n = 52) 
White females  
(n = 10) 
CD3+/CD4+ cell count 
cells μl-1 
Mean ± s.d. 622 ± 236 525 ± 161 651 ± 236 597 ± 237 792 ± 247 
CD3+/CD4+ % Mean ± s.d. 31 ± 10 31 ± 7 32 ± 9 30 ± 11 36 ± 7 
CD3+/CD8+ cell count 
cells μl-1 
Median 
(IQR) 
796 
(555 – 1031) 
583 
(449 – 933) 
802 
(615 – 995) 
815 
(549 – 1180) 
682 
(473 – 973) 
CD3+/CD8+ % 
Median 
(IQR) 
40 
(33 – 50) 
41 
(31 – 50) 
39 
(34 – 49) 
42 
(36 – 53) 
31 
(27 – 40) 
CD4:CD8 
Median 
(IQR) 
0.806 
(0.514 – 1.090) 
0.866 
(0.582 – 1.044) 
0.759 
(0.555 – 1.164) 
0.722 
(0.437 – 1.036) 
1.149 
(0.851 – 1.499) 
 
Table 6.7. Distribution of current CD3+/CD4+ cell count, current CD3+/CD4+ cell percentage, current CD3+/CD8+ cell count, 
current CD3+/ CD8+ percentage and current CD3+/CD4+ cell to CD3+/CD8+ cell count ratio (CD4:CD8) in all patients (n = 
114), black males (n = 15), black females (n = 37), white males (n = 52) and white females (n = 10) within the Phase Two 
study population 
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Current CD3+/CD4+ 
cell count 
Current CD3+/CD4+ 
percentage 
Current CD3+/CD8+ 
cell count 
Current CD3+/CD8+ 
percentage 
CD4:CD8 
r p-value r p-value r p-value r p-value r p-value 
Age years -0.179 .057 -0.018 .851 -0.172 .067 -0.010 .914 -0.001 .994 
Body mass index      
kg m-2 
0.021 .828 0.019 .839 -0.078 .409 -0.144 .126 0.096 .312 
Years since HIV 
diagnosis 
0.153 .103 0.131 .166 0.007 .939 -0.062 .515 0.135 .153 
Nadir CD4 cell count 
cells μl-1 
0.410 <.001 0.410 <.001 0.060 .523 -0.058 .543 0.282 .002 
Duration of 
continuous ART mo. 
0.175 .065 0.225 .017 -0.137 .149 -0.224 .018 0.270 .004 
Duration of 
cumulative ART mo. 
0.153 .107 0.170 .073 -0.080 .399 -0.162 .089 0.210 .026 
 
Table 6.8. Relationships between general and HIV disease-specific factors and current CD3+/CD4+ cell count, current 
CD3+/CD4+ cell percentage, current CD3+/CD8+ cell count, current CD3+/ CD8+ percentage and current CD3+/CD4+ cell to 
CD3+/CD8+ cell count ratio (CD4:CD8) in the Phase Two study population (n = 114) (ART = antiretroviral therapy, mo. = 
months)  
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  n 
Current CD3+/CD4+ cell 
count cells μl-1 p-value 
Mean s.d. 
Plasma HIV RNA  
<40 copies ml-1 
No 13 503 229 
.053 
Yes 101 637 233 
Plasma HIV RNA  
<200 copies ml-1 
No 7 576 267 
.582 
Yes 106 627 235 
Current ART 
No 4 549 217 
.533 
Yes 110 623 237 
Ever ART 
No 3 600 236 
.869 
Yes 111 623 237 
 
Table 6.9. Differences in current CD3+/CD4+ cell count according to 
plasma HIV RNA and current or ever exposure to antiretroviral therapy 
(ART) in the Phase Two study population  
 
 
 
 
 
 
 
 
  n 
Current CD3+/CD4+ cell 
percentage p-value 
Mean s.d. 
Plasma HIV RNA  
<40 copies ml-1 
No 13 26 10 
.041 
Yes 101 32 10 
Plasma HIV RNA  
<200 copies ml-1 
No 7 27 10 
.200 
Yes 106 32 10 
Current ART 
No 4 26 6 
.304 
Yes 110 32 10 
Ever ART 
No 3 28 5 
.604 
Yes 111 31 10 
 
Table 6.10. Differences in current CD3+/CD4+ cell percentage according 
to plasma HIV RNA and current or ever exposure to antiretroviral 
therapy (ART) in the Phase Two study population  
 
 
 
 
 267 
  n 
Current CD3+/CD8+ cell 
count cells μl-1 p-value 
Median IQR 
Plasma HIV RNA  
<40 copies ml-1 
No 13 938 683 – 1288 
.050 
Yes 101 785 532 – 1013 
Plasma HIV RNA  
<200 copies ml-1 
No 7 987 898 – 1306 
.030 
Yes 106 789 539 – 1025  
Current ART 
No 4 1129 708 – 1481 
.114 
Yes 110 791 548 - 1025 
Ever ART 
No 3 1270 - 
.183 
Yes 111 796 551 – 1023 
 
Table 6.11. Differences in current CD3+/CD8+ cell count according to 
plasma HIV RNA and current or ever exposure to antiretroviral therapy 
(ART) in the Phase Two study population  
 
 
 
 
 
 
 
 
  n 
Current CD3+/CD8+ cell 
percentage p-value 
Median IQR 
Plasma HIV RNA  
<40 copies ml-1 
No 13 53 45 – 57 
.002 
Yes 101 39 33 – 46 
Plasma HIV RNA  
<200 copies ml-1 
No 7 53 50 – 54 
.015 
Yes 106 39 33 – 47 
Current ART 
No 4 52 50 – 53  
.032 
Yes 110 39 33 – 48 
Ever ART 
No 3 53 - 
.049 
Yes 111 39 33 – 48 
 
Table 6.12. Differences in current CD3+/CD8+ percentage according to 
plasma HIV RNA and current or ever exposure to antiretroviral therapy 
(ART) in the Phase Two study population  
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  n 
CD4:CD8 
p-value 
Median IQR 
Plasma HIV RNA  
<40 copies ml-1 
No 13 0.447 0.308 – 0.699 
.007 
Yes 101 0.866 0.571 – 1.116 
Plasma HIV RNA  
<200 copies ml-1 
No 7 0.447 0.403 – 0.552 
.044 
Yes 106 0.835 0.555 – 1.104 
Current ART 
No 4 0.493 0.411 – 0.617 
.069 
Yes 110 0.827 0.519 – 1.104 
Ever ART 
No 3 0.552 - 
.183 
Yes 111 0.821 0.515 – 1.092 
 
Table 6.13. Differences in current CD3+/CD8+ cell count ratio (CD4:CD8) 
according to plasma HIV RNA and current or ever exposure to 
antiretroviral therapy (ART) in the Phase Two study population  
 
 
 
6.3.2 Relationships between T cell CD4 and CD8 subsets and BMD and 25-
hydroxyvitamin D in PLWH 
 
No significant association was observed between current CD4 cell count, 
current CD4 %, current CD8 count, current CD8 % or current CD4:CD8 with 
BMD at any site (n = 114) or with 25-OH-D (n = 81) (Table 6.14). (The 
relationship between nadir CD4 cell count with both BMD and 25-OH-D3 has 
already been described in Chapters 4 and 5 respectively.) 
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Current CD3+/CD4+ 
cell count 
Current CD3+/CD4+ 
percentage 
Current CD3+/CD8+ 
cell count 
Current CD3+/CD8+ 
percentage 
CD4:CD8 
r p-value r p-value r p-value r p-value r p-value 
Lumbar spine BMD    
g cm-2  
0.120 .202 0.080 .399 -0.090 .339 -0.180 .055 0.125 .186 
Total hip BMD                      
g cm-2 
0.061 .521 0.034 .722 -0.035 .709 -0.199 .206 0.055 .558 
Femoral neck BMD      
g cm-2 
0.059 .534 0.029 .758 -0.030 .749 -0.161 .086 0.072 .444 
Total body BMD          
g cm-2 
0.071 .452 -0.043 .652 -0.006 .953 -0.058 .542 -0.024 .801 
25-hydroxyvitamin D 
nmol l-1 
0.028a .802 -0.060a .595 0.083a .462 0.037a .742 -0.050a .656 
 
a 33 missing values              
 
Table 6.14. Relationships between lumbar spine, total hip, femoral neck and total body bone mineral density (BMD) and 
25-hydroxyvitamin D and current CD3+/CD4+ cell count, current CD3+/CD4+ cell percentage, current CD3+/CD8+ cell count, 
current CD3+/ CD8+ percentage and current CD3+/CD4+ cell to CD3+/CD8+ cell count ratio (CD4:CD8) in the Phase Two 
study population (n = 114)  
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6.4 Distribution and associations of T cell activation markers and their 
relationships with BMD and 25-hydroxyvitamin D in PLWH 
 
6.4.1 Distribution and general and HIV disease-specific associations of T cell 
activation markers in PLWH 
 
The distributions of percentage CD25+ CD3+/CD4+ T cells  (% CD25+ 
CD3+/CD4+), percentage HLA-DR+ CD3+/CD4+ T cells  (% HLA-DR+ 
CD3+/CD4+), percentage CD25+ CD3+/CD8+ T cells (% CD25+ CD3+/CD8+) 
and percentage HLA-DR+ CD3+/CD8+ T cells (% HLA-DR+ CD3+/CD8+) are 
shown for all Phase Two patients and by race / gender patient subgroups in 
Table 6.15. Examples of populations with both low % CD25+ and low % HLA-
DR+, relatively high % CD25+ but low % HLA-DR+ and low % CD25+ but 
relatively high % HLA-DR+ are demonstrated for CD3+/CD4+ lymphocyte 
populations in Figures 6.7a, 6.7b and 6.7c respectively. 
 
CD25 data was available in 101 of the 114 patients within the Phase Two 
study population. HLA-DR data was only available in 26 patients, however, 
and in more black patients (n = 20) than white patients (n = 6). There was no 
significant difference in the % CD25+ in either CD3+/CD4+ or CD3+/CD8+ T 
cells between any patient race / gender subgroup, nor in the % HLA-DR+ in 
either CD3+/CD4+ or CD3+/CD8+ T cells between black males and black 
females (numbers of white patients with HLA-DR data were too small to allow 
meaningful comparisons). 
 
The relationships between the percentage positive cells with each T cell 
activation marker and age, BMI, percentage of subtotal body fat, T cell CD4 
and CD8 subsets and HIV disease-specific factors are summarised in Table 
6.16. In addition, differences in % CD25+ CD3+/CD4+, % HLA-DR+ 
CD3+/CD4+, % CD25+ CD3+/CD8+ and % HLA-DR+ CD3+/CD8+ according to 
patient plasma HIV RNA and ART exposure are summarised in Tables 6.17 to 
6.20.
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All                            
(n = 101) 
Black males  
(n = 14) 
Black females 
(n = 30) 
White males  
(n = 47) 
White females  
(n = 10) 
% CD25+ CD3+/CD4+ 
Median 
(IQR) 
10.3 
(6.9 – 14.6) 
12.3 
(4.8 – 14.2) 
9.4 
(7.4 – 12.5) 
11.0 
(6.4 – 21.2) 
9.7 
(7.3 – 15.8) 
% HLA-DR+ CD3+/CD4+  
Median 
(IQR) 
1.8a 
(1.2 – 2.6) 
2.08b 
(0.9 – 2.7) 
1.6c 
(1.1 – 2.0) 
1.9d 
(–) 
2.5e 
(0.8 – 4.4) 
% CD25+ CD3+/CD8+  
Median 
(IQR) 
0.9 
(0.4 – 2.1) 
0.5 
(0.3 – 1.0) 
0.6 
(0.3 – 1.1) 
1.3 
(0.6 – 3.0) 
0.9 
(0.4 – 2.0) 
% HLA-DR+ CD3+/CD8+  
Median 
(IQR) 
4.9a 
(2.6 – 8.1) 
5.1b 
(3.4 – 9.2) 
4.7c 
(2.1 – 6.6) 
3.1d 
(–) 
5.1e 
(1.8 – 9.8) 
   
a 75 missing values              b 6 missing values                 c 18 missing values                 d 45 missing values            e 6 missing values            
           
Table 6.15. Distribution of percentage CD25+ CD3+/CD4+, percentage HLA-DR+ CD3+/CD4+, percentage CD25+ CD3+/CD8+ 
and percentage HLA-DR+ CD3+/CD8+ in all patients (n = 101), black males (n = 14), black females (n = 30), white males (n = 
47) and white females (n = 10) within the Phase Two study population
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Figure 6.7a. Example of both low CD25+ and low HLA-DR+ percentage 
populations in CD3+/CD4+ T cells 
 
 
Figure 6.7b. Example of relatively high CD25+ but low HLA-DR+ 
percentage populations in CD3+/CD4+ T cells 
 
 
Figure 6.7c. Example of low CD25+ but relatively high HLA-DR+ 
percentage populations in CD3+/CD4+ T cells 
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% CD25+ CD3+/CD4+  % HLA-DR+ CD3+/CD4+  % CD25+ CD3+/CD8+  % HLA-DR+ CD3+/CD8+  
r p-value r p-value r p-value r p-value 
Age years  0.064 .525 0.436 .026 0.200 .045 0.182 .372 
BMI kg m-2 0.057 .573 0.067 .745 -0.065 .516 0.224 .271 
Subtotal body fat % -0.090 .369 0.032 .877 -0.230 .021 0.201 0.326 
Nadir CD4 cell count cells μl-1 -0.073 .471 0.030 .883 -0.143 .155 -0.038 .854 
CD3+/CD4+ cell count cells μl-1 -0.366 <.001 -0.111 .588 -0.187 .062 -0.147 .472 
CD3+/CD4+ % -0.410 <.001 -0.143 .485 -0.220 .027 -0.079 .701 
CD3+/CD8+ cell count cells μl-1 0.123 .220 0.006 .975 0.086 .395 0.037 .859 
CD3+/CD8+ % 0.245 .014 -0.011 .958 0.122 .224 0.144 .481 
CD4:CD8 -0.394 <.001 -0.080 .696 -0.204 .041 -0.171 .405 
Years since HIV diagnosis -0.013 .893 -0.032 .875 -0.148 .140 -0.136 .506 
Duration of continuous ART mo. -0.124 .221 -0.128 .541 0.082 .419 -0.118 .573 
Duration of cumulative ART mo. -0.059 .562 -0.098 .642 0.141 .161 -0.083 .693 
 
 
Table 6.16. Relationships between general factors, immunological markers and HIV disease-specific factors and 
percentage CD25+ CD3+/CD4+ (n = 101), percentage HLA-DR+ CD3+/CD4+  (n = 26), % CD25+ CD3+/CD8+ (n = 101) and 
percentage HLA-DR+ CD3+/CD8+ (n = 26) in the Phase Two study population (ART = antiretroviral therapy, mo. = months) 
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  n 
% CD25+ CD3+/CD4+  
p-value 
Median IQR 
Plasma HIV RNA  
<40 copies ml-1 
No 12 13.1 7.5 – 21.6 
.193 
Yes 89 10.3 6.6 – 14.4 
Plasma HIV RNA  
<200 copies ml-1 
No 7 10.3 5.85 – 21.9 
.543 
Yes 93 10.3 5.69 – 14.5 
Current ART 
No 4 12.4 7.0 – 20.0 
.585 
Yes 97 10.3 6.9 – 14.6 
Current TDF 
No 29 10.3 6.4 – 15.4 
.705 
Yes 72 10.4 6.8 – 14.7 
Current ABC 
No 75 10.7 7.1 – 14.7 
.172 
Yes 26 8.4 5.3 – 14.4 
Current PI 
Yes 55 9.9 6.1 – 16.0 
.921 
No 46 10.4 10.4 – 14.4 
Current NNRTI 
Yes 50 10.1 7.5 – 15.8 
.374 
No 51 10.5 5.5 – 14.4 
Current EFV 
Yes 69 10.3 7.3 – 15.9 
.459 
No 32 10.6 4.5 – 14.0 
Current NVP 
Yes 93 10.3 6.9 – 14.4 
.403 
No 8 12.9 6.8 – 19.2 
 
Table 6.17. Differences in percentage CD25+ CD3+/CD4+ T cells within the 
Phase Two study population according to plasma HIV RNA and current 
exposure to antiretroviral therapy (ART) and specific ART drugs and 
drug classes (TDF = tenofovir disoproxil; ABC = abacavir; PI = protease 
inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; EFV = 
efavirenz; NVP = nevirapine) 
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  n 
% HLA-DR+ CD3+/CD4+  
p-value 
Median IQR 
Plasma HIV RNA  
<40 copies ml-1 
No 3 2.9 - 
.182 
Yes 23 1.7 1.1 – 2.2 
Plasma HIV RNA  
<200 copies ml-1 
No 2 2.5 - 
.443 
Yes 24 1.8 1.1 – 2.5 
Current ART 
No 1 1.7 - 
.923 
Yes 25 1.8 1.2 – 2.0 
Current TDF 
No 6 1.5 0.9 – 1.9 
.123 
Yes 20 1.9 1.8 – 2.8 
Current ABC 
No 20 1.9 1.5 – 2.7 
.196 
Yes 6 1.1 0.9 – 2.3 
Current PI 
No 5 2.0 1.1 – 2.5 
.742 
Yes 21 1.7 1.2 – 2.6 
Current NNRTI 
No 12 1.7 1.2 – 3.1 
1.000 
Yes 14 1.9 1.1 – 2.2 
Current EFV 
No 16 1.7 1.0 – 3.1 
1.000 
Yes 10 1.9 1.3 – 2.2 
Current NVP 
No 24 1.8 1.2 – 2.7 
.554 
Yes 2 1.4 - 
 
Table 6.18. Differences in percentage HLA-DR+ CD3+/CD4+ T cells within 
the Phase Two study population according to plasma HIV RNA and 
current exposure to antiretroviral therapy (ART) and specific ART drugs 
and drug classes (TDF = tenofovir disoproxil; ABC = abacavir; PI = 
protease inhibitor; NNRTI = non-nucleoside reverse transcriptase 
inhibitor; EFV = efavirenz; NVP = nevirapine) 
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  n 
% CD25+ CD3+/CD8+  
p-value 
Median IQR 
Plasma HIV RNA  
<40 copies ml-1 
No 12 1.1 0.6 – 1.3 
.737 
Yes 89 0.9 0.4 – 2.1 
Plasma HIV RNA  
<200 copies ml-1 
No 7 1.0 0.6 – 1.3 
.930 
Yes 93 0.9 0.4 – 2.1 
Current ART 
No 4 0.8 0.2 – 2.7 
.731 
Yes 97 0.9 0.4 – 2.1 
Current TDF 
No 29 0.9 0.5 – 1.8 
.982 
Yes 72 0.9 0.4 – 2.1 
Current ABC 
No 75 0.9 0.4 – 2.4 
.622 
Yes 26 0.8 0.5 – 1.6 
Current PI 
No 55 1.0 0.5 – 2.2 
.392 
Yes 46 1.7 0.3 – 2.0 
Current NNRTI 
No 50 1.0 0.4 – 2.4 
.105 
Yes 51 0.7 0.4 – 1.6 
Current EFV 
No 69 1.0 0.4 – 2.1 
.829 
Yes 32 0.7 0.4 – 2.0 
Current NVP 
No 93 0.9 0.4 – 2.1 
.466 
Yes 8 1.1 0.5 – 3.1 
 
Table 6.19. Differences in percentage CD25+ CD3+/CD8+ T cells within the 
Phase Two study population according to plasma HIV RNA and current 
exposure to antiretroviral therapy (ART) and specific ART drugs and 
drug classes (TDF = tenofovir disoproxil; ABC = abacavir; PI = protease 
inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; EFV = 
efavirenz; NVP = nevirapine) 
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  n 
% HLA-DR+ CD3+/CD8+  
p-value 
Median IQR 
Plasma HIV RNA  
<40 copies ml-1 
No 3 6.0 - 
.312 
Yes 23 4.9 2.2 – 8.1 
Plasma HIV RNA  
<200 copies ml-1 
No 2 7.1 - 
.443 
Yes 24 4.9 2.3 – 7.7 
Current ART 
No 1 3.8 - 
.846 
Yes 25 5.0 2.4 – 8.2 
Current TDF 
No 6 2.8 1.7 – 4.3 
.072 
Yes 20 5.1 3.0 – 8.9 
Current ABC 
No 20 5.1 3.4 – 8.9 
.006 
Yes 6 2.0 1.4 – 3.5 
Current PI 
No 5 5.0 2.5 – 5.7 
1.000 
Yes 21 4.6 2.4 – 8.7 
Current NNRTI 
No 12 4.2 2.7 – 8.5 
.801 
Yes 14 5.0 2.7 – 8.1 
Current EFV 
No 16 4.2 2.3 – 8.0 
.816 
Yes 10 5.0 3.0 – 8.3 
Current NVP 
No 24 4.9 2.7 – 8.3 
.886 
Yes 2 4.5 - 
 
Table 6.20. Differences in percentage HLA-DR+ CD3+/CD8+ T cells within 
the Phase Two study population according to plasma HIV RNA and 
current exposure to antiretroviral therapy (ART) and specific ART drugs 
and drug classes (TDF = tenofovir disoproxil; ABC = abacavir; PI = 
protease inhibitor; NNRTI = non-nucleoside reverse transcriptase 
inhibitor; EFV = efavirenz; NVP = nevirapine) 
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A significant positive correlation was observed between age and both % HLA-
DR+ CD3+/CD4+ T cells (r = 0.436, p = 0.026) and % CD25+ CD3+/CD8+ T 
cells (r = 0.200, p = 0.045) (Table 6.16). Whilst there was no significant 
correlation between BMI and any individual T cell activation marker, there was 
a significant negative correlation between the percentage of subtotal body fat 
and % CD25+ CD3+/CD8+ T cells (r = -0.230, p = 0.021) (Table 6.16). 
 
There was a significant negative correlation between current CD4 cell count, 
CD4 % and CD4:CD8 and % CD25+ CD3+/CD4+ T-cells (r = -0.366, p < 0.001 
for current CD4 cell count, r = -0.410, p < 0.001 for CD4 % and r = -0.394, p < 
0.001 for CD4:CD8) (Table 6.16). 
 
There was no significant relationship between any T cell activation marker 
and the number of years since HIV diagnosis or continuous or cumulative 
duration of ART (Table 6.16). Furthermore, there was no significant difference 
in the percentage of positive cells with any T cell activation marker between 
patients either currently on or not currently on any ART or any specific ARV 
drug class or specific ARV drug (Tables 6.16 to 6.20), with the exception of 
the few patients currently on abacavir (n = 6), who had significantly higher % 
HLA-DR+ CD3+/CD8+ T cells than patients not currently on abacavir (n = 20) 
(p = 0.006) (Table 6.20). 
 
The relationships between the percentage of positive cells with any T cell 
activation marker and inflammatory markers – D-dimer, hs-CRP and IL-6 – 
are detailed in Table 6.21. (No IL-6 data was available in patients with HLA-
DR data). There was a significant positive correlation between D-dimer and % 
CD25+ CD3+/CD8+ T cells (r = 0.253, p = 0.022), hs-CRP and % HLA-DR+ 
CD3+/CD8+ T cells (r = 0.572, p = 0.003) and IL-6 and CD25+ CD3+/CD4+ T 
cells (r = 0.328, p = 0.039).
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% CD25+ CD3+/CD4+ % HLA-DR+ CD3+/CD4+  % CD25+ CD3+/CD8+  % HLA-DR+ CD3+/CD8+  
n r p-value n r p-value n r p-value n r p-value 
D-dimer μg l-1 82 0.181 .104 25 0.141 .502 80 0.253 .022 25 -0.048 .821 
hs-CRP mg l-1 83 0.128 .248 25 0.252 .225 83 -0.004 .974 25 0.572 .003 
IL-6 pg ml-1 40 0.328 .039 0 - - 40 0.171 0.292 0 - - 
 
 
Table 6.21. Relationships between D-dimer, highly-sensitive CRP (hs-CRP) and interleukin-6 (IL-6) and percentage CD25+ 
CD3+/CD4+, percentage HLA-DR+ CD3+/CD4+, percentage CD25+ CD3+/CD8+ and percentage HLA-DR+ CD3+/CD8+ in the 
Phase Two study population  
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6.4.2 Relationships between T cell activation markers and BMD and 25-
hydroxyvitamin D in PLWH 
 
No significant association was observed between % CD25+ CD3+/CD4+, % 
HLA-DR+ CD3+/CD4+, % CD25+ CD3+/CD8+ or % HLA-DR+ CD3+/CD8+ T 
cells and BMD at any site (Table 6.22). There was, however, a trend to higher 
25-OH-D with higher % CD25+ CD3+/CD4+, % HLA-DR+ CD3+/CD4+, % 
CD25+ CD3+/CD8+ and % HLA-DR+ CD3+/CD8+ T cell populations, with a 
significant positive correlation between 25-OH-D and both % HLA-DR+ 
CD3+/CD4+ (p < 0.001) and % CD25+ CD3+/CD8+ T cell populations (p = 
0.003) (Table 6.22 and Figure 6.8). These associations remained significant 
after adjustment for patient race, season of 25-OH-D sampling, current 
efavirenz use and race-adjusted eGFR. 
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% CD25+ CD3+/CD4+  % HLA-DR+ CD3+/CD4+  % CD25+ CD3+/CD8+  % HLA-DR+ CD3+/CD8+  
r p-value r p-value r p-value r p-value 
Lumbar spine BMD    
g cm-2  
-0.018 .855 -0.116b .573 -0.124 .217 -0.065e .751 
Total hip BMD                      
g cm-2 
0.013 .901 -0.117b .568 -0.154 .124 -0.019e .925 
Femoral neck BMD      
g cm-2 
-0.049 .626 -0.202b .322 -0.138 .170 -0.044e .831 
Total body BMD           
g cm-2 
0.048 .637 -0.050b .807 -0.047 .637 0.130e .526 
25-hydroxyvitamin D 
nmol l-1 
0.205a .082 0.800c <.001 0.348d .003 0.419f .094 
 
  a 28 missing values                 b 75 missing values                   d 28 missing values                e 75 missing values     
     c 84 missing values                      f  84 missing values     
   
Table 6.22. Relationships between lumbar spine, total hip, femoral neck and total body bone mineral density (BMD) and 
25-hydroxyvitamin D and percentage CD25+ CD3+/CD4+, percentage HLA-DR+ CD3+/CD4+, percentage CD25+ CD3+/CD8+ and 
percentage HLA-DR+ CD3+/CD8+ T cell populations in the Phase Two study population (n = 101).  
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Figure 6.8. Relationship between 25-hydroxyvitamin D and percentage 
CD25+ CD3+/CD4+ (n = 73), percentage HLA-DR+ CD3+/CD4+ (n = 17), 
percentage CD25+ CD3+/CD8+ (n = 73) and percentage HLA-DR+ 
CD3+/CD8+ T cell populations (n = 17) in the Phase Two study population  
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6.5 Distribution and associations of peripheral blood monocyte population 
subsets and their relationships with BMD and 25-hydroxyvitamin D3 in PLWH 
 
6.5.1 Distribution and general and HIV disease-specific associations of 
peripheral blood monocyte population subsets in PLWH 
 
The distribution of relative proportions (expressed as percentages) of 
peripheral blood monocyte population subsets – classical (CD14++ CD16-), 
intermediate (CD14++ CD16+) and non-classical (CD14dim CD16++) – are 
detailed in Table 6.23 for all Phase Two patients in whom monocyte data was 
available (n = 26), as well as for black and white patient subgroups (n = 20 
and n = 6 respectively). The percentage of classical monocytes was, overall, 
higher than the percentage of intermediate and non-classical monocytes and 
the percentage of non-classical monocytes was higher than the percentage of 
intermediate monocytes. There was no significant difference in the relative 
proportions of each monocyte population subset between black and white 
patients. Examples of patients with relatively high percentages of intermediate 
and non-classical monocyte population subsets are demonstrated in Figures 
6.9a and 6.9b respectively. 
 
 
The relationships between the percentage of each peripheral blood monocyte 
population subset with age, BMI, subtotal body fat percentage, T cell 
immunological markers and HIV disease-specific factors are summarised in 
Table 6.24. In addition, differences in the percentages of each peripheral 
blood monocyte population subset according to patient plasma HIV RNA and 
ART exposure are summarised in Tables 6.25 to 6.27. There was a significant 
positive correlation between the percentage of classical monocytes and 
current CD4 cell count (r = 0.490, p = 0.011), current CD4 % (r = 0.692, p < 
0.001) and CD4:CD8 (r = 0.665, p < .001) and a significant negative 
correlation between the percentage of non-classical monocytes and current 
CD4 cell count (r = -0.458, p = 0.019), current CD4 % (r = -0.735, p < 0.001) 
and CD4:CD8 (r = -0.693, p < 0.001) (Table 6.24).  
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All                            
(n = 26) 
Black 
(n = 20) 
White 
(n = 6) 
% Classical 
Median 
(IQR) 
78.6 
(69.5 – 83.8) 
77.2 
(67.8 – 83.0) 
81.4 
(70.0 – 87.9) 
% Intermediate 
Median 
(IQR) 
7.1 
(5.5 – 10.3) 
7.1 
(5.8 – 11.0) 
7.2 
(3.1 – 8.9) 
% Non-classical 
Median 
(IQR) 
12.7 
(7.4– 19.4) 
13.3 
(7.7 – 20.8) 
10.3 
(3.6 – 22.9) 
           
 
Table 6.23. Distribution of relative proportions (%) of classical (CD14++ CD16-), intermediate (CD14++ CD16+) and non-
classical (CD14dim CD16++) peripheral blood monocyte population subsets in all patients (n = 26), black patients (n = 20) 
and white patients (n = 6) within the Phase Two study population for whom monocyte data was available
 285 
 
Figure 6.9a. Example of a relatively high percentage of intermediate 
(CD14++ CD16+) and low percentage of non-classical (CD14dim CD16++) 
peripheral blood monocytes 
 
 
 
Figure 6.9b. Example of a relatively high percentage of non-classical 
(CD14dim CD16++) peripheral blood monocytes 
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% Classical  % Intermediate % Non-classical 
r p-value r p-value r p-value 
Age years  -0.123 .549 -0.100 .628 0.179 .381 
BMI kg m-2 -0.004 .985 0.018 .931 0.003 .989 
Subtotal body fat % -0.167 .414 0.147 .472 0.061 .769 
Nadir CD4 cell count cells μl-1 0.076 .714 0.131 .525 -0.062 .765 
CD3+/CD4+ cell count cells μl-1 0.490 .011 -0.019 .927 -0.458 .019 
CD3+/CD4+ % 0.692 <.001 -0.055 .789 -0.735 <.001 
CD3+/CD8+ cell count cells μl-1 -0.324 .107 0.130 .526 0.346 .083 
CD3+/CD8+ % -0.542 .004 0.149 .469 0.520 .007 
CD4:CD8 0.665 <.001 -0.078 .705 -0.693 <.001 
Years since HIV diagnosis 0.035 .866 -0.097 .637 -0.089 .665 
Duration of continuous ART mo. 0.046 .827 -0.293 .156 -0.052 .807 
Duration of cumulative ART mo. -0.003 .990 -0.276 .182 -0.009 .965 
 
 
Table 6.24. Relationships between general factors, immunological markers and HIV disease-specific factors and relative 
proportions (%) of classical (CD14++ CD16-), intermediate (CD14++ CD16+) and non-classical (CD14dim CD16++) peripheral 
blood monocyte population subsets in all patients within the Phase Two study population for whom monocyte data was 
available (n = 26) (mo. = months)
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  n 
% Classical 
p-value 
Median IQR 
Plasma HIV RNA  
<40 copies ml-1 
No 3 55.2 - 
.012 
Yes 23 79.8 72.6 – 83.9 
Plasma HIV RNA  
<200 copies ml-1 
No 2 61.1 - 
.074 
Yes 24 79.7 71.9 – 83.9 
Current ART 
No 1 66.9 - 
.462 
Yes 25 79.6 71.0 – 83.8 
Ever ART 
No 1 66.9 - 
.462 
Yes 25 79.6 71.0 – 83.8 
 
Table 6.25. Differences in relative proportion (%) of classical (CD14++ 
CD16-) peripheral blood monocytes in all patients within the Phase Two 
study population for whom monocyte data was available (n = 26) 
according to plasma HIV RNA and current or ever exposure to 
antiretroviral therapy (ART)  
 
 
 
 
  n 
% Intermediate 
p-value 
Median IQR 
Plasma HIV RNA  
<40 copies ml-1 
No 3 11.4 - 
.352 
Yes 23 6.8 4.8 – 8.2 
Plasma HIV RNA  
<200 copies ml-1 
No 2 13.2 - 
.074 
Yes 24 6.7 5.0 – 8.2 
Current ART 
No 1 15.0 - 
.231 
Yes 25 6.8 5.3 – 9.1 
Ever ART 
No 1 15.0 - 
.231 
Yes 25 6.8 5.3 – 9.1 
 
Table 6.26. Differences in relative proportion (%) of intermediate (CD14++ 
CD16+) peripheral blood monocytes in all patients within the Phase Two 
study population for whom monocyte data was available (n = 26) 
according to plasma HIV RNA and current or ever exposure to 
antiretroviral therapy (ART)  
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  n 
% Non-classical 
p-value 
Median IQR 
Plasma HIV RNA  
<40 copies ml-1 
No 3 33.5 - 
.041 
Yes 23 11.7 7.4 – 17.1 
Plasma HIV RNA  
<200 copies ml-1 
No 2 25.5 - 
.222 
Yes 24 12.1 7.4 – 18.2 
Current ART 
No 1 17.4 - 
.615 
Yes 25 12.4 7.4 – 20.3 
Ever ART 
No 1 17.4 - 
.615 
Yes 25 12.4 7.4 – 20.3 
 
Table 6.27. Differences in relative proportion (%) of non-classical 
(CD14dim CD16++) peripheral blood monocytes in all patients within the 
Phase Two study population for whom monocyte data was available (n = 
26) according to plasma HIV RNA and current or ever exposure to 
antiretroviral therapy (ART)  
 
 
In contrast, there was a significant negative correlation between the 
percentage of classical monocytes and current CD8 % (r = -0.542, p = 0.004) 
and a significant positive correlation between the percentage of non-classical 
monocytes and current CD8 % (r = 0.520, p = 0.007) (Table 6.24). 
 
The percentage of classical monocytes was significantly lower and the 
percentage of non-classical monocytes significantly higher in the few patients 
with unsuppressed plasma HIV RNA ≥ 40 copies ml-1 (n = 3) compared to 
those with suppressed plasma HIV RNA <40 copies ml-1 (n = 23) (p = 0.012 
and p = 0.041 for percentage classical and percentage non-classical 
monocytes respectively) (Tables 6.25 and 6.27). 
 
No significant relationship was observed between the relative proportion of 
any peripheral blood monocyte population subset and D-dimer or hs-CRP, as 
detailed in Table 6.28. (No IL-6 data was available in the 26 patients with 
monocyte data).  
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% Classical  % Intermediate % Non-classical 
r p-value r p-value r p-value 
D-dimer μg l-1 0.377 .099 -0.277 .180 -0.156 .456 
hs-CRP mg l-1 -0.115 .584 0.090 .670 -0.042 .842 
 
 
 
Table 6.28. Relationships between D-dimer and highly-sensitive CRP (hs-CRP) and interleukin-6 (IL-6) and relative 
proportions (%) of classical (CD14++ CD16-), intermediate (CD14++ CD16+) and non-classical (CD14dim CD16++) peripheral 
blood monocyte population subsets for all patients within the Phase Two study population for whom monocyte data was 
available (n = 26) 
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6.5.2 Relationships between peripheral blood monocyte population subsets 
and BMD and 25-hydroxyvitamin D in PLWH 
 
The relationship between the relative proportions (percentage) of classical, 
intermediate and non-classical peripheral blood monocyte population subsets 
with BMD and 25-OH D are detailed in Tables 6.29, 6.30 and 6.31 for all, 
black and white patients within the Phase Two study population for whom 
monocyte data was available.  
 
In all patients, there was a trend to increased lumbar spine and total body 
BMD with a higher percentage of classical monocytes, coupled with a trend to 
reduced BMD at each site with a higher percentage of non-classical 
monocytes; the percentage of non-classical monocytes was significantly 
negatively correlated with lumbar spine BMD (r = -0.391, p = 0.048). A similar 
trend was observed in black patients, with a trend to higher BMD at all sites 
with a higher percentage of classical monocytes and lower BMD at all sites 
with a higher percentage of non-classical monocytes; significant correlations 
were observed between the percentage of classical monocytes and total BMD 
(r = 0.496, p = 0.026) and between non-classical monocytes and hip BMD (r = 
-0.477, p = 0.034). The relationship between lumbar spine BMD and the 
percentage of both classical and non-classical monocytes was similar in white 
patients; in contrast to black patients, however, total hip, femoral neck and 
total body BMD each decreased with a higher percentage of classical 
monocytes and increased with a higher percentage of non-classical 
monocytes. 
 
There was no significant relationship observed between the relative 
proportions of classical, intermediate or non-classical peripheral blood 
monocyte population subsets and 25-OH-D in all patients or in black patients. 
In white patients, however, a significant negative correlation was seen 
between 25-OH-D3 and the percentage of classical monocytes (r = -0.900, p = 
0.037), with a trend to increased 25-OH-D with higher percentages of both 
intermediate and non-classical monocytes (r = 0.600, p = 0.285 and r = 0.800, 
p = 0.104 for intermediate and non-classical monocytes respectively).
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% Classical  % Intermediate % Non-classical 
r p-value r p-value r p-value 
Lumbar spine BMD    
g cm-2  
0.271 .180 0.258 .203 -0.391 .048 
Total hip BMD                      
g cm-2 
0.095 .643 0.011 .959 -0.148 .470 
Femoral neck BMD      
g cm-2 
0.093 .652 0.126 .539 -0.175 .391 
Total body BMD           
g cm-2 
0.281 .164 0.012 .952 -0.179 .380 
25-hydroxyvitamin D 
nmol l-1 
0.097 0.711 -0.065 .804 0.038 .885 
 
 
 
Table 6.29. Relationships between lumbar spine, total hip, femoral neck and total bone mineral density (BMD) and 25-
hydroxyvitamin D and relative proportions (%) of classical (CD14++ CD16-), intermediate (CD14++ CD16+) and non-classical 
(CD14dim CD16++) peripheral blood monocyte population subsets for all patients within the Phase Two study population for 
whom monocyte data was available (n = 26) 
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% Classical  % Intermediate % Non-classical 
r p-value r p-value r p-value 
Lumbar spine BMD    
g cm-2  
0.256 .276 0.083 .729 -0.435 .056 
Total hip BMD                      
g cm-2 
0.336 .148 -0.122 .609 -0.477 .034 
Femoral neck BMD      
g cm-2 
0.247 .294 0.059 .806 -0.406 .076 
Total body BMD           
g cm-2 
0.496 .026 -0.164 .490 -0.414 .070 
25-hydroxyvitamin D3 
nmol l-1 
0.049 .880 -0.336 .286 0.063 .846 
 
 
 
Table 6.30. Relationships between lumbar spine, total hip, femoral neck and total body bone mineral density (BMD) and 
25-hydroxyvitamin D and between relative proportions (%) of classical (CD14++ CD16-), intermediate (CD14++ CD16+) and 
non-classical (CD14dim CD16++) peripheral blood monocyte population subsets for black patients within the Phase Two 
study population for whom monocyte data was available (n = 20)
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% Classical  % Intermediate % Non-classical 
r p-value r p-value r p-value 
Lumbar spine BMD    
g cm-2  
0.314 .544 0.714 .111 -0.486 .329 
Total hip BMD                      
g cm-2 
-0.543 .266 0.200 .704 0.429 .397 
Femoral neck BMD      
g cm-2 
-0.314 .544 0.314 .544 0.257 .623 
Total body BMD 
g cm-2 
-0.086 .872 -0.029 .957 0.143 .787 
25-hydroxyvitamin D 
nmol l-1 
-0.900 .037 0.600 .285 0.800 .104 
 
 
 
Table 6.31. Relationships between lumbar spine, total hip, femoral neck and total body bone mineral density (BMD) and 
25-hydroxyvitamin D and between relative proportions (%) of classical (CD14++ CD16-), intermediate (CD14++ CD16+) and 
non-classical (CD14dim CD16++) peripheral blood monocyte population subsets for white patients within the Phase Two 
study population for whom monocyte data was available (n = 6) 
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6.6 Discussion 
 
The overwhelming majority of patients included in the Phase Two study 
population were well established on ART – median continuous ART duration 
64 months (IQR 32 – 122) – with suppressed plasma HIV RNA – less than 40 
copies ml-1 in 101 (88.6%) patients and less than 200 ml-1 in 107 (93.9%) 
patients – and with good immune reconstitution – median current CD4 cell 
count 616 cells μl-1 (IQR 437 – 783). Only four (3.5%) patients were not 
currently on ART and only three (2.6%) patients were ART-naïve. That no 
correlation was identified between BMD and either IL-6, hs-CRP or D-dimer 
within the ART-stable Phase Two study population is in keeping with the 
findings from one other cross-sectional study also performed in ART-stable 
patients (Erlandson et al. 2014). Interestingly, both hs-CRP and D-dimer 
increased significantly with increases in both BMI and percentage of subtotal 
body fat. As there is a strong positive correlation between BMI and BMD, 
larger BMD increases with increases in BMI may offset any BMD decreases 
secondary to higher levels of inflammation in ART-stable patients. 
 
The findings of this study support the hypothesis that only pre-ART initiation 
levels of inflammatory markers are significantly associated with BMD in PLWH 
– with greater bone loss observed within the first two years of ART initiation 
with higher pre-ART levels of IL-6 and hs-CRP (Hileman et al. 2014, Brown et 
al. 2015) – and that levels of inflammatory markers in ART-stable patients are 
not significantly associated with BMD. Of note, IL-6 data was only analysed in 
a small subset of Phase Two patients (n = 41, 36.0%) and should ideally be 
assessed across the wider Phase Two cohort to further verify these findings. 
Longitudinal BMD data would also be valuable to confirm whether or not 
levels of inflammatory markers in ART-stable patients determine future bone 
loss. 
 
No relationship was identified between either current CD4 cell count or CD4 
cell percentage and BMD within the ART-stable Phase Two study population. 
Only four Phase Two patients had current CD4 cell counts <200 cells ul-1, 
however, probably too few to assess a significant difference in BMD between 
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patients with low versus high current CD4 cell count, which has been 
observed elsewhere (Yong et al. 2011). No relationship was identified 
between nadir CD4 cell count and BMD either, however (Chapter 4), in spite 
of 58 (50.9%) Phase Two patients having a nadir CD4 cell count <200 cells  
μl-1. As observed with markers of inflammation, it may be that whilst low nadir 
or ART baseline CD4 cell counts can influence the degree of bone loss within 
the first one to two years following ART initiation, this influence does not 
persist at a significant level beyond this time point and is therefore no longer 
seen in an ART-stable population. This could explain why, whilst an inverse 
CD4:CD8 (< 1) can persist following immune reconstitution in patients with 
low nadir CD4 counts, current CD4:CD8 (< 1 in 76 Phase Two patients) was 
also not significantly associated with BMD in this ART-stable population. 
CD4:CD8 does influence the risk of other NICMs in ART-stable HIV-positive 
populations, however (Serrano-Villar et al. 2014a, Serrano-Villar et al. 2014b, 
Castilho et al. 2016) and it may be justifiable to assess the relationship 
between CD4:CD8 ratio and BMD in PLWH a larger cohort. 
 
In keeping with Erlandson et al. 2014, but in contrast to Gazzola et al. 2013, T 
cell activation markers were not found to correlate significantly with BMD in 
the Phase Two study population. Of note, whilst % HLA-DR+ CD3+/CD4+ and 
% HLA-DR+ CD3+/CD8+ T cell populations were assessed within each study, 
different “second” markers of T cell activation were used – % CD25 (in this 
Phase Two study), % CD28 (Gazzola et al. 2013) and % CD38 (Erlandson et 
al. 2014) – and therefore findings between these studies are not necessarily 
comparable. Moreover, HLA-DR data was only available in a small subset of 
the Phase Two study population (n = 26, 22.8%) and this small sample size is 
likely to negatively impact upon the potential to identify significant correlations. 
Furthermore, as activated T cells have a relatively short half-life before 
undergoing apoptosis (Carreño et al. 2006), real-time measurements in stable 
patients are unlikely to reflect past immune activation and therefore correlate 
poorly with BMD. The simultaneous measurement of bone turnover markers 
and BMD longitudinally could improve current understanding of the role of T 
cell activation in reduced BMD in PLWH. 
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A trend to an increased percentage of circulating non-classical (CD14dim 
CD16++) monocytes with reduced BMD was observed within the Phase Two 
study population for all BMD sites, with a significant negative correlation 
observed between percentage of non-classical monocytes and lumbar spine 
BMD. Monocyte population subset data was available in only 26 Phase Two 
patients, however, of whom a majority (76.9%) were black African. This 
finding cannot necessarily be extrapolated to all white patients, therefore. A 
larger study (Erlandson et al. 2014), which included142 HIV-positive ART-
stable patients, of whom 69% were of black race, demonstrated no correlation 
between percentage of non-classical monocytes and lumbar spine BMD 
 
Of interest, having a higher percentage of non-classical monocytes was 
significantly associated with HIV disease-specific factors typically associated 
with either late HIV presentation or poorer HIV disease control, namely lower 
current CD4 cell count and CD4 %, lower CD4:CD8 and having an 
unsuppressed plasma HIV RNA. None of these factors in isolation have had 
independent significant associations with BMD identified within the Phase 
Two cross-sectional study of mostly ART-stable patients. Whilst these factors 
are recoverable with ART initiation, expanded non-classical monocyte 
population subsets can persist, with no change in non-classical monocyte 
population size at one year following ART initiation in one study (Han et al. 
2009). Non-classical monocytes may therefore act as a lasting footprint of 
past immune dysregulation, increased bone turnover and BMD loss and 
therefore may correlate better with current BMD – a summation of past bone 
turnover activity – than current recovered CD4 cell count, CD4 %, CD4:CD8 
or plasma HIV RNA. 
 
No significant relationship was observed between 25-OH-D and inflammatory 
or immunological markers within this study. In contrast to expectation, 25-OH-
D was higher (not lower) with higher levels of T cell immune activation, with a 
significant positive correlation observed between 25-OH-D and both % HLA-
DR+ CD3+/CD4+ and % CD25+ CD3+/CD8+ T cell populations. Also contrary to 
expectation, 25-OH-D was higher (not lower) with an increased percentage of 
non-classical monocytes. These unexpected findings may be explained by the 
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small sample size of this study, particularly with respect to monocyte analysis, 
as well as a failure to adjust for unidentified confounding factors, in the 
context of multiple potential vitamin D predictors. These findings also 
demonstrate the complex, multidirectional and perhaps not always predictable 
relationship between vitamin D, the immune system and inflammation.  
 
 
6.7 Conclusions 
 
1. There was no significant association observed between inflammatory 
markers (D-dimer, hs-CRP or IL-6) with BMD or 25-OH-D. 
 
2. There was no significant association observed between current CD4 cell 
count, current CD4 %, current CD8 cell count, current CD8 % or 
CD4:CD8 ratio with BMD or 25-OH-D. 
 
3. There was no significant association between T cell activation markers (% 
CD25+ CD3+/CD4+, % HLA-DR+ CD3+/CD4+, % CD25+ CD3+/CD8+ or % 
HLA-DR+ CD3+/CD8+ T cell populations) with BMD; there was, however, a 
trend to increased 25-OH-D with increased percentage positivity of each 
T-cell activation marker which was significant for both % HLA-DR+ 
CD3+/CD4+ and % CD25+ CD3+/CD8+ T-cell populations independent of 
other predictors of 25-OH-D. 
 
4. There was a trend to decreased BMD at each site with a higher 
percentage of peripheral blood non-classical monocytes, which was 
significant for lumbar spine BMD; a higher percentage of peripheral blood 
non-classical monocytes was significantly associated with factors typically 
associated with either late HIV presentation or poorer HIV disease control; 
overall, there was no significant relationship between the relative 
proportions of peripheral blood monocyte population subsets and 25-OH-
D. 
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7. FRAX® as a tool for the assessment of fracture risk in people living 
with HIV 
 
7.1 Introduction 
 
The WHO FRAX® tool (www.shef.ac.uk/FRAX) has been validated as an 
effective tool for predicting fracture risk in men and women 40 to 90 years of 
age, incorporating clinical risk factors, with or without femoral neck BMD 
measurements if available (Kanis et al. 2008a; Johansson et al. 2009; Kanis 
et al. 2009). FRAX® provides an estimate of an individual’s 10-year probability 
of major osteoporotic fracture (hip, clinical vertebral, wrist or proximal 
humerus) or hip fracture alone. In the UK, its output has been coupled to a 
guideline from the National Osteoporosis Guideline Group (NOGG) to 
determine who should be considered for BMD assessment and/or therapy to 
reduce fracture risk (Kanis et al. 2008b; Compston et al. 2009).  
 
FRAX® is recommended for use in PLWH in both national and international 
HIV guidelines (BHIVA 2016; EACS 2017). EACS recommend FRAX® score 
calculation in PLWH aged 40 years or more, with the added recommendation 
to consider incorporating HIV infection into FRAX® as a “secondary 
osteoporosis” risk factor (EACS 2017). In addition to patients with high 
FRAX®-calculated 10-year probability of fracture, EACS also recommends 
BMD measurement directly, irrespective of FRAX®, in PLWH within any of the 
following groups: post-menopausal women; men more than or equal to 50 
years of age; those with a history of fragility fracture; those with a high risk for 
falls; those with clinical hypogonadism; and those who have been on oral 
glucocorticoid treatment (at least 5 mg prednisolone daily or equivalent) for 
more than three months (EACS 2017).  
 
FRAX® does not incorporate HIV-disease specific risk factors for fracture, 
however, and therefore the appropriateness of its use in PLWH remains a 
subject of research. Assessing FRAX® within HIV cohorts has been limited by 
a lack of longitudinal studies with sufficient follow up time to allow a 
comparison of baseline FRAX® probabilities with ten year actual fragility 
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fracture incidence. Furthermore, outside the context of large population 
studies, the incidence of fragility fractures is too small within studied HIV 
cohorts to support any meaningful analysis. FRAX® has therefore been 
compared to BMD – a sub-optimal yet pragmatic surrogate for actual ten year 
fracture incidence, with several FRAX®-incorporated risk factors mediating at 
least part of their effect by altering BMD.   
 
An Australian cross-sectional study compared FRAX®-calculated 10-year 
probabilities of fragility fracture to BMD in 153 predominantly male HIV-
positive patients (race not stated), median age 48 years and median BMI 24.5 
kg m-2, and found no significant difference in FRAX®-calculated probabilities 
between patients with normal BMD and those with reduced BMD (n = 65, 
42.5%) (Calmy et al. 2009). Two smaller cross-sectional Italian studies also 
observed poor sensitivity of FRAX® for the prediction of HIV-positive patients 
with reduced BMD (Gazzola et al. 2010; Pepe et al. 2012). In one of these two 
studies, modification of FRAX®, with inclusion of HIV as a “secondary 
osteoporosis” risk factor, improved its sensitivity of reduced BMD prediction, 
but remained suboptimal (37.5% sensitivity with HIV as a “secondary 
osteoporosis” risk factor versus 22% without) (Gazzola et al. 2010). 
 
Two studies in PLWH have compared FRAX®-calculated 10-year probabilities 
of fragility fracture (estimated incidence) to actual 10-year fragility fracture 
incidence (observed incidence). The first of these was a retrospective data 
review of exclusively male HIV-positive patients 50 to 70 years of age within 
the US Veterans Ageing Cohort Study Virtual Cohort (Yin et al. 2016). 
Osteoporotic fracture incidence was derived from ICD-9-CM diagnostic codes. 
Of note, data on parental hip fracture and the presence of other “secondary 
osteoporosis” risk factors were not available and therefore not included in 
FRAX® calculations, thereby lowering estimated fragility fracture incidence 
within the study population overall. Observed/estimated fragility fracture 
incidence ratios (O/E ratios) were compared in 24,451 HIV-positive males with 
age-matched HIV-negative male controls. FRAX® was found to be a poorer 
predictor of fragility fracture incidence in HIV-positive males versus HIV-
negative males (O/E ratio 1.62, 95% CI 1.45, 1.81 versus O/E ratio 1.29, 95% 
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CI 1.19, 1.40). The observed fragility fracture incidence was actually quite low, 
however. Furthermore, there was a high prevalence of HCV co-infection 
within HIV-positive males – an additional potential fracture risk factor (Lo Re 
et al. 2012) not incorporated into FRAX®. The accuracy of FRAX® was worse 
in HIV-positive males with higher FRAX®-calculated 10-year probability of 
major osteoporotic fracture, including in older males.  Of interest, the inclusion 
of HIV as a “secondary osteoporosis” risk factor improved the correlation 
between FRAX® and observed fragility fracture incidence in HIV-positive 
males (O/E ratio 1.20, 95% CI 1.08, 1.34). 
 
The second of these studies is the only published prospective longitudinal 
study to date that compares FRAX®-calculated estimated fragility fracture risk 
and observed fracture incidence in PLWH (Yang et al. 2018). Similar to the 
retrospective male study, this exclusively female US study also demonstrated 
that FRAX® was a poorer predictor of fragility fracture incidence in 900 HIV-
positive females than in 248 HIV-negative females (O/E ratio 5.05 compared 
with 3.26 for major osteoporotic fracture and 19.78 compared with 7.94 for hip 
fracture in HIV-positive and HIV-negative females respectively). Again, as 
seen in male patients, O/E ratios for HIV-positive females improved with the 
inclusion of HIV as a “secondary osteoporosis” risk factor, with further 
improvement observed for hip O/E ratios when femoral neck BMD data was 
also incorporated into FRAX® (O/E ratio 4.00). 
 
There have been no publications to date comparing the performance of 
FRAX® – with or without inclusion of HIV as a “secondary osteoporosis” risk 
factor – in black versus white HIV-positive patients. 
 
This chapter aims to identify whether there may be a subset of PLWH in 
whom FRAX® may be a useful tool for fracture risk assessment, by answering 
the following specific questions: 
 
1. How well does FRAX® predict fragility fracture incidence – using BMD as 
a surrogate for actual fracture incidence – in the Sheffield HIV Cohort? 
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2. Does FRAX® perform better or worse in black versus white HIV-positive 
patients, in low fracture risk patients compared to high fracture risk 
patients, or for different BMD sites? 
 
 
3. Does the inclusion of HIV into FRAX® as a “secondary osteoporosis” risk 
factor improve the performance of FRAX® in PLWH? 
 
4. To what extent do FRAX® probabilities calculated with femoral neck BMD 
differ from FRAX® probabilities calculated without BMD and are 
differences between these greater or smaller in black HIV-positive 
patients compared to white HIV-positive patients or in low fracture risk 
patients compared to high fracture risk patients?  
 
5. Could HIV disease-specific risk factors be used with FRAX® to improve its 
correlation with BMD and therefore to improve fracture risk assessment in 
PLWH? 
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7.2 Relationship between FRAX® 10-year probability of major osteoporotic 
and hip fracture (calculated without femoral neck BMD) and BMD in PLWH 
 
The distributions of FRAX® 10-year probability of major osteoporotic fracture 
(“FRAX® major”) and FRAX® 10-year probability of hip fracture (“FRAX® hip”) 
– both calculated without femoral neck BMD and without incorporating HIV as 
a “secondary osteoporosis” risk factor – are shown in Table 7.1 for all (n = 
114), black (n = 52) and white (n = 62) patients within the Phase Two study 
population. The US Black FRAX® tool was used in all black patients (in the 
absence of other black race country-specific tools being available). Country-
specific FRAX® tools were used in white patients (UK tool for white British and 
Irish patients (n = 57); country-specific tools for individual patients from 
Australia, Chile, Malta, Portugal and Slovakia respectively). “FRAX® major” 
and “FRAX® hip” were significantly lower in black patients than in white 
patients (p < 0.001 for both). 
 
The correlations between both “FRAX® major” and lumbar spine, total hip, 
femoral neck and total body BMD and between “FRAX® hip” and total hip and 
femoral neck BMD are shown in Table 7.2 for all, black and white patients 
within the Phase Two study population. In all patients and in black patients 
(Figures 7.1 and 7.2), there was a significant negative correlation between 
both “FRAX® major” with BMD at every site and “FRAX® hip” with BMD at the 
total hip and femoral neck. In white patients, however, there was no significant 
correlation between “FRAX® major” and BMD at any site (Figure 7.3). There 
was, however, a significant negative correlation between “FRAX® hip” and 
total hip BMD, although not between “FRAX® hip” femoral neck BMD (Figure 
7.4). 
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All patients 
(n = 114) 
Black patients 
(n = 52) 
White patients 
(n = 62) 
“FRAX® major” % 
Median 2.6 1.0 3.6 
IQR 1.1 – 4.1 0.7 – 1.9 2.6 – 6.0 
Range 0.5 – 15.0 0.5 – 6.2 1.5 – 15.0 
“FRAX® hip” % 
Median 0.2 0.0 0.4 
IQR 0.0 – 0.5 0.0 – 0.1 0.2 – 0.9 
Range 0.0 – 3.6 0.0 – 1.8 0.1 – 3.6 
 
Table 7.1. Distribution of FRAX® 10-year probability of major osteoporotic fracture (“FRAX® major”) and hip fracture 
(“FRAX® hip”) (both calculated without femoral neck BMD and without incorporating HIV as a “secondary osteoporosis” 
risk factor) in all (n = 114), black (n = 52) and white (n = 62) patients within the Phase Two study population
 304 
 
BMD site 
All (n = 114) Black (n = 52) White (n = 62) 
FRAX® major FRAX® hip FRAX® major FRAX® hip FRAX® major FRAX® hip 
r p r p r p r p r p r p 
L-spine -0.243 .009 - - -0.405 .003 - - -0.120 .354 - - 
Total hip -0.324 <.001 -0.384 <.001 -0.295 .034 -0.410 .003 -0.245 .055 -0.275 .030 
Femoral 
neck 
-0.408 <.001 -0.462 <.001 -0.434 .001 -0.545 <.001 -0.211 .100 -0.233 .068 
Total 
body 
-0.288 .002 - - -0.370 .007 - - -0.203 .114 - - 
 
Table 7.2. Relationship between FRAX® 10-year probability of major osteoporotic fracture (“FRAX® major”) and hip 
fracture (“FRAX® hip”) (both calculated without femoral neck BMD and without incorporating HIV as a “secondary 
osteoporosis” risk factor) and lumbar (L-) spine, total hip, femoral neck and total body BMD in all (n = 114), black (n = 52) 
and white (n = 62) patients within the Phase Two study population 
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Figure 7.1. Relationship between FRAX® 10-year probability of major 
osteoporotic fracture (“FRAX® major”) (calculated without femoral neck 
BMD and without incorporating HIV as a “secondary osteoporosis” risk 
factor) and lumbar (L-) spine, total hip, femoral neck and total body BMD 
in black (n = 52) patients within the Phase Two study population 
 
 
 
 
Figure 7.2. Relationship between FRAX® 10-year probability of hip 
fracture (“FRAX® hip”) (calculated without femoral neck BMD and 
without incorporating HIV as a “secondary osteoporosis” risk factor) 
and total hip and femoral neck BMD in black (n = 52) patients within the 
Phase Two study population  
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Figure 7.3. Relationship between FRAX® 10-year probability of major 
osteoporotic fracture (“FRAX® major”) (calculated without femoral neck 
BMD and without incorporating HIV as a “secondary osteoporosis” risk 
factor) and lumbar (L-) spine, total hip, femoral neck and total body BMD 
in white (n = 62) patients within the Phase Two study population 
 
 
 
 
Figure 7.4. Relationship between FRAX® 10-year probability of hip 
fracture (“FRAX® hip”) (calculated without femoral neck BMD and 
without incorporating HIV as a “secondary osteoporosis” risk factor) 
and total hip and femoral neck BMD in white (n = 62) patients within the 
Phase Two study population 
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The relationship between FRAX® and BMD was also analysed by assessing 
the differences in BMD between Phase Two patients with either low, 
intermediate or high FRAX® probabilities.  
 
In all patients (n = 114), low, intermediate and high “FRAX® major” 
probabilities were defined as ≤ 1.9% (n = 39), 2.0 – 3.6% (n = 39) and ≥ 3.7% 
(n = 36) and low, intermediate and high “FRAX® hip” probabilities were 
defined as ≤ 0.1% (n = 51), 0.2 – 0.4% (n = 32) and ≥ 0.5% (n = 31).  
 
Whilst differences in both lumbar spine and total BMD between “FRAX® 
major” low, intermediate and high probability tertiles were not significant (F 
(2,111) = 2.315, p = 0.301 for lumbar spine; F (2,111) = 2.777, p = 0.067 for 
total BMD), differences between both total hip and femoral neck BMD and 
“FRAX® major” low, intermediate and high probability tertiles were significant 
(F (2,111) = 4.045, p = 0.020 for hip; and F (2,111) = 8.033, p = 0.001 for 
femoral neck) (Table 7.3 and Figure 7.5). There was good differentiation in 
both total hip and femoral neck BMD between both “FRAX® major” low and 
intermediate probability tertiles (p = 0.075 for total hip; p = 0.005 for femoral 
neck) and between “FRAX® major” low and high probability tertiles (p = 0.006 
for total hip; p < 0.001 for femoral neck). There was no clear differentiation in 
total hip and femoral neck BMD between “FRAX® major” intermediate and 
high probability tertiles, however (p = 0.295 for total hip; p = 0.441 for femoral 
neck). 
 
There were significant differences in both total hip and femoral neck BMD 
between “FRAX® hip” low, intermediate and high probability tertiles (F (2,111) 
= 8.785, p < 0.001 for total hip; F (2,111) = 9.658, p < 0.001 for femoral neck), 
with good differentiation in both total hip and femoral neck BMD between both 
“FRAX® hip” low and high probability tertiles (p < 0.001 for both total hip and 
femoral neck) and between “FRAX® hip” intermediate and high probability 
tertiles (p = 0.010 for total hip; p = 0.030 for femoral neck) (Table 7.4 and 
Figure 7.6). There was less clear differentiation in total hip and femoral neck 
BMD between “FRAX® hip” low and intermediate probability tertiles, however 
(p = 0.301 for total hip, p = 0.054 for femoral neck). 
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 n 
L-spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p Mean ± s.d. p Mean ± s.d. p Mean ± s.d. p 
Low 39 1.039 ± .124 
.089 
1.003 ± .117 
.075 
0.878 ± .138 
.005 
1.132 ± .090 
.093 
Intermediate 39 0.991 ± .124 0.952 ± .133 0.789 ± .132 1.094 ± .093 
Low 39 1.039 ± .124 
.052 
1.003 ± .117 
.006 
0.878 ± .138 
<.001 
1.132 ± .090 
.023 
High 36 0.979 ± .139 0.919 ± .138 0.767 ± .108 1.078 ± .108 
Intermediate 39 0.991 ± .124 
.708 
0.952 ± .133 
.295 
0.789 ± .132 
.441 
1.094 ± .093 
.526 
High 36 0.979 ± .139 0.919 ± .138 0.767 ± .108 1.078 ± .108 
One-way ANOVA 114 - .103 - .020 - .001 - .067 
 
Table 7.3. Differences in lumbar (L-) spine, total hip, femoral neck and total body BMD in all Phase Two study patients (n = 
114) with either low, intermediate or high FRAX® 10-year probability of major osteoporotic fracture (“FRAX® major”) 
(calculated without femoral neck BMD and without incorporating HIV as a “secondary osteoporosis” risk factor) 
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 n 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Mean ± s.d. p Mean ± s.d. p 
Low 51 0.999 ± .113 
.301 
0.863 ± .130 
.054 
Intermediate 32 0.971 ± .130 0.806 ± .129 
Low 51 0.999 ± .113 
<.001 
0.863 ± .130 
<.001 
High 31 0.882 ± .136 0.737 ± .116 
Intermediate 32 0.971 ± .130 
.010 
0.806 ± .129 
.030 
High 31 0.882 ± .136 0.737 ± .116 
One-way ANOVA 114 - <.001 - <.001 
 
 
Table 7.4. Differences in total hip and femoral neck BMD in all Phase Two study patients (n = 114) with either low, 
intermediate or high FRAX® 10-year probability of hip fracture (“FRAX® hip”) (calculated without femoral neck BMD and 
without incorporating HIV as a “secondary osteoporosis” risk factor) 
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Figure 7.5. Differences in lumbar (L-) spine, total hip, femoral neck and 
total body BMD in all Phase Two study patients (n = 114) with either low 
(n = 39), intermediate (n = 39) or high (n = 36) FRAX® 10-year probability 
of major osteoporotic fracture 
 
 
 
 
Figure 7.6. Differences in total hip and femoral neck BMD in all Phase 
Two study patients (n = 114) with either low (n = 51), intermediate (n = 
32) or high (n = 31) FRAX® 10-year probability of hip fracture 
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Analysis by FRAX® probability tertiles was also performed within black and 
white patient subgroups. In black patients (n = 52), low, intermediate and high 
“FRAX® major” probabilities were defined as ≤ 0.8% (n = 20), 0.9 – 1.5% (n = 
16) and ≥ 1.6% (n = 16) and low, intermediate and high “FRAX® hip” 
probabilities were defined as 0.0% (n = 28), 0.1% (n = 12) and ≥ 0.2% (n = 
12). Differences in BMD between low, intermediate and high “FRAX® major” 
probabilities and between low, intermediate and high “FRAX® hip” 
probabilities are shown for black patients in Tables 7.5 and 7.6 respectively. 
 
There was a significant difference in both lumbar spine and total body BMD 
between black patients with low, intermediate or high “FRAX® major” 
probabilities (F (2,49) = 3.683, p = 0.032 for lumbar spine; F (2,49) = 3.699, p 
= 0.032 for total body BMD) (Table 7.5). There was also a significant 
difference in both total hip and femoral neck BMD between patients with low, 
intermediate or high “FRAX® hip” probabilities (F (2,49) = 5.127, p = 0.010 for 
total hip; F (2,49) = 7.550, p = 0.001 for femoral neck) (Table 7.6).  
 
Lumbar spine and total body BMD were significantly greater in black patients 
with low “FRAX® major” probabilities compared with patients with high 
“FRAX® major” probabilities (p = 0.011 for lumbar spine; p = 0.013 for total 
body BMD); total body BMD was also significantly greater in black patients 
with intermediate “FRAX® major” probabilities compared with high “FRAX® 
major” probabilities (p = 0.032) (Table 7.5 and Figure 7.7). Differences in both 
lumbar spine and total body BMD between black patients with either low or 
intermediate “FRAX® major” probabilities were not significant, however. 
 
In comparison, total hip and femoral neck BMD were significantly greater in 
black patients with low “FRAX® hip” probabilities compared with those with 
either intermediate (p = 0.027 for total hip; p = 0.004 for femoral neck) or high 
(p = 0.005 for total hip; p = 0.004 for femoral neck) “FRAX® hip” probabilities, 
although with no significant difference in BMD between black patients with 
either intermediate or high “FRAX® hip” probabilities (Table 7.6 and Figure 
7.8). 
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 n 
L-spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p Mean ± s.d. p Mean ± s.d. p Mean ± s.d. p 
Low 20 1.064 ± .122 
.373 
1.033 ± .119 
.988 
0.879 ± .134 
.917 
1.129 ± .074 
.764 
Intermediate 16 1.026 ± .132 1.003 ± .124 0.884 ± .154 1.139 ± .112 
Low 20 1.064 ± .122 
.011 
1.033 ± .119 
.259 
0.879 ± .134 
.055 
1.129 ± .074 
.013 
High 16 0.947 ± .137 0.955 ± .136 0.789 ± .137 1.060 ± .083 
Intermediate 16 1.026 ± .132 
.107 
1.003 ± .124 
.304 
0.884 ± .154 
.074 
1.139 ± .112 
.032 
High 16 0.947 ± .137 0.955 ± .136 0.789 ± .137 1.060 ± .083 
One-way ANOVA 52 - .032 - .446 - .103 - .032 
 
Table 7.5. Differences in lumbar (L-) spine, total hip, femoral neck and total body BMD in Phase Two study population 
black patients with either low, intermediate or high FRAX® 10-year probability of major osteoporotic fracture (“FRAX® 
major”) (calculated without femoral neck BMD and without incorporating HIV as a “secondary osteoporosis” risk factor) 
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 n 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Mean ± s.d. p Mean ± s.d. p 
Low 28 1.036 ± .112 
.005 
0.917 ± .135 
.004 
Intermediate 12 0.927 ± .085 0.786 ± .087 
Low 28 1.036 ± .112 
.027 
0.917 ± .135 
.004 
High 12 0.938 ± .149 0.770 ± .150 
Intermediate 12 0.927 ± .085 
.832 
0.786 ± .087 
.448 
High 12 0.938 ± .149 0.770 ± .150 
One-way ANOVA 52 - .010 - .001 
 
 
Table 7.6. Differences in total hip and femoral neck BMD in Phase Two study population black patients with either low, 
intermediate or high FRAX® 10-year probability of hip fracture (“FRAX® hip”) (calculated without femoral neck BMD and 
without incorporating HIV as a “secondary osteoporosis” risk factor) 
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Figure 7.7. Differences in lumbar (L-) spine, total hip, femoral neck and 
total body BMD in Phase Two study population black patients with either 
low (n = 20), intermediate (n = 16) or high (n = 16) FRAX® 10-year 
probability of major osteoporotic fracture 
 
 
 
Figure 7.8. Differences in total hip and femoral neck BMD in Phase Two 
study population black patients with either low (n = 28), intermediate (n 
= 12) or high (n = 12) FRAX® 10-year probability of hip fracture 
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In white patients (n = 62), low, intermediate and high “FRAX® major” 
probabilities were defined as ≤ 2.8% (n = 19), 2.9 – 4.9% (n = 21) and ≥ 5.0% 
(n = 22) and low, intermediate and high “FRAX® hip” probabilities were 
defined as ≤ 0.2% (n = 24), 0.3 – 0.7% (n = 18) and ≥ 0.8% (n = 20). 
Differences in BMD between low, intermediate and high “FRAX® major” 
probabilities and between low, intermediate and high “FRAX® hip” 
probabilities are shown for white patients in Tables 7.7 and 7.8 respectively. 
 
There was no significant difference in BMD at any site between white patients 
with low, intermediate or high “FRAX® major” probabilities (Table 7.7 and 
Figure 7.9). There was, however a significant difference in hip BMD between 
white patients with low, intermediate or high “FRAX® hip” probabilities (F 
(2,59) = 3.794, p = 0.028) (Table 7.8). Both total hip and femoral neck BMD 
were significantly greater in white patients with low “FRAX® hip” probabilities 
compared with high FRAX® hip” probabilities (p = 0.008 for total hip, p = 0.044 
for femoral neck), but with no significant difference in BMD between white 
patients with either low or intermediate “FRAX® hip” probabilities, or with 
either intermediate or high “FRAX® hip” probabilities (Table 7.8 and Figure 
7.10). 
 
Correlations between BMD and “FRAX® major” or “FRAX® hip” were further 
analysed for Phase Two patients within low, intermediate and high “FRAX® 
major” or “FRAX® hip” probability tertiles (Table 7.9). In general, BMD 
correlated better with “FRAX® major” in patients within low and intermediate 
“FRAX® major” probability tertiles (Figures 7.11 and 7.12) and less well in 
patients within the high “FRAX® major” probability tertile. A not dissimilar 
pattern was observed for “FRAX® hip”, with a significant correlation identified 
between both total hip and femoral neck BMD and “FRAX® hip” in patients 
within the low “FRAX® hip” probability tertile (r = -0.379, p = 0.006 for total hip; 
r = -0.498, p < 0.001 for femoral neck), but with no significant correlation 
between either total hip or femoral neck BMD with “FRAX® hip” in patients 
within either the intermediate or high “FRAX® hip” probability tertiles. 
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 n 
L-spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p Mean ± s.d. p Mean ± s.d. p Mean ± s.d. p 
Low 19 1.004 ± .141 
.665 
0.979 ± .137 
.181 
0.815 ± .138 
.134 
1.123 ± .106 
.193 
Intermediate 21 0.988 ± .092 0.924 ± .119 0.760 ± .085 1.080 ± .102 
Low 19 1.004 ± .141 
.750 
0.979 ± .137 
.113 
0.815 ± .138 
.215 
1.123 ± .106 
.265 
High 22 0.990 ± .143 0.908 ± .143 0.764 ± .120 1.084 ± .117 
Intermediate 21 0.988 ± .092 
.956 
0.924 ± .119 
.688 
0.760 ± .085 
.898 
1.080 ± .102 
.910 
High 22 0.990 ± .143 0.908 ± .143 0.764 ± .120 1.084 ± .117 
One-way ANOVA 62 - .909 - .218 - .259 - .385 
 
Table 7.7. Differences in lumbar (L-) spine, total hip, femoral neck and total body BMD in Phase Two study population 
white patients with either low, intermediate or high FRAX® 10-year probability of major osteoporotic (“FRAX® major”) 
(calculated without femoral neck BMD and without incorporating HIV as a “secondary osteoporosis” risk factor) 
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 n 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Mean ± s.d. p Mean ± s.d. p 
Low 24 0.988 ± .128 
.136 
0.817 ± .126 
.162 
Intermediate 18 0.926 ± .135 0.765 ± .108 
Low 24 0.988 ± .128 
.008 
0.817 ± .126 
.044 
High 20 0.881 ± .125 0.744 ± .103 
Intermediate 18 0.926 ± .135 
.297 
0.765 ± .108 
.557 
High 20 0.881 ± .125 0.744 ± .103 
One-way ANOVA 62 - .028 - .096 
 
 
Table 7.8. Differences in total hip and femoral neck BMD in Phase Two study population white patients with either low, 
intermediate or high FRAX® 10-year probability of hip fracture (“FRAX® hip”) (calculated without femoral neck BMD and 
without incorporating HIV as a “secondary osteoporosis” risk factor) 
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Figure 7.9. Differences in lumbar (L-) spine, total hip, femoral neck and 
total body BMD in Phase Two study population white patients with either 
low (n = 20), intermediate (n = 21) or high (n = 21) FRAX® 10-year 
probability of major osteoporotic fracture 
 
 
 
Figure 7.10. Differences in total hip and femoral neck BMD in Phase Two 
study population white patients with either low (n = 28), intermediate (n 
= 12) or high (n = 12) FRAX® 10-year probability of hip fracture  
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BMD site 
Low FRAX® probability Intermediate FRAX® probability High FRAX® probability 
FRAX® major  
(n = 39) 
FRAX® hip  
(n = 51) 
FRAX® major  
(n = 39) 
FRAX® hip 
(n = 32) 
FRAX® major 
(n = 36) 
FRAX® hip 
(n = 31) 
r p r p r p r p r p r p 
L-spine -0.446 .004 - - -0.076 .664 - - -0.167 .330 - - 
Total hip -0.294 .069 -0.379 .006 -0.382 .017 -0.187 .305 -0.281 .097 -0.205 .157 
Femoral 
neck 
-0.355 .027 -0.498 <.001 -0.393 .013 -0.119 .516 -0.301 .074 0.893 .399 
Total 
body 
-0.196 .231 - - -0.223 .172 - - -0.147 .394 - - 
 
Table 7.9. Relationship between FRAX® 10-year probability of major osteoporotic fracture (“FRAX® major”) and hip 
fracture (“FRAX® hip”) (both calculated without femoral neck BMD and without incorporating HIV as a “secondary 
osteoporosis” risk factor) and lumbar (L-) spine, total hip, femoral neck and total body BMD in Phase Two patients with 
either low, intermediate or high “FRAX® major” or “FRAX® hip” probabilities  
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Figure 7.11. Relationship between FRAX® 10-year probability of major 
osteoporotic fracture (“FRAX® major”) (calculated without femoral neck 
BMD and without incorporating HIV as a “secondary osteoporosis” risk 
factor) and lumbar (L-) spine, total hip, femoral neck and total body BMD 
in Phase Two patients within the low “FRAX® major” probability tertile (n 
= 39) 
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Figure 7.12. Relationship between FRAX® 10-year probability of major 
osteoporotic fracture (“FRAX® major”) (calculated without femoral neck 
BMD and without incorporating HIV as a “secondary osteoporosis” risk 
factor) and lumbar (L-) spine, total hip, femoral neck and total body BMD 
in Phase Two patients within the intermediate “FRAX® major” probability 
tertile (n = 39) 
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7.3 Relationship between “modified” FRAX® 10-year probability of major 
osteoporotic and hip fracture (calculated with HIV as a “secondary 
osteoporosis” risk factor, but without femoral neck BMD) and BMD in PLWH 
 
“Modified” FRAX® 10-year probability of major osteoporotic fracture (“modified 
FRAX® major”) and FRAX® 10-year probability of fracture hip fracture 
(“modified FRAX® hip”) were each calculated by incorporating HIV into FRAX® 
by inclusion of HIV as a “secondary osteoporosis” risk factor.  
 
The distributions of “FRAX® major” and “FRAX® hip” are compared in Table 
7.10 to the distributions of “modified FRAX® major” and “modified FRAX® hip” 
respectively for all, black and white Phase Two patients without one or more 
“other disorder strongly associated with osteoporosis” (defined in Chapter 4) 
(n = 75, n = 41 and n = 34 for all, white and black patients respectively). 
(Phase Two patients with one or more “other disorder strongly associated with 
osteoporosis” (n = 39, 34.2%) have already had FRAX® probabilities 
calculated with the presence of at least one “secondary osteoporosis” risk 
factor.) The changes in median “FRAX® major” and “FRAX® hip” by inclusion 
of HIV as a “secondary osteoporosis” risk factor were +0.2% and +0.1% 
respectively in black patients and +0.8% and +0.1% respectively in white 
patients. 
 
The correlations between “modified FRAX® major” and “modified FRAX® hip” 
with lumbar spine, total hip, femoral neck and total body BMD are shown in 
Table 7.11 for all, black and white Phase Two patients without one or more 
“other disorder strongly associated with osteoporosis”. In all patients and in 
both black and white patient subgroups, both “modified FRAX® major” and 
“modified FRAX® hip” correlated less well with BMD at each site than 
unmodified “FRAX® major” and “FRAX® hip” (compare with Table 7.2).  
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All patients 
(n = 75) 
Black patients 
(n = 41) 
White patients 
(n = 34) 
“FRAX® major” % 
Median 2.4 1.0 2.9 
IQR 0.8 – 2.9 0.7 – 1.6 2.5 – 4.0 
Range 0.5 – 11.0 0.5 – 3.6 2.1 – 11.0 
“Modified FRAX® major” % 
Median 3.2 1.2 3.7 
IQR 1.1 – 3.9 1.0 – 2.0 3.3 – 5.5 
Range 0.6 – 15.0 0.6 – 5.2 2.8 – 15.0 
“FRAX® hip” % 
Median 0.1 0.0 0.2 
IQR 0.0 – 0.2 0.0 – 0.1 0.1 – 0.5 
Range 0.0 – 3.3 0.0 – 1.2 0.1 – 3.3 
“Modified FRAX® hip” % 
Median 0.2 0.1 0.3 
IQR 0.1 – 0.4 0.0 – 0.2 0.2 – 0.8 
Range 0.0 – 5.8 0.0 – 2.0 0.1 – 5.8 
 
Table 7.10. Distributions of FRAX® 10-year probability of major osteoporotic fracture (“FRAX® major”) and hip fracture 
(“FRAX® hip”) (each calculated without femoral neck BMD and without incorporating HIV as a “secondary osteoporosis” 
risk factor) compared to the distributions of “modified FRAX® major” and “modified FRAX® hip” (each calculated without 
femoral neck BMD but with incorporation of HIV as a “secondary osteoporosis” risk factor) in all (n = 75), black (n = 41) 
and white (n = 34) patients within the Phase Two study population without one or more “other disorder strongly 
associated with osteoporosis” prior to incorporation of HIV as a “secondary osteoporosis” risk factor 
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BMD site 
All (n = 75) Black (n = 41) White (n = 34) 
Modified  
FRAX® major 
Modified 
FRAX® hip 
Modified 
FRAX® major 
Modified 
FRAX® hip 
Modified 
FRAX® major 
Modified 
FRAX® hip 
r p r p r p r p r p r p 
L-spine -0.199 .087 - - -0.266 .092 - - -0.114 .522 - - 
Total hip -0.265 .022 -0.265 .021 -0.162 .311 -0.217 .172 -0.184 .299 -0.087 .626 
Femoral 
neck 
-0.363 .001 -0.360 .002 -0.321 .040 -0.358 .022 -0.166 .347 -0.070 .694 
Total 
body 
-0.188 .107 - - -0.076 .636 - - -0.173 .328 - - 
 
Table 7.11. Relationship between “modified” FRAX® 10-year probability of major osteoporotic (“modified FRAX® major”) 
and hip fracture (“modified FRAX® hip”) (each calculated without femoral neck BMD but with incorporation of HIV as a 
“secondary osteoporosis” risk factor) and lumbar (L-) spine, total hip, femoral neck and total body BMD in all (n = 75), 
black (n = 41) and white (n = 34) patients within the Phase Two study population without one or more “other disorder 
strongly associated with osteoporosis” prior to incorporation of HIV as a “secondary osteoporosis” risk factor 
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The distributions of “FRAX® major” and “FRAX® hip” are compared to the 
distributions of “modified FRAX® major” and “modified FRAX® hip” in Table 
7.12 for all, black and white patients within the Phase Two study population, 
irrespective of the presence or absence of one or more “other disorder 
strongly associated with osteoporosis (n = 114, n = 52 and n = 62 for all, black 
and white patients respectively). This analysis includes 39 patients with one or 
more “other disorder strongly associated with osteoporosis” (in whom 
“modified FRAX® major” and “modified FRAX® hip” are unchanged compared 
“FRAX® major” and “FRAX® hip” respectively), alongside 75 patients without 
one or more “other disorder strongly associated with osteoporosis” (in whom 
“modified FRAX® major” and “modified FRAX® hip” are equal or greater than 
“FRAX® major” and “modified FRAX® hip” respectively). The changes in 
median “FRAX® major” and “FRAX® hip” by inclusion of HIV as a “secondary 
osteoporosis” risk factor were +0.7% and +0.1% respectively in all patients, 
+0.3% and +0.1% respectively in black patients and +0.6% and +0.0% 
respectively in white patients. 
 
The correlations between “modified FRAX® major” and “modified FRAX® hip” 
with lumbar spine, total hip, femoral neck and total body BMD are shown for 
all, black and white Phase Two patients in Table 7.13 (compare with Table 
7.2).  
 
In all patients, there was no difference in correlation with BMD at any site 
between “FRAX® major” and  “modified FRAX® major”, with each having a 
significant negative correlation with BMD at each site. “Modified FRAX® hip” 
correlated slightly less well with BMD at the total hip and femoral neck than 
“FRAX® hip”, albeit with a maintained significant negative correlation between 
“modified FRAX® hip” and total hip and femoral neck BMD  
 
In black patients, “modified FRAX® major” and “modified FRAX® hip” 
correlated less well with BMD at each site than “FRAX® major” and “FRAX® 
hip”, with loss of significance of correlation between “modified FRAX® major” 
and lumbar spine, total hip and total body BMD, although with maintained 
significant negative correlation between “modified FRAX® major” and femoral  
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All patients 
(n = 114) 
Black patients 
(n = 52) 
White patients 
(n = 62) 
“FRAX® major” % 
Median 2.6 1.0 3.6 
IQR 1.1 – 4.1 0.7 – 1.9 2.6 – 6.0 
Range 0.5 – 15.0 0.5 – 6.2 1.5 – 15.0 
“Modified FRAX® major” % 
Median 3.3 1.3 4.2 
IQR 1.4 – 5.1 1.0 – 2.5 3.3 – 6.4 
Range 0.6 – 15.0 0.6 – 6.2 1.4 – 15.0 
“FRAX® hip” % 
Median 0.2 0.0 0.4 
IQR 0.0 – 0.5 0.0 – 0.1 0.2 – 0.9 
Range 0.0 – 3.6 0.0 – 1.8 0.1 – 3.6 
“Modified FRAX® hip” % 
Median 0.3 0.1 0.4 
IQR 0.1 – 0.6 0 – 0.2 0.3 – 1.3 
Range 0.0 – 5.8 0 – 2.0 0.1 – 5.8 
 
Table 7.12. Distributions of FRAX® 10-year probability of major osteoporotic fracture (“FRAX® major”) and hip fracture 
(“FRAX® hip”) (each calculated without femoral neck BMD and without incorporating HIV as a “secondary osteoporosis” 
risk factor) compared to the distributions of “modified FRAX® major” and “modified FRAX® hip” (each calculated without 
femoral neck BMD but with incorporation of HIV as a “secondary osteoporosis” risk factor) in all (n = 114), black (n = 52) 
and white (n = 62) Phase Two patients, irrespective of the presence or absence of one or more  “other disorder strongly 
associated with osteoporosis” prior to incorporation of HIV as a “secondary osteoporosis” risk factor 
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BMD site 
All (n = 114) Black (n = 52) White (n = 62) 
Modified  
FRAX® major 
Modified 
FRAX® hip 
Modified 
FRAX® major 
Modified 
FRAX® hip 
Modified 
FRAX® major 
Modified 
FRAX® hip 
r p r p r p r p r p r p 
L-spine -0.271 .004 - - -0.348 .012 - - -0.237 .064 - - 
Total hip -0.328 <.001 -0.334 <.001 -0.189 .181 -0.282 .043 -0.360 .016 -0.227 .077 
Femoral 
neck 
-0.413 <.001 -0.412 <.001 -0.404 .003 -0.460 .001 -0.241 .059 -0.174 .177 
Total 
body 
-0.256 .006 - - -0.240 .087 - - -0.213 .097 - - 
 
Table 7.13. Relationship between modified FRAX® 10-year probability of major osteoporotic fracture (“modified FRAX® 
major”) and hip fracture (“modified FRAX® hip”) (each calculated without femoral neck BMD but with incorporation of HIV 
as a “secondary osteoporosis” risk factor) with lumbar (L-) spine, total hip, femoral neck and total body BMD in all (n = 
114), black (n = 52) and white (n = 62) Phase Two patients, irrespective of the presence or absence of one or more  “other 
disorder strongly associated with osteoporosis” prior to incorporation of HIV as a “secondary osteoporosis” risk factor
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neck BMD and between “modified FRAX® hip” and both total hip and femoral 
neck BMD.  
 
In white patients, “modified FRAX® major” correlated better with BMD at all 
sites compared to “FRAX® major”, with significant negative correlation 
between “modified FRAX® major” and total hip BMD (p = 0.016). “Modified 
FRAX® hip” correlated less well with total hip and femoral neck BMD than 
“FRAX® hip” in white patients, however, with loss of significant correlation with 
total hip BMD. 
 
Tables 7.14 and 7.15 and Figures 7.13 and 7.14 demonstrate the differences 
in BMD between white patients with either low, intermediate or high “modified 
FRAX® major” and “modified FRAX® hip” probabilities. Low, intermediate and 
high probabilities were defined as ≤ 2.8% (n = 22), 2.9 – 4.1% (n = 20) and ≥ 
4.2% (n = 20) for “modified FRAX® major” and ≤ 0.1% (n = 18), 0.2 – 0.4% (n 
= 24) and ≥ 0.5% (n = 20) for “modified FRAX® hip”. 
 
 
There was no significant difference in BMD at any site between white patients 
with low, intermediate or high “modified FRAX® major” probabilities on one-
way analysis of variance (Table 7.14 and Figure 7.13), as previously observed 
in white patients for unmodified “FRAX® major” (Table 7.7 and Figure 7.9).  
 
In contrast to unmodified “FRAX® hip” (Table 7.8 and Figure 7.10), there was 
no significant difference in total hip BMD between white patients with low, 
intermediate or high “modified FRAX® hip” probabilities on one-way analysis 
of variance (Table 7.15 and Figure 7.14). Total hip BMD was significantly 
greater in white patients with low “modified FRAX® hip” probabilities compared 
with those with high “modified FRAX® hip” probabilities, however (p = 0.045). 
Similarly to unmodified “FRAX® hip” (Table 7.8 and Figure 7.10), however, 
there was no significant difference in femoral neck BMD between white 
patients with low, intermediate or high “modified FRAX® hip” probabilities on 
one-way analysis of variance (Table 7.15 and Figure 7.14). 
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 n 
L-spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p Mean ± s.d. p Mean ± s.d. p Mean ± s.d. p 
Low 24 1.021 ± .141 
.242 
0.972 ± .146 
.188 
0.807 ± .132 
.272 
1.124 ± .108 
.101 
Intermediate 19 0.977 ± .089 0.919 ± .102 0.769 ± .082 1.072 ± .090 
Low 24 1.021 ± .141 
.288 
0.972 ± .146 
.151 
0.807 ± .132 
.168 
1.124 ± .108 
.224 
High 19 0.975 ± .136 0.906 ± .145 0.752 ± .123 1.080 ± .123 
Intermediate 19 0.977 ± .089 
.960 
0.919 ± .102 
.758 
0.769 ± .082 
.627 
1.072 ± .090 
.814 
High 19 0.975 ± .136 0.906 ± .145 0.752 ± .123 1.080 ± .123 
One-way ANOVA 62 - .395 - .236 - .280 - .239 
 
Table 7.14. Differences in lumbar (L-) spine, total hip, femoral neck and total body BMD in white Phase Two patients (n = 
62) with either low, intermediate or high “modified” FRAX® 10-year probability of major osteoporotic fracture, calculated 
without femoral neck BMD but with incorporation of HIV as a “secondary osteoporosis” risk factor (“modified FRAX® 
major”)
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 n 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Mean ± s.d. p Mean ± s.d. p 
Low 24 0.978 ± .129 
.090 
0.808 ± .122 
.173 
Intermediate 17 0.906 ± .141 0.758 ± .112 
Low 24 0.978 ± .129 
.045 
0.808 ± .122 
.134 
High 18 0.898 ± .126 0.755 ± .108 
Intermediate 17 0.906 ± .141 
.852 
0.758 ± .112 
.926 
High 18 0.898 ± .126 0.755 ± .108 
One-way ANOVA 62 - .084 - .214 
 
 
Table 7.15. Differences in total hip and femoral neck BMD in white Phase Two patients (n = 62) with either low, 
intermediate or high “modified” FRAX® 10-year probability of hip fracture, calculated without femoral neck BMD but with 
incorporation of HIV as a “secondary osteoporosis” risk factor (“modified FRAX® hip”) 
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Figure 7.13. Differences in lumbar (L-) spine, total hip, femoral neck and 
total body BMD in white Phase Two patients with either low (n = 22), 
intermediate (n = 20) or high (n = 20) “modified” FRAX® 10-year 
probability of major osteoporotic fracture, calculated without femoral 
neck BMD but with incorporation of HIV as a “secondary osteoporosis” 
risk factor (“modified FRAX® major”) 
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Figure 7.14. Differences in total hip and femoral neck BMD in white 
Phase Two patients with either low (n = 18), intermediate (n = 24) or high 
(n = 20) “modified” FRAX® 10-year probability of hip fracture, calculated 
without femoral neck BMD but with incorporation of HIV as a “secondary 
osteoporosis” risk factor (“modified FRAX® hip”) 
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7.4 FRAX® 10-year probability of major osteoporotic and hip fracture 
calculated with femoral neck BMD compared to FRAX® 10-year probability of 
major osteoporotic and hip fracture calculated without femoral neck BMD in 
PLWH 
 
The mean difference ± s.d. (positive or negative change) in “FRAX® major 
with BMD” compared to “FRAX® major” was 0.88 ± 2.02% in all patients, 0.36 
± 0.72% in black patients and 1.31 ± 2.59% in white patients. The mean 
difference in “FRAX® hip with BMD” compared to “FRAX® hip” was 0.59 ± 
2.11% in all patients, 0.18 ± 0.61% in black patients and 0.93 ± 2.76% in 
white patients. The percentage change in “FRAX® major with BMD” and 
“FRAX® hip with BMD” compared to FRAX® 10-year probability of major 
osteoporotic and hip fracture calculated without femoral neck BMD (“FRAX® 
major” and “FRAX® hip”) is shown in Figures 7.15 and 7.16 for black and 
white patients respectively.  
 
In black patients, “FRAX® major with BMD” decreased by ≥ 1% in 2 (3.8%) 
patients, decreased by < 1 % in 13 (25%) patients, was unchanged in 10 
(19.2%) patients, increased by < 1% in 25 (48.1%) patients and increased by 
≥ 1% in 2 (3.8%) patients compared to “FRAX® major”. “FRAX® hip with BMD” 
decreased by ≥ 0.5% in 1 (1.9%) patient, decreased by < 0.5 % in 13 (25.0%) 
patients, was unchanged in 31 (59.6%) patients, increased by < 0.5% in 5 
(9.6%) patients and increased by ≥ 0.5% in 2 (3.8%) patients compared to 
“FRAX® hip”.  
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Figure 7.15. Percentage change in FRAX® 10-year probability of major 
osteoporotic (A) and hip fracture (B) when calculated with femoral neck 
BMD compared to without femoral neck BMD in black patients within the 
Phase Two study population (n = 52) 
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Figure 7.16. Percentage change in FRAX® 10-year probability of major 
osteoporotic (A) and hip fracture (B) when calculated with femoral neck 
BMD compared to without femoral neck BMD in white patients within the 
Phase Two study population (n = 62) 
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“FRAX® major with BMD” and “FRAX® hip with BMD” increased by ≥ 1% and 
≥ 0.5% respectively in the same two black patients. Further characteristics of 
these two patients are detailed in Table 7.16. Both patients were in the high 
10-year probability tertiles for both major osteoporotic and hip fracture in black 
patients, based on baseline “FRAX® major” and “FRAX® hip”, with each  
patient having two or more general fracture risk factors (age and alcohol 
excess in one and low BMI, prior fragility fracture, current smoking, alcohol 
excess and prolonged immobility in the other). One patient also had HIV 
disease-specific factors associated with reduced BMD within this cohort, 
namely long duration of cumulative PI exposure (186 months, with 130 
months concurrent exposure to tenofovir DF) and a high percentage of non-
classical monocytes (33.5%, with an associated low CD4:CD8 of 0.466). 
 
In white patients, there was greater divergence between FRAX® probabilities 
calculated with femoral neck BMD compared to those calculated without 
femoral neck BMD than in black patients (Figure 7.16). “FRAX® major with 
BMD” decreased by ≥ 1% in 10 (16.1%) patients, decreased by < 1 % in 18 
(29.0%) patients, was unchanged in 3 (4.8%) patients, increased by < 1% in 
21 (33.9%) patients and increased by ≥ 1% in 10 (16.1%) patients compared 
to “FRAX® major”. “FRAX® hip with BMD” decreased by ≥ 0.5% in 10 (16.1%) 
patient, decreased by < 0.5 % in 17 (27.4%) patients, was unchanged in 8 
(12.9%) patients, increased by < 0.5% in 13 (25.0%) patients and increased 
by ≥ 0.5% in 14 (26.9%) patients compared to “FRAX® hip”. 
 
“FRAX® major with BMD” increased by ≥ 5% in two patients. “FRAX® hip with 
BMD” increased by ≥ 2.5% in the same two patients, as well as in one 
additional patient. Further characteristics of these three patients are detailed 
in Table 7.17. The patient with the largest increase in FRAX® scores following 
inclusion of BMD data had the highest baseline “FRAX® major” and “FRAX® 
hip” prior to BMD inclusion, with multiple general fracture risk factors. No data 
was available regarding non-classical monocytes in these three patients, 
although all three patients had low nadir CD4 cell counts and low CD4:CD8. 
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 Patient 1 Patient 2 
FRAX® major % 3.6 6.2 
FRAX® major with BMD % 7.5 9.3 
Increase in FRAX® major with BMD 
vs. FRAX® major % 
3.9 3.1 
FRAX® major with BMD: FRAX® major 
ratio 
2.1 1.5 
FRAX® hip % 1.2 1.8 
FRAX® hip with BMD % 3.8 5.4 
Increase in FRAX® hip with BMD” vs. 
FRAX® hip % 
2.6 3.6 
FRAX® hip with BMD: FRAX® hip ratio 3.2 3.0 
Gender Male Male 
Age years 72 54 
BMI kg m-2 24.7 20.6 
Other general fracture risk factors Alcohol 
Fragility fracture 
Smoking 
Alcohol 
“Other” (immobility) 
Years diagnosed with HIV  20.9 12.2 
Nadir CD4 cell count cells μl-1 190 260 
Current CD4 cell count cells μl-1 437 657 
CD4:CD8 ratio 0.466 0.740 
% Non-classical monocytes 33.5 No data available 
Hepatitis B or C co-infection No Yes (HBV) 
Duration of cumulative PI exposure 
months 
186 0 
Duration of cumulative TDF exposure 
months 
130 67 
 
Table 7.16. Characteristics of black patients within the Phase Two study 
population with an increase in either “FRAX® major with BMD” by ≥ 1% 
compared to “FRAX® major” or “FRAX® hip with BMD” by ≥ 0.5% 
compared to “FRAX® hip”  
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 Patient 1 Patient 2 Patient 3 
FRAX® major % 15.0 3.5 11.0 
FRAX® major with BMD % 34.0 8.0 16.0 
Increase in FRAX® major with 
BMD vs. FRAX® major % 
19.0 4.5 5.0 
FRAX® major with BMD: FRAX® 
major ratio 
2.3 2.3 1.5 
FRAX® hip % 3.6 0.4 0.7 
FRAX® hip with BMD % 25.0 4.5 4.1 
Increase in FRAX® hip with BMD” 
vs. FRAX® hip % 
21.4 4.1 3.4 
FRAX® hip with BMD: FRAX® hip 
ratio 
6.9 11.3 5.9 
NOGG guidance without BMD Treat Measure BMD Measure BMD 
NOGG guidance with BMD Treat Treat Treat 
Gender Male Male Male 
Age years 49 35 49 
BMI kg m-2 28.2 16.9 23.4 
Other general fracture risk 
factors 
Fragility fracture 
Smoking 
Steroids 
Alcohol 
“Other” 
(immobility & 
hypogonadim) 
None 
“Other”  
(chronic 
diarrhoea) 
Years diagnosed with HIV  22.8 2.3 0.4 
Nadir CD4 cell count cells μl-1 4 43 3 
Current CD4 cell count cells μl-1 212 713 20 
CD4:CD8 ratio 0.275 0.515 0.232 
% Non-classical monocytes No data No data No data 
Hepatitis B or C co-infection No No No 
Duration of cumulative PI 
exposure months 
0 0 0 
Duration of cumulative TDF 
exposure months 
160 23 15 
 
Table 7.17. Characteristics of white patients within the Phase Two study 
population with an increase in either “FRAX® major with BMD” by ≥ 5% 
compared to “FRAX® major” or “FRAX® hip with BMD” by ≥ 2.5% 
compared to “FRAX® hip”  
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In these three white patients, as well as in the other 54 white British and Irish 
patients, for whom NOGG clinical guidance was available as part of the UK 
FRAX® tool calculation, inclusion of BMD data into FRAX® did not alter the 
ultimate clinical outcome in any patient with respect to treatment for reduced 
BMD, compared to clinical management based on guidance generated from 
FRAX® without BMD data (see Table 7.18).  
 
The difference (positive or negative change) between “FRAX® major with 
BMD” and “FRAX® hip with BMD” and “FRAX® major” and “FRAX® hip” 
respectively was significantly greater in patients with higher baseline “FRAX® 
major” and “FRAX® hip” in all, black and white Phase Two patients (Figure 
7.17). 
 
 
 
NOGG clinical guidance Number of 
patients  
(%) Based on “FRAX
® major / hip”  
(without BMD) 
Based on “FRAX® major / hip  
with BMD” 
Lifestyle advice and reassure 
Lifestyle advice and reassure 36 (63.2) 
Treat 0 (0.0) 
Measure BMD 
Lifestyle advice and reassure 15 (26.3) 
Treat 4 (7.0) 
Treat 
Lifestyle advice and reassure 0 (0.0) 
Treat 2 (3.5) 
 
Table 7.18. National Osteoporosis Guideline Group (NOGG) clinical 
guidance based on FRAX® 10-year probability of major osteoporotic and 
hip fracture calculated without femoral neck BMD (“FRAX® major” and 
“FRAX® hip”) compared with NOGG clinical guidance based on FRAX® 
10-year probability of major osteoporotic and hip fracture calculated 
with femoral neck BMD (“FRAX® major with BMD” and “FRAX® hip with 
BMD”) in white British and Irish patients within the Phase Two study 
population (n = 57)  
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Figure 7.17. Relationship between FRAX® 10-year probability of major 
osteoporotic fracture (“FRAX® major”) and hip fracture (“FRAX® hip”) 
(each calculated without femoral neck BMD and without incorporating 
HIV as a “secondary risk factor”) and the difference between “FRAX® 
major” and “FRAX® major with BMD” and between “FRAX® hip” and 
“FRAX® hip with BMD” respectively in all (n = 114), black (n = 52) and 
white (n = 62) patients within the Phase Two study population 
  
0 5 10 15
0
5
10
15
20
“FRAXâ major” (%)
D
if
fe
re
n
c
e
 b
e
tw
e
e
n
 “
F
R
A
X
â
 m
a
jo
r”
 
a
n
d
 “
F
R
A
X
â
 m
a
jo
r 
w
it
h
 B
M
D
”
All patients
r = 0.648
p < 0.001***
0 2 4 6 8
0
1
2
3
4
5
“FRAXâ major” (%) 
D
if
fe
re
n
c
e
 b
e
tw
e
e
n
 “
F
R
A
X
â
 m
a
jo
r”
 
a
n
d
 “
F
R
A
X
â
 m
a
jo
r 
w
it
h
 B
M
D
”
Black patients
r = 0.549
p < 0.001***
0 5 10 15
0
5
10
15
20
“FRAXâ major” (%) 
D
if
fe
re
n
c
e
 b
e
tw
e
e
n
 “
F
R
A
X
â
 m
a
jo
r”
 
a
n
d
 “
F
R
A
X
â
 m
a
jo
r 
w
it
h
 B
M
D
”
White patients
r = 0.374
p = 0.003**
0 1 2 3 4
0
5
10
15
20
25
“FRAX® hip” (%) 
D
if
fe
re
n
c
e
 b
e
tw
e
e
n
 “
F
R
A
X
â
 h
ip
”
 
a
n
d
 “
F
R
A
X
â
 h
ip
 w
it
h
 B
M
D
”
All patients
r = 0.797
p < 0.001***
0.0 0.5 1.0 1.5 2.0
0
1
2
3
4
“FRAX® hip” (%) 
D
if
fe
re
n
c
e
 b
e
tw
e
e
n
 “
F
R
A
X
â
 h
ip
”
 
a
n
d
 “
F
R
A
X
â
 h
ip
 w
it
h
 B
M
D
”
Black patients
r = 0.753
p < 0.001***
0 1 2 3 4
0
5
10
15
20
25
“FRAXâ hip” (%)
D
if
fe
re
n
c
e
 b
e
tw
e
e
n
 “
F
R
A
X
â
 h
ip
” 
a
n
d
 “
F
R
A
X
â
 h
ip
 w
it
h
 B
M
D
”
White patients
r = 0.556
p < 0.001***
 341 
7.5 Consideration of HIV disease-specific factors alongside FRAX® to improve 
fracture risk assessment in PLWH 
 
Within the Phase Two study population, few HIV disease-specific factors were 
found to have a significant relationship with BMD: cumulative PI exposure (for 
total hip and femoral neck BMD only) (Chapter 4); probable PRTD (for lumbar 
spine BMD only and only identified in one patient) (Chapter 5); and 
percentage of peripheral blood non-classical monocytes (for lumbar spine 
BMD only). 
 
Cumulative number of months of PI exposure was not a significant 
determinant of either total hip or femoral neck BMD when analysed alongside 
either “FRAX® major” and “FRAX® hip” in multivariate analysis (p = 0.265 and 
p = 0.305 with “FRAX® major” and “FRAX® hip” respectively for total hip BMD 
and p = 0.258 and p = 0.304 with “FRAX® major” and “FRAX® hip” 
respectively for femoral neck BMD), in which “FRAX® major” and “FRAX® hip” 
were both significant predictors of both total hip and femoral neck BMD (p < 
0.001 and p = 0.001 with “FRAX® major” and “FRAX® hip” respectively for 
total hip BMD; p < 0.001 with both “FRAX® major” and “FRAX® hip” for 
femoral neck BMD). 
 
The percentage of peripheral blood non-classical monocytes was a significant 
predictor of lumbar spine BMD (p = 0.007) when analysed alongside “FRAX® 
major” in a multivariate analysis, although analysis was only possible in the 26 
patients in whom monocyte data was available and in only four white patients. 
 
 
7.6 Discussion 
 
FRAX® was designed to predict future fragility risk – not BMD. Given the 
paucity of fragility fractures within the Sheffield HIV Cohort, as well as the lack 
of prospective fragility fracture incidence data, the analysis within this chapter 
has focused on the relationship between FRAX® and BMD in PLWH, with 
BMD used as an acknowledged sub-optimal yet pragmatic alternative to ten 
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year fragility fracture incidence in order to allow the assessment of FRAX® 
within this HIV-positive population.  
 
The significant negative correlations observed between “FRAX® major” and 
each BMD site and between “FRAX® hip” and both total hip and femoral neck 
BMD is perhaps unsurprising, considering that FRAX®-incorporated general 
fracture risk factors were the predominant determinants of BMD within this 
study population (Chapter 4). FRAX® correlated less well with BMD in white 
patients, however, particularly with respect to “FRAX® major” and both lumbar 
spine and total body BMD. FRAX® also correlated less well with BMD in high 
(although predominantly white) fracture risk patients than in low (although 
predominantly black) fracture risk patients. Furthermore, there was poorer 
differentiation in BMD between patients of low, intermediate or high “FRAX® 
major” or “FRAX® hip” probabilities in white patients compared to black 
patients, between “FRAX® major” and BMD at any site compared to “FRAX® 
hip” and total hip or femoral neck BMD and between intermediate and high 
risk patients than between either low and high risk patients or (in general, but 
not always) between low and intermediate risk patients. 
 
The difference (positive or negative change) between FRAX® calculated with 
inclusion of femoral neck BMD compared to baseline FRAX® calculated 
without femoral neck BMD was also greater in white patients than in black 
patients and in higher fracture risk patients than in lower fracture risk patients, 
with the difference increasing almost exponentially with higher baseline 
FRAX®-probabilities, again suggesting that FRAX® correlates better with BMD 
in black and lower risk HIV-positive patients than in white and higher risk HIV-
positive patients. Of note, however, the difference in FRAX® calculated with 
inclusion of femoral neck BMD compared to baseline FRAX® calculated 
without femoral neck BMD was not sufficient in any white patient, for whom 
NOGG clinical management guidance was available, to alter patient clinical 
outcome in terms of treatment for reduced BMD. 
  
The observation that FRAX® correlates less well with BMD in white and higher 
risk patients is consistent with other published data. FRAX®-correlated poorly 
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with BMD in one cross-sectional study of almost entirely male and assumed 
predominantly white HIV-positive patients in Australia (Calmy et al. 2009). 
Moreover, in both longitudinal studies comparing FRAX® to 10-year fragility 
fracture incidence, FRAX® was less accurate in higher risk patients, including 
in older patients (Yin et al. 2016, Yang et al. 2018). 
 
Why FRAX® correlates less well with BMD in both white and higher risk 
patients than in black and lower risk patients remains to be confirmed. It 
seems likely that, whilst perhaps not the main determinants of reduced BMD 
or of future fragility fracture risk, HIV disease-specific factors still do contribute 
to reduced BMD and fracture risk in PLWH. The effect of HIV disease-specific 
factors appears to be minimal when fracture risk attributed to general risk 
factors is low, but greater when fracture risk attributed to general risk factors 
is higher, with more exaggerated differences and greater discordance 
between FRAX® and BMD when fracture risk is high. As black patients 
generally have higher BMD and lower fracture risk compared to white patients 
– with FRAX® calculated using race-specific FRAX® tools – this could explain 
why, in general, FRAX® correlates better with BMD in black patients than in 
white patients.  
 
Interestingly, modifying FRAX® by including HIV as a “secondary 
osteoporosis” risk factor, as recommended in some HIV clinical guidelines 
(EACS 2017), actually weakened the correlation between FRAX® and BMD in 
black patients and between “FRAX® hip” and hip and femoral neck BMD in 
white patients, with improvement in correlation observed only between 
“FRAX® major” and BMD at each site in white patients. One explanation for 
this observation could be that the addition of HIV as a “secondary 
osteoporosis” risk factor may overcompensate for any difference caused by 
HIV disease-specific factors between predicted fracture risk and BMD / actual 
fracture risk where the difference is small, e.g. in black patients or at the total 
hip or femoral neck, making “modified” FRAX® less accurate than unmodified 
FRAX®. Where that difference is larger, however, e.g. in white and higher risk 
patients or at the lumbar spine or for total body BMD, the addition of HIV as a 
“secondary osteoporosis” risk factor may partially, but incompletely, address 
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the difference caused by HIV disease-specific factors between predicted 
fracture risk and BMD / actual fracture risk, improving the correlation between 
FRAX® and BMD, although with correlations still not statistically significant. 
 
Our observations are in contrast to the findings of both longitudinal studies, in 
which “modified” FRAX® was a better predictor of 10-year fragility fracture 
incidence than unmodified FRAX® (Yin et al. 2016, Yang et al. 2018). Neither 
of these two studies included data comparing the performance of FRAX® with 
or without modification in black versus white patient subgroups, however, 
presenting only pooled population data. In addition, patients in at least one of 
these studies were significantly older than patients within the Phase Two 
study population (Yin et al. 2016) and therefore with higher baseline fracture 
risk, in whom “modified” FRAX® may perform better than unmodified FRAX®. 
In that same study, the very high prevalence of HCV coinfection (33.2%) 
within the HIV-positive group – an established fracture risk factor (Lo Re et al. 
2012) also not included within FRAX® – may also contributed to FRAX® 
performing less well in terms of prediction of actual fragility fracture incidence. 
The comparatively low prevalence of HCV coinfection within the Phase Two 
study population (no patients with current HCV infection and only two (1.8%) 
with past cleared HCV infection) may also explain why FRAX® seemed to 
perform better within this study, albeit in terms of BMD correlation as opposed 
to actual fragility fracture incidence. 
 
The absence of an HIV-negative control group in this study precludes 
comparative analysis of the performance of FRAX® in PLWH versus the 
general population. Other published data suggest that FRAX® performs less 
well in PLWH compared to HIV-negative control groups, however (Yin et al. 
2016, Yang et al. 2018). With respect to HIV disease-specific factors that may 
improve fracture risk assessment in PLWH, the duration of cumulative PI 
exposure did not significantly enhance the prediction of total hip or femoral 
neck BMD over and above FRAX® in the Phase Two study population in 
multivariate analysis, in spite of the duration of cumulative PI exposure being 
a significant independent determinant of total hip and femoral neck BMD in 
addition to FRAX®-incorporated general risk factors within the Phase Two 
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study population.  The percentage of non-classical monocytes did enhance 
the prediction of lumbar spine BMD over and above FRAX®, however, albeit 
within a small subset of 26 Phase Two patients only for whom monocyte data 
was available and which included only four white patients. The interaction 
between the relative proportions of monocyte populations, BMD and FRAX® 
may therefore warrant further study in a larger population with a more equal 
balance of black and white patients. 
 
Extrapolating these Phase Two study findings to inform recommendations for 
use in the wider clinical setting is limited by the lack of longitudinal 10-year 
fracture incidence data. The Phase Two study population is also relatively 
small and of a relatively young age with relatively low fracture risk overall, 
which could provide false reassurance as to the validity of FRAX® for use as a 
fracture risk assessment tool in PLWH. 
 
Nevertheless, with a paucity of published data assessing the performance of 
FRAX® in PLWH and pending the availability of further prospective 10-year 
fragility fracture incidence data collected from larger HIV-positive populations, 
it would seem appropriate, in the interim, to recommend FRAX® as a tool to 
use for fracture risk assessment in PWLH, particularly in black patients and in 
lower risk patients, to recommend that modification of FRAX® by incorporating 
HIV as a “secondary osteoporosis” risk factor should only be considered in 
non-black patients to assess 10-year probability of non-hip major osteoporotic 
fracture and to recommend that FRAX® should be sufficient as a practical and 
inexpensive first-line screening tool to assess fracture risk in PLWH, to further 
identify patients who require BMD measurement and/or treatment for reduced 
BMD, without the need to “bypass” FRAX®  and perform BMD measurements 
directly within specific HIV-positive patient groups. 
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7.7 Conclusions 
 
1. “FRAX® major” and  “FRAX® hip” correlate well with BMD at all sites in 
black patients and should be considered for use without modification for 
fracture risk assessment in PLWH of black race. 
 
2. “FRAX® major” does not correlate well with BMD at any site in white 
patients and should not be used without modification for fracture risk 
assessment in PLWH of white race; “FRAX® hip” does correlate well with 
total hip BMD in white patients, however, and could be considered for 
use without modification for hip fracture risk assessment in PLWH of 
white race. 
 
3. “Modified FRAX® major” and “modified FRAX® hip” – incorporating HIV 
as a “secondary osteoporosis” risk factor – correlate less well with BMD 
at all sites in black patients than unmodified “FRAX® major” and “FRAX® 
hip”; “modified FRAX® major” and “modified FRAX® hip” should therefore 
not be used for fracture risk assessment in PLWH of black race. 
 
4. “Modified FRAX® major” has improved correlation with BMD at all 
respective sites in white patients than unmodified “FRAX® major” and 
could be used pragmatically for fracture risk assessment in PLWH of 
white race. 
 
5. “Modified FRAX® hip” correlates less well with total hip and femoral neck 
BMD than unmodified “FRAX® hip” and should therefore not be used for 
hip fracture risk assessment in PLWH of white race. 
 
6. The difference between “FRAX® major with BMD” and “FRAX® major” 
and between “FRAX® hip with BMD” and “FRAX® hip” was greater in 
white patients than in black patients and in patients with high baseline 
“FRAX® major” and “FRAX® hip” calculated fracture risk than in patients 
with low baseline fracture risk, but without change to patient clinical 
outcome; BMD measurement is therefore not necessary for initial 
fracture risk assessment in PLWH, in whom “FRAX® major” 
(incorporating HIV as a “secondary osteoporotic” risk factor in white 
patients) and “FRAX® hip” can be used instead.  
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7. There may a role for using the percentage of peripheral blood non-
classical monocytes alongside FRAX® to improve the prediction of 
lumbar spine BMD and therefore major osteoporotic fracture risk 
assessment in PLWH, but evaluation in a larger number of patients and 
in more white patients is required. 
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8. Discussion 
 
This thesis represents the first in depth analysis of bone health and fracture 
risk within the Sheffield HIV Cohort. One of the main attributes of the Sheffield 
HIV Cohort – and a key strength of this study – is its inclusion of large and 
relatively equal numbers of both black and white HIV-positive patients. This 
has enabled a more detailed exploration of the differences in fracture risk 
factor prevalence, BMD, FRAX® probabilities and the correlation of FRAX® 
probabilities to BMD within these two distinct subpopulations than in other 
studies performed in less heterogeneous HIV-positive cohorts. 
 
This study has identified that the prevalence of general fracture risk factors 
differs between black and white HIV-positive patients living in the UK, with 
general risk factor prevalence higher in white patients and especially in white 
male patients. Moreover, BMI (inversely correlated to BMD and fracture risk) 
was significantly higher in black patients – more specifically in black female 
patients – compared with white patients. In keeping with these findings, 
fragility fracture risk attributed to general risk factors, calculated using FRAX®, 
was higher in white patients than in black patients (although with FRAX® 
probabilities calculated using race-specific tools already incorporating lower 
fracture risk in black patients independent of other risk factors). Whilst FRAX® 
probabilities were higher in white patients, they were still relatively low in the 
context of the relatively young age of our study population (mean 40.7 ± 9.6 
years). Furthermore, within this low fracture risk population, there was a very 
low prevalence of fragility fractures, reported in five patients only (0.8%), all 
with at least one general risk factor and three with high FRAX® probabilities.  
 
The Phase One study findings support the notion that general fracture risk 
factors are the key contributors to fracture risk in PLWH, over and above HIV 
disease-specific factors. One could therefore postulate that it is an 
overrepresentation of general risk factors in PLWH and less an effect of other 
HIV-disease specific factors that results in the higher prevalence of reduced 
BMD and increased fragility fracture incidence consistently reported in PLWH 
when compared to HIV-negative control populations (Brown and Qaqish 2006; 
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Triant et al. 2008; Goh et al. 2018). As our cohort ages and fracture risk 
increases, one would then expect fragility fracture incidence to increase, with 
a greater incidence in white patients with higher prevalence of general risk 
factors than in black patients. The absence of an HIV-negative control 
population within which to confirm lower comparative prevalence of general 
fracture risk factors precludes the ability to confirm this, however. Conversely, 
it would be reasonable to argue that HIV disease-specific factors do 
contribute, but that their effect on fracture risk is not yet apparent in our 
relatively young cohort; several studies have shown that divergence in 
fracture incidence between HIV-positive and HIV-negative populations may 
not occur until patients reach their fifth or sixth decades (Triant et al. 2008; 
Gonciulea et al. 2017).  
 
The Phase Two study findings were also in agreement with the theory that 
general risk factors have a greater influence on fracture risk in PLWH than 
HIV-disease specific factors, however. In this cohort of relatively young age 
and high BMI, the prevalence of reduced BMD was lower in comparison to 
other HIV cohorts (Brown and Qaqish 2006; Goh et al. 2018), including 
cohorts with significant proportions of black patients (Arnsten et al. 2006, 
Arnsten et al. 2007, Jones et al. 2008, Libois et al. 2010).  Moreover, we 
identified that the significant independent determinants of BMD in our cohort 
were all FRAX®-incorporated general risk factors, with BMI the strongest 
predictor of BMD at all sites. The only HIV disease-specific factor found to 
have a significant independent association with BMD within our cohort was 
cumulative PI exposure. It is possible that our study was not sensitive enough 
– through size or patient selection – to identify other HIV disease-specific 
factors that might have smaller effects on BMD. Our findings are in 
accordance with larger studies, however, which have also found general risk 
factors to be the main significant determinants of BMD and fracture incidence 
in PLWH (Womack et al. 2011; Carr et al. 2015) and PI exposure to be one of 
the most consistently identified HIV disease-specific factors also significantly 
associated with BMD and fracture incidence in PLWH (Brown and Qaqish 
2006; Womack et al. 2011). 
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Regarding 25-OH-D, our findings with respect to its significant independent 
determinants in PLWH, namely race, season of sampling and efavirenz use, 
and its lack of relationship with BMD, are in line with other published data in 
PLWH (Welz et al. 2010; Dao et al. 2011; Sherwood et al. 2012; Cotter, et al. 
2014; Wohl et al. 2014). Whilst vitamin D deficiency is undoubtedly highly 
prevalent in PLWH, which the results of this study support, it is less clear as to 
whether or not vitamin D deficiency is significantly more prevalent in PLWH 
compared to the general population and, moreover, whether or not vitamin D 
deficiency contributes to the higher prevalence of reduced BMD and 
increased fragility fracture incidence seen in PLWH. Vitamin D deficiency 
could still affect fracture risk independently to any effect on BMD and has 
been linked to an increase risk of hip fracture in older HIV-negative males 
(Cauley et al. 2010). More evidence is needed to determine whether or not 
vitamin D deficiency is associated with increased fragility fracture prevalence 
in PLWH, however, and whether or not blanket 25-OH-D testing still has a 
place in routine fracture risk assessment for all HIV-positive patients, as is 
currently recommended by some guidelines (EACS 2017).  
 
The significant association between PRTD and reduced BMD, observed 
within in our study, has also been identified elsewhere (Calmy et al. 2009). 
Our diagnosis of possible PRTD in one Phase Two patient only, in spite of two 
thirds of patients being on tenofovir DF with or without a PI, also supports 
other publications reporting PRTD to be very rare in PLWH taking tenofovir 
DF (Nelson et al. 2007, Woodward et al. 2009). 
 
In our ART-stable Phase Two cohort, we did not identify any correlation 
between BMD and markers of inflammation or T cell immune activation. This 
is in line with the observations of Erlandson et al. (2014) from another ART-
stable cohort and consistent with the growing consensus that it is baseline 
levels of markers of inflammation and T cell immune activation prior to ART 
initiation – and not levels in patients well established on ART – that are the 
more important determinants of BMD (Hileman et al. 2014; Brown et al. 2015). 
We did not identify a significant relationship between CD4:CD8 and BMD 
either and to our knowledge this has not been reported previously. Moreover, 
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we did identify a significant negative correlation between the percentage of 
non-classical monocytes and lumbar spine BMD, another novel finding, albeit 
within a small subset of 26 Phase Two patients only. Our theory is that, unlike 
other immune activation markers, non-classical monocytes persist as a 
footprint of past inflammation and immune dysregulation – supported by data 
from Han et al. (2009) – and could therefore be used to identify patients who 
experienced greater bone loss following a longer period of uncontrolled HIV 
viraemia and associated heightened inflammation, immune activation and 
bone turnover prior to their HIV diagnosis and their initiation and stabilisation 
on ART, or during subsequent intermittent but unsustained viral replication 
and immune activation after ART initiation. 
 
We acknowledge BMD as an imperfect means of assessing the validity of 
FRAX® in PLWH, but argue that other studies that have compared FRAX® to 
actual ten-year fragility fracture incidence in HIV-positive populations with low 
fracture incidence (Yin et al. 2016; Yang et al. 2018) are also imperfect. We 
maintain, therefore, that the use of BMD to assess the performance of FRAX® 
within this low fracture prevalence population, in whom ten-year fracture 
incidence data was also absent, was pragmatic and not unreasonable. Unlike 
the few other studies that have compared FRAX® with BMD in PLWH (Calmy 
et al. 2009; Gazzola et al. 2010; Pepe et al. 2012), our study was designed 
specifically to detect differences in BMD between patients within either low, 
intermediate and high risk FRAX® probability tertiles and to assess differences 
in the correlation between BMD and FRAX® probabilities between black and 
white patients. This is the first study to identify that FRAX® does correlate well 
with BMD in PLWH overall and specifically in black patients, patients with low 
FRAX® probabilities and for total hip and femoral neck assessment. 
Furthermore, there was significant differentiation in BMD between low and 
high fracture risk tertiles. Importantly, we also observed that modification of 
FRAX® by including HIV as a “secondary osteoporosis” risk factor – advised 
by some clinical guidelines (EACS 2017) – actually worsened the correlation 
between BMD and FRAX® for most patients. The main exception to this was 
the relationship between FRAX® and lumbar spine and total body BMD in 
white patients, where FRAX® did not correlate well and was improved by 
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including HIV as a “secondary osteoporosis” risk factor. The percentage 
change in FRAX® with femoral neck BMD compared to without was greater in 
white patients also, especially in higher fracture risk patients, but with no white 
patients transitioning from low to high fracture risk with inclusion of BMD data 
and therefore with no alteration to ultimate clinical outcome.  
 
In conclusion, our findings support the notion that FRAX®-incorporated 
general fracture risk factors are the main determinants of bone health in 
PLWH and that FRAX® could be an appropriate fracture risk assessment tool 
for use in HIV clinical management, modifying with inclusion of HIV as a 
“secondary osteoporosis” risk factor only to assess major osteoporotic 
fracture risk in white patients. Validation of these findings with actual ten-year 
fracture incidence will be important. Whilst we will be in a position to collect 
ten-year follow up data from the Phase One study population from autumn 
2019, ideally much larger longitudinal population studies with sufficiently high 
fracture incidence will be needed to validate the use of FRAX® in PLWH, 
requiring co-ordinated national or international prospective high quality data 
collection and, if possible, an HIV-negative control population. 
  
HIV disease-specific factors probably do play a smaller role in bone health in 
PLWH, which is magnified in higher risk patients. The percentage of non-
classical monocytes may be a useful marker to identify patients in whom past 
or intermittent low-level HIV inflammation and immune activation has had a 
significant impact on BMD and who might be at higher risk of fracture; our 
own future work should also focus on exploring this further in a larger subset 
of patients.  
 
Ultimately, however, with global efforts now focusing on diagnosing and 
treating HIV earlier in its natural history and with increasing availability of 
effective PI- and tenofovir DF-free ART regimens, the difference in reduced 
BMD prevalence and fragility fracture incidence between HIV-positive and 
HIV-negative populations may diminish over time, giving confidence to HIV 
clinicians to adopt the same fracture risk assessment tools validated and used 
in the general population for use in PLWH. 
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Appendix 1. Chapter 4 supplementary results 
 
A1.1 Phase Two race / gender patient subgroup analyses 
 
Tables A1.1 to A1.4 show the relationship between age, weight, height and 
BMI and lumbar spine, total hip, femoral neck and total body BMD in black 
male, black female, white male and white female patient subgroups 
respectively. 
 
Tables A1.5 to A1.16 detail the differences in lumbar spine, total hip, femoral 
neck and total body BMD in black male, black female, white male and white 
female patient subgroups according to the presence or absence of both 
FRAX®-incorporated and non-FRAX® general fracture risk factors. 
 
Tables A1.17 to A1.24 relate to HIV disease-specific fracture risk factors 
unrelated to antiretroviral therapy. Tables A3.17, A3.19, A3.21 and A3.23 
describe the relationship between time since HIV diagnosis and nadir CD4 
count and lumbar spine, total hip, femoral neck and total body BMD in black 
male, black female, white male and white female patient subgroups 
respectively. Tables A1.18, A1.20, A1.22 and A1.24 detail the differences in 
lumbar spine, total hip, femoral neck and total body BMD in black male, black 
female, white male and white female patient subgroups according to the 
presence or absence of other fracture risk factors HIV disease-specific 
fracture risk factors unrelated to antiretroviral therapy. 
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Black male patients     
(n = 15) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
r p-value r p-value r p-value r p-value 
Age -0.462 .083 -0.321 .243 -0.200 .474 -0.155 .581 
Height 0.338 .218 0.510 .052 0.364 .182 0.392 .149 
Weight 0.531 .042 0.640 .010 0.649 .009 0.194 .488 
BMI 0.436 .104 0.564 .028 0.632 .011 0.068 .810 
 
Table A1.1. Relationship between age, height, weight and BMI and lumbar spine, total hip, femoral neck and total 
body BMD in black male patients (n=15)  
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Black female patients     
(n = 37) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
r p-value r p-value r p-value r p-value 
Age -0.084 .623 0.058 .732 -0.213 .205 -0.079 .643 
Height 0.248 .139 0.174 .302 0.178 .292 0.134 .428 
Weight 0.457 .004 0.636 .000 0.390 .017 0.367 .026 
BMI 0.405 .013 0.665 .000 0.398 .015 0.367 .026 
 
Table A1.2. Relationship between age, height, weight and BMI and lumbar spine, total hip, femoral neck and total 
body BMD in black male patients (n=37)  
 
 388 
  
White male patients     
(n = 52) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
r p-value r p-value r p-value r p-value 
Age -0.055 .697 -0.094 .507 -0.105 .461 -0.139 .327 
Height 0.142 .314 0.148 .295 0.104 .464 0.168 .235 
Weight 0.404 .003 0.348 .011 0.297 .032 0.191 .176 
BMI 0.275 .049 0.292 .036 0.239 .089 0.128 .365 
 
Table A1.3. Relationship between age, height, weight and BMI and lumbar spine, total hip, femoral neck and total 
body BMD in white male patients (n=52)  
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White female patients     
(n = 10) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
r p-value r p-value r p-value r p-value 
Age -0.176 .627 -0.212 .556 -0.103 .777 -0.127 .726 
Height 0.480 .160 0.271 .449 0.328 .355 0.480 .161 
Weight 0.662 .037 0.671 .034 0.725 .018 0.596 .069 
BMI 0.576 .082 0.503 .138 0.733 .016 0.273 .446 
 
Table A1.4. Relationship between age, height, weight and BMI and lumbar spine, total hip, femoral neck and total 
body BMD in white female patients (n=10)  
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Fracture risk factor 
Risk 
factor 
present 
n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Current smoking 
No 13 (86.7) 0.992 ± .128 
.124 
1.019 ± .125 
.065 
0.859 ± .160 
.177 
1.113 ± .079 
.277 
Yes 2 (13.3) 0.824 ± .192 0.807 ± .247 0.682 ± .197 1.189 ± .151 
Current alcohol 
≥3 units d-1 
No 11 (73.3) 1.023 ± .101 
.010 
1.052 ± .088 
.004 
0.903 ± .012 
.005 
1.146 ± .780 
.100 
Yes 4 (26.7) 0.824 ± .147 0.821 ± .176 0.649 ± .150 1.062 ± .092 
Fragility fracture 
history 
No 13 (86.7) 0.977 ± .119 
.619 
1.005 ± .117 
.383 
0.837 ± .143 
.907 
1.122 ± .092 
.861 
Yes 2 (13.3) 0.921 ± .328 0.899 ± .378 0.821 ± .394 1.134 ± .075 
Significant steroid 
exposure 
No 15 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Parental hip fracture 
No 15 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Rheumatoid arthritis 
No 15 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Other disorders* 
No 12 (80.0) 0.992 ± .131 
.258 
1.020 ± .131 
.145 
0.864 ± .164 
.200 
1.138 ± .090 
.203 
Yes 3 (20.0) 0.884 ± .183 0.874 ± .210 0.721 ± .170 1.065 ± .052 
 
*other disorders strongly associated with osteoporosis, including: chronic diarrhoea, prolonged immobility, hyopgonadism, chronic 
obstructive pulmonary disease, malabsorption, inflammatory bowel disease, untreated hyperthyroidism, type 1 diabetes mellitus, 
liver cirrhosis, organ transplant recipient and osteogenesis imperfecta (no patients recruited to Phase 2 with latter four disorders) 
 
Table A1.5. Differences in lumbar spine, total hip, femoral neck and total body BMD in Phase 2 black male patients (n=15) 
according to presence or absence of FRAX®-incorporated general fracture risk factors  
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Fracture risk factor 
Risk 
factor 
present 
n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Chronic diarrhoea 
No 15 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Prolonged immobility 
No 14 (93.3) 0.991 ± .124 
.035 
1.163 ± .121 
.009 
0.856 ± .154 
.071 
1.126 ± .898 
.633 
Yes 1 (6.7) 0.689 0.632 0.543  1.081 
Male hypogonadism 
No 13 (86.7) 0.968 ± .151 
.904 
0.990 ± .165 
.967 
0.839 ± .180 
.828 
1.133 ± .087 
.259 
Yes 2 (13.3) 0.982 ± .098 0.995 ± .015 0.810 ± .101 1.057 ± .071 
Chronic obstructive 
pulmonary disease 
No 15 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Malabsorption 
No 15 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Inflammatory bowel 
disease 
No 15 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Untreated 
hyperthyroidism 
No 15 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
 
Table A1.6. Differences in lumbar spine, total hip, femoral neck and total body BMD in Phase 2 black male patients (n=15) 
according to presence or absence of FRAX®-incorporated “other disorders strongly associated with osteoporosis” 
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Fracture risk factor 
Risk 
factor 
present 
n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Current smoking 
No 36 (97.3) 1.040 ± .129 
.157 
0.989 ± .116 
.502 
0.863 ± .137 
.449 
1.108 ± .098 
.339 
Yes 1 (2.7) 0.850 0.910 0.757 1.012 
Current alcohol 
≥3 units d-1 
No 37 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Fragility fracture 
history 
No 35 (94.6) 1.046 ± .124 
.033 
0.987 ± .117 
.982 
0.865 ± .139 
.373 
1.112 ± .095 
.137 
Yes 2 (5.4) 0.845 ± .141 0.985 ± .120 0.776 ± .009 1.005 ± .144 
Significant steroid 
exposure 
No 36 (97.3) 1.035 ± .133 
.954 
0.985 ± .116 
.547 
0.860 ± .138 
.984 
1.108 ± .098 
.334 
Yes 1 (2.7) 1.027 1.057 0.863 1.011 
Parental hip fracture 
No 36 (97.3) 1.034 ± .133 
.801 
0.985 ± .116 
.524 
0.861 ± .138 
.778 
1.107 ± .099 
.755 
Yes 1 (2.7) 1.068 1.061 0.822 1.075 
Rheumatoid arthritis 
No 37 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Other disorders* 
No 29 (78.4) 1.046 ± .128 
.319 
0.100 ± .119 
.244 
0.868 ± .148 
.494 
1.128 ± .942 
.007 
Yes 8 (21.6) 0.993 ± .145 0.945 ± .095 0.831 ± .080 1.026 ± .068 
 
*other disorders strongly associated with osteoporosis, including: chronic diarrhoea, prolonged immobility, hyopgonadism, chronic 
obstructive pulmonary disease, malabsorption, inflammatory bowel disease, untreated hyperthyroidism, type 1 diabetes mellitus, 
liver cirrhosis, organ transplant recipient and osteogenesis imperfecta (no patients recruited to Phase 2 with latter four disorders) 
 
Table A1.7. Differences in lumbar spine, total hip, femoral neck and total body BMD in Phase 2 black female patients 
(n=37) according to presence or absence of FRAX®-incorporated general fracture risk factors  
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Fracture risk factor 
Risk 
factor 
present 
n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Chronic diarrhoea 
No 34 (91.9) 1.030 ± .131 
.468 
0.987 ± .117 
.996 
0.856 ± .140 
.537 
1.110 ± .100 
.363 
Yes 3 (8.1) 1.088 ± .143 0.987 ± .117 0.908 ± .080 1.056 ± .067 
Prolonged immobility 
No 35 (94.6) 1.035 ± .135 
.934 
0.989 ± .115 
.705 
0.861 ± .140 
.840 
1.109 ± .100 
.407 
Yes 2 (5.4) 1.027 ± .058 0.956 ± .148 0.841 ± .027 1.049 ± .037 
Female 
hypogonadism 
No 34 (91.9) 1.046 ± .126 
.068 
0.996 ± .116 
.119 
0.867 ± .140 
.332 
1.116 ± .094 
.037 
Yes 3 (8.1) 0.903 ± .143 0.887 ± .023 0.786 ± .018 0.994 ± .080 
Chronic obstructive 
pulmonary disease 
No 37 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Malabsorption 
No 37 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Inflammatory bowel 
disease 
No 37 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Untreated 
hyperthyroidism 
No 36 (97.3) 1.038 ± .131 
.320 
0.990 ± .115 
.318 
0.863 ± .137 
.387 
1.109 ± .097 
.201 
Yes 1 (2.7) .904 .872 .742 .981 
 
Table A1.8. Differences in lumbar spine, total hip, femoral neck and total body BMD in Phase 2 black female patients 
(n=37) according to presence or absence of FRAX®-incorporated “other disorders strongly associated with osteoporosis” 
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Fracture risk factor 
Risk 
factor 
present 
n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Current smoking 
No 36 (69.2) 0.997 ± .132 
.763 
0.945 ± .133 
.503 
0.788 ± .114 
.272 
1.103 ± .111 
.923 
Yes 16 (30.8) 0.986 ± .089 0.918 ± .117 0.752 ± .085 1.100 ± .076 
Current alcohol 
≥3 units d-1 
No 38 (73.1) 0.993 ± .125 
.884 
0.945 ± .141 
.449 
0.787 ± .113 
.248 
1.110 ± .109 
.368 
Yes 14 (26.9) 0.998 ± .110 0.914 ± .099 0.749 ± .084 1.081 ± .074 
Fragility fracture 
history 
No 48 (92.3) 0.999 ± .109 
.362 
0.944 ± .125 
.165 
0.782 ± .102 
.222 
1.107 ± .102 
.260 
Yes 4 (7.7) 0.941 ± .234 0.849 ± .190 0.714 ± .149 1.047 ± .074 
Significant steroid 
exposure 
No 46 (88.5) 0.985 ± .115 
.079 
0.930 ± .123 
.290 
0.769 ± .100 
.156 
1.089 ± .093 
.007 
Yes 6 (11.5) 1.075 ± .138 0.990 ± .186 0.835 ± .146 1.205 ± .110 
Parental hip fracture 
No 50 (96.2) 0.994 ± .119 
.869 
0.936 ± .125 
.818 
0.778 ± .102 
.792 
1.099 ± .100 
.358 
Yes 2 (3.8) 1.008 ± .192 0.958 ± .329 0.757 ± .265 1.167 ± .129 
Rheumatoid arthritis 
No 51 (98.1) 0.997 ± .119 
.225 
0.942 ± .126 
.032 
0.781 ± .103 
.045 
1.104 ± .100 
.237 
Yes 1 (1.9) 0.849 0.662 0.567 0.983 
Other disorders* 
No 30 (57.7) 0.995 ± .125 
.967 
0.956 ± .133 
.232 
0.795 ± .100 
.156 
1.107 ± .098 
.696 
Yes 22 (42.3) 0.993 ± .116 0.911 ± .125 0.753 ± .112 1.096 ± .023 
 
*other disorders strongly associated with osteoporosis, including: chronic diarrhoea, prolonged immobility, hyopgonadism, chronic 
obstructive pulmonary disease, malabsorption, inflammatory bowel disease, untreated hyperthyroidism, type 1 diabetes mellitus, 
liver cirrhosis, organ transplant recipient and osteogenesis imperfecta (no patients recruited to Phase 2 with latter four disorders) 
 
Table A1.9. Differences in lumbar spine, total hip, femoral neck and total body BMD in Phase 2 white male patients (n=52) 
according to presence or absence of FRAX®-incorporated general fracture risk factors  
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Fracture risk factor 
Risk 
factor 
present 
n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Chronic diarrhoea 
No 43 (82.7) 0.993 ± .126 
.939 
0.948 ± .131 
.172 
0.790 ± .106 
.050 
1.101 ± .103 
.930 
Yes 9 (17.3) 0.997 ± .089 0.882 ± .120 0.714 ± .087 1.105 ± .095 
Prolonged immobility 
No 44 (84.6) 0.995 ± .109 
.900 
0.940 ± .129 
.721 
0.778 ± .097 
.945 
1.098 ± .094 
.532 
Yes 8 (15.4) 0.989 ± .176 0.921 ± .149 0.774 ± .156 1.123 ± .138 
Male hypogonadism 
No 47 (90.4) 0.997 ± .125 
.587 
0.941 ± .129 
.517 
0.781 ± .105 
.341 
1.108 ± .103 
.188 
Yes 5 (9.6) 0.966 ± .051 0.900 ± .161 0.733 ± .122 1.045 ± .056 
Chronic obstructive 
pulmonary disease 
No 50 (96.2) 0.995 ± .122 
.886 
0.938 ± .132 
.710 
0.779 ± .107 
.516 
1.104 ± .103 
.558 
Yes 2 (3.8) 0.982 ± .034 0.903 ± .131 0.728 ± .087 1.061 ± .026 
Malabsorption 
No 51 (98.1) 0.995 ± .121 
.653 
0.937 ± .132 
.928 
0.779 ± .106 
.228 
1.103 ± .102 
.790 
Yes 1 (1.9) 0.940 0.925 0.649 1.075 
Inflammatory bowel 
disease 
No 51 (98.1) 0.988 ± .114 
.014 
0.934 ± .131 
.296 
0.774 ± .106 
.244 
1.102 ± .102 
.969 
Yes 1 (1.9) 1.281 1.073 0.901 1.106 
Untreated 
hyperthyroidism 
No 52 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
 
Table A1.10. Differences in lumbar spine, total hip, femoral neck and total body BMD in Phase 2 white male patients (n=52) 
according to presence or absence of FRAX®-incorporated “other disorders strongly associated with osteoporosis”  
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Fracture risk factor 
Risk 
factor 
present 
n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Current smoking 
No 7 (70.0) 0.962 ± .059 
.433 
0.888 ± .120 
.259 
0.732 ± .068 
.105 
1.019 ± .081 
.241 
Yes 3 (30.0) 1.054 ± .308 1.020 ± .237 0.919 ± .272 1.140 ± .240 
Current alcohol 
≥3 units d-1 
No 9 (90.0) 0.993 ± .169 
.858 
0.931 ± .171 
.830 
0.793 ± .175 
.778 
1.066 ± .148 
.552 
Yes 1 (10.0) 0.960 0.891 0.739 0.961 
Fragility fracture 
history 
No 8 (80.0) 1.000 ± .178 
.661 
0.943 ± .166 
.569 
0.784 ± .184 
.901 
1.072 ± .156 
.489 
Yes 2 (20.0) 0.942 ± .033 0.864 ± .183 0.802 ± .107 0.988 ± .062 
Significant steroid 
exposure 
No 10 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Parental hip fracture 
No 10 (10.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Rheumatoid arthritis 
No 10 (10.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Other disorders* 
No 4 (40.0) 1.039 ± .239 
.456 
0.922 ± .237 
.942 
0.821 ± .263 
.635 
1.093 ± .218 
.525 
Yes 6 (60.0) .0957 ± .091 0.931 ± .116 0.766 ± .083 1.030 ± .082 
 
*other disorders strongly associated with osteoporosis, including: chronic diarrhoea, prolonged immobility, hyopgonadism, chronic 
obstructive pulmonary disease, malabsorption, inflammatory bowel disease, untreated hyperthyroidism, type 1 diabetes mellitus, 
liver cirrhosis, organ transplant recipient and osteogenesis imperfecta (no patients recruited to Phase 2 with latter four disorders) 
 
Table A1.11. Differences in lumbar spine, total hip, femoral neck and total body BMD in Phase 2 white female patients 
(n=10) according to presence or absence of FRAX®-incorporated general fracture risk factors  
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Fracture risk factor 
Risk 
factor 
present 
n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Chronic diarrhoea 
No 7 (70.0) 1.003 ± .193 
.703 
0.936 ± .192 
.810 
0.793 ± .197 
.887 
1.084 ± .165 
.360 
Yes 3 (30.0) 0.958 ± .009 0.907 ± .080 0.775 ± .090 0.988 ± .038 
Prolonged immobility 
No 8 (80.0) 1.014 ± .164 
.358 
0.941 ± .176 
.625 
0.808 ± .181 
.472 
1.063 ± .159 
.730 
Yes 2 (20.0) 0.891 ± .128 0.873 ± .107 0.707 ± .053 1.021 ± .066 
Female 
hypogonadism 
No 9 (90.0) 0.979 ± .165 
.560 
0.906 ± .156 
.236 
0.780 ± .175 
.696 
1.042 ± .146 
.418 
Yes 1 (10.0) 1.085 1.118 0.855 1.173 
Chronic obstructive 
pulmonary disease 
No 10 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Malabsorption 
No 10 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Inflammatory bowel 
disease 
No 10 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Untreated 
hyperthyroidism 
No 10 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
 
Table A1.12. Differences in lumbar spine, total hip, femoral neck and total body BMD in all Phase 2 white female patients 
(n=10) according to presence or absence of FRAX®-incorporated “other disorders strongly associated with osteoporosis” 
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Fracture risk factor 
Risk 
factor 
present 
n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
SSRI exposure 
No 13 (86.7) 0.985 ± .127 
.302 
1.017 ± .126 
.087 
0.854 ± .160 
.284 
1.128 ± .093 
.627 
Yes 2 (13.3) 0.870 ± .256 0.819 ± .264 0.712 ± .239 1.094 ± .018 
PPI exposure more 
than 5 years 
No 14 (93.3) 0.983 ± .139 
.226 
1.010 ± .138 
.060 
0.859 ± .148 
.039 
1.132 ± .084 
.184 
Yes 1 (6.7) 0.799 0.716 0.506 1.009 
Cannabis use 
No 13 (86.7) 0.966 ± .152 
.793 
0.990 ± .165 
.970 
0.838 ± .183 
.898 
1.106 ± .076 
.040 
Yes 2 (13.3) 0.996 ± .051 0.995 ± .183 0.820 ± .001 1.239 ± .080 
Other recreational 
drug use 
No 15 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Significant opiate use 
No 15 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
 
Table A1.13. Differences in lumbar spine, total hip, femoral neck and total body BMD in Phase 2 black male patients (n=15) 
according to presence or absence of non-FRAX®-incorporated other general fracture risk factors 
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Fracture risk factor 
Risk 
factor 
present 
n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
SSRI exposure 
No 29 (78.4) 1.033 ± .109 
.939 
0.972 ± .098 
.125 
0.848 ± .106 
.306 
1.109 ± .091 
.692 
Yes 8 (21.6) 1.038 ± .204 1.042 ± .158 0.905 ± .219 1.093 ± .128 
PPI exposure more 
than 5 years 
No 35 (94.6) 1.022 ± .119 
.013 
0.982 ± .111 
.269 
0.852 ± .125 
.123 
1.101 ± .098 
.243 
Yes 2 (5.4) 1.254 ± .187 1.076 ± .211 1.000 ± .304 1.186 ± .080 
Cannabis use 
No 36 (97.3) 1.035 ± .133 
.962 
0.984 ± .115 
.305 
0.859 ± .138 
.664 
1.104 ± .099 
.432 
Yes 1 (2.7) 1.041 1.105 0.920 1.183 
Other recreational 
drug use 
No 37 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Significant opiate use 
No 37 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Primary amenorrhoea 
No 30 (81.1) 1.029 ± .133 
.591 
0.982 ± .108 
.574 
0.852 ± .023 
.481 
1.102 ± .097 
.655 
Yes 7 (18.9) 1.059 ± .126 1.010 ± .149 0.893 ± .174 1.121 ± .111 
Secondary 
amenorrhoea 
No 17 (45.9) 1.041 ± .153 
.787 
1.000 ± .117 
.532 
0.872 ± .145 
.641 
1.101 ± .119 
.809 
Yes 20 (54.1) 1.029 ± .113 0.976 ± .116 0.850 ± .132 1.109 ± .079 
Depo-provera® use 
No 24 (64.9) 1.039 ± .142 
.774 
0.993 ± .125 
.656 
0.875 ± .157 
.370 
1.109 ± .113 
.783 
Yes 13 (35.1) 1.026 ± .113 0.975 ± .097 0.832 ± .087 1.100 ± .067 
 
Table A1.14. Differences in lumbar spine, total hip, femoral neck and total body BMD in Phase 2 black female patients 
(n=37) according to presence or absence of non-FRAX®-incorporated other general fracture risk factors 
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Fracture risk factor 
Risk 
factor 
present 
n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
SSRI exposure 
No 34 (65.4) 0.992 ± .121 
.862 
0.938 ± .121 
.907 
0.778 ± .102 
.888 
1.095 ± .090 
.492 
Yes 18 (34.6) 0.998 ± .122 0.934 ± .152 0.774 ± .117 1.115 ± .121 
PPI exposure more 
than 5 years 
No 49 (94.2) 0.995 ± .123 
.791 
0.935 ± .128 
.690 
0.773 ± .104 
.312 
1.100 ± .102 
.511 
Yes 3 (5.8) 0.976 ± .019 0.966 ± .198 0.838 ± .157 1.140 ± .096 
Cannabis use 
No 37 (71.2) 0.997 ± .104 
.809 
0.949 ± .135 
.316 
0.781 ± .111 
.656 
1.095 ± .097 
.459 
Yes 15 (28.8) 0.988 ± .157 0.908 ± .120 0.766 ± .096 1.119 ± .112 
Other recreational 
drug use 
No 39 (75.0) 1.009 ± .113 
.111 
0.948 ± .135 
.281 
0.781 ± .111 
.628 
1.111 ± .111 
.238 
Yes 13 (25.0) 0.948 ± .132 0.903 ± .115 0.764 ± .094 1.073 ± .058 
Significant opiate use 
No 51 (98.1) 0.991 ± .119 
.210 
0.932 ± .127 
.049 
0.774 ± .105 
.112 
1.099 ± .099 
.120 
Yes 1 (1.9) 1.144 1.191 0.944 1.258 
 
Table A1.15. Differences in lumbar spine, total hip, femoral neck and total body BMD in Phase 2 white male patients (n=52) 
according according to presence or absence of non-FRAX®-incorporated other general fracture risk factors 
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Fracture risk factor 
Risk 
factor 
present 
n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
SSRI exposure 
No 3 (30.0) 0.948 ± .033 
.621 
0.879 ± .061 
.568 
0.726 ± .017 
.477 
1.024 ± .049 
.683 
Yes 7 (70.0) 1.007 ± .191 0.948 ± .191 0.814 ± .197 1.068 ± .171 
PPI exposure more 
than 5 years 
No 8 (80.0) 1.017 ± .163 
.306 
0.948 ± .175 
.450 
0.809 ± .181 
.460 
1.077 ± .154 
.364 
Yes 2 (20.0) 0.881 ± .112 0.844 ± .067 0.704 ± .049 0.968 ± .009 
Cannabis use 
No 6 (60.0) 0.962 ± .065 
.537 
0.887 ± .132 
.366 
0.731 ± .074 
.198 
1.028 ± .084 
.502 
Yes 4 (40.0) 1.031 ± .256 0.988 ± .204 0.874 ± .239 1.095 ± .215 
Other recreational 
drug use 
No 9 (90.0) 0.993 ± .169 
.858 
0.931 ± .171 
.830 
0.793 ± .175 
.778 
1.066 ± .148 
.522 
Yes 1 (10.0) 0.960 0.891 0.739 0.961 
Significant opiate use 
No 9 (90.0) 1.011 ± .154 
.232 
0.942 ± .165 
.429 
0.801 ± .171 
.485 
1.064 ± .149 
.582 
Yes 1 (10.0) 0.801 0.797 0.669 0.974 
Primary amenorrhoea 
No 10 (10.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Secondary 
amenorrhoea 
No 9 (90.0) 0.993 ± .169 
.858 
0.931 ± .171 
.830 
0.793 ± .175 
.778 
1.066 ± .148 
.522 
Yes 1 (10.0) 0.960 0.891 0.739 0.961 
Depo-provera® use 
No 7 (70.0) 0.945 ± .085 
.190 
0.897 ± .131 
.399 
0.758 ± .078 
.422 
1.028 ± .077 
.390 
Yes 3 (30.0) 1.094 ± .263 0.998 ± .237 0.857 ± .310 1.118 ± .257 
 
Table A1.16. Differences in lumbar spine, total hip, femoral neck and total body BMD in Phase 2 white female patients 
(n=10) according to presence or absence of non-FRAX®-incorporated other general fracture risk factors 
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HIV disease-specific fracture risk factor 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
r p-value r p-value r p-value r p-value 
Time since HIV diagnosis years -0.568 .027 -0.322 .226 -0.311 .260 -0.489 .064 
Nadir CD4 counta cells/μL -0.455 .102 -0.582 .029 -0.719 .004 -0.248 .392 
 
a 1 missing value (n=14) 
 
Table A1.17. Relationship between time since HIV diagnosis and nadir CD4 count and lumbar spine, total hip, femoral 
neck and total body BMD in black male patients (n=15) 
 
HIV disease-specific 
fracture risk factor 
Risk 
factor 
present 
n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Mode of HIV 
acquisition 
Hetero 14 (93.3) 0.971 ± .148 
.945 
0.991 ± .159 
.954 
0.836 ± .176 
.933 
1.111 ± .076 
.036 
MSM 1 (6.7) 0.960 0.982 0.821 1.295 
Serious illness at time 
of HIV diagnosis 
No 12 (80.0) 0.945 ± .118 
.255 
0.982 ±.127 
.674 
0.819 ± .118 
.483 
1.126 ± .090 
.811 
Yes 3 (20.0) 1.056 ± .225 1.026 ± .268 0.899 ± .341 1.112 ± .092 
Previous intensive 
care admission 
No 15 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Chronic HBV infection 
No 14 (93.3) 0.990 ± .124 
.035 
1.016 ± .121 
.009 
0.856 ± .154 
.071 
1.126 ± .090 
.633 
Yes 1 (6.7) 0.689 0.632 0.543 1.081 
Current or past 
chronic HCV infection 
No 14 (93.3) 0.971 ± .148 
.945 
0.991 ± .159 
.954 
0.836 ± .176 
.933 
1.111 ± .076 
.036 
Yes 1 (6.7) 0.960 0.982 0.821 1.295 
Lipodystrophy 
No 13 (86.7) 0.971 ± .153 
.935 
0.993 ± .162 
.901 
0.834 ± .179 
.930 
1.121 ± .092 
.759 
Yes 2 (13.3) 0.962 ± .027 0.977 ± .114 0.846 ± .127 1.142 ± .062 
 
Table A1.18. Differences in lumbar spine, total hip, femoral neck and total body BMD in black male patients (n=15) 
according to presence or absence of HIV disease-specific fracture risk factors (“Hetero” = HIV acquisition through sexual 
intercourse between a man and woman, “MSM” = HIV acquisition through sexual intercourse between men)
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HIV disease-specific fracture risk factor 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
r p-value r p-value r p-value r p-value 
Time since HIV diagnosis years 0.013 .941 0.007 .967 -0.044 .796 -0.060 .725 
Nadir CD4 counta cells/μL -0.177 .302 0.031 .859 -0.053 .761 0.083 .632 
 
a 1 missing value (n=36) 
 
Table A1.19. Relationship between time since HIV diagnosis and nadir CD4 count and lumbar spine, total hip, femoral 
neck and total body BMD in black female patients (n=37) 
 
HIV disease-specific 
fracture risk factor 
Risk 
factor 
present 
n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Mode of HIV 
acquisition 
Hetero 37 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
MSM 0 (0.0) - - - - 
Serious illness at time 
of HIV diagnosis 
No 22 (59.5) 1.007 ± .138 
.130 
0.973 ± .103 
.379 
0.843 ± .133 
.348 
1.086 ± .092 
.136 
Yes 15 (40.5) 1.074 ± .113 1.008 ± .132 0.886 ± .142 1.135 ± .102 
Previous intensive 
care admission 
No 34 (91.9) 1.030 ± .131 
.505 
0.979 ± .117 
.170 
0.862 ± .141 
.779 
1.105 ± .102 
.939 
Yes 3 (8.1) 1.084 ± .149 1.075 ± .018 0.839 ± .067 1.110 ± .037 
Chronic HBV infection 
No 36  (97.3) 1.030 ± .130 
.200 
0.986 ± .116 
.639 
0.859 ± .138 
.828 
1.103 ± .098 
.348 
Yes 1 (2.7) 1.202 1.041 0.890 1.198 
Current or past 
chronic HCV infection 
No 37 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Lipodystrophy 
No 37 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
 
Table A1.20. Differences in lumbar spine, total hip, femoral neck and total body BMD black female patients (n=37) 
according to presence or absence of HIV disease-specific fracture risk factors (“Hetero” = HIV acquisition through sexual 
intercourse between a man and woman, “MSM” = HIV acquisition through sexual intercourse between men)
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HIV disease-specific fracture risk factor 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
r p-value r p-value r p-value r p-value 
Time since HIV diagnosis years -0.136 .337 -0.043 .760 -0.047 .743 -0.102 .473 
Nadir CD4 count cells/μL 0.071 .618 0.142 .314 0.121 .393 0.008 .958 
 
Table A1.21. Relationship between time since HIV diagnosis and nadir CD4 count and lumbar spine, total hip, femoral 
neck and total body BMD in white male patients (n=52) 
 
 
HIV disease-specific 
fracture risk factor 
Risk 
factor 
present 
n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Mode of HIV 
acquisition 
Hetero 14 (26.9) 1.043 ± .142 
.085 
0.935 ± .109 
.947 
0.789 ± .097 
.697 
1.125 ± .119 
.340 
MSM 37 (71.2) 0.977 ± .108 0.938 ± .141 0.776 ± .110 1.094 ± .095 
Serious illness at time 
of HIV diagnosis 
No 40 (76.9) 1.010 ± .125 
.089 
0.949 ± .123 
.235 
0.785 ± .098 
.293 
1.103 ± .106 
.876 
Yes 12 (23.1) 0.942 ± .086 0.897 ± .152 0.748 ± .132 1.098 ± .084 
Previous intensive 
care admission 
No 47 (90.4) 0.991 ± .117 
.602 
0.938 ± .132 
.808 
0.776 ± .101 
.906 
1.100 ± .105 
.627 
Yes 5 (9.6) 1.021 ± .158 0.923 ± .126 0.782 ± .162 1.123 ± .054 
Chronic HBV infection 
No 50 (96.2) 0.994 ± .121 
.892 
0.935 ± .133 
.630 
0.775 ± .108 
.537 
1.104 ± .102 
.511 
Yes 2 (3.8) 1.006 ± .124 0.981 ± .011 0.823 ± .067 1.055 ± .054 
Current or past 
chronic HCV infection 
No 52 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Lipodystrophy 
No 42 (80.8) 0.986 ± .107 
.339 
0.935 ± .129 
.868 
0.771 ± .109 
.397 
1.104 ± .105 
.771 
Yes 10 (19.2) 1.027 ± .168 0.943 ± .143 0.803 ± .093 1.094 ± .086 
 
Table A1.22. Differences in lumbar spine, total hip, femoral neck and total body BMD in white male patients (n=52) 
according to presence or absence of HIV disease-specific fracture risk factors (“Hetero” = HIV acquisition through sexual 
intecourse between a man and woman, “MSM” = HIV acquisition through sexual intercourse between men)
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HIV disease-specific fracture risk factor 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
r p-value r p-value r p-value r p-value 
Time since HIV diagnosis years 0.055 .881 0.248 .489 0.236 .511 0.285 .425 
Nadir CD4 count cells/μL -0.236 .511 -0.200 .580 -0.418 .229 0.212 .556 
 
Table A1.23. Relationship between time since HIV diagnosis and nadir CD4 count and lumbar spine, total hip, femoral 
neck and total body BMD in white female patients (n=10) 
 
 
HIV disease-specific 
fracture risk factor 
Risk 
factor 
present 
n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Mode of HIV 
acquisition 
Hetero 9 (90.0) - 
- 
- 
- 
- 
- 
- 
- 
MSM 0 (0.0) - - - - 
Serious illness at time 
of HIV diagnosis 
No 8 (80.0) 0.994 ± .180 
.862 
0.929 ± .183 
.948 
0.780 ± .187 
.686 
1.065 ± .158 
.681 
Yes 2 (20.0) 0.971 ± .015 0.920 ± .041 0.752 ± .003 1.015 ± .076 
Previous intensive 
care admission 
No 10 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Chronic HBV infection 
No 10 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Current or past 
chronic HCV infection 
No 9 (90.0) 1.011 ± .154 
.232 
0.942 ± .165 
.429 
0.801 ± .171 
.485 
1.064 ± .149 
.582 
Yes 1 (10.0) 0.801 0.797 0.669 0.974 
Lipodystrophy 
No 10 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
 
Table A1.24. Differences in lumbar spine, total hip, femoral neck and total body BMD in white female patients (n=10) 
according to presence or absence of HIV disease-specific fracture risk factors (“Hetero” = HIV acquisition through sexual 
intercourse between a man and woman, “MSM” = HIV acquisition through sexual intercourse between men)   
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HIV antiretroviral 
therapy-related 
factor 
Exposure 
or 
presence 
n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Current ART 
No 0 (0.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 15 (0.0) - - - - 
Ever ART 
No 0 (0.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 15 (0.0) - - - - 
Plasma HIV RNA    
<40 copies/ml 
No 2 (13.3) 0.871 ± .102 
.307 
0.807 ± .128 
.064 
0.631 ± .176 
.063 
1.054 ± .063 
.237 
Yes 13 (86.7) 0.985 ± .144 1.019 ± .139 0.867 ± .151 1.134 ± .087 
Plasma HIV RNA    
<200 copies/ml 
No 1 (6.7) 0.799 
.226 
0.716 
.060 
0.506 
.039 
1.009 
.184 
Yes 14 (93.3) 0.982 ± .139 1.010 ± .138 0.859 ± .148 1.132 ± .084 
 
Table A1.25. Differences in lumbar spine, total hip, femoral neck and total body BMD in black male patients (n = 15) 
according to exposure to or presence of general HIV antiretroviral therapy (ART)-related factors 
 
 
 
HIV antiretroviral therapy-related factor 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
r p-value r p-value r p-value r p-value 
Continuous number of months on ART  -0.282 .308 -0.254 .362 -0.111 .694 -0.389 .152 
Cumulative number of months ever on ART -0.368 .177 -0.296 .283 -0.161 .567 -0.521 .046 
 
Table A1.26. Relationship between continuous number of months on antiretroviral therapy (ART) at time of BMD 
measurement or cumulative number of months ever on ART with lumbar spine, total hip, femoral neck and total body BMD 
in black male patients (n = 15) 
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HIV antiretroviral 
therapy-related 
factor 
Exposure  n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Current NRTI 
No 0 (0.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 15 (0.0) - - - - 
Ever NRTI 
No 0 (0.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 15 (0.0) - - - - 
Current TDF 
No 4 (3.5) 0.900 ± .145 
.263 
0.956 ± .221 
.611 
0.843 ± .204 
.915 
1.140 ± .076 
.669 
Yes 11 (96.5) 0.996 ± .139 1.003 ± .132 0.832 ± .166 1.117 ± .094 
Ever TDF 
No 3 (20.0) 0.970 ± .046 
.999 
1.064 ± .057 
.375 
0.944 ± .049 
.227 
1.160 ± .080 
.437 
Yes 12 (80.0) 0.970 ± .159 0.972 ± .165 0.808 ± .179 1.114 ± .090 
Current ABC 
No 11 (96.5) 0.996 ± .139 
.263 
1.003 ± .132 
.611 
0.832 ± .166 
.915 
1.117 ± .094 
.669 
Yes 4 (3.5) 0.900 ± .145 0.956 ± .221 0.843 ± .204 1.140 ± .076 
Ever ABC 
No 9 (60.0) 0.984 ± .143 
.659 
0.997 ± .130 
.850 
0.811 ± .155 
.517 
1.112 ± .101 
.544 
Yes 6 (40.0) 0.949 ± .151 0.981 ± .195 0.872 ± .197 1.141 ± .066 
Current AZT 
No 14 (93.3) 0.990 ± .124 
.035 
1.016 ± .121 
.009 
0.856 ± .154 
.071 
1.126 ± .090 
.633 
Yes 1 (6.7) 0.689 0.632 0.543 1.081 
Ever AZT 
No 9 (60.0) 0.996 ± .092 
.416 
1.037 ± .088 
.155 
0.881 ± .114 
.289 
1.149 ± .086 
.166 
Yes 6 (40.0) 0.932 ± .201 0.921 ± .208 0.767 ± .224 1.085 ± .081 
 
Table A1.27. Differences in lumbar spine, total hip, femoral neck and total body BMD in black male patients (n = 15)) 
according to current or ever exposure to at least one nucleos(t)ide reverse transcriptase inhibitor (NRTI), tenofovir 
disoproxil fumarate (TDF), abacavir (ABC) and zidovudine (AZT) 
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HIV antiretroviral therapy-related factor 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
r p-value r p-value r p-value r p-value 
Continuous number of months on NRTI  -0.104 .713 -0.100 .723 0.096 .732 -0.196 .483 
Cumulative number of months ever on NRTI -0.286 .302 -0.246 .376 -0.096 .732 -0.475 .074 
Continuous number of months on TDF 0.227 .416 -0.088 .754 -0.130 .645 -0.243 .382 
Cumulative number of months ever on TDF -0.172 .540 -0.409 .130 -0.441 .100 -0.573 .025 
Continuous number of months on ABC -0.243 .383 0.096 .733 0.270 .330 0.101 .721 
Cumulative number of months ever on ABC -0.157 .576 0.105 .710 0.337 .220 0.155 .580 
Continuous number of months on AZT -0.433 .107 -0.433 .107 -0.371 .173 -0.186 .508 
Cumulative number of months ever on AZT -0.145 .606 -0.338 .217 -0.302 .274 -0.306 .267 
 
Table A1.28. Relationship between continuous number of months on or cumulative number of months ever on either at 
least one NRTI (nucleos(t)ide reverse transcriptase inhibitors), tenofovir disoproxil fumarate (TDF), abacavir (ABC) or 
zidovudine (AZT) with lumbar spine, total hip, femoral neck and total body BMD in black male patients (n = 15) 
 
 
 
 
 
 
 
 
  
 409 
HIV antiretroviral 
therapy-related 
factor 
Exposure  n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Current NNRTI 
No 7 (46.7)  0.920 ± .146 
.212 
0.903 ± .167 
.032 
0.738 ± .158 
.031 
1.074 ± .052 
.035 
Yes 8 (53.3) 1.014 ± .132 1.067 ± .092 0.920 ± .135 1.167 ± .092 
Ever NNRTI 
No 3 (20.0) 0.911 ± .218 
.442 
0.906 ± .239 
.299 
0.761 ± .192 
.419 
1.100 ± .042 
.617 
Yes 12 (80.0) 0.985 ± .126 1.012 ± .130 0.854 ± .167 1.129 ± .096 
Current EFV 
No 9 (60.0) 0.953 ± .148 
.579 
0.950 ± .173 
.212 
0.800 ± .189 
.344 
1.099 ± .067 
.197 
Yes 6 (40.0) 0.996 ± .142 1.053 ± .098 0.888 ± .133 1.150 ± .107 
Ever EFV 
No 4 (26.7) 0.929 ± .181 
.515 
0.944 ± .210 
.495 
0.805 ± .179 
.693 
1.121 ± .055 
.957 
Yes 11 (73.3) 0.985 ± .132 1.010 ± .135 0.846 ± .173 1.124 ± .099 
Current NVP 
No 14 (93.3) 0.969 ± .148 
.940 
0.986 ± .157 
.666 
0.828 ± .173 
.559 
1.119 ± .089 
.478 
Yes 1 (6.7) 0.981 1.058 0.936 1.186 
Ever NVP 
No 14 (93.3) 0.969 ± .148 
.940 
0.986 ± .157 
.666 
0.828 ± .173 
.559 
1.119 ± .089 
.478 
Yes 1 (6.7) 0.981 1.058 0.936 1.186 
 
Table A1.29. Differences in lumbar spine, total hip, femoral neck and total body BMD in black male patients (n = 15) 
according to current or ever exposure to at least one non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz 
(EFV) and nevirapine (NVP) 
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HIV antiretroviral therapy-related factor 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
r p-value r p-value r p-value r p-value 
Continuous number of months on NNRTI  0.398 .141 0.575 .025 0.590 .021 0.570 .027 
Cumulative number of months ever on NNRTI 0.186 .506 0.290 .294 0.319 .247 0.090 .751 
Continuous number of months on EFV 0.197 .481 0.338 .217 0.214 .445 0.298 .280 
Cumulative number of months ever on EFV 0.146 .604 0.150 .595 0.103 .716 -0.085 .764 
Continuous number of months on NVP 0.000 1.000 0.124 .660 0.247 .374 0.247 .374 
Cumulative number of months ever on NVP 0.000 1.000 0.124 .660 0.247 .374 0.247 .374 
 
Table A1.30. Relationship between continuous number of months on or cumulative number of months ever on, at time of 
BMD measurement, at least one non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz (EFV) or nevirapine 
(NVP) with lumbar spine, total hip, femoral neck and total body BMD in black male patients (n = 15) 
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HIV antiretroviral 
therapy-related 
factor 
Exposure  n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Current PI 
No 9 (60.0) 1.003 ± .128 
.292 
1.058 ± .091 
.030 
0.900 ± .140 
.066 
1.149 ± .101 
.179 
Yes 6 (40.0) 0.921 ± .160 0.889 ± .178 0.738 ± .173 1.086 ± .046 
Ever PI 
No 7 (46.7) 1.005 ± .075 
.397 
1.057 ± .071 
.118 
0.897 ± .123 
.195 
1.175 ± .088 
.027 
Yes 8 (53.3) 0.940 ± .183 0.933 ± .185 0.781 ± .193 1.079 ± .060 
Current INI 
No 14 (93.3) 0.974 ± .147 
.694 
0.991 ± .159 
.967 
0.842 ± .173 
.572 
1.132 ± .084 
.172 
Yes 1 (6.7) 0.913 0.984 0.738 1.006 
Ever INI 
No 14 (93.3) 0.974 ± .147 
.694 
0.991 ± .159 
.967 
0.842 ± .173 
.572 
1.132 ± .084 
.172 
Yes 1 (6.7) 0.913 0.984 0.738 1.006 
 
Table A1.31. Differences in lumbar spine, total hip, femoral neck and total body BMD in black male patients (n = 15) 
according to current or ever exposure to at least one protease inhibitor (PI) or integrase inhibitor (INI) 
 
 
HIV antiretroviral therapy-related factor 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
r p-value r p-value r p-value r p-value 
Continuous number of months on PI -0.395 .145 -0.536 .039 -0.403 .136 -0.483 .068 
Cumulative number of months ever on PI -0.350 .201 -0.471 .077 -0.358 .191 -0.614 .015 
Continuous number of months on INI -0.247 .374 -0.124 .660 -0.247 .374 -0.371 .173 
Cumulative number of months ever on INI -0.247 .374 -0.124 .660 -0.247 .374 -0.371 .173 
 
Table A1.32. Relationship between continuous number of months on or cumulative number of months ever on, at time of 
BMD measurement, at least one protease inhibitor (PI) or integrase inhibitor (INI) with lumbar spine, total hip, femoral 
neck and total body BMD in black male patients (n = 15) 
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HIV antiretroviral 
therapy-related 
factor 
Exposure 
or 
presence 
n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Current ART 
No 3 (8.1) 1.027 ± .109 
.918 
0.993 ± .085 
.925 
0.787 ± .147 
.337 
1.127 ± .044 
.706 
Yes 34 (91.9) 1.035 ± .134 0.987 ± .118 0.867 ± .136 1.104 ± .102 
Ever ART 
No 2 (5.4) 1.069 ± .115 
.713 
0.955 ± .075 
.690 
0.789 ± .208 
.456 
1.137 ± .057 
.655 
Yes 35 (94.6) 1.033 ± .133 0.989 ± .117 0.864 ± .135 1.104 ± .100 
Plasma HIV RNA    
<40 copies/ml 
No 6 (16.2) 1.066 ± .122 
.533 
1.063 ± .124 
.140 
0.887 ± .214 
.610 
1.144 ± .085 
.310 
Yes 31 (83.8) 1.029 ± .134 0.972 ± .109 0.855 ± .121 1.098 ± .100 
Plasma HIV RNA    
<200 copies/ml 
No 5 (13.5) 1.083 ± .128 
.388 
1.064 ± .138 
.109 
0.891 ± .239 
.591 
1.151 ± .092 
.269 
Yes 32 (86.5) 1.027 ± .132 0.975 ± .109 0.855 ± .119 1.099 ± .098 
 
Table A1.33. Differences in lumbar spine, total hip, femoral neck and total body BMD in black female patients (n = 37) 
according to exposure to or presence of general HIV antiretroviral therapy (ART)-related factors 
 
 
 
HIV antiretroviral therapy-related factor 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
r p-value r p-value r p-value r p-value 
Continuous number of months on ARTa  0.150 .391 0.092 .599 0.038 .829 0.017 .924 
Cumulative number of months ever on ARTa 0.125 .474 0.083 .635 0.001 .995 -0.025 .887 
 
a 2 missing values (n=35) 
 
Table A1.34. Relationship between continuous number of months on antiretroviral therapy (ART) at time of BMD 
measurement or cumulative number of months ever on ART with lumbar spine, total hip, femoral neck and total body BMD 
in black female patients (n = 37) 
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HIV antiretroviral 
therapy-related 
factor 
Exposure  n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Current NRTI 
No 3 (8.1) 1.073 ± .082 
.605 
0.997 ± .090 
.883 
0.873 ± .206 
.870 
1.152 ± .049 
.402 
Yes 34 (91.9) 1.031 ± .135 0.986 ± .118 0.859 ± .133 1.102 ± .101 
Ever NRTI 
No 2 (5.4) 1.069 ± .115 
.713 
0.955 ± .075 
.690 
0.789 ± .208 
.456 
1.137 ± .057 
.655 
Yes 35 (94.6) 1.033 ± .133 0.989 ± .117 0.864 ± .135 1.104 ± .100 
Current TDF 
No 16 (43.2) 1.060 ± .140 
.312 
0.999 ± .102 
.665 
0.866 ± .130 
.814 
1.110 ± .088 
.815 
Yes 21 (56.8) 1.015 ± .124 0.980 ± .126 0.856 ± .144 1.102 ± .107 
Ever TDF 
No 13 (35.1) 1.089 ± .124 
.076 
1.006 ± .105 
.464 
0.878 ± .141 
.563 
1.134 ± .067 
.195 
Yes 24 (64.9) 1.007 ± .129 0.977 ± .121 0.850 ± .136 1.090 ± .109 
Current ABC 
No 23 (62.2) 1.023 ± .122 
.501 
0.990 ± .117 
.844 
0.865 ± .146 
.785 
1.110 ± .105 
.727 
Yes 14 (37.8) 1.054 ± .147 0.982 ± .117 0.852 ± .123 1.098 ± .090 
Ever ABC 
No 17 (45.9) 1.032 ± .128 
.938 
0.995 ± .131 
.703 
0.879 ± .166 
.439 
1.118 ± .106 
.493 
Yes 20 (54.1) 1.036 ± .137 0.980 ± .103 0.844 ± .107 1.095 ± .092 
Current AZT 
No 37 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Ever AZT 
No 22 (59.5) 1.045 ± .149 
.554 
0.986 ± .119 
.936 
0.867 ± .149 
.729 
1.097 ± .090 
.504 
Yes 15 (40.5) 1.019 ± .103 0.989 ± .113 0.861 ± .120 1.119 ± .111 
 
Table A1.35. Differences in lumbar spine, total hip, femoral neck and total body BMD in black female patients (n = 37) 
according to current or ever exposure to at least one nucleos(t)ide reverse transcriptase inhibitor (NRTI), tenofovir 
disoproxil fumarate (TDF), abacavir (ABC) and zidovudine (AZT) 
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HIV antiretroviral therapy-related factor 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
r p-value r p-value r p-value r p-value 
Continuous number of months on NRTIa  0.131 .453 0.069 .693 0.013 .943 0.000 .998 
Cumulative number of months ever on NRTIa 0.116 .507 0.076 .663 -0.004 .982 -0.026 .884 
Continuous number of months on TDF -0.176 .298 -0.194 .249 -0.164 .331 -0.164 .333 
Cumulative number of months ever on TDF -0.159 .348 -0.225 .180 -0.207 .219 -0.250 .136 
Continuous number of months on ABCb 0.154 .370 -0.013 .939 -0.068 .694 0.027 .875 
Cumulative number of months ever on ABCb 0.054 .754 0.004 .979 -0.098 .571 -0.085 .621 
Continuous number of months on AZT - - - - - - - - 
Cumulative number of months ever on AZTa -0.096 .582 .114 .515 .115 .509 .109 .533 
 
a 2 missing values (n=35) 
b 1 missing value (n=36)  
 
Table A1.36. Relationship between continuous number of months on or cumulative number of months ever on either at 
least one NRTI (nucleos(t)ide reverse transcriptase inhibitors), tenofovir disoproxil fumarate (TDF), abacavir (ABC) or 
zidovudine (AZT) with lumbar spine, total hip, femoral neck and total body BMD in black female patients (n = 37) 
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HIV antiretroviral 
therapy-related 
factor 
Exposure  n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Current NNRTI 
No 16 (43.2) 1.018 ± .118 
.516 
0.979 ± .112 
.712 
0.860 ± .141 
.980 
1.122 ± .078 
.380 
Yes 21 (56.8) 1.047 ± .142 0.993 ± .120 0.861 ± .136 1.093 ± .111 
Ever NNRTI 
No 7 (18.9) 1.054 ± .134 
.665 
1.025 ± .125 
.336 
0.901 ± .197 
.388 
1.166 ± .069 
.069 
Yes 30 (81.1) 1.030 ± .132 0.978 ± .113 0.851 ± .121 1.092 ± .099 
Current EFV 
No 23 (62.2) 1.050 ± .133 
.384 
1.001 ± .110 
.353 
0.879 ± .148 
.282 
1.126 ± .080 
.104 
Yes 14 (37.8) 1.010 ± .130 0.964 ± .123 0.829 ± .112 1.072 ± .117 
Ever EFV 
No 14 (37.8) 1.083 ± .144 
.081 
1.030 ± .114 
.076 
0.912 ± .176 
.072 
1.154 ± .074 
.018 
Yes 23 (62.2) 1.005 ± .116 0.961 ± .110 0.829 ± .097 1.077 ± .101 
Current NVP 
No 34 (91.9) 1.022 ± .122 
.044 
0.980 ± .111 
.225 
0.853 ± .127 
.298 
1.103 ± .099 
.631 
Yes 3 (8.1) 1.180 ± .179 1.065 ± .158 0.940 ± .244 1.132 ± .095 
Ever NVP 
No 29 (78.4) 1.024 ± .125 
.335 
0.970 ± .109 
.080 
0.840 ± .122 
.124 
1.091 ± .090 
.184 
Yes 8 (21.6) 1.075 ± .155 1.060 ± .123 0.932 ± .169 1.158 ± .116 
 
Table A1.37. Differences in lumbar spine, total hip, femoral neck and total body BMD in black female patients (n = 37) 
according to current or ever exposure to at least one non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz 
(EFV) and nevirapine (NVP) 
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HIV antiretroviral therapy-related factor 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
r p-value r p-value r p-value r p-value 
Continuous number of months on NNRTIa 0.121 .481 0.029 .868 -0.096 .578 -0.228 .181 
Cumulative number of months ever on NNRTIb 0.109 .535 0.008 .962 -0.101 .563 -0.311 .069 
Continuous number of months on EFV -0.074 .664 -0.150 .376 -0.199 .238 -0.344 .037 
Cumulative number of months ever on EFVa -0.161 .349 -0.224 .190 -0.249 .143 -0.458 .005 
Continuous number of months on NVPa 0.174 .309 0.064 .713 -0.113 .511 -0.047 .785 
Cumulative number of months ever on NVPa 0.094 .587 0.203 .234 0.125 .468 0.161 .348 
 
a 1 missing value (n=36) 
b 2 missing values (n=35) 
 
Table A1.38. Relationship between continuous number of months on or cumulative number of months ever on, at time of 
BMD measurement, at least one non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz (EFV) or nevirapine 
(NVP) with lumbar spine, total hip, femoral neck and total body BMD in black female patients (n = 37)   
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HIV antiretroviral 
therapy-related 
factor 
Exposure  n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Current PI 
No 23 (62.2) 1.048 ± .138 
.432 
0.982 ± .115 
.760 
0.845 ± .133 
.381 
1.093 ± .106 
.333 
Yes 14 (37.8) 1.013 ± .121 0.995 ± .119 0.886 ± .143 1.126 ± .084 
Ever PI 
No 15 (40.5) 1.074 ± .153 
.134 
1.010 ± .113 
.323 
0.879 ± .145 
.486 
1.107 ± .109 
.933 
Yes 22 (59.5) 1.008 ± .110 0.971 ± .117 0.847 ± .132 1.105 ± .092 
Current INI 
No 35 (94.6) 1.029 ± .132 
.287 
0.988 ± .117 
.878 
0.861 ± .140 
.931 
1.103 ± .100 
.524 
Yes 2 (5.4) 1.132 ± .099 0.975 ± .094 0.852 ± .054 1.150 ± .069 
Ever INI 
No 32 (86.5) 1.021 ± .131 
.123 
0.977 ± .109 
.168 
0.841 ± .120 
.025 
1.093 ± .096 
.042 
Yes 5 (13.5) 1.119 ± .112 1.054 ± .144 0.985 ± .181 1.188 ± .074 
 
Table A1.39. Differences in lumbar spine, total hip, femoral neck and total body BMD in black female patients (n = 37) 
according to current or ever exposure to at least one protease inhibitor (PI) or integrase inhibitor (INI) 
 
 
HIV antiretroviral therapy-related factor 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
r p-value r p-value r p-value r p-value 
Continuous number of months on PIa -0.272 .109 -0.001 .997 0.094 .586 0.144 .403 
Cumulative number of months ever on PIb -0.341 .045 -0.126 .470 -0.052 .768 0.065 .709 
Continuous number of months on INI 0.215 .200 -0.018 .915 0.037 .828 0.161 .341 
Cumulative number of months ever on INI 0.292 .080 0.204 .226 0.323 .051 0.359 .029 
 
a 1 missing value (n=36) 
b 2 missing values (n=35) 
 
Table A1.40. Relationship between continuous number of months on or cumulative number of months ever on, at time of 
BMD measurement, at least one protease inhibitor (PI) or integrase inhibitor (INI) with lumbar spine, total hip, femoral 
neck and total body BMD in black female patients (n = 37) 
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HIV antiretroviral 
therapy-related 
factor 
Exposure 
or 
presence 
n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Current ART 
No 1 (1.9) 1.032 
.753 
1.031 
.470 
0.847 
.509 
1.177 
.459 
Yes 51 (98.1) 0.993 ± .121 0.935 ± .131 0.775 ± .107 1.101 ± .101 
Ever ART 
No 1 (1.9) 1.032 
.753 
1.031 
.470 
0.847 
.509 
1.177 
.459 
Yes 51 (98.1) 0.993 ± .121 0.935 ± .131 0.775 ± .107 1.101 ± .101 
Plasma HIV RNA    
<40 copies/ml 
No 4 (7.7) 0.960 ± .065 
.553 
0.995 ± .161 
.363 
0.838 ± .130 
.237 
1.152 ± .076 
.308 
Yes 48 (92.3) 0.997 ± .123 0.932 ± .129 0.772 ± .104 1.098 ± .102 
Plasma HIV RNA    
<200 copies/ml 
No 2 (3.8) 0.954 ± .111 
.630 
1.005 ± .038 
.460 
0.816 ± .044 
.601 
1.123 ± .077 
.773 
Yes 50 (96.2) 0.999 ± .121 0.934 ± .133 0.775 ± .108 1.101 ± .102 
 
Table A1.41. Differences in lumbar spine, total hip, femoral neck and total body BMD in white male patients (n = 52) 
according to exposure to or presence of general HIV antiretroviral therapy (ART)-related factors 
 
 
 
HIV antiretroviral therapy-related factor 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
r p-value r p-value r p-value r p-value 
Continuous number of months on ART  -0.152 .282 -0.195 .167 -0.158 .264 -0.218 .121 
Cumulative number of months ever on ART -0.067 .638 -0.040 .778 -0.019 .892 -0.065 .646 
 
Table A1.42. Relationship between continuous number of months on antiretroviral therapy (ART) at time of BMD 
measurement or cumulative number of months ever on ART with lumbar spine, total hip, femoral neck and total body BMD 
in white male patients (n = 52) 
 
 419 
HIV antiretroviral 
therapy-related 
factor 
Exposure  n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Current NRTI 
No 2 (3.8) 0.997 ± .049 
.972 
0.910 ± .171 
.773 
0.777 ± .099 
.998 
1.148 ± .042 
.521 
Yes 50 (96.2) 0.994 ± .122 0.938 ± .131 0.777 ± .108 1.100 ± .102 
Ever NRTI 
No 1 (1.9) 1.032 
.753 
1.031 
.470 
0.847 
.509 
1.177 
.459 
Yes 51 (98.1) 0.993 ± .121 0.935 ± .131 0.775 ± .107 1.101 ± .101 
Current TDF 
No 14 (26.9) 0.980 ± .128 
.619 
0.934 ± .120 
.914 
0.761 ± .092 
.527 
1.098 ± .101 
.862 
Yes 38 (73.1) 0.999 ± .118 0.938 ± .136 0.783 ± .112 1.104 ± .102 
Ever TDF 
No 12 (23.1) 0.985 ± .138 
.772 
0.946 ± .123 
.777 
0.775 ± .091 
.952 
1.098 ± .109 
.883 
Yes 40 (76.9) 0.997 ± .116 0.934 ± .134 0.777 ± .111 1.103 ± .100 
Current ABC 
No 41 (78.8) 0.995 ± .116 
.889 
0.936 ± .134 
.969 
0.781 ± .109 
.558 
1.104 ± .099 
.764 
Yes 11 (21.2) 0.990 ± .138 0.938 ± .125 0.760 ± .099 1.094 ± .111 
Ever ABC 
No 29 (55.8) 1.000 ± .116 
.671 
0.949 ± .125 
.439 
0.788 ± .112 
.412 
1.099 ± .090 
.839 
Yes 23 (44.2) 0.986 ± .127 0.921 ± .138 0.763 ± .099 1.105 ± .116 
Current AZT 
No 49 (94.2) 0.998 ± .121 
.395 
0.933 ± .130 
.443 
0.774 ± .107 
.475 
1.100 ± .100 
.668 
Yes 3 (5.8) 0.936 ± .089 0.994 ± .155 0.820 ± .095 1.127 ± .130 
Ever AZT 
No 33 (63.5) 0.987 ± .098 
.593 
0.924 ± .123 
.352 
0.766 ± .112 
.357 
1.090 ± .082 
.265 
Yes 19 (36.5) 1.006 ± .152 0.959 ± .144 0.795 ± .095 1.123 ± .127 
 
Table A1.43. Differences in lumbar spine, total hip, femoral neck and total body BMD in white male patients (n = 52) 
according to current or ever exposure to at least one nucleos(t)ide reverse transcriptase inhibitor (NRTI), tenofovir 
disoproxil fumarate (TDF), abacavir (ABC) and zidovudine (AZT) 
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HIV antiretroviral therapy-related factor 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
r p-value r p-value r p-value r p-value 
Continuous number of months on NRTI  -0.127 .371 -0.142 .316 -0.126 .373 -0.238 .090 
Cumulative number of months ever on NRTI -0.102 .471 -0.085 .548 -0.042 .770 -0.475 .074 
Continuous number of months on TDF 0.021 .884 -0.100 .479 -0.006 .967 -0.096 .499 
Cumulative number of months ever on TDF 0.043 .765 0.001 .993 0.087 .540 0.005 .971 
Continuous number of months on ABC -0.020 .888 0.016 .910 -0.097 .492 -0.069 .629 
Cumulative number of months ever on ABC -0.066 .640 -0.118 .403 -0.160 .259 -0.051 .720 
Continuous number of months on AZT -0.130 .357 0.046 .744 0.063 .659 0.017 .903 
Cumulative number of months ever on AZT 0.053 .708 0.103 .468 0.112 .428 0.112 .429 
 
Table A1.44. Relationship between continuous number of months on or cumulative number of months ever on either at 
least one NRTI (nucleos(t)ide reverse transcriptase inhibitors), tenofovir disoproxil fumarate (TDF), abacavir (ABC) or 
zidovudine (AZT) with lumbar spine, total hip, femoral neck and total body BMD in white male patients (n = 52) 
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HIV antiretroviral 
therapy-related 
factor 
Exposure  n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Current NNRTI 
No 27 (51.9) 0.990 ± .112 
.809 
0.935 ± .135 
.898 
0.775 ± .118 
.885 
1.111 ± .095 
.498 
Yes 25 (48.1) 0.998 ± .130 0.939 ± .128 0.779 ± .094 1.092 ± .108 
Ever NNRTI 
No 9 (17.3) 0.942 ± .086 
.157 
0.886 ± .124 
.206 
0.741 ± .111 
.265 
1.092 ± .067 
.740 
Yes 43 (82.7) 1.005 ± .124 0.947 ± .131 0.784 ± .105 1.104 ± .107 
Current EFV 
No 37 (71.2) 0.985 ± .121 
.376 
0.935 ± .140 
.907 
0.780 ± .115 
.774 
1.110 ± .110 
.391 
Yes 15 (28.8) 1.017 ± .117 0.940 ± .110 0.770 ± .083 1.083 ± .073 
Ever EFV 
No 18 (34.6) 0.989 ± .138 
.817 
0.905 ± .138 
.208 
0.750 ± .116 
.182 
1.121 ± .114 
.331 
Yes 34 (65.4) 0.999 ± .111 0.954 ± .125 0.791 ± .099 1.092 ± .093 
Current NVP 
No 47 (90.4) 0.997 ± .117 
.627 
0.940 ± .127 
.630 
0.777 ± .105 
.957 
1.101 ± .097 
.899 
Yes 5 (9.6) 0.969 ± .154 0.910 ± .176 0.779 ± .132 1.108 ± .147 
Ever NVP 
No 40 (76.9) 0.991 ± .105 
.719 
0.948 ± .125 
.281 
0.782 ± .104 
.569 
1.094 ± .087 
.293 
Yes 12 (23.1) 1.005 ± .164 0.901 ± .148 0.761 ± .117 1.129 ± .139 
 
Table A1.45. Differences in lumbar spine, total hip, femoral neck and total body BMD in white male patients (n = 52) 
according to current or ever exposure to at least one non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz 
(EFV) and nevirapine (NVP) 
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HIV antiretroviral therapy-related factor 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
r p-value r p-value r p-value r p-value 
Continuous number of months on NNRTI  0.073 .607 0.061 .667 0.066 .640 -0.103 .470 
Cumulative number of months ever on NNRTI 0.155 .272 0.175 .214 0.201 .152 0.024 .866 
Continuous number of months on EFV 0.137 .331 0.085 .547 0.002 .988 -0.073 .607 
Cumulative number of months ever on EFV 0.182 .196 0.274 .049 0.258 .064 0.000 .999 
Continuous number of months on NVP -0.024 .867 -0.106 .453 0.016 .910 0.044 .757 
Cumulative number of months ever on NVP 0.055 .700 -0.151 .286 -0.072 .611 0.152 .281 
 
Table A1.46. Relationship between continuous number of months on or cumulative number of months ever on, at time of 
BMD measurement, at least one non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz (EFV) or nevirapine 
(NVP) with lumbar spine, hip, femoral neck and total body BMD in white male patients (n = 52) 
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HIV antiretroviral 
therapy-related 
factor 
Exposure  n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Current PI 
No 27 (51.9) 0.992 ± .109 
.875 
0.939 ± .129 
.902 
0.771 ± .105 
.701 
1.088 ± .084 
.318 
Yes 25 (48.1) 0.997 ± .133 0.934 ± .135 0.783 ± .110 1.117 ± .117 
Ever PI 
No 22 (42.3) 0.995 ± .119 
.950 
0.948 ± .127 
.593 
0.776 ± .100 
.964 
1.093 ± .090 
.590 
Yes 30 (57.7) 0.993 ± .123 0.928 ± .135 0.777 ± .112 1.109 ± .109 
Current INI 
No 46 (88.5) 1.003 ± .124 
.155 
0.950 ± .127 
.037 
0.791 ± .100 
.007 
1.106 ± .107 
.488 
Yes 6 (11.5) 0.928 ± .056 0.833 ± .119 0.668 ± .100 1.075 ± .017 
Ever INI 
No 45 (86.5) 1.002 ± .125 
.219 
0.946 ± .124 
.228 
0.788 ± .099 
.055 
1.101 ± .105 
.966 
Yes 7 (13.5) 0.941 ± .063 0.881 ± .168 0.705 ± .133 1.104 ± .078 
 
Table A1.47. Differences in lumbar spine, total hip, femoral neck and total body BMD in white male patients (n = 52) 
according to current or ever exposure to at least one protease inhibitor (PI) or integrase inhibitor (INI) 
 
 
HIV antiretroviral therapy-related factor 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
r p-value r p-value r p-value r p-value 
Continuous number of months on PI -0.116 .413 -0.144 .310 -0.126 .373 0.007 .959 
Cumulative number of months ever on PI -0.138 .331 -0.232 .097 -0.213 .130 -0.077 .585 
Continuous number of months on INI -0.226 .107 -0.307 .027 -0.399 .014 -0.098 .491 
Cumulative number of months ever on INI -0.180 .203 -0.199 .157 -0.238 .089 -0.003 .985 
 
Table A1.48. Relationship between continuous number of months on or cumulative number of months ever on, at time of 
BMD measurement, at least one protease inhibitor (PI) or integrase inhibitor (INI) with lumbar spine, total hip, femoral 
neck and total body BMD in white male patients (n = 52) 
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HIV antiretroviral 
therapy-related 
factor 
Exposure 
or 
presence 
n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Current ART 
No 0 (0.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 10 (100.0) - - - - 
Ever ART 
No 0 (0.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 10 (100.0) - - - - 
Plasma HIV RNA    
<40 copies/ml 
No 0 (0.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 10 (100.0) - - - - 
Plasma HIV RNA    
<200 copies/ml 
No 0 (0.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 10 (100.0) - - - - 
 
Table A1.49. Differences in lumbar spine, total hip, femoral neck and total body BMD in white female patients (n = 10) 
according to exposure to or presence of general HIV antiretroviral therapy (ART)-related factors 
 
 
 
HIV antiretroviral therapy-related factor 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
r p-value r p-value r p-value r p-value 
Continuous number of months on ART  -0.042 .907 0.067 .855 0.139 .701 0.115 .751 
Cumulative number of months ever on ART -0.042 .907 0.067 .855 0.139 .701 0.115 .751 
 
Table A1.50. Relationship between continuous number of months on antiretroviral therapy (ART) at time of BMD 
measurement or cumulative number of months ever on ART with lumbar spine, total hip, femoral neck and total body BMD 
in white female patients (n = 10) 
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HIV antiretroviral 
therapy-related 
factor 
Exposure  n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Current NRTI 
No 0 (0.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 10 (100.0) - - - - 
Ever NRTI 
No 0 (0.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 10 (100.0) - - - - 
Current TDF 
No 1 (10.0) 0.916 
.654 
0.852 
.654 
0.726 
.719 
1.034 
.887 
Yes 90 (90.0) 0.998 ± .167 0.936 ± .170 0.795 ± .175 1.057 ± .152 
Ever TDF 
No 0 (0.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 10 (100.0) - - - - 
Current ABC 
No 7 (70.0) 1.028 ± .172 
.264 
0.954 ± .186 
.467 
0.820 ± .192 
.383 
1.068 ± .172 
.693 
Yes 3 (30.0) 0.899 ± .091 0.866 ± .077 0.713 ± .039 1.025 ± .048 
Ever ABC 
No 7 (70.0) 1.028 ± .172 
.264 
0.954 ± .186 
.467 
0.820 ± .192 
.383 
1.068 ± .172 
.693 
Yes 3 (30.0) 0.899 ± .091 0.866 ± .077 0.713 ± .039 1.025 ± .048 
Current AZT 
No 10 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Ever AZT 
No 8 (80.0) 1.016 ± .163 
.318 
0.935 ± .175 
.775 
0.792 ± .180 
.901 
1.068 ± .159 
.593 
Yes 2 (20.0) 0.883 ± .116 0.895 ± .139 0.774 ± .147 1.003 ± .040 
 
Table A1.51. Differences in lumbar spine, total hip, femoral neck and total body BMD in white female patients (n = 10) 
according to current or ever exposure to at least one nucleos(t)ide reverse transcriptase inhibitor (NRTI), tenofovir 
disoproxil fumarate (TDF), abacavir (ABC) and zidovudine (AZT) 
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HIV antiretroviral therapy-related factor 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
r p-value r p-value r p-value r p-value 
Continuous number of months on NRTI  -0.042 .907 0.067 .855 0.139 .701 0.115 .751 
Cumulative number of months ever on NRTI -0.042 .907 0.067 .855 0.139 .701 0.115 .751 
Continuous number of months on TDF 0.127 .726 0.055 .881 0.188 .603 -0.018 .960 
Cumulative number of months ever on TDF -0.036 .920 0.043 .907 0.146 .688 0.079 .828 
Continuous number of months on ABC -0.425 .221 -0.231 .521 -0.291 .415 0.142 .696 
Cumulative number of months ever on ABC -0.425 .221 -0.231 .521 -0.291 .415 0.142 .696 
Continuous number of months on AZT - - - - - - - - 
Cumulative number of months ever on AZT -0.311 .381 -0.138 .703 -0.061 .868 -0.104 .775 
 
Table A1.52. Relationship between continuous number of months on or cumulative number of months ever on either at 
least one NRTI (nucleos(t)ide reverse transcriptase inhibitors), tenofovir disoproxil fumarate (TDF), abacavir (ABC) or 
zidovudine (AZT) with lumbar spine, total hip, femoral neck and total body BMD in white female patients (n = 10) 
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HIV antiretroviral 
therapy-related 
factor 
Exposure  n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Current NNRTI 
No 5 (50.0) 0.915 ± .070 
.149 
0.845 ± .083 
.110 
0.721 ± .030 
.222 
0.996 ± .053 
.211 
Yes 5 (50.0) 1.064 ± .196 1.010 ± .188 0.855 ± .224 1.114 ± .187 
Ever NNRTI 
No 5 (50.0) 0.915 ± .070 
.149 
0.845 ± .083 
.110 
0.721 ± .030 
.222 
0.996 ± .053 
.211 
Yes 5 (50.0) 1.064 ± .196 1.010 ± .188 0.855 ± .224 1.114 ± .187 
Current EFV 
No 7 (70.0) 0.941 ± .085 
.148 
0.882 ± .124 
.193 
0.726 ± .072 
.068 
1.019 ± .080 
.247 
Yes 3 (30.0) 1.103 ± .254 1.033 ± .219 0.932 ± .254 1.139 ± .241 
Ever EFV 
No 7 (70.0) 0.941 ± .085 
.148 
0.882 ± .124 
.193 
0.726 ± .072 
.068 
1.019 ± .080 
.247 
Yes 3 (30.0) 1.103 ± .254 1.033 ± .219 0.932 ± .254 1.139 ± .241 
Current NVP 
No 10 (100.0) - 
- 
- 
- 
- 
- 
- 
- 
Yes 0 (0.0) - - - - 
Ever NVP 
No 9 (90.0) 0.992 ± .169 
.882 
0.920 ± .170 
.692 
0.778 ± .173 
.599 
1.058 ± .152 
.871 
Yes 1 (10.0) 0.965 0.994 0.878 1.031 
 
Table A1.53. Differences in lumbar spine, total hip, femoral neck and total body BMD in white female patients (n = 10) 
according to current or ever exposure to at least one non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz 
(EFV) and nevirapine (NVP) 
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HIV antiretroviral therapy-related factor 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
r p-value r p-value r p-value r p-value 
Continuous number of months on NNRTI  0.588 .074 0.537 .110 0.394 .259 0.407 .243 
Cumulative number of months ever on NNRTI 0.588 .074 0.537 .110 0.394 .259 0.407 .243 
Continuous number of months on EFV 0.455 .187 0.440 .203 0.425 .221 0.246 .493 
Cumulative number of months ever on EFV 0.455 .187 0.440 .203 0.425 .221 0.246 .493 
Continuous number of months on NVP - - - - - - - - 
Cumulative number of months ever on NVP 0.174 .631 0.290 .416 0.406 .244 0.058 .873 
 
Table A1.54. Relationship between continuous number of months on or cumulative number of months ever on, at time of 
BMD measurement, at least one non-nucleoside reverse transcriptase inhibitor (NNRTI), efavirenz (EFV) or nevirapine 
(NVP) with lumbar spine, total hip, femoral neck and total body BMD in white female patients (n = 10) 
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HIV antiretroviral 
therapy-related 
factor 
Exposure  n (%) 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value Mean ± s.d. p-value 
Current PI 
No 6 (60.0) 1.050 ± .179 
.150 
1.000 ± .170 
.081 
0.836 ± .205 
.285 
1.106 ± .168 
.180 
Yes 4 (40.0) 0.899 ± .068 0.819 ± .068 0.715 ± .031 0.978 ± .039 
Ever PI 
No 7 (70.0) 0.999 ± .075 
.908 
0.982 ± .141 
.515 
0.814 ± .091 
.766 
1.058 ± .104 
.966 
Yes 3 (30.0) 0.985 ± .190 0.904 ± .175 0.777 ± .195 1.054 ± .165 
Current INI 
No 9 (90.0) 0.991 ± .169 
.959 
0.925 ± .172 
.898 
0.793 ± .176 
.798 
1.054 ± .152 
.931 
Yes 1 (10.0) 0.981 0.949 0.744 1.068 
Ever INI 
No 8 (80.0) 0.994 ± .180 
.862 
0.929 ± .183 
.948 
0.800 ± .187 
.686 
1.065 ± .158 
.681 
Yes 2 (20.0) 0.971 0.920 ± .041 0.742 ± .003 1.015 ± .076 
 
Table A1.55. Differences in lumbar spine, total hip, femoral neck and total body BMD in white female patients (n = 10) 
according to current or ever exposure to at least one protease inhibitor (PI) or integrase inhibitor (INI) 
 
 
HIV antiretroviral therapy-related factor 
Lumbar spine BMD 
g cm-2 
Total hip BMD 
g cm-2 
Femoral neck BMD 
g cm-2 
Total body BMD 
g cm-2 
r p-value r p-value r p-value r p-value 
Continuous number of months on PI -0.792 .006 -0.601 .066 -0.430 .215 -0.464 .176 
Cumulative number of months ever on PI -0.138 .331 -0.485 .156 -0.387 .270 -0.178 .623 
Continuous number of months on INI 0.290 .416 0.174 .631 0.174 .631 0.290 .416 
Cumulative number of months ever on INI 0.242 .500 0.164 .650 0.164 .650 -0.138 .703 
 
Table A1.56. Relationship between continuous number of months on or cumulative number of months ever on, at time of 
BMD measurement, at least one protease inhibitor (PI) or integrase inhibitor (INI) with lumbar spine, total hip, femoral 
neck and total body BMD in white female patients (n = 10) 
A1.2 Multivariate analysis of clinical determinants of BMD backward 
elimination  
 
The backward elimination process to identify covariates and factors with 
significant association with BMD are detailed in Tables A1.57a-f, A1.58a-e, 
A1.59a-f and A1.60a-c for lumbar spine, total hip, femoral neck and total body 
BMD respectively. 
 
 
Covariate / factor Wald Chi-Square p-value 
Age 1.207 .272 
BMI 18.677 .000 
Fragility fracture history 4.202 .040 
Current AZT 0.329 .566 
Cumulative no. of months on PI 1.397 .237 
Other recreational drug use 0.073 .788 
Cumulative no. of months on NNRTI 0.000 .991 
MSM route of HIV acquisition 0.218 .641 
 
Akaike’s Information Criterion (AIC) = -160.090 
 
Table A1.57a. Backward elimination step 1 for lumbar spine BMD 
 
 
 
 
 
 
Covariate / factor Wald Chi-Square p-value 
Age 1.318 .251 
BMI 19.089 .000 
Fragility fracture history 4.261 .039 
Current AZT 0.329 .566 
Cumulative no. of months on PI 1.521 .217 
Other recreational drug use 0.073 .788 
MSM route of HIV acquisition 0.221 .638 
 
Akaike’s Information Criterion (AIC) = -162.090 
 
Table A1.57b. Backward elimination step 2 for lumbar spine BMD 
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Covariate / factor Wald Chi-Square p-value 
Age 1.247 .264 
BMI 19.062 .000 
Fragility fracture history 4.754 .029 
Current AZT 0.364 .546 
Cumulative no. of months on PI 1.713 .191 
MSM route of HIV acquisition 0.169 .681 
 
Akaike’s Information Criterion (AIC) = -164.017 
 
Table A1.57c. Backward elimination step 3 for lumbar spine BMD 
 
 
 
 
Covariate / factor Wald Chi-Square p-value 
Age 1.209 .271 
BMI 20.117 .000 
Fragility fracture history 4.757 .029 
Current AZT 0.314 .575 
Cumulative no. of months on PI 1.779 .182 
 
Akaike’s Information Criterion (AIC) = -165.849 
 
Table A1.57d. Backward elimination step 4 for lumbar spine BMD 
 
 
 
 
 
Covariate / factor Wald Chi-Square p-value 
Age 1.241 .265 
BMI 22.075 .000 
Fragility fracture history 5.987 .014 
Cumulative no. of months on PI 1.773 .183 
 
Akaike’s Information Criterion (AIC) = -167.535 
 
Table A1.57e. Backward elimination step 5 for lumbar spine BMD 
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Covariate / factor Wald Chi-Square p-value 
Age 2.051 .152 
BMI 27.964 .000 
Fragility fracture history 8.069 .005 
 
Akaike’s Information Criterion (AIC) = -167.776 
 
Table A1.57f. Backward elimination step 6 for lumbar spine BMD 
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Covariate / factor Wald Chi-Square p-value 
Age 0.346 .556 
BMI 24.182 .000 
Fragility fracture history 3.809 .051 
Current alcohol ≤ 3 units d-1 0.310 .578 
Rheumatoid arthritis 4.805 .028 
Other disorder 4.430 .035 
Other recreational drug use 0.001 .974 
Cumulative no. of months on AZT 2.113 .146 
Cumulative no. of months on PI 4.863 .027 
Cumulative no. of months on NNRTI 0.022 .882 
Current INI 0.425 .515 
 
Akaike’s Information Criterion (AIC) = -163.190 
 
Table A1.58a. Backward elimination step 1 for total hip BMD 
 
 
 
 
 
 
Covariate / factor Wald Chi-Square p-value 
Age 0.374 .541 
BMI 24.351 .000 
Fragility fracture history 4.054 .044 
Current alcohol ≤ 3 units d-1 0.325 .568 
Rheumatoid arthritis 4.824 .028 
Other disorder 4.429 .035 
Cumulative no. of months on AZT 2.115 .146 
Cumulative no. of months on PI 4.881 .027 
Cumulative no. of months on NNRTI 0.023 .880 
Current INI 0.429 .512 
 
Akaike’s Information Criterion (AIC) = -165.189 
 
Table A1.58b. Backward elimination step 2 for total hip BMD 
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Covariate / factor Wald Chi-Square p-value 
Age 0.353 .553 
BMI 25.089 .000 
Fragility fracture history 4.237 .040 
Current alcohol ≤ 3 units d-1 0.327 .567 
Rheumatoid arthritis 4.832 .028 
Other disorder 4.426 .035 
Cumulative no. of months on AZT 2.433 .119 
Cumulative no. of months on PI 5.768 .016 
Current INI 0.448 .503 
 
Akaike’s Information Criterion (AIC) = -167.166 
 
Table A1.58c. Backward elimination step 3 for total hip BMD 
 
 
 
 
 
 
Covariate / factor Wald Chi-Square p-value 
Age 0.409 .523 
BMI 26.856 .000 
Fragility fracture history 4.393 .036 
Rheumatoid arthritis 4.702 .030 
Other disorder 4.563 .033 
Cumulative no. of months on AZT 2.398 .121 
Cumulative no. of months on PI 6.337 .012 
Current INI 0.490 .484 
 
Akaike’s Information Criterion (AIC) = -168.139 
 
Table A1.58d. Backward elimination step 4 for total hip BMD 
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Covariate / factor Wald Chi-Square p-value 
Age 0.398 .528 
BMI 26.669 .000 
Fragility fracture history 4.286 .038 
Rheumatoid arthritis 4.687 .030 
Other disorder 6.086 .014 
Cumulative no. of months on AZT 3.404 .065 
Cumulative no. of months on PI 8.484 .004 
 
Akaike’s Information Criterion (AIC) = -170.350 
 
Table A1.58e. Backward elimination step 5 for total hip BMD 
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Covariate / factor Wald Chi-Square p-value 
Age 2.465 .116 
BMI 20.224 .000 
Current tobacco smoking 0.024 .878 
Current alcohol ≤ 3 units d-1 2.516 .113 
Rheumatoid arthritis 3.334 .068 
Other disorder 3.410 .065 
MSM route of HIV acquisition 0.017 .897 
Cumulative no. of months on AZT 1.569 .210 
Cumulative no. of months on PI 2.894 .089 
Cumulative no. of months on NNRTI 0.000 .999 
Current INI 1.770 .183 
 
Akaike’s Information Criterion (AIC) = -162.405 
 
Table A1.59a. Backward elimination step 1 for femoral neck BMD 
 
 
 
 
 
 
 
Covariate / factor Wald Chi-Square p-value 
Age 2.678 .102 
BMI 20.615 .000 
Current tobacco smoking 0.024 .878 
Current alcohol ≤ 3 units d-1 2.516 .113 
Rheumatoid arthritis 3.338 .068 
Other disorder 3.410 .065 
MSM route of HIV acquisition 0.017 .896 
Cumulative no. of months on AZT 1.692 .193 
Cumulative no. of months on PI 3.285 .070 
Current INI 1.782 .182 
 
Akaike’s Information Criterion (AIC) = -164.405 
 
Table A1.59b. Backward elimination step 2 for femoral neck BMD 
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Covariate / factor Wald Chi-Square p-value 
Age 2.661 .103 
BMI 22.370 .000 
Current tobacco smoking 0.031 .861 
Current alcohol ≤ 3 units d-1 2.504 .114 
Rheumatoid arthritis 3.321 .068 
Other disorder 3.433 .064 
Cumulative no. of months on AZT 1.706 .191 
Cumulative no. of months on PI 3.366 .067 
Current INI 1.767 .184 
 
Akaike’s Information Criterion (AIC) = -166.388 
 
Table A1.59c. Backward elimination step 3 for femoral neck BMD 
 
 
 
 
 
 
 
Covariate / factor Wald Chi-Square p-value 
Age 2.747 .097 
BMI 22.647 .000 
Current alcohol ≤ 3 units d-1 2.481 .115 
Rheumatoid arthritis 3.378 .066 
Other disorder 3.402 .065 
Cumulative no. of months on AZT 1.750 .186 
Cumulative no. of months on PI 3.335 .068 
Current INI 1.749 .186 
 
Akaike’s Information Criterion (AIC) = -168.358 
 
Table A1.59d. Backward elimination step 4 for femoral neck BMD 
 
 
 
 
 
 
 
 
 
 
 
 438 
Covariate / factor Wald Chi-Square p-value 
Age 2.635 .105 
BMI 22.150 .000 
Current alcohol ≤ 3 units d-1 2.666 .103 
Rheumatoid arthritis 3.340 .068 
Other disorder 5.463 .019 
Cumulative no. of months on AZT 3.269 .071 
Cumulative no. of months on PI 5.553 .018 
 
Akaike’s Information Criterion (AIC) = -168.622 
 
Table A1.59e. Backward elimination step 5 for femoral neck BMD 
 
 
 
 
 
 
 
 
Covariate / factor Wald Chi-Square p-value 
Age 3.026 .082 
BMI 24.874 .000 
Rheumatoid arthritis 2.991 .084 
Other disorder 5.994 .014 
Cumulative no. of months on AZT 3.154 .076 
Cumulative no. of months on PI 7.278 .007 
 
Akaike’s Information Criterion (AIC) = -167.988 
 
Table A1.59f. Backward elimination step 6 for femoral neck BMD 
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Covariate / factor Wald Chi-Square p-value 
Age 0.556 .456 
BMI 3.848 .050 
Fragility fracture history 5.275 .022 
Significant steroid exposure 8.764 .003 
Other disorder 6.427 .011 
MSM route of HIV acquisition 0.005 .946 
Continuous no. of months on TDF 1.423 .233 
 
Akaike’s Information Criterion (AIC) = -197.674 
 
Table A1.60a. Backward elimination step 1 for total body BMD 
 
 
 
 
 
Covariate / factor Wald Chi-Square p-value 
Age 0.552 .458 
BMI 4.383 .036 
Fragility fracture history 5.284 .022 
Significant steroid exposure 9.416 .002 
Other disorder 6.458 .011 
Continuous no. of months on TDF 1.441 .230 
 
Akaike’s Information Criterion (AIC) = -199.670 
 
Table A1.60b. Backward elimination step 2 for total body BMD 
 
 
 
 
 
Covariate / factor Wald Chi-Square p-value 
Age 0.742 .389 
BMI 4.727 .030 
Fragility fracture history 5.549 .018 
Significant steroid exposure 9.277 .002 
Other disorder 6.242 .012 
 
Akaike’s Information Criterion (AIC) = -200.238 
 
Table A1.60c. Backward elimination step 3 for total body BMD 
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Appendix 2. Chapter 5 supplementary results 
 
A2.1 Multivariate analysis of determinants of 25-hydroxyvitamin D backward 
elimination  
 
The backward elimination process to identify covariates and factors with 
significant association with 25-hydroxyvitamin D are detailed in Tables A2.1a-
d. 
 
 
Covariate / factor Wald Chi-Square p-value 
White race 57.938 <.001 
Summer sampling 8.660 .003 
Female gender 2.797 .094 
Current efavirenz exposure 7.678 .006 
Age 0.020 .888 
Nadir CD4 cell count 0.795 .372 
 
Akaike’s Information Criterion (AIC) = 4872.364 
 
Table A2.1a. Backward elimination step 1  
 
 
 
 
 
 
Covariate / factor Wald Chi-Square p-value 
White race 59.362 <.001 
Summer sampling 8.677 <.001 
Female gender 2.831 .092 
Current efavirenz exposure 7.671 .006 
Nadir CD4 cell count 0.776 .378 
 
Akaike’s Information Criterion (AIC) = 4870.384 
 
Table A2.1b. Backward elimination step 2  
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Covariate / factor Wald Chi-Square p-value 
White race 63.083 <.001 
Summer sampling 8.426 .004 
Female gender 2.623 .105 
Current efavirenz exposure 9.174 .002 
 
Akaike’s Information Criterion (AIC) = 4869.159 
 
Table A2.1c. Backward elimination step 3  
 
 
 
 
 
Covariate / factor Wald Chi-Square p-value 
White race 98.189 <.001 
Summer sampling 8.011 .005 
Current efavirenz exposure 7.825 .005 
 
Akaike’s Information Criterion (AIC) = 4869.776 
 
Table A2.1d. Backward elimination step 4  
  
 442 
A2.2 Multivariate analysis of determinants of serum phosphate backward 
elimination  
 
The backward elimination process to identify covariates and factors with 
significant association with serum phosphate are detailed in Tables A2.2a to 
A2.2d. 
 
Covariate / factor Wald Chi-Square p-value 
White race 0.285 .594 
Female gender 2.938 .087 
Race-adjusted eGFR <90 ml min-1 2.014 .156 
Current CD4 cell count 6.854 .009 
Cumulative exposure to NRTI 0.749 .387 
Cumulative exposure to NNRTI 1.460 .227 
 
Akaike’s Information Criterion (AIC) = -74.083 
 
Table A2.2a. Backward elimination step 1  
 
 
Covariate / factor Wald Chi-Square p-value 
Female gender 5.128 .024 
Race-adjusted eGFR <90 ml min-1 2.943 .086 
Current CD4 cell count 6.559 .010 
Cumulative exposure to NRTI 0.787 .375 
Cumulative exposure to NNRTI 1.270 .260 
 
Akaike’s Information Criterion (AIC) = -75.299 
 
Table A2.2b. Backward elimination step 2 
 
 
Covariate / factor Wald Chi-Square p-value 
Female gender 5.209 .022 
Race-adjusted eGFR <90 ml min-1 3.676 .055 
Current CD4 cell count 6.059 .014 
Cumulative exposure to NNRTI 3.276 .070 
 
Akaike’s Information Criterion (AIC) = -75.299 
 
Table A2.2c. Backward elimination step 3 
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Covariate / factor Wald Chi-Square p-value 
Female gender 5.436 .020 
Race-adjusted eGFR <90 ml min-1 5.201 .023 
Current CD4 cell count 4.928 .026 
 
Akaike’s Information Criterion (AIC) = -74.089 
 
Table A2.2d. Backward elimination step 4 
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A2.3 Multivariate analysis of determinants of tubular reabsorption of 
phosphate backward elimination  
 
The backward elimination process to identify covariates and factors with 
significant association with tubular reabsorption of phosphate are detailed in 
Tables A2.3a and A2.3g. 
 
Covariate / factor Wald Chi-Square p-value 
White race 0.871 .351 
Female gender 1.428 .232 
Age 1.481 .224 
BMI 0.462 .496 
Race-adjusted eGFR <90 ml min-1 13.300 <.001 
25-hydroxyvitamin D 0.223 .637 
Parathyroid hormone 0.003 .955 
Current exposure to efavirenz 2.814 .093 
Continuous exposure to PI 0.010 .919 
 
Akaike’s Information Criterion (AIC) = 525.453 
 
Table A2.3a. Backward elimination step 1  
 
 
 
Covariate / factor Wald Chi-Square p-value 
White race 0.945 .331 
Female gender 1.426 .232 
Age 1.538 .215 
BMI 0.492 .483 
Race-adjusted eGFR <90 ml min-1 13.693 <.001 
25-hydroxyvitamin D 0.245 .621 
Current exposure to efavirenz 2.911 .088 
Continuous exposure to PI 0.011 .918 
 
Akaike’s Information Criterion (AIC) = 523.456 
 
Table A2.3b. Backward elimination step 2 
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Covariate / factor Wald Chi-Square p-value 
White race 0.946 .331 
Female gender 1.547 .214 
Age 1.543 .214 
BMI 0.544 .461 
Race-adjusted eGFR <90 ml min-1 13.991 <.001 
25-hydroxyvitamin D 0.245 .620 
Current exposure to efavirenz 2.956 .086 
 
Akaike’s Information Criterion (AIC) = 521.467 
 
Table A2.3c. Backward elimination step 3 
 
 
 
 
 
Covariate / factor Wald Chi-Square p-value 
White race 1.305 .253 
Female gender 1.388 .239 
Age 1.885 .170 
BMI 0.668 .414 
Race-adjusted eGFR <90 ml min-1 14.494 <.001 
Current exposure to efavirenz 3.166 .075 
 
Akaike’s Information Criterion (AIC) = 519.712 
 
Table A2.3d. Backward elimination step 4 
 
 
 
 
 
Covariate / factor Wald Chi-Square p-value 
White race 1.930 .165 
Female gender 2.560 .110 
Age 1.439 .230 
Race-adjusted eGFR <90 ml min-1 14.036 <.001 
Current exposure to efavirenz 4.189 .041 
 
Akaike’s Information Criterion (AIC) = 518.377 
 
Table A2.3e. Backward elimination step 5 
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Covariate / factor Wald Chi-Square p-value 
White race 1.652 .199 
Female gender 2.878 .090 
Race-adjusted eGFR <90 ml min-1 22.227 <.001 
Current exposure to efavirenz 4.548 .033 
 
Akaike’s Information Criterion (AIC) = 518.377 
 
Table A2.3f. Backward elimination step 6 
 
 
 
 
 
Covariate / factor Wald Chi-Square p-value 
Female gender 6.218 .013 
Race-adjusted eGFR <90 ml min-1 28.504 <.001 
Current exposure to efavirenz 4.649 .031 
 
Akaike’s Information Criterion (AIC) = 517.437 
 
Table A2.3g. Backward elimination step 7 
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